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Abstract
Host cell invasion by apicomplexan parasites involves multiple molecular interactions at the 
parasite-host cell interface, many of which provide likely targets for drug or vaccine-mediated 
intervention. Apical membrane antigen-1 (AMA-1) is an essential, widely conserved type I 
integral membrane protein which is mobilised onto the parasite surface from microhenries just 
prior to invasion. Antibodies to AMA-1 can prevent invasion. In the case of the malaria parasite, 
antibodies to AMA-1 can also protect against blood-stage infection in vivo and Plasmodium 
falciparum AMA-1 (RAMA-1) is a prime candidate for inclusion in a blood-stage malaria 
vaccine. Rational vaccine design would benefit from a clearer understanding of PfAMA-1 
function and the delineation of functionally important domains of the protein. A COS-7 cell- 
surface expression system, combined with a mutagenesis-based screen, was used to identify a 
series of residues critical for the binding of a monoclonal antibody that interferes with PfAMA-1 
function. Most of these residues lie in a single disulfide-constrained domain of the molecule. Our 
data indicate that this domain is of particular functional and immunological significance.
In contrast to studies of AMA1 from other species of Plasmodium, we have been unable to 
identify a role for PfAMAI in erythrocyte binding using this system. This result may be due to 
the absence of essential parasite factors in this heterologous system. Furthermore, it has not 
been possible to identify any associated parasite proteins. Thus, the role of AMA1 in invasion is 
still unclear.
Much of this work has relied on use of the Pfamal synthetic gene (sgPfamal). To validate the 
use of this gene sequence and show functionality of the gene product in the parasite, 
transfection studies were carried out. Attempts are underway to replace the endogenous gene 
sequence with a haemagglutinin (HA) tagged version of the synthetic gene. Expression of the 
sgPfamal gene product has been confirmed by immunofluorescence assay, as well as correct 
localisation to the apical end of the parasite. Disruption of the endogenous gene sequence 
remains to be confirmed.
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Chapter 1
Introduction 
1.1: Parasites of the phylum Apicomplexa
Apicomplexan parasites are obligate intracellular protozoa, responsible for numerous diseases 
of medical and veterinary importance. Parasites of this phylum infect a variety of intermediate 
hosts, such as humans (in the case of Plasmodium, Toxoplasma, and Cryptosporidium), cattle 
(Theileria and Babesia) and poultry (Eimeria) and most require more than one host to complete 
their complex life cycles (Blackman and Bannister, 2001). Many of these parasites are initially 
transmitted to a vertebrate host by an insect vector, where they undergo cycles of asexual and 
sexual differentiation respectively. Toxoplasma is unusual in that the entire life cycle occurs in 
vertebrate host species, the sexual cycle occurring in the intestine of the feline host. Typically 
these parasites are adapted to invasion of a single host-cell type by a specific cell-invasive life­
cycle stage, or zoite. Toxoplasma is again exceptional in that the asexual stage has evolved the 
ability to invade and develop within a range of cell types in diverse host species (Smith, 1995).
Despite clear differences between parasites of this phylum there are many common features 
shared by them. During the asexual cycle, zoites actively invade host cells where they undergo 
nuclear division and replication, generating multiple daughter zoites (Kappe et al., 1999). The 
parasitised cell is lysed, the parasites released are able to invade new host cells and the cycle 
repeats in this ordered manner, regulated by the circadiam rhythm of the parasite. The sexual 
cycle typically does not involve repeating cycles of nuclear division and replication to generate 
daughter zoites of the same type but involves the progression from one developmental stage to 
another, each stage undergoing an amplification step.
1.1.1: Host cell invasion by Apicomplexa
The sole function of apicomplexan zoites is to invade new host cells (Fig 1.1.). Despite the 
diverse range of host cell types invaded by parasites of this phylum, the zoite stages share 
considerable morphological similarity. In addition, the organellar arrangement within these cells 
is highly polarised, reflecting the directionality of the invasion process. Invasion of the host cell 
involves a rapid and highly complex cascade of molecular interactions and physiological events 
(Preiser et al., 2000; Dubremetz et al., 1998). On first contacting the host cell an initial weak 
interaction occurs. This is followed by zoite re-orientation, which brings its apical region into 
direct contact with the host cell surface. A tight junction forms between the zoite surface and the 
host cell plasma membrane, the surface of which subsequently invaginates. The tight junction 
moves around the parasite surface, from anterior to posterior, maintaining contact with both
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membranes at the point of entry as the parasite is internalised by a parasite driven process. The 
host cell membrane then seals, enclosing the zoite within a parasitophorous vacuole (PV).
1.1.2: Secretory organelles of apicomplexan parasites
As already discussed, apicomplexan parasites invade a wide range of different host cell types. 
Despite this, the overall mechanism and many of the molecules involved are probably common 
to all members of the phylum. Apicomplexan zoites also share morphological features 
diagnostic of the phylum. At the anterior end there is a specialised collection of organelles, 
known collectively as the apical complex (Dubremetz et al., 1998). This is composed of three 
types of secretory organelle (rhoptries, micronemes and dense granules) as well as an apical 
polar ring and, in some apicomplexa, a conoid (Soldati et al., 2004). The presence of the apical 
complex in all invasive stages of apicomplexan parasites suggests that the organelles of which 
it is composed play a role in host cell invasion by these parasites. These organelles release 
their contents in a tightly regulated manner during red blood cells (RBC) invasion. Micronemal 
proteins are thought to be involved primarily in host cell recognition and binding as well as 
parasite motility, rhoptry proteins in PV formation, and dense granule proteins in restructuring of 
the PV membrane (PVM) at and following invasion (Dubremetz et al., 1998).
1.2: Malaria, the challenge facing the global community
Over 50% of the world’s population is exposed to malaria, representing an increase of nearly 
10% in the last decade (Hay et al., 2004). In developing countries, malaria affects 300 -  500 
million people yearly with up to 3 million, largely children, dying from the severe forms of the 
disease (WHO, Roll Back Malaria). Until recently malaria was controlled in, or eradicated from, 
several areas of the world. However, the disruptive effects of political or civil unrest, together 
with the emergence of insecticide resistant mosquito vectors and multi-drug resistant parasites 
have contributed to resurgences of the disease, which in some cases has resulted in near 
catastrophic epidemics. Snow et al. (2004) have suggested that the burden of malaria not only 
increases malaria specific mortality but contributes to "all-cause" mortality. As an example of 
this, at least 10% of paediatric HIV infection in sub-Saharan Africa is thought to result from 
unsafe blood transfusion (Lackritz, 1998). As severe childhood anaemia resulting from malaria 
is often treated by blood transfusion, children with malaria are therefore often at increased risk 
of exposure to HIV from contaminated blood (Ekvall, 2003).
1.2.1: Plasmodium; guilt by association
Human malaria is caused by four species of protozoan parasites, Plasmodium falciparum, P. 
vivax, P. ovale and P. malariae. P. falciparum is associated with the most severe forms of the 
disease, leading to high levels of morbidity and mortality. A number of other Plasmodium
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species that infect simians, rodents and birds, are important experimental models. The 
Plasmodium life cycle requires vertebrate and invertebrate host species (Fig 1.1), and the 
parasite is transmitted to the vertebrate host by the female Anopheline mosquito during a blood 
meal.
The most characteristic symptom of the disease is cyclical fever occurring every 12, 24 or 72 
hours (Medical Parasitology (1999), 8th edition). Cycle length is dependent on parasite species. 
In more severe forms of the disease, characteristic of falciparum malaria, cerebral malaria, 
anaemia and organ dysfunction may also occur. Continuous exposure to the disease results in 
a large degree of clinical immunity but this is rapidly lost if exposure is interrupted (WHO).
1.2.2: The life cycle of the Plasmodium parasite
The life cycle of Plasmodium parasites, as for all apicomplexans, is complex (see Fig 1.2). The 
sexual stage of the cycle begins in the vertebrate host with gametocytogenesis and continues in 
the mosquito vector. The drop in temperature along with other factors in the mosquito mid-gut 
stimulate the maturation of male (micro-) and female (macro-) gametocytes into micro- and 
macrogametes respectively. Fertilisation results in the formation of zygotes (ookinetes) that 
penetrate the mid-gut wall and form oocysts. Development of the oocyst results in the 
production of large numbers of haploid sporozoites. These migrate to the mosquito salivary 
glands from where they are injected into the blood stream of the vertebrate host at the next 
blood meal. This invasive parasite stage migrates to the host liver and invades hepatocytes. 
Here a rapid cycle of asexual replication occurs, generating up to 104 infective merozoites per 
exo-erythrocytic schizont that are eventually released to invade circulating RBCs. The intra- 
erythrocytic parasite cycle involves cyclical asexual replication and nuclear division 
(schizogony). The mature schizont ruptures, releasing 8 - 3 2  daughter merozoites (depending 
on the parasite species; Garnham, 1966). These merozoites immediately infect new RBCs and 
the cycle repeats until adaptive immune responses or chemotherapy controls it or the host dies. 
Destruction of RBCs by intra-erythrocytic parasite replication is responsible for the 
manifestations of the uncomplicated disease. The erythrocytic cycle of P. falciparum (but not of 
most other Plasmodium species) can be maintained in vitro (Trager and Jensen, 1976). This 
important development enabled a range of experimental studies investigating the processes of 
merozoite invasion of, and growth within, RBCs and how this can be inhibited or blocked.
1.3: Tackling the disease
Despite great advances in basic scientific and medical research, malaria is still a global problem 
affecting many of the world’s poorest nations. The implementation and maintenance of 
preventative measures continues to be a problem. Two main strategies exist for the control of 
malaria, namely vector control or eradication, aiming at the disruption of malaria transmission,
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and parasite control in the form of chemotherapy and vaccination. The transmission of malaria 
is affected by climate, the incidence of disease increasing in the rainy season, coinciding with 
the mosquito's breeding season. Vector control involves personal preventative measures such 
as the use of insect repellents and bed nets as well as community based preventative measures 
such as insecticides or environmental control of transmission. The use of insecticide treated bed 
nets has in fact proven to be one of the simplest, cheapest and most effective measures for the 
prevention of morbidity and mortality resulting from malaria in Africa and Asia (Whitty et al. 
2005).
1.3.1: Chemotherapy
Anti-malarial drugs are amongst the most commonly used drugs in the tropics (White, 2004). 
Their misuse is widespread and is considered largely to be responsible for the evolution of drug 
resistance in Plasmodium. Korenromp et al. (2003) argue that drug resistance is likely to be the 
cause of the doubling in child mortality attributed to malaria in eastern and southern Africa. 
Chloroquine and sulfadoxine pyrimethamine resistance are widespread (Roper et al., 2003) 
(Takechi et al., 2001). In addition, resistance to the drug mefloquine has also been reported. A 
distinct class of antimalarials, the artemisinins are more effective at reducing parasitaemia (by 
about 104 parasites per asexual cycle) than any other anti-malarial. In addition, they inhibit 
gametocyte production, thus potentially reducing transmission (Price et al., 1996). It has 
increasingly been accepted that drug combination therapy is the best way to delay the inevitable 
development of drug resistance, particularly where an artemisinin derivative is included as one 
of the partners (White, 1999; WHO 2001). Used as part of a combination therapy artemesin 
need only be taken for a short period (three days) increasing the likelihood of the drug being 
taken at a sufficient dose for a sufficient duration, while decreasing the likelihood of resistance 
being developed to it (Nosten, 1994; Yeung et al., 2004). More accurate diagnostic procedures 
are required to reduce the inappropriate use of anti-malarials and prevent drug resistance. This 
is however expensive and requires implementation at the community level where the majority of 
childhood fever is managed (Bjorkman and Bhattarai, 2005).
1.3.2: Vaccine design
The need for a cheap, effective anti-malarial vaccine has never been more pressing. However, 
consistent with much earlier data, Jeffrey et al. (1966) demonstrated that while the course of an 
infection could be considerably altered by previous exposure to homologous and heterologous 
strains of Plasmodium, "solid" immunity did not develop in humans. Furthermore, naturally 
acquired immunity develops slowly and requires the persistence of low-density parasitaemia for 
maintenance of immune memory and effective immunity to "disease" (Struik and Riley, 2004). 
This suggests that a successful malaria vaccine will require repeated boosts or parasite 
infections to maintain its efficacy (Carvalho et al., 2002).
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A classical approach to vaccine design has been the use of inactivated or attenuated 
pathogens. This approach has proven effective at inducing immunity to a number of pathogens, 
and similar approaches have been explored in malaria vaccine development. (Nussenzweig et 
al., 1967) demonstrated that mice immunised with radiation-attenuated P. bergei sporozoites 
were protected against subsequent challenge with infectious sporozoites. It was subsequently 
shown that immunisation of human volunteers with irradiated P. falciparum or P. vivax 
sporozoites similarly protects against subsequent challenge with fully infectious sporozoites of 
the same species (Clyde, 1975; McCarthy and Clyde, 1977; Hoffman et al., 2002; Luke and 
Hoffman, 2003). However, the sporozoites must be delivered alive by intravenous injection or by 
the bite of an infected mosquito (Hoffman et al., 2002). The logistic and ethical implications of 
this have led to this approach being generally abandoned in favour of subunit vaccines.
The choice of component(s) of a subunit vaccine is not straightforward. As for chemotherapeutic 
targets, a vaccine candidate must be parasite specific. Furthermore, it must be accessible to the 
host immune system. The complexity of the parasite life cycle raises the issue of which stage it 
is best to target. Several approaches to subunit vaccines have been considered including single 
component vaccines, designed to specifically target a single parasite stage, as well as multi- 
component vaccines, usually directed against several stages. The high-level replication rate of 
the parasite, particularly in the liver stage, may overwhelm vaccine induced humoural immune 
responses. It follows therefore that a vaccine designed to target a single parasite stage must be 
extremely efficient, as any parasites escaping the vaccine induced immune response will result 
in a full infection. For this reason several groups have taken a multi-component, multi-stage 
approach (D'Alessandro et al., 1995; Doolan et al., 1997), while others have suggested a need 
for vaccine induction of cellular as well as humoural immune responses (Pombo et al., 2002; 
Ballou et al., 2004). A further approach to vaccine design is that of transmission-blocking 
vaccines (Williamson et al., 1996; Shahabuddin et al., 1998; Tsuboi et al., 2003). These are 
designed to target the sexual stages of the parasite in the mosquito and would therefore not 
affect the progress of disease in the infected individual. This approach would require the 
continued control of disease by chemotherapeutic means. Alternatively, transmission-blocking 
components could be used in conjunction with antigens from other parasite stages in a multi- 
component, multi-stage approach.
Subunit vaccine candidates from different stages of the Plasmodium life cycle have been 
identified, usually on the basis of evidence indicating that an antibody response against these 
proteins can inhibit parasite replication in vitro or protect against natural or experimental 
challenge in vivo. These include the major sporozoite surface protein circumsporozoite protein 
(CSP), the major surface antigen of merozoites, merozoite surface protein 1 (MSP1) and the 
microneme protein apical membrane antigen 1 (AMA1) among others. The CSP based vaccine 
RTS.S/AS02 has been shown to provide reproducible short-term immunity (Stoute et al., 1997; 
Bojang et al., 2001). However, vaccine efficacy was estimated at only 34% overall, falling to 0%
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in the last 6 weeks of surveillance (Bojang et al. 2001). In an attempt to extend this protection 
further, the Walter Reed Army Institute for Research (WRAIR) plan to develop a RTS,S/AS02 
based multi-stage multi-component vaccine that includes the blood stage antigens AMA1 and 
MSP1 and the liver stage antigen-1 (LSA1). Phase 2 trials to determine the efficacy of these 
antigens alone are planned before combining them with RTS,S (Heppner et al., 2005).
These studies, among many others, demonstrate the difficulties associated with devising 
effective subunit vaccines. Over the last 25 years, attempts to identify vaccine candidate 
antigens and develop a subunit vaccine against malaria have produced mixed results. 
Furthermore, no subunit vaccine has been produced that possesses an efficacy anywhere near 
the levels identified for attenuated sporozoite vaccines, prompting some investigators to suggest 
a return to the more traditional approach of attenuated sporozoite vaccines (Luke and Hoffman, 
2003; Hoffman et al., 2002). In a 10 year study, Hoffman et al. (2002) demonstrated that 
immunity resulting from immunization of human volunteers with attenuated sporozoites, 
administered via the bites of irradiated mosquitoes, was not strain-specific and lasted over 42 
weeks. Furthermore, protective immunity was dose dependent, reaching 94% in volunteers 
immunised by over 1000 infective bites compared with 33% in those immunised with between 
200 and 1000 infective bites. The development of in vitro culture methods for P. falciparum 
(Trager and Jensen, 1976) and reports of the routine, reliable production of mosquitoes carrying 
infectious sporozoites (McConkey et al., 2003) have been used in support of this idea. 
Nevertheless, the difficulties associated with producing sufficient viable attenuated sporozoites 
and devising a suitable method for administering them - particularly to indigenous populations of 
malaria-endemic countries - still stands in the way of such a vaccine. As the bite of an infected 
mosquito delivers 10 - 100 sporozoites, then 104 - 105 sporozoites would be required to 
complete each immunisation program. Attempts are in progress to improve the efficiency of 
sporozoite yield per mosquito (Luke and Hoffman, 2003) and to determine whether attenuated 
sporozoites can be effectively administered by some means other than intravenously (Luke and 
Hoffman, 2003).
In summary, despite a considerable amount of effort in this direction, a human vaccine against 
malaria is clearly some way from production.
1.4: Erythrocyte invasion by Plasmodium merozoites
The erythrocytic stage of the malaria parasite life cycle is the stage responsible for the 
symptoms of disease. If this cycle could be blocked or regulated, the morbidity associated with it 
would be reduced. For this reason a considerable amount of research has been directed at 
understanding the mechanisms of erythrocyte invasion by Plasmodium merozoites.
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Like the invasive stages of other apicomplexan parasites, Plasmodium merozoites possess the 
characteristic apical complex at their anterior end (Fig 1.3.). Immuno-electron microscopy data 
indicate that the organelles within this complex form during the final round of nuclear division in 
schizont development (Bannister et al., 2000a). The apical complex is comprised of two pear- 
shaped rhoptries, up to 40 micronemes, and numerous dense granules, as well as three polar 
rings (Bannister et al., 2000a; Bannister and Mitchell, 2003; Bannister and Mitchell, 2003). 
Unlike some apicomplexan parasites there is no conoid (Bannister et al., 2000a).
Mature merozoites exit from the parasitised erythrocyte by a two-step protease dependent 
egress (Salmon et al., 2001; Wickham et al., 2003). The free merozoites make an initial weak 
interaction with circulating erythrocytes (Mitchell et al., 2004). This interaction is random, occurs 
between any point on the parasite surface and the RBC surface and is reversible. Invasion only 
occurs if the parasite then reorientates such that its apical tip contacts the erythrocyte surface. 
Attachment at this point induces deformation and rapid transient oscillation of the RBC 
membrane (Dvorak et al., 1975; Miller et al., 1979a), although this can also occur in the 
absence of apical orientation (Mitchell et al., 2004). These oscillations may assist in 
reorientation of the parasite. As with other apicomplexans, apical contact with the erythrocyte 
results in formation of an electron-dense tight junction between the two membranes (Aikawa et 
al., 1978). Junction formation appears to commit the parasite to the invasion pathway (Sinnis 
and Sim, 1997). The RBC membrane then undergoes invagination to form the PV, into which 
the parasite moves. During invasion the uniform surface coat of the merozoite is excluded from 
the internalised portion of the parasite (Aikawa et al., 1978). Similarly, the intra-membrane 
particles (IMP) found in the RBC membrane are largely absent from the PVM (Aikawa et al., 
1981). Internalisation of the merozoite is an active, parasite driven process that can be inhibited 
by the actin capping and depolymerising agent cytochalasin B (Miller et al., 1979a). 
Furthermore, P. falciparum myosin A (Pfmyo-A) has been identified between the plasma 
membrane and cisternal membrane of the merozoites within very late schizonts and is thought 
to be a principal component of the P. falciparum invasion motility machinery (Pinder et al., 1998; 
Pinder et al., 2000). As the parasite enters the deepening invagination in the RBC surface, the 
tight junction maintains a circumferential interaction between the two membranes at the 
entrance (Aikawa et al., 1978). Thus, the junction traverses the parasite surface from anterior to 
posterior before finally closing the entrance to engulf the parasite in the PVM (Aikawa et al., 
1978).
1.5: Apical organelles of Plasmodium merozoites
The initial weak interaction between the parasite and the RBC can occur at any point of the 
parasite surface and resident merozoite surface proteins, such as MSP1, are evenly distributed 
across the merozoite surface. It is therefore likely that such proteins mediate these initial 
interactions (Hall et al., 1984; Nikodem and Davidson, 2000; Goel et al., 2003). Throughout
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RBC invasion the contents of the apical organelles are secreted in a tightly regulated manner 
and it is thought that these are involved in steps subsequent to the initial binding. Micronemes 
develop after the fourth round of mitotic division, while the merozoites are budding from the 
schizont surface (Margos et al., 2004). Proteins secreted from these organelles are thought to 
contribute to the specificity of the invasion process (Triglia et al., 2000), the reorientation of the 
parasite (Mitchell et al., 2004) and may irreversibly commit the cell to invasion by mediating tight 
junction formation (Miller et al., 1979a). Rhoptries are the first of the secretory organelles to 
develop, forming at the periphery of the schizont during the second nuclear division (Bannister 
et al., 2000b; Margos et al., 2004). Immuno-electron microscopy (IEM) data indicate that the 
rhoptry contents are segregated into basal or apical duct regions of the organelle (Bannister et 
al., 2000b). These organelles secrete their contents at the time of tight junction formation and 
merozoite internalisation (Dubremetz et al., 1998). Rhoptry proteins have been shown to modify 
the PVM and the erythrocyte membrane in newly invaded rings (Sam-Yellowe et al., 1988; Sam- 
Yellowe et al., 2004). The last of the secretory organelles to develop are the dense granules. 
These appear close to the nucleus when the parasite has nearly completed budding but is still 
attached to the residual body (Margos et al., 2004). As the merozoite enters the host cell the 
dense granules move to the periphery of the parasite and release their contents into the PV 
(Torii et al., 1989; Atkinson and Aikawa, 1990; Culvenor et al., 1991). Here they are believed to 
elicit further expansion of the PVM or interact with the cytoskeleton of the erythrocyte 
membrane (Foley et al., 1991; Da Silva et al., 1994). Table 1.1 summarises the current 
understanding of some the key apical organelle proteins.
Proteins found on the surface of the invasive merozoite (resident surface proteins as well as 
those originating from the apical organelles) are considered valuable tools for vaccine 
development. Not only are these proteins believed to be involved in host cell invasion, they are 
also accessible to the immune system. One challenge faced by those attempting to develop an 
effective vaccine against malaria is that many malaria antigens possess multiple polymorphic 
amino acid residues, resulting in considerable immunological heterogeneity. Non-synonymous 
polymorphisms are considered to be the result of immune selection pressure. Escalante et al. 
(1998) demonstrated that antigens expressed on the surface of P. falciparum infected RBCs 
were more polymorphic than those localised internally or expressed during the sexual stages of 
the parasite life cycle. This phenomenon is attributed to the strong selection pressure upon such 
antigens, forcing them to develop mutations, thus enabling evasion of the host immune system 
(Hughes and Hughes, 1995). Antigens currently being considered for a potential blood stage 
vaccine are resident merozoite surface proteins and components of the apical organelles, such 
as MSP1 and AMA1 respectively. The prevalence of polymorphic residues in such antigens 
suggests that an effective immune response can be induced against them (Conway and Polley 
2002). However, such diversity poses problems for vaccine design based on these antigens.
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1.6: The Duffy binding-like erythrocyte binding protein (DBL-EBP) super 
family of Plasmodium
Adams et al. (1992) identified the prototypic members of a superfamily of erythrocyte binding 
proteins (EBPs) also referred to as the erythrocyte binding-like (EBL) family, characterised by 
the presence of two types of cysteine rich domain in the extracellular region of the protein: a 
DBL domain (known as region II) and a highly conserved carboxy-terminal c-cys domain, of 
unknown function (known as region VI) (Chitnis and Miller, 1994). Greater conservation exists 
among the c-cys domains than is seen among the amino-terminal DBL domains (Adams et al., 
1992). The function of the c-cys domain is unknown, but the degree of conservation perhaps 
indicates a conserved function within the different EBPs. These two regions are separated by a 
non-homologous hydrophilic stretch (regions lll-V) (Fang et al., 1991; Adams et al., 1992). The 
ebl gene family encode two groups of proteins, differing according to whether they have a single 
or tandem (designated F1 and F2) DBL domain. The Duffy binding proteins of P. knowlesi and 
P. vivax have a single DBL domain, whereas the P. falciparum erythrocyte binding protein EBA- 
175 and other erythrocyte binding proteins (named JESEBL, BAEBL, PEBL, and EBL1) have 
tandem DBL domains. Proteins from this family are all type I integral membrane proteins, having 
an N-terminal extracellular domain and C-terminal cytoplasmic tail, separated by a putative 
transmembrane domain (TMD) (Adams et al., 1992).
A striking feature of this family is the conserved intron/exon structure of their genes. For most 
ebl genes a single exon encodes the signal peptide and extracellular domain, a second exon 
encodes the transmembrane region and two exons encode the cytoplasmic domain. The maebl 
genes and the P. vivax and P. knowlesi dbp-ebl genes have an additional intron between the 
coding sequence for the signal peptide and that for the extracellular domain (Kappe et al., 
1998c; Adams et al., 1992).
Genes encoding members of the EBP family are usually single copy. Plasmodium species 
clearly utilise different receptor molecules depending on their host cell of preference, allowing 
them to invade mature RBCs in the case of P. falciparum and reticulocytes in the case of P 
vivax. There may also be a need for the parasite to be able to recognise the RBCs of 
phenotypically diverse hosts whose RBC membranes may reflect this diversity. These 
organisms therefore deploy a family of related proteins to mediate erythrocyte binding during 
invasion, rather than products of a multigene family. The distinction between a protein 
superfamily and multigene family is somewhat arbitrary. It could be argued that the difference 
between a family of related proteins and proteins encoded by a multigene family is that the 
former mediate similar processes but display different functional specificities and variable levels 
of homology to other members of the superfamily. By comparison, the latter exhibit the same 
specificities but different antigenicity, their function being protected by differential expression of 
family members in which homology is retained within the family. In agreement with this,
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members of the DBL-EBP superfamily of proteins that participate in erythrocyte invasion by 
merozoites do so by mediating erythrocyte binding. These proteins exhibit different receptor 
specificities. The erythrocyte membrane protein 1 family of P. falciparum (PfEMP-1) encoded by 
a multi-gene family (the var gene family) are variant surface antigens that also contain a DBL 
domain and are therefore members of the DBL-EBP superfamily. PfEMPI is implicated in 
cytoadherence of trophozoite and schizont stage parasites to the host endothelium in the brain 
and placenta as well as resetting (Leech et al., 1984; Chen et al., 1998). PfEMPI mediates 
these processes by interacting with CD36, Thrombospondin (TSP) and intercellular adhesion 
molecule (ICAM) on the endothelial surface (Pasloske et al., 1994) and complement-receptor 1 
(CR1) on the erythrocyte surface (Rowe et al., 1997). By contrast, the 235 kDa protein-family of 
P. yoelii (Py235), encoded by 35 genes in the P. yoelii genome, is implicated in erythrocyte 
invasion by P. yoelii merozoites (Oka et al., 1984; Holder and Freeman, 1984). However, 
Preiser et al. (2002) demonstrated that distinct (seemingly stage specific) subsets of py235 
genes are transcribed in P. yoelii oocysts, sporozoites, liver-stage and erythrocytic merozoites. 
Clearly, oocyst expressed Py235 mediates different receptor binding specificities in the 
mosquito host than do proteins expressed in asexual stage parasites in the vertebrate host. It is 
unclear whether Py235 variants expressed in the asexual stages of the parasite life cycle are 
able to mediate the interactions required for oocyst-sporozoite migration to the salivary glands. 
In addition, Smith et al. (1995) suggest that expression of different var genes correlates with 
alterations in cytoadherent phenotypes. However, this study looked at the correlation between 
ICAM1 binding potential by P. falciparum clones and the presence of a specific var transcript. 
This does not rule out the possibility that switches in PfEMPI expression merely alter the affinity 
of binding rather than the specificity of binding. Chen et al. (2000) identified three independent 
binding domains within the PfEMPI ectodomain that mediate binding to different host receptors. 
It is possible that different combinations of variants of these domains confer different binding 
phenotypes and also possibly the virulence phenotype on the parasite. Therefore the question 
still remains whether subsets of PfEMP-1 proteins provide the adhesive properties required by 
the parasite in different scenarios such as cerebral or placental sequestration, and rosetting? 
These findings highlight the potential problem associated with drawing a distinction between 
members of a multigene family and structural/functional protein families. Nevertheless, the 
presence of multiple EBPs within a parasites genome may allow the utilisation of different host 
cell receptors, adding to the redundancy of the invasion process. In summary, this single DBL- 
containing superfamily therefore provides the parasite with two distinct survival mechanisms: 
one that provides invasion pathway redundancy and the other that results in a variant antigen 
repertoire (Michon et al., 2002; Mayer et al., 2004).
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1.6.1: The Duffy blood group binding antigen of P. knowlesi and P. vivax
During invasion, P. knowlesi and P. vivax merozoites depend on recognition of an epitope on 
the Duffy blood group antigen (a chemokine receptor) on the erythrocyte surface (Miller et al., 
1975; Miller and Carter, 1976; Haynes et al., 1988; Wertheimer and Barnwell, 1989; Horuk et 
al., 1993). The chymotrypsin sensitive motif recognised by these parasites lies within a 35 
amino acid stretch at the N-terminus of the extracellular domain of the human and rhesus 
monkey Duffy antigen (Ranjan and Chitnis, 1999). They therefore invade only Duffy-positive 
erythrocytes. In the absence of this antigen, they form the initial attachment with the host RBC 
and undergo reorientation, but are unable to complete tight junction formation and invasion 
(Miller et al., 1979b). This observation provided some of the earliest evidence indicating that 
invasion comprises a series of mechanistically distinct steps, involving a cascade of different 
molecules.
The P. knowlesi genome encodes three Duffy binding-like proteins (a, p and y) (Adams et al., 
1990). The P. knowlesi p and y proteins bind Duffy-independent receptors (sialic acid and some 
unidentified determinant respectively) on rhesus monkey erythrocytes (Chitnis and Miller, 1994; 
Ranjan and Chitnis, 1999). The a protein binds the Duffy blood group antigen on human 
erythrocytes. P. knowlesi parasites invade trypsin treated Duffy-negative human RBC and 
rhesus erythrocytes rendered Duffy-negative by chymotrypsin treatment (Haynes et al., 1988). 
This finding suggests that, under certain circumstances, invasion by these parasites can 
continue via an alternative pathway, or bypass certain Duffy antigen dependent steps in the 
pathway.
Mild proteolysis with trypsin demonstrated that region II of the P. knowlesi a-gene product 
consists of two structurally distinct modules (major and minor), linked by a protease susceptible 
linker region (Singh et al., 2003). The major module, from cysteines 5 to 8 of this domain, 
encompasses the erythrocyte binding domain. The equivalent region of the P. vivax protein 
showed similar binding properties. The non-functional surrounding region may however 
contribute to the affinity and specificity of binding (Ranjan and Chitnis, 1999).
1.6.2: The erythrocyte binding antigen 175 (EBA-175) of P. falciparum
Different clones of P. falciparum have been shown to use alternative receptors and pathways 
(Mitchell et al., 1986; Perkins and Holt, 1988; Dolan et al., 1994). The well characterised EBA- 
175 of P. falciparum binds trypsin sensitive terminal sialic acid (Neu5Ac(a2-3)Gal) on O-linked 
oligosaccharides of glycophorin A on the RBC surface (Orlandi et al., 1992; Sim et al., 1994a). 
Neuraminidase treatment of erythrocytes, which results in removal of sialic acid from the 
erythrocyte surface, reduces invasion by P. falciparum. However, the parasite is still able to 
infect En(a-) cells that lack glycophorin A, indicating that this molecule alone cannot be the sole
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receptor for P. falciparum (Miller et al., 1977). The existence of a sialic acid independent 
pathway has been demonstrated (Dolan et al., 1990), as has the use, by invasive merozoites, of 
glycophorins B and C as erythrocyte receptors (Dolan et al., 1994; Maier et al., 2003). 
Furthermore, partial disruption of the eba-175 gene in P. falciparum did not abrogate invasion 
as parasites switched to a sialic acid independent invasion pathway (Reed et al., 2000; Kaneko 
et al., 2000).
Antibodies recognising region II of EBA-175 blocked invasion of sialic acid dependent (FVO) 
and independent (3D7) strains of P. falciparum parasites, leading to the suggestion that this 
parasite receptor may utilise alternative pathways (Narum et al., 2000). Alternatively, invasion- 
inhibition of 3D7 parasites by these antibodies may result from steric hindrance of some other 
parasite receptor molecule. In support of this, disruption of the eba-175 locus in 3D7 parasites 
had no effect on merozoite invasion efficiency, indicating that the sialic acid independent nature 
of 3D7 parasites is not a result of EBA-175 utilising an alternative pathway (Duraisingh et al., 
2003b). However, loss of EBA-175 function severely reduced the invasion efficiency of 
merozoites into chymotrypsin treated erythrocytes (glycophorin A is the predominant 
chymotrypsin resistant receptor), compared to wild type 3D7 parasites. This finding suggests 
that the EBA-175 gene product is functional in wild type 3D7 parasites and is a component of 
the dominant chymotrypsin resistant invasion pathway. This supports the existence of multiple 
invasion pathways, relying on different/unique erythrocyte binding-like {ebl) gene products and 
variable RBC receptors/ligands (Chitnis and Blackman, 2000).
1.6.3: The 140 kDa erythrocyte binding protein of Plasmodium
An additional ebl gene has been identified on chromosome 13 of the P. falciparum (3D7 strain) 
genome sequence (Mayer et al., 2001). The gene sequence predicts a structure typical of DBL- 
EBP, namely two cysteine rich domains, regions II and VI, a TMD and a cytoplasmic domain. 
The exon/intron structure of the corresponding gene from Dd2/Nm parasites is identical to that 
of EBA-175. The 140 kDa protein encoded by this gene (known as BAEBL, see table 1.1), 
immunoprecipitated from P. falciparum culture supernatants, binds normal, but not 
neuraminidase treated, human erythrocytes (Thompson et al., 2004; Narum et al., 2002). Narum 
et al. (2002) identified a 50% reduction in the ability of BAEBL to bind trypsin treated human 
erythrocytes, while Thompson et al. (2001) observed no such effect. Under these conditions 
binding of EBA-175 to human erythrocytes is completely abrogated. Thus, these related DBL- 
EBPs have different receptor specificities. Mayer et al. (2001) suggested that unlike EBA-175, 
the receptor for BAEBL on human erythrocyte is glycophorin C/D. Furthermore, Maier et al.
(2003) identified the receptor as glycophorin C. By comparison, Thompson etal. (2001) suggest 
a protease resistant receptor on the host erythrocyte for BAEBL, which is inconsistent with it 
being glycophorin C. In a second study, Mayer et al. (2002) suggested that four polymorphic 
sites found in the erythrocyte binding domain of BAEBL (region II) enabled this molecule, from
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different parasite strains, to utilise alternative host erythrocyte receptors. Thompson et al. (2002) 
identified a parasite line that lacked BAEBL, showing that this gene product in not essential for 
parasite survival and confirming the redundancy of these invasion pathways.
1.6.4: The merozoite antigen erythrocyte binding ligand (MAEBL)
Kappe et al. (1997) initially identified a sub-family of erythrocyte binding proteins in the rodent 
parasites P. yoelii and P. berghei, however, homologues are present and highly conserved 
throughout the genus (Kappe et al., 1998). The intron/exon structure of the maebl gene, as well 
as the homology in the predicted protein sequence for its carboxy-terminal cysteine rich domain, 
transmembrane region and cytoplasmic tail, identify it as a member of the DBL family. However, 
MAEBL is unique in that it shows more sequence homology in its amino-terminal cysteine rich 
region to AMA1 than it does to the corresponding region of other ebl gene products (Kappe et 
al., 1998). This region is comprised of two cysteine rich domains M1 and M2, each bearing 
considerable deduced amino acid similarity to the cysteine rich domains I and II (Dl-ll) of AMA1 
(see below) (Kappe et al. 1998). Homology with AMA1 derives mainly from the conservation of 
cysteine residues. The Ml and M2 domains of MAEBL share 40% sequence homology, each 
containing 16 cysteines of which 10 are conserved in AMA1 Dl-ll.
Analysis of P. yoelii mixed stage parasites by indirect immunofluorescence (IFA) analysis, using 
antibodies raised against M2 of MAEBL, has shown co-localisation with AMA1 and the 235 kDa 
rhoptry protein (Noe and Adams, 1998). These findings, along with other studies (Noe et al., 
2000; Ghai et al., 2002), seem to suggest that MAEBL localises to the rhoptries of developing 
merozoites. However, IEM studies have localised P. falciparum AMA1 to the micronemes 
(Bannister et al. 2003). This indicates that either the localisation of MAEBL in P. yoelii and P. 
falciparum is different or, possibly, the mixed-stage nature of the P. yoelii parasites used 
confused the issue. Further IEM is required to fully resolve this matter. Rhoptry localisation is 
however supported by the finding that the maebl transcript pattern peaks in mid to late 
trophozoites, and is absent in late schizonts (Blair et al., 2002). By comparison, transcripts for 
other ebl genes (eba-175, baebl, peb/and jesebl) are most abundant in late schizogony. These 
findings are consistent with the timing of rhoptry (4 nuclei stage) and microneme (16 nuclei 
stage) development (Margos et al., 2004). In mature P. yoelii merozoites, MAEBL and AMA1 
localise to the merozoite surface (Peterson et al., 1989; Kappe et al., 1997). This has never 
been observed for other DBL-EBPs. However, as for EBA-175 (Sim et al., 1990) and AMA1 
(Margos et al., 2004; Howell et al., 2005), the extracellular domain was not detectable in ring or 
trophozoite stage parasites using anti-M2 antibodies (Ghai et al., 2002). Targeted disruption of 
the maebl gene locus indicates that, like BAEBL, this gene product is not essential for parasite 
survival in blood stages (Fu et al., 2005).
13
Expression of the P. yoelii MAEBL domains M1 and M2 in membrane bound form on the 
surface of COS-7 cells has been used to show that M1 and M2 bind murine, but not human, 
erythrocytes; however, M2 binds with higher efficiency (Kappe et al., 1998c). Similarly, a soluble 
recombinant form of P. falciparum MAEBL (PfMAEBL) M2 domain exhibited high affinity binding 
for human erythrocytes (Ghai et al., 2002). Papain treatment of human erythrocytes completely 
abrogated PfMAEBL binding, whereas trypsin treatment merely reduced it (Ghai et al., 2002). 
Neuraminidase on the other hand slightly increased binding. Thus, PfMAEBL recognises a 
peptide-based determinant on the erythrocyte surface that is distinct from the receptor 
recognised by EBA-175.
1.7: Merozoite surface protein 1 (MSP1)
Many resident merozoite surface proteins have been identified, several of which could 
potentially be involved in making the initial interaction between the parasite and host cell. One 
example, and the most comprehensively studied in P. falciparum, is MSP1 which gene 
disruption experiments suggest is functionally important, if not essential, in the erythrocytic 
stage of the parasite life cycle (O'Donnell et al., 2000).
Like many merozoite stage antigens, MSP1 is proteolytically processed. This generates a 
complex of polypeptides that are linked to the merozoite surface via a 
glycosylphosphatidylinositol (GPI) anchor (Holder and Freeman, 1982; Lyon et al., 1986; 
McBride and Heidrich, 1987). Subsequent to schizont rupture, a further processing step occurs 
within the 42kDa membrane bound fragment (Blackman et al., 1991b; Miller et al., 1993). A 
33kDa amino-terminal fragment (MSPI33) is released, exposing a carboxyl-terminal 19kDa 
fragment (MSP119) at the merozoite surface, consisting of two epidermal growth factor (EGF)- 
like domains (Blackman et al., 1990; Blackman et al., 1996; Morgan et al., 1999; Chitarra et al., 
1999). This 19kDa fragment is carried into the erythrocyte on invasion and can be detected in a 
circumferential localisation in ring stage parasites (Blackman, 1994). Antibodies found to block 
this secondary processing also block erythrocyte invasion (Blackman, 1994). This processing 
step goes rapidly to completion during the invasion process, suggesting it is of functional 
significance (Blackman et al., 1996).
Whether the release of MSP133 is required to break some parasite-host interaction, or to expose 
the functional MSP119 fragment is unknown. However, invasion-inhibitory monoclonal and 
polyclonal antibodies exist that recognise epitopes in the EGF domains of MSP119 (Blackman et 
al., 1990; Chang et al., 1992; Spencer Valero et al., 1998; O'Donnell et al., 2000). Studies to 
assess the role of antibodies acquired against MSP119 in immune or semi-immune individuals in 
malaria endemic areas indicate a protective role for this antigen (Egan et al., 1995; Egan et al., 
1996; de Koning-Ward et al., 2003; O'Donnell et al., 2001). In other systems EGF-like domains 
have been shown to play a role in adhesion, suggesting that MSP119 might have an adhesive
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function in invasion. However, initial reports of the erythrocyte binding activity of MSP1 were 
inconclusive (Perkins et al., 1998; Nikodem and Davidson, 2000; Rodriguez et al., 2002). 
MSP119 is functionally constrained across distantly related species of Plasmodium (O'Donnell et 
al., 2002) suggesting that it plays a highly conserved role. Two recent studies identify Band 3 as 
the host cell receptor for MSP1 (Goel et al., 2003; Li et al., 2004b). Li et al. (2004b) suggested 
that MSP1 and MSP9 form a complex that interacts with a Band 3 homo-dimer on the RBC 
surface. Whatever the precise role of MSP1, its circumferential localisation on the surface of the 
merozoite suggests that if it does play an erythrocyte-binding role in invasion, it does so by 
facilitating the initial interaction with the host cell.
1.8: Apical membrane antigen 1 (AMA1)
Apical membrane antigen 1 (AMA1) is widely regarded as a leading candidate for inclusion in a 
blood stage malaria vaccine (Waters et al., 1991). Identified initially in P. knowlesi, homologues 
of AMA1 have been found in all species of Plasmodium (Deans et al., 1982; Marshall et al., 
1989; Peterson et al., 1990; Waters et al., 1990; Waters et al., 1991; Cheng and Saul, 1994; 
Dutta et al., 1995; Kappe and Adams, 1996; Marshall et al., 1996; Kocken et al., 2000) 
Therefore it is possible that vaccine development involving AMA1 may have broad applications.
In Plasmodium, AMA1 is the product of a single copy gene. However, apparently two additional, 
less well conserved homologous are present in the genome of T. gondii. Expressed towards the 
end of the fourth nuclear division in developing Plasmodium schizonts (Margos et al., 2004) 
AMA1 is a type I integral membrane protein comprising an N-terminal ectodomain, a 21 amino 
acid transmembrane region and a 55 amino acid, C-terminal cytoplasmic tail (Fig 1.4) (Peterson 
et al., 1989). Upon synthesis, AMA1 is targeted to the micronemes of developing merozoites 
(Healer et al., 2002; Bannister et al., 2003). Around the time of schizont rupture, AMA1 is 
released, via the apical prominence, onto the surface of the merozoite (Peterson et al., 1989). 
Surface localisation of AMA1 can be occasionally detected in merozoites within schizonts, 
following budding (Peterson et al., 1989; Margos et al., 2004). This indicates that interaction 
with a new host cell is not a prerequisite for AMA1 release from the micronemes.
Attempts to disrupt the amal gene locus in P. falciparum (Triglia et al., 2000) and T. gondii 
(Hehl et al., 2000) have proven unsuccessful using traditional reverse genetics approaches. 
However, the recent development of a conditional knock-out system for T. gondii, has allowed 
the controlled disruption of the am al gene locus in this parasite (Mital et al., 2005). The inability 
to disrupt the gene locus completely in earlier studies had led to the suggestion that this gene 
product was essential for apicomplexan parasite survival. Mital et al. (2005) disrupted the 
endogenous T. gondii amal (Tgamal) gene in parasites expressing a myc-tagged version of 
TgAMAI under the control of a tetracycline-sensitive conditional promoter. When fully active, 
expression of myc-tagged TgAMAI from this promoter was only 10% the level of TgAMAI in
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wild type parasites; invasion efficiency for these parasites was indistinguishable from that of wild 
type parasites. Down-regulation of promoter activity resulted in a decrease in myc-tagged 
TgAMAI expression to 0.5% the level of TgAMAI in wild type parasites. This being the average 
figure, some parasites must have expressed myc-tagged TgAMAI at a level between 0.5 and 
10%, perhaps above the critical threshold required for invasion. Alternatively, the two 
homologues of AMA1 identified in the T. gondii genome may function in some alternative 
invasion pathway. Such homologues have not been identified in any Plasmodium genome. 
Downregulation of the conditional Tgamal gene resulted in an 85% decrease in invasion 
efficiency. Taken together, these results suggest that, at least in Plasmodium and probably also 
in Toxoplasma, AMA1 is an essential gene product that plays a critical role in invasion.
1.8.1: Structure of AMA1
At the amino acid level, AMA1 is highly conserved among Plasmodium species, having at least 
50% identity in pair-wise comparison of known sequences (Marshall et al., 1989). Furthermore, 
structurally important residues are positionally conserved (Waters et al., 1990). Most notably, 
the AMA1 ectodomain from all species of Plasmodium contains 16 absolutely conserved 
cysteine residues all of which participate in intra-molecular disulphide bonds (Hodder et al., 
1996; Nair et al., 2002). That these bonds constrain the molecule to form three sub-domains 
(Dl, Dll and Dill) has been confirmed by the solution of the P. vivax AMA1 (PvAMAI) crystal 
structure (Pizarro et al., 2005). Figure 1.4 shows a schematic representation of the domain 
structure of P.falciparum AMA1 (PfAMAI). That the first 10 of these cysteine residues, found in 
Dl and Dll, are conserved in the AMA1 orthologues of the apicomplexans T. gondii (Hehl et al., 
2000; Donahue et al., 2000) and Babesia bovis (Gaffar et al., 2004) suggests that the disulphide 
bonding pattern observed in these domains, and thus possibly the domain structure, is 
conserved in these phyla.
The core structure of both Dl and Dll comprise so-called Plasminogen Apple Nematode (PAN) 
motifs (Pizarro et al. 2005), a family of protein domains that include N domains of members of 
the plasminogen/hepatocyte growth factor family, A- or apple domains or the plasma 
predallikrein/coagulation factor XI and domains found in various nematode proteins (Tordai et 
al. 1999). Present in functionally diverse molecules, PAN domains can generally be described 
as mediating adhesion, via protein-protein or protein-carbohydrate interactions. In AMA1, these 
domains have been extensively modified. PAN domains are normally characterised by the 
presence of six cysteine residues, all involved in disulphide bonding. Domain I of AMA1 has 
! three disulphide bonds and Dll has only two; however, only the disulphide bond linking 
cysteines 2 and 5 in each of these domains is consistent with those found in the normal PAN 
module (Bai et al., 2005; Pizarro et al. 2005). The central five-stranded, anti-parallel (3-sheet is 
' packed against a twelve residue a-helix on one face and a double stranded (3-sheet on the other 
(Bai et al., 2005; Chesne-Seck et al. in press) and these conform well to previously published
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structures. In addition, about 50% of Dl lacks secondary structure, with multiple ordered but 
flexible loops that extend from the core PAN structure. By contrast, Dll has a more closely 
packed secondary structure, with a single long loop (denoted the Dll loop) extending from its 
surface (Bai et al., 2005). The Dll loop interacts with a hydrophobic pocket in Dl, contributing 
two of the nine amino acid residues that line the pocket (Bai et al., 2005). The Dll loop is 
invariant in length in different Plasmodium orthologues; however, it has low sequence identity 
(21%) (Chesne-Seck et al. in press). This loop is slightly longer in AMA1 from Babasia bovis 
AMA1 (BbAMAI), and about half the length in TgAMAI (Chesne-Seck et al. in press).
By comparison, domain III shows no homology to any known polypeptide fold (Pizzaro et al. 
2005). Sequence identity between orthologues in Plasmodium in this domain is 33%, compared 
to 39% overall. This domain in AMA1 shows the least homology in orthologues from parasites of 
different phyla. In BbAMAI only four cysteine residues exist in Dill, however, these align with 
four of those in Plasmodium sequences and possibly form disulphide bonds corresponding to 
Cys443-Cys502 and Cys490-Cys507 in PfAMAI (Chesne-Seck et al. in press). In contrast, 
TgAMAI has six cysteine residues in Dill, only two of which align with cysteines in Dill of 
Plasmodium sequences (Chesne-Seck et al. in press). However, in Plasmodium AMA1, these 
cysteines do not interact to form a disulphide bond. Thus, none of the disulphide bonds in Dill of 
TgAMAI align with those of orthologues from Plasmodium. It is possible therefore that Dill of 
BbAMAI bears some structural similarity to that of Plasmodium orthologues, however, TgAMAI 
is likely to be structurally distinct. Like Plasmodium, merozoites of B. bovis merozoites invade 
and develop within erythrocytes, while T. gondii tachyzoites invades nucleated cells. It is 
possible that differences observed in the structure of these AMA1 orthologues may reflect 
differences in host cell specificity.
1.8.2: Proteolytic processing of AM A1
A schematic representation of AMA1 processing can be found in figure 1.5. PfAMAI is 
synthesized as an 83 kDa precursor containing a N-terminal prodomain, which is absent in 
AMA1 from all other Plasmodium species studied, except the chimpanzee parasite, P. 
reichenowi. Around the time of schizont rupture, PfAMAI is proteolytically processed, the 
prodomain being removed, leaving a 66 kDa membrane-bound fragment which is released from 
the micronemes and redistributed across the merozoite surface (Peterson et al., 1989, Narum 
and Thomas, 1994). After further proteolytic processing the molecule is shed from the merozoite 
surface as a 48 kDa fragment, known as PfAMAI 48 (Howell et al., 2001). About 30% of the 48 
kDa fragment undergoes an additional cleavage within Dill, producing two fragments held 
together by a disulphide bond, the larger of which is known as PfAMAI44 (Howell et al., 2003). 
Once PfAMAI is shed from the parasite surface, no further processing occurs, suggesting that 
this internal cleavage is mediated by a parasite protease. This internal cleavage is possibly 
conserved in AMA1 from other species of Plasmodium, since in P. knowlesi AMA1 (PkAMAI)
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two fragments, of 44 kDa and 42 kDa, were identified in Western blot analysis of parasite 
culture supernatants and free merozoites, under reducing conditions (Deans, 1984). Similar to 
the ratio of PfAMAI^ to PfAMAI48 in P. falciparum, the 42 kDa PkAMAI species appear to be 
about half the intensity of the 44 kDa form (Deans, 1984). If this situation is analogous to that in 
P. falciparum, under non-reducing conditions these should be observed as a single band, the 42 
kDa fragment being disulphide bonded to the C-terminus of the 44 kDa fragment; however, this 
has not been investigated. The functional significance of this internal cleavage is unknown. In T. 
gondii a similar shedding process occurs, but here the shed TgAMAI fragment migrates as a 
single band of 54 kDa under reducing conditions in Western blot analysis suggesting that the 
additional internal cleavage within TgAMAI Dill does not occur to any significant extent (Hehl et 
al., 2000); however, as noted above DIM in TgAMAI is probably structurally distinct from that in 
Plasmodium AMA1. After shedding of the ectodomain, the TMD region and cytoplasmic tail are 
carried into the RBC with the invading parasite (Howell et al., 2005). Dutta et al. (2003) 
demonstrated that invasion inhibitory Abs raised against PfAMAI functioned by blocking 
shedding. This raises the possibility that, as for MSP1 in Plasmodium (Blackman et al., 1994) 
and the microneme protein MIC2 in Toxoplasma (Brassier et al., 2003), processing of AMA1 is 
essential for invasion. The development of a system for conditional gene expression in P. 
falciparum will allow a thorough analysis of the functional significance of AMA1 processing and 
shedding in invasion (Meissner and Soldati, 2005).
Evidence from protease inhibitor studies suggests that a single calcium-dependent, serine 
protease mediates shedding of both PfAMAI and MSP1 (Howell et al., 2003). This was an 
unexpected finding since the cleavage sites of these two proteins lies within structurally quite 
different motifs; these are RAEVT517-518SNNEV for PfAMAI (Howell et al., 2003) and 
LQGML286-287NISQH for MSP1 (Blackman et al., 1991a). Previously identified "sheddases" 
appear to be dependent on the presence of conformationally unrestrained peptides surrounding 
the cleavage bond and its distance from the membrane, and -  unusual among proteases - their 
recognition of these motifs is often apparently not dependent on the precise amino acid 
sequence within them (Schwager et al., 2001). The Thr517-Ser518 site at which the PfAMAI 
ectodomain is cleaved lies 29 amino acid residues from the membrane, an appropriate distance 
for cleavage by a sheddase, and the membrane bound parasite protease responsible has 
therefore been named merozoite-surface sheddase or MESH (Howell etal. 2005). As discussed 
above, the C-terminal 19 kDa fragment of PfMSPI is comprised of two EGF domains that form 
an inverted U-shaped structure (Morgan et al., 1999) thus bringing the cleavage site into close 
proximity to the membrane and making it readily accessible to MESH. The subtilisin-like serine 
protease SUB2, released from micronemes onto the surface of the merozoite around the time of 
schizont rupture, has been identified as the Plasmodium MESH responsible for shedding of 
AMA1 and MSP1 (Harris etal. submitted). SUB2 has no homologue in T. gondii and, consistent 
with this, shedding of TgAMAI occurs at an intra-membrane location and is mediated by a 
member of the serine protease family known as rhomboids (Howell et al., 2005). These seven-
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pass transmembrane proteins cleave their substrates within the membrane. Microneme proteins 
of Plasmodium, such as EBA-175, are also quite probably shed at intra-membrane sites, 
presumably also by rhomboids (Blackman, unpublished data). Inhibition of normal PfAMAI 
processing results in an alternative shed form of 52 kDa. Identification of the shedding site that 
results in this aberrant form suggests that it lies within the membrane (Howell et al., 2003a). 
Why some microneme proteins of Plasmodium are shed at intra-membrane sites while others, 
such as AMA1, are processed at sites outside the membrane is unclear.
1.8.3: Polymorphisms within the AMA1 ectodomain 
1.8.3.1: Selection pressure on the PfAMAI ectodomain
Unlike a number of other malarial antigens, AMA1 does not possess any of the tandem repeat 
motifs thought to act as a "smoke screen" to "distract" the immune system (Peterson et al., 
1989, Waters et al., 1991). However, several studies have highlighted the presence of 
polymorphic residues in the AMA1 ectodomain (Thomas et al., 1990; Oliveira et al., 1996). Most 
of these are the result of non-synonymous substitutions, meaning that mutations in the gene 
sequence give rise to amino acid residues that are different from those found in the original 
sequence. While the prevalence of non-synonymous substitutions in the sequence encoding the 
PfAMAI ectodomain indicates positive diversifying selection, the low abundance of synonymous 
substitutions may result instead from the limited availability of synonymous substitutions due to 
the biased codon usage observed in P. falciparum (Escalante et al., 1998b; Endo et al. 1996). 
However, the codon bias observed in P. reichenowi is comparable to that of P. falciparum, yet 
P. reichenowi exhibits more synonymous than non-synonymous substitution in its amal 
sequence (Kocken et al., 2000; Escalante et al., 2001; Polley and Conway, 2001). This 
suggests that the non-synonymous substitutions in the Pfamal sequence are under direct 
selection pressure from the host immune system.
1.8.3.2: AMA1 as the target of protective immune responses
That polymorphic residues in PfAMAI are the targets of protective immune responses is 
supported by both in vitro and field studies. Healer et al. (2004) generated transgenic P. 
falciparum parasite lines expressing heterologous Pfamal allelic forms. Using these transgenic 
lines they demonstrated conclusively the strain specificity of antibody (Ab) mediated invasion- 
inhibition in in vitro culture. In a study of P. falciparum patients from an area of endemic malaria 
in Papua New Guinea, Cortes et al. (2003) found an association between certain polymorphic 
residues on AMA1 and clinical disease in children but not in older individuals. They suggested 
that some residues are less immunogenic than others, thus requiring longer exposure for the 
development of an effective immune response. In a recent study, this group demonstrated that 
the age dependence of the prevalence and titre of anti-PfAMA1 Abs was paralleled by the 
development of protective immune responses (Cortes et al., 2005). They also observed an 
increase in prevalence of Abs directed against Dll and Dill with age, suggesting a role for Abs
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against these more highly conserved regions in immunity. However, the evidence of natural 
selection on polymorphisms in the AMA1 ectodomain (largely Dl) argues strongly for their being 
a target of protective immune responses.
1.8.3.3: The hyper-variable region of AMA1
Marshall et al. (1996) identified a hyper-variable region (HVR) within Dl of the PfAMAI 
ectodomain. They proposed that the allelic forms of Pfamal could be categorised into families 
based on the restriction fragment length polymorphisms (RFLP) of the HVRs amplified by PCR 
from the amal sequences of different strains of P. falciparum. Eisen et al. (1999) identified four 
Pfamal allelic families based on the PCR-RFLP method. This group suggested that in addition 
to polymorphisms resulting from point mutation, sequence variability also occurred as a result of 
intragenic recombination, as they identified a gene sequence containing polymorphisms 
diagnostic of two allelic families.
1.8.3.4: Domain bias of the protective immune response
Most non-synonymous substitutions are primarily found in the sequence encoding Dl (Verra and 
Hughes, 2000; Polley and Conway, 2001; Polley et al., 2003; Chesne-Seck et al. in press). 
These studies found evidence for balancing selection in Dl and Dill, but not Dll, suggesting that 
Dl and Dill, but not Dll, are targets for protective immune responses.
The recently solved crystal structure of Dl and Dll of the PfAMAI ectodomain shows all the 
polymorphic residues in this region to be surface exposed (Bai et al., 2005). This supports the 
notion that the polymorphic nature of these residues results from positive immune selection 
pressure. Comparisons between the P. falciparum AMA1 sequence and the crystal structure of 
the full-length ectodomain of PvAMAI, suggests this to be true within Dill as well (Pizarro et al., 
2005; Chesne-Seck et al. in press). In an extensive analysis of 356 PfAMAI published 
sequences, Chesne-Seck etal. (in press) identified 32 polymorphic sites in Dl, 11 in Dll and 9 in 
Dill, most of which are dimorphic. In the same study, analysis of 232 sequences covering Dl of 
PvAMAI led to the identification of 17 polymorphic sites, 10 of which are also polymorphic in 
PfAMAI. In addition, unlike the situation in PvAMAI, all but four of the polymorphic residues in 
Dl and Dll appear to be positioned down one face of the ectodomain, suggesting that only this 
face is exposed on the surface of the parasite (Chesne-Seck et al. in press; Bai et al. 2005). 
Thus, the non-polymorphic face either lies close to the merozoite membrane or interacts with 
some other parasite protein, in both cases being inaccessible to the host immune system. Due 
to the level of polymorphism observed in accessible regions of the PfAMAI ectodomain, it has 
been suggested that multiple allelic forms should be used in a vaccine to maximise the 
likelihood of generating a protective response.
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1.8.4: AMA1 as a vaccine candidate
1.8.4.1: The immunogenic nature of AMA1
The immunogenic nature of AMA1 supports its inclusion in a blood stage vaccine against 
malaria. Indeed, PkAMAI (or Pk66) was first identified because a monoclonal antibody (mAb) 
raised against it blocked merozoite invasion of RBC in vitro (Deans et al., 1982). Since then 
other mAbs, as well as their F(ab)2 and Fab fragments, have been identified that are invasion 
inhibitory (Thomas et al., 1984; Kocken et al., 1998b; Dutta et al., 2005). Furthermore, 
immunization of mice and monkeys with native or recombinant forms of AMA1 protects against 
homologous challenge (Deans et al., 1988; Collins et al., 1994; Crewther et al., 1996b; Anders 
et al., 1998; Narum et al., 2000; Hodder et al., 2001). Deans et al. (1988) immunised rhesus 
macaque monkeys with PkAMAI purified from parasites. After immunisation, the level of 
invasion inhibitory antibodies was high, but these diminished rapidly thereafter. After the first 
challenge most of the immunised monkeys required drug treatment to clear the parasitaemia. 
The monkeys were immunised a second time and then re-challenged. This time the pattern of 
infection was completely different, with all PkAMAI immunised monkeys showing solid 
immunity. Control monkeys, that had been drug cured following the primary infection, displayed 
a similar infection course to their first infection. This suggests that AMA1 is a potent immunogen 
that can prime the immune system and confer protection against otherwise lethal challenge.
A high prevalence of naturally induced Abs to AMA1 has been found in human populations 
living in malaria endemic regions (Thomas et al., 1994; Rodrigues et al., 2005). Furthermore, 
there appears to be a correlation between age and anti-AMA1 seropositivity, although this 
appears to show some regional variability, possibly related to the level of exposure (Thomas et 
al., 1994; Dorfman et al., 2005; Rodrigues et al., 2005). Rodrigues et al. (2005) found that 
individuals suffering a primary P. vivax infection had a significantly lower frequency of anti- 
AMA1 immunoglobulin G (IgG) - predominantly lgG1 - than individuals who had suffered 
previous infections. By comparison, no difference was observed in the frequency of AMA1 
specific IgM between these groups. Dorfman et al. (2005) demonstrated a deficiency of memory 
B-cells specific for PfAMAI in blood samples from individuals living in a malaria endemic region 
of Kenya. As memory B-cells are believed to be essential for long-term immunity in humans, this 
may explain the short-lived nature of the Ab response to this malaria antigen. Immunisation of 
mice with reduced and alkylated recombinant P. chabaudi AM A1 (PcAMAI) does not provide 
protection against subsequent P. chabaudi challenge (Crewther et al., 1996; Anders et al., 
1998). Furthermore, invasion inhibitory anti-PfAMA1 Abs do not recognise reduced and 
alkylated forms of PfAMAI (Kocken et al., 1998a; Dutta et al., 2002). This suggests that 
protective Abs recognise conformation dependent, reduction sensitive epitopes.
Passively transferred anti-PcAMA1 polyclonal Abs, modulate parasitaemia in challenged mice, 
protecting them against an otherwise lethal infection (Crewther et al., 1996). However, this
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protection is only demonstrated after homologous challenge. Challenge with a heterologous 
strain of P. chabaudi results in a full-blown infection. The amal sequences from these two 
parasite strains (DS and 556KA) differ by 55 codons, resulting in 36 amino acid substitutions, 21 
of which lie in the HVR in Dl (Crewther et al., 1996). Whether these particular polymorphisms 
are responsible for the strain specificity of this protection is unclear. Hodder et al. (2001) 
demonstrated that rabbit Abs raised against PfAMAI from the clone 3D7 were able to inhibit 
erythrocyte invasion by this parasite in vitro and, to a varying degree, other heterologous P. 
falciparum strains. Invasion by the closely related parasite strain D10 (differs in AMA1 sequence 
by only 8 amino acids) was more strongly inhibited by these Abs than the homologous 3D7 
parasites, while inhibition of the more distantly related strain HB3 (AMA1 sequences differ by 23 
amino acids) was less potent. There is clearly some degree of inhibitory Ab cross-reactivity 
between P. falciparum strains, which is not surprising considering that the PfAMAI sequences 
share 95% identity. One question that needs to be addressed is whether the potency of Abs 
against conserved regions of the molecule can be specifically enhanced to improve the "multi- 
strain1 efficacy of a vaccine.
In an extensive study of the immunogenicity of the PfAMAI ectodomain, Lalitha et al. (2004) 
demonstrated that domains I and II together (Dl-ll) induce growth/invasion inhibitory Abs in 
rabbits at a level about one third that induced by the full length ectodomain (Dl-lll). This study 
reported no invasion-inhibition with Abs raised against any of the individual domains alone or 
domains II and III combined (Dll-Ill) or I and III combined (Dl+lll). This raises the possibility that 
inhibitory Abs recognise epitopes that overlap more than one domain. Mueller et al. (2003) 
however, identified two peptides from within loop I of Dill that are recognised by certain mAbs 
that block erythrocyte invasion in vitro. These peptides were also recognised by hyper-immune 
serum from individuals in malaria endemic areas. Polley et al. (2004) attempted to identify the 
domains of PfAMAI responsible for protection by studying serum samples from individuals living 
in two areas of endemic malaria. They found that although Abs to Dill were rare, Dl-ll linked to 
the prodomain was less strongly associated with protection than Dl-lll. These findings, taken 
together, suggest that although Dill overall may not be highly immunogenic, there are certain, 
possibly cryptic, epitopes found in this region of the PfAMAI ectodomain that elicit protective Ab 
responses. A vaccine against malaria would seek to artificially enhance these responses.
1.8.4.2: Attempts to dissect the immune response against AM A 1
Burns et al. (2004) suggested that immunity induced by vaccination with AMA1 was Ab 
dependent. However, Ab responses induced by AMA1 based vaccines appear to be short lived 
(Deans et al., 1988; Pan et al., 2004). This is clearly a problem for any long-term AMA1 based 
vaccine strategy. Using the P. chabaudi system, Xu etal. (2000) demonstrated that Ab, induced 
after immunisation of mice with AMA1, was critical for controlling infection and preventing death. 
They also showed however, that CD4+ T-cells acted independently of Ab to help control 
parasitaemia. Attempts have been made to identify immuno-dominant and cryptic T-cell
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epitopes within the ectodomain of PfAMAI. Such epitopes may induce more potent, long-term 
immune responses than the intact molecule, within which they may be masked. In a vaccine, 
these epitopes could be combined to produce a tightly focussed immune response. Results 
from these studies have been mixed. Salvatore et al. (2002) identified two antigenic peptides 
from tryptic digestion of PcAMAI that contain effective epitopes for T-helper cells and B-cells in 
mice. However, these Abs are not protective in homologous P. chabaudi challenge. Lai et al. 
(1996) identified several T-cell determinants in PfAMAI using the amphipathic scores 
determined by a computer algorithm. Of these, six were demonstrated to induce proliferation of 
peripheral blood mononuclear cells from individuals with life-long malaria exposure but not from 
individuals not previously exposured to malaria. Three of these peptides represent highly 
conserved regions, which is of interest when considering a vaccine capable of transcending 
parasite strain differences although the protection conferred by these peptides was not 
determined. Amante et al. (1997) screened overlapping, 20-mer peptides from the entire 
PcAMAI sequence for the presence of immunodominant and cryptic T-cell epitopes. Ten 
peptides were identified as containing cryptic determinants. Two of these peptides (designated 
P4 and P5) contain a ten residue region of overlap, which contains the cryptic determinant and 
is conserved in AMA1 from all strains of P. chabaudi. These peptides are not recognised by 
mice immunised with recombinant PcAMAI. However, mice immunised with either of these 
peptides responded strongly to recombinant PcAMAI. Adoptive transfer of a T-cell line specific 
for peptide P4, but not P5, was able to aid the production of PcAMAI specific Abs in athymic 
(nude) mice following P. chabaudi challenge. Furthermore, adoptive transfer of T-cells specific 
for a pool of eleven peptides, that included P4 and P5, protected 50% of nude mice against 
lethal P. chabaudi infection. This study suggests that peptides containing putative T-cell 
determinants can be used successfully to prime an anti-AMA1/anti-parasite response.
1.8.4.3: Clinical and pre-clinical vaccination trials involving AMA1
Pre-clinical studies in rabbits assessing the efficacy of a PfAMAI based vaccine used 
recombinant PfAMAI from two strains of parasite (FVO and 3D7) expressed in the yeast Pichia 
pastoris (Kennedy et al., 2002). This study demonstrated Ab titres to both antigens to be high 
when administered alone or in combination. Effective growth inhibition was observed against the 
homologous strain in vitro but was reduced against the heterologous strain. In rabbits 
immunised with the antigens combined, the parasite growth-inhibitory properties of the induced 
Abs were not enhanced over that seen with Abs from sera of single antigen immunised animals 
tested against heterologous parasites. Phase 1 clinical trials to assess the safety and efficacy of 
a vaccine based on these two allelic forms of PfAMAI in formulation with the aluminium based 
adjuvant Alhydrogel in malaria naive human volunteers, showed it to be well tolerated (Malkin et 
al., 2005). Both allelic variants were comparably recognised. Furthermore, the Ab titre was 
found to correlate with the percentage invasion-inhibition in vitro, which ranged from 14 to 54%, 
both strains being inhibited equally. Phase 1 clinical trials have also been carried out using the 
refolded ectodomain of the 3D7 allelic form of PfAMAI following expression in E. coli (Saul et
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al., 2005). Potency and toxicity of the formulation (with adjuvant ISA720) were tested in mice. 
Unfortunately, the potency of the formulation decreased dramatically during the study and 
though 6 of the 29 malaria naive human volunteers seroconverted, Ab responses were 
generally very low and it was impossible to draw any meaningful conclusions from the study.
It is unlikely, considering the polymorphic nature of many malarial antigens, that a vaccine 
comprising a single subunit antigen will have long-term success. For this reason, many groups 
are considering AMA1 as a candidate in combination with other malaria blood stage antigens, 
particularly MSP1. Stowers et al. (2002) combined the FVO allelic form of PfAMAI, expressed 
in P. pastoris, with PfMSP142 from the same strain of parasite, this time expressed in a 
baculovirus system. This study assessed protection of this combination in Aotus vociferans 
monkeys. The Ab titre to the PfAMAI component of the vaccine, but not the PfMSP142 
component, correlated with protection. The overall efficacy of the vaccine was not significantly 
better than that for PfAMAI alone. Burns et al. (2004) assessed the efficacy of the response 
induced by different adjuvant formulations in a PcAMAI/PcMSP142 vaccine. A high level of 
protection was observed in mice immunised with an adjuvant Quil A formulation, using relatively 
low doses of antigen. When used alone, PcAMAI provided slightly more protection than 
PcMSP142, despite Ab titres being higher to PcMSP142. However, on challenge of immunised 
mice, the combined formulation resulted in a significantly greater reduction in peak parasitaemia 
over that seen with either antigen administered alone. In addition, these workers demonstrated 
that above a critical level, additional Ab was not accompanied by an increase in protection. This 
suggests that Ab levels alone are not absolutely reliable tools for determining protection against 
malaria. In an effort to better define the protective responses associated with either antigen, this 
group immunised immune-deficient mice with the Quil A formulations of these antigens (Burns 
et al., 2004). They deduced that while protection provided by PcAMAI was Ab dependent (as 
previously mentioned) PcMSP142 protection also required both Ab and cell mediated responses. 
This antigen combination should therefore induce both humoural and cell mediated responses 
to malaria, a requirement that has been reported previously, at least for clearance of P. 
chaba udi infection.
Pan et al. (2004) made a chimeric construct of PfAMAI Dill and PfMSP119, linked via a hinge 
region. Immunisation in rabbits with this construct induced high Ab titres to both antigens that 
inhibited parasite growth in vitro by over 95%. Immunisation of rhesus Macaca mulatta monkeys 
resulted in a strong Ab response to both antigens (Pan et al. 2004). The ability of serum from 
these monkeys to inhibit growth of P. falciparum parasites when cultured in vitro, correlated with 
the number of immunisations. A decrease in growth inhibition was observed only two months 
after the last immunisation though the reason for this was not determined. The group also 
reported proliferation of lymphocytes isolated from the immunised monkeys, in response to 
stimulation with this antigen. Whether this cellular response can function synergistically with Abs 
to this chimeric antigen and provide long-term immunity to malaria in vivo was not investigated.
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1.8.4.4: Alternative delivery systems
1.8.4.4.1: Vaccinia virus: Several groups have investigated the use of alternative delivery 
systems in the hope of promoting a long-lived immune response. Vaccinia virus induces broad 
and effective immune responses. The use of this as a delivery system for malarial antigens 
could help to boost the immune response in the recipient, while overcoming problems 
associated with storage, transport and delivery of recombinant protein based vaccines. Pye et 
al. (1991) attempted to construct a recombinant vaccinia virus against P. falciparum malaria, 
using the four P.falciparum blood stage antigens (Pf) ring associated erythrocyte surface 
antigen (PfRESA), PfMSPI, PfMSP2 and PfAMAI. Saimiri sciurus monkeys were immunised 
with vaccinia virus constructs expressing these antigens and were challenged with P. 
falciparum. Antibody titres to the four antigens increased to varying degrees post challenge (a 
good Ab response was observed to PfAMAI). However, no difference was observed in the 
course of infection between the immunised and control monkeys. This result suggested that the 
inability of this vaccine to provide protection may result from problems with the vector or with 
suboptimal expression of the foreign genes. In another study, the highly attenuated NYVAC 
strain of vaccinia virus was used (Tine et al., 1996). A malaria vaccine based on this strain has 
previously been shown to confer protection in experimental challenge (Lanar et al., 1996). 
Seven P. falciparum antigens were used in this study; PfCSP, P. falciparum sporozoite surface 
protein 2 (PfSSP2), PfMSPI, serine repeat antigen (SERA), PfAMAI, the 25 kDa sexual stage 
antigen Pfs25 and LSA1. These were inserted into the NYVAC vector to generate the construct 
NYVAC-Pf7. Expression of all of these malaria antigens was confirmed by immunoprecipitation 
from NYVAC-Pf7 infected HeLa cells. Immunisation of mice, rabbits and rhesus macaque 
monkeys resulted in no detectable adverse effects. Serum from immunised monkeys 
recognised antigens expressed in the different parasite stages. Identification of Abs directed 
against PfAMAI, PfLSAI and SERA was not carried out. However, Abs to PfCSP, PfSSP2, 
PfMSPI and Pfs25 were detected in all monkeys. The protective efficacy of this vaccine has yet 
to be determined.
1.8.4.4.2: DNA vaccines: These are promising tools for the simultaneous delivery of multiple 
antigens. Rogers et al. (1999) investigated the use of DNA vaccine technology for the delivery 
of four P. vivax antigens. This vaccine included two pre-erythrocytic stage antigens CSP 
(PvCSP) and SSP2 (PvSSP2) and the two erythrocytic stage antigens MSP1 (PvMSPI) and 
AMA1 (PvAMAI). Transient transfection in mammalian UM449 cells resulted in expression of all 
four antigens. Serum from mice immunised with the vaccine plasmids recognised sporozoites 
(PvCSP, PvSSP2 and PvAMAI) or infected erythrocytes (PvAMAI and PvMSPI) in 
immunofluorescence assay and in Western blot analysis. Sera from PvCSP immunised mice 
was unable to inhibit invasion of cultured hepatocytes by P. vivax sporozoites in an assay in 
which a protective anti-PvCSP mAb (NVS3) inhibited invasion by 90%. Nor did they recognise 
the amino acid motif AGDR, contained within the central repeat sequence of CSP, recognised 
by this mAb. Sera raised against PvAMAI did not recognise AMA1 from reduced sporozoite or
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infected erythrocyte protein extracts in Western blot. The ability of this conformation dependent 
antibody response to confer protection was not tested in this animal model. In a further study, 
Rogers et al. (2001) used the same four antigens, this time from P. knowlesi, in a prime-boost 
vaccine strategy. Macaca mulatta (rhesus) monkeys were immunised three times with plasmid 
DNA encoding the antigens. Six months after the final immunisation they were boosted with 
recombinant canarypox viruses encoding the four antigens. Only one monkey displayed 
complete protection after challenge with P. knowlesi sporozoites. Parasitaemia in the remaining 
immunised monkeys was significantly lower than that of the control group on days 9 to 12 post 
challenge. In contrast, the slopes of the parasitaemia curves, from patency to peak 
parasitaemia, did not differ significantly between the two groups. The group suggested that the 
limited protection observed in the immunised monkeys was probably directed against the pre- 
erythrocytic stages resulting in fewer liver stage schizonts completing their development. This 
would result in a lower initial blood stage infection and an extended pre-patent period. Why this 
strategy was unable to induce an effective immune response against the blood stage antigens 
used here is unclear. However it does highlight the fact that an ineffective pre-erythrocytic stage 
vaccine merely delays the detection of infection, but does not alter its final course. It is also 
worth noting that as AMA1 is expressed in merozoites as well as sporozoites, the protective 
response induced in these animals was unlikely to be induced by this antigen, unless AMA1 
function in these parasite stages is different.
One possible complication arising from the use of multi-component vaccines is that of antigenic 
competition. Instead of the components of a vaccine inducing an immune response that is 
equivalent to the sum of the responses induced to the antigens when used alone, antigenic 
competition results in the immune response to one antigen down-regulating the response to the 
other. Ideally, the individual immune responses within a multi-component vaccine should be at 
least as good as those induced when used alone. A study to investigate the antigenic 
competition between antigens expressed from DNA vaccine plasmids administered together, 
considered the three P. falciparum erythrocytic stage antigens PfAMAI, PfMSPI and EBA175 
(Jones et al., 2002). No antigenic competition was observed in the combined vaccine. In 
addition, the collective Ab activities of the trivalent vaccine gave a higher overall Ab titre in IFA 
than that resulting from immunisation with any of the antigens individually. Rainczuk et al.
(2004) have investigated the use of a bicistronic DNA delivery system for delivery of a PcAMAI 
and PcMSP4/5 based vaccine. This group suggest that a bicistronic vaccine expression system 
may increase the efficiency of antigen delivery and promote the likelihood of synergistic 
responses between the antigens. The system utilises an internal ribosome entry site positioned 
between the two coding sequences, allowing ribosome attachment and translation of the 
downstream sequence (Pfmspl fused to the monocyte chemotactic protein 3, MCP-3, coding 
sequence). Translation of the upstream sequence (Pfamat fused to a tissue plasminogen 
activator secretion signal) relies on cap-dependent mechanisms. Intra-muscular delivery of this 
vaccine enhanced survival of mice after challenge with 105 P. chabaudi infected erythrocytes.
26
The stimulation of splenocytes, isolated from immunised animals, with either recombinant 
antigen resulted in cell proliferation. The presence of MCP-3 fused to AMA1 would recruit 
dendritic cells to the site of antigen expression and enhance priming of naive T-cells by both 
antigens. This bicistronic DNA delivery system may prove to be a useful tool for the delivery of a 
multiple antigen malaria vaccine.
The weight of evidence suggests that while an Ab response to AMA1 is extremely potent 
against the malaria parasite, it is short lived. Indeed, field studies suggest that Ab responses to 
blood stage antigens in general are short lived (Cavanagh et al., 1998; Giha et al., 1999). To 
overcome this problem a vaccine must be designed either to primarily include T-cell 
determinants from the AMA1 ectodomain or to combine AMA1 with some other parasite antigen 
that primarily induces a cellular response. In view of the polymorphic nature of many malaria 
antigens, a combination of these two approaches would probably give the best wide-ranging, 
long-term results. However, the more components included in a vaccine increase not only the 
cost but also the difficulty of ensuring minimal batch variability. The target population for a 
malaria vaccine is largely the developing world; therefore, the expense of a multi-component 
vaccine could prove prohibitive.
1.8.5: Function of AMA1 in invasion
The function of AMA1 in host cell invasion is unknown. As discussed earlier, proteins residing in 
the micronemes of apicomplexan parasites are thought to be involved in parasite attachment to 
host cells and tight junction formation. Its localisation within the micronemes of Plasmodium 
merozoites and sporozoites, as well as Babesia merozoites and Toxoplasma tachyzoites 
indicates a role for AMA1 at this stage in the process. Furthermore, the inability to disrupt the 
gene encoding PfAMAI indicates that its function is essential for parasite survival.
1.8.5.1: RBC Binding
In apicomplexan parasites, micronemes appear largely to house parasite adhesins involved in 
host cell binding and tight junction formation (Adams et al., 1990; Kaneko et al., 2000; Mayer et 
al., 2001; Gilberger et al., 2003b). Each of the cysteine rich domains (M1 and M2) of MAEBL, 
show sequence identity to Dl-ll of AMA1 (Hodder et al., 1996; Kappe et al., 1998a). The MAEBL 
domains M1 and M2 have been demonstrated to bind erythrocytes (Kappe et al., 1998a). 
Together, these findings have led this, and other, group(s) to suggest that AMA1 is involved in 
RBC binding. Peptides derived from PfAMAI bind human erythrocyte and block merozoite 
invasion (Urquiza et al., 2000; Salazar et al., 2002; Cubillos et al., 2002). Replacement of the 
amal gene in P. falciparum parasites with that of P. chabaudi, by reverse genetics, partially 
complemented the function of PfAMAI, but crucially, enhanced the invasive capability of these 
parasites for murine erythrocytes (Triglia et al., 2000). Thus, AMA1 must play a direct role in 
determining host cell specificity. In addition, in the presence of the rat mAb (R31C2) against
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PkAMAI that inhibits P. knowlesi invasion of rhesus erythrocytes, there is formation of the initial 
long-range (12 nm) attachment between the parasite and erythrocyte membranes, however, the 
intimate interaction (4 nm) resulting from tight junction formation does not form (Mitchell et al., 
2004). Expression of P. yoelii AMA1 (PyAMAI) Dl-ll and to a significantly lesser extent the full- 
length ectodomain, on the surface of COS-7 cells facilitated the binding of rodent but not human 
erythrocytes to these cells (Fraser et al., 2001). By contrast, Kato et al. (2005) demonstrated 
binding of Dill of PfAMAI, expressed on the surface of CHO cells, to trypsin treated human 
erythrocytes although Dl-ll and the full-length ectodomain did not bind. However, in contrast to 
all these results using recombinant protein, the PfAMAI shed forms from P. falciparum 
parasites cultured in vitro failed to bind human erythrocytes (Howell et al., 2001; E. Knuepfer, 
personal communication).
1.8.5.2: Re-localisation o f AMA1 on the merozoite surface
The cytoplasmic tail of PfAMAI is highly conserved across all Plasmodium species suggesting 
that it has an essential, conserved function. Howell et al. (2001) proposed that the cytoplasmic 
tail of AMA1 interacts with an actomyosin motor at the merozoite surface in a manner similar to 
that described for the T. gondii tachyzoite microneme protein 2 (MIC2) (Carruthers and Sibley, 
1997) and the Plasmodium sporozoite protein thrombospondin-related anonymous protein 
(TRAP) (Kappe et al., 1999; Matuschewski et al., 2002). After secretion from the microneme, 
both MIC2 and TRAP are capped in a cytochalasin D sensitive manner towards the parasite’s 
posterior end, before being proteolytically cleaved from the surface. The capping of these 
proteins from the anterior to posterior end of the parasite is thought to be responsible for 
propulsion of the parasite during gliding motility and invasion (Kappe et al., 1999). Cytochalasin 
D inhibits actin polymerisation. The sensitivity of MIC2 and TRAP capping to cytochalasin D 
implicates the actomyosin motor in these processes. In contrast, redistribution of PfAMAI 
across the merozoite surface is unaffected by cytochalasin D at levels that block merozoite 
invasion of erythrocytes (Howell et al., 2003a). This suggests the involvement of an alternative 
cytoskeletal motor. Alternatively, AMA1 may redistribute across the parasite surface simply by 
diffusion, which is consistent with its circumferential distribution in free merozoites. If the C- 
terminus of the molecule is not involved in interaction with the actomyosin motor its conserved 
nature suggests that it is involved in some alternative, conserved invasion related process.
1.8.5.3: Signal transduction
The degree of homology within the cytoplasmic tail of AMA1 across apicomplexan taxa is not so 
conserved as between Plasmodium species (Hehl et al., 2000, Gaffar et al. 2005) and this 
region in TgAMAI and BbAMAI differs considerably from Plasmodium AMA1. However, one of 
two terminal tyrosine residues (positions Y621 and Y622 in PfAMAI), a SFW motif (position 
601-603 in PfAMAI) and a threonine residue (position T613 of PfAMAI), all of which are 
absolutely conserved in AMA1 across Plasmodium, are also conserved in TgAMAI. Of these, 
only the W603 and T613 (in the P. falciparum sequence) are conserved in BbAMAI. However,
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Y585 and S610 that are conserved in AMA1 from all Plasmodium species are also conserved in 
BbAMAI. Tyrosine, serine and threonine residues are potential candidates for phosphorylation. 
The abundance of such conserved residues in the cytoplasmic tail could support the putative 
involvement of AMA1 in signal transduction (Waters et al., 1990). Mass spectrometric analysis 
of PfAMAI derived from late stage schizonts (Howell et al., 2001) and immunoprecipitation of 
[35S] methionine metabolically labelled schizonts, using an anti-phosphotyrosine mAb (Narum 
and Thomas, 1994b) has indicated that the terminal tyrosine residues do not undergo 
phosphorylation at this stage of the parasite life cycle. This does not rule out the possibility that 
these residues participate in signal transduction during merozoite invasion of host erythrocytes 
and that phosphorylation occurs only after merozoites release from schizonts. Detection of the 
cytoplasmic tail of PfAMAI in ring stage parasites indicates that it is taken into the RBC with the 
merozoite (Narum and Thomas, 1994b; Howell et al., 2005). It is possible that these residues 
are phosphorylated and function in the early intra-erythrocytic stage of development.
1.9. Aims of this project
The main aim of this project was to attempt to characterise the function of this essential parasite 
molecule. This relied on the use of recombinant protein expressed in heterologous eukaryotic 
systems. The conformation of these recombinant forms was assessed using the mAb 4G2dc1 
(4G2dc1 expressing hybridoma cells were the kind gift of Alan Thomas, Biomedical Primate 
Research Centre, The Netherlands) that recognises a conformation dependent, reduction 
sensitive epitope in the ectodomain of PfAMAI (Kocken et al., 1998a).
The assertion that AMA1 participates in erythrocyte invasion by mediating host cell recognition 
and binding was investigated using the system adopted by (Fraser et al., 2001). The ectodomain 
of PfAMAI was expressed on the surface of COS-7 cells with its cognate transmembrane and 
cytoplasmic domains. It was predicted that the presence of the transmembrane and cytoplasmic 
domains would ensure the presentation of the molecule in the correct orientation on the cell 
surface. The erythrocyte binding potential of the PfAMAI ectodomain was further investigated 
using the soluble, Pichia pastoris expressed ectodomain immobilised on a solid support. The 
requirement for other parasite proteins in AMA1 mediated erythrocyte binding was assessed by 
immunoprecipitation of PfAMAI from highly segmented schizonts and merozoites, using the mAb 
4G2dc1. Partner proteins should be co-precipitated.
In an attempt to identify the functionally important region(s) of the PfAMAI ectodomain, the 
epitope recognised by the rat mAb 4G2dc1, that also inhibits invasion of human erythrocytes by 
P. falciparum merozoites, was characterised (Kocken et al., 1998a). Antibody molecules are large 
(about 160 kDa), thus, invasion-inhibition may result from non-specific steric hindrance. However, 
the epitope recognised by 4G2dc1 may be located within a region of AMA1 that is important for its 
function. To distinguish between these two possibilities, it was necessary to determine the effects
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of the 4G2 Fab fragments on invasion, since steric hindrance of AMA1 function should be 
reduced with this Ab fragment. The epitope recognised by this mAb lies within Dl-ll of the PfAMAI 
ectodomain (Lalitha et al., 2004). In the current study, site directed mutagenesis was performed 
within this region of the ectodomain in an attempt to specifically disrupt 4G2dc1 recognition, 
without altering the overall architecture of the molecule. The mutant forms, expressed in COS-7 
cells, were assessed for mAb 4G2dc1 recognition.
Microneme (Carruthers et al., 1999a) and rhoptry (Mital et al., 2005) secretion during host cell 
invasion by apicomplexan parasites requires signal transduction across the parasites plasma 
membrane. The role of AMA1 in this process was assessed by investigation of the 
phosphorylation status of the PfAMAI cytoplasmic tail in segmented schizonts and free 
merozoites. Parasites lysates were examined in Western blot analysis, using antibodies specific 
for phospho-serine, -threonine or -tyrosine.
All protein expression in this study relied on the use of a synthetic Pfamal gene (sgPfamal) 
designed for use in the methylotrophic yeast P. pastoris by Kocken et al. (2002). A full description 
of this gene can be found in section 6.1. Several amino acid substitutions were introduced in 
designing this gene, and it was therefore desirable to assess the functionality of this gene in P. 
falciparum. Plasmid vectors were designed for single or double homologous recombination into 
the P. falciparum genome, to replace the endogenous Pfamal gene with a haemagglutinin (HA) 
epitope tagged version of sgPfamal (sgPfamal/HA). Integration was assessed by Southern blot 
analysis and indirect immunofluorescence analysis of segmented schizonts and merozoites. 
Furthermore, the effect of the HA epitope tag on protein expression and function was assessed 
by integration of the tag into the endogenous Pfama 1 gene sequence.
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Table 1.1: Summary of several key apical organelle proteins, their location and any 
features or functions currently identified.
Antigen Organ. Suggested Function(s)/Features
RAP1 R Member of low molecular weight (LMW) complex. Involved in targeting 
of LMW complex to rhoptries. Non-essential for blood-stage growth 
(Howard et al., 1998; Baldi et al., 2000)
RAP2 R Member of a LMW complex. Targeting to rhoptries can be disrupted by 
knock-out of the rap1 gene (Baldi et al., 2000).
RAP3 R Member of a LMW complex.
RhopHI R Member of a high molecular weight (HMW) complex.
RhopH2 R Member of a HMW complex.
RhopH3 R Member of a HMW complex. Binds RBC components and may be 
inserted into RBC plasma membrane (Sam-Yellowe et al., 1988; Sam- 
Yellowe and Perkins, 1991; Ndengele et al., 1995; Doury et al., 1997).
MAEBL R Erythrocyte binding protein. Expression can be disrupted without 
effecting blood-stage growth, but prevents infection of salivary glands by 
mid-gut sporozoites in the mosquito. (Kappe et al., 1998a; Noe and 
Adams, 1998; Fu et al., 2005)
AMA1 M Possible function in RBC binding, reorientation, specificity of host cell 
recognition. Essential for blood-stage growth (Kappe et al., 1998a; 
Triglia et al., 2000; Fraser et al., 2001; Mitchell et al., 2004; Triglia et al. 
2001,).
EBA-175 M Possible function in tight junction formation. Binds sialic acid on 
glycophorin A on RBC surface. Non-essential for blood-stage growth 
(Sim et al., 1990; Adams et al., 1992; Orlandi et al., 1992; Kaneko et al., 
2000; Reed et al., 2000).
BAEBL M Erythrocyte binding protein. Binds Glycophorin C on RBC surface. 
(Mayer et al., 2001; Narum et al., 2002)
DBPs M Tight junction formation in P. vivax and P. knowlesi. Binds Duffy blood 
group antigen on Duffy positive erythrocytes. (Miller et al., 1975; Miller 
etal., 1976; Haynes et al., 1988; Horuk et al., 1993)
SUB2 M Subtilisin-like serine protease. MSP1 and AMA1 sheddase. (Hackett et 
al., 1999; Barale et al., 1999; Howell et al., 2003a)
SUB1 DG Subtilisin-like serine protease. Minimal recognition sequence VXXD, 
physiological substrate unknown. (Blackman et al., 1998 ; Sajid et al., 
2000 ; Jean et al., 2003)
RESA DG Associates with spectrin in erythrocyte cytoskeleton in newly invaded 
rings. (Foley et al., 1991; Da Silva et al., 1994)
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Figure 1.1: Host cell invasion by the Plasmodium merozoite
(1) When the Plasmodium merozoite contacts a host erythrocyte, an initial weak interaction 
occurs between the parasite and the host cell membranes that may be mediated by parasite 
surface proteins. The parasite then reorientates, by a parasite driven or random process, until 
its apical end is in contact with the erythrocyte membrane. (2) A tight junction forms at the point 
of contact, irreversibly committing the parasite to RBC invasion. Proteins secreted from the 
micronemes may be involved in parasite reorientation and tight junction formation. (3) The RBC 
plasma membrane invaginates at the point of tight junction formation and the parasite is 
internalised in a parasite actinomyosin motor driven process. Parasite penetration of the host 
cell is coupled with the active redistribution or capping of apical organellar proteins towards the 
posterior of the parasite. A key feature of apicomplexan invasion is the shedding of parasite 
surface proteins by a tight junction-associated parasite protease. By comparison, invasion 
proteins accumulate in the tight junction and extra-cellular surface and are shed from the 
posterior end of the parasite when invasion in nearly complete. The rhoptry organelles release 
their contents into the developing parasitophorous vacuole (PV) and may be involved in 
modification of the PV membrane. As the parasite enters the host cell, the tight junction 
migrates in an anterior to posterior direction around the parasite surface, maintaining contact 
with the two membranes. When the parasite is completely internalised, the erythrocyte 
plasmalemma pinches off behind the parasite, enclosing it within the PV. Dense granule 
proteins may not be directly involved in the invasion process, but in P. knowlesi dense granules 
have been shown to release their contents by exocytosis into the PV. This event occurs 
concomitantly with the localised enlargement of the PVM, in which finger like projections 
protrude from the PVM extending into the erythrocyte cytoplasm. Host cell invasion by other 
apicomplexan protozoa, shares many of the key features of Plasmodium invasion.
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Figure 1.2: The life cycle of Plasmodium falciparum parasites
Male (micro-) and female (macro-) gameocytes are taken up by the female Anopheles mosquito 
in a blood meal. The drop in pH and temperature in the mosquito midgut triggers 
gametogenesis. Microgametocytes undergo a process of maturation known as exflagellation to 
generate microgametes, while macrogametocytes mature to form macrogametes. (1) The male 
and female gametes fuse to form the diploid zygote, which matures to form the ookinete. This 
penetrates the midgut wall and develops in the area between the endothelium and the basal 
lamina, to form the oocyst. (2) Within the oocysts, haploid sporoblasts undergo numerous 
rounds of nuclear divisions, producing thousands of midgut sporozoites (sporogony). The 
oocysts rupture, releasing the sporozoites which then migrate to the mosquito salivary gland 
ducts.
The mosquito injects salivary gland sporozoites into the blood stream of the vertebrate host 
during the next blood meal. From there the sporozoites migrate to the liver, where they invade 
parenchyma cells, beginning the cycle of exoerythrocytic (pre-erythrocytic) schizogony. (3) Here 
the sporozoites develop into liver trophozoites (feeding stages) and ultimately schizonts, 
undergoing multiple rounds of nuclear replication and division, producing thousands of 
merozoites. The liver schizont ruptures, releasing the merozoites into the blood stream, where 
they invade erythrocytes, and so begins the erythrocytic schizogonic cycle (4). The erythrocytic 
stage of the parasite life cycle is responsible for the pathology of the disease and for this reason 
is of greatest clinical significance. This stage of the life cycle is also the focus of this study and 
for this reason it will be considered in greater detail later (Fig 1.3). During the erythrocytic cycle, 
some merozoites invading erythrocytes deviate from this pathway and differentiate into micro- or 
macrogametocytes that move to the peripheral circulation from where they can infect feeding 
mosquitoes.
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Figure 1.3: The erythrocytic cycle
(A) Within the erythrocyte, the parasite develops through ring (1), trophozoite (2) and schizont 
stages (3a and b), undergoing several rounds of nuclear replication and division, to produce 8 - 
24 merozoites (3b) per schizont, depending on the parasite species. Nuclear division appears to 
be fairly relaxed, and deviations from these figures are not unusual. The erythrocytic schizont 
ruptures (4) releasing the merozoites into the blood stream where they invade fresh 
erythrocytes (5) and the cycle repeats. Merozoites are free in the circulation for a brief period 
between schizont rupture and reinvasion and during this period they are vulnerable to 
chemotherapeutic intervention and immune attack. Thus, the merozoite is of particular interest 
as a drug target and in vaccine design.
(B) The P. falciparum blood stage merozoite is about 1.6 pm long and 1.0 pm wide. This 
parasite stage exhibits a clearly polarised morphology. Three classes of secretory organelles 
are found apically located, the rhoptries, micronemes and dense granules. The two pear shaped 
rhoptries are about 650 nm long and 300 nm wide at their widest part. The micronemes are 
more numerous (about 40 per merozoite) but these elongated organelles are only about 120 nm 
by 40 nm and cluster around the rhoptry neck. The dense granules are located in the apical 
cytoplasm and are about 80 nm in diameter. Secretion from all of these organelles is tightly 
regulated during the invasion process. The nucleus adopts a basal location. The plasma 
membrane is connected via filamentous cross-bridges to two additional membranes, together 
forming the pellicle. Running down the length of the parasite are two (sometimes three) sub- 
pellicular microtubules that play an essential role in the invasion process. Three polar rings are 
positioned at the apical tip of the parasite, the third of which anchors the microtubules at their 
apical end. Towards the apical end of the parasite are a plastid (apicoplast) and a single 
mitochondrion that lie beneath the band of microtubules, the plastid being attached to them. In 
addition, numerous free ribosomes are also located towards the apical end, ready for the 
required burst of protein synthesis by the parasite immediately after invasion.
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Figure 1.4: Schematic representation of the PfAMAI domain structure and disulphide 
bond pattern
PfAMAI is comprised of an N-terminal signal peptide (SP) that is responsible for targeting 
AMA1 to the secretory pathway. In P. falciparum this is followed by a prodomain (PD), though 
this is absent in other species of Plasmodium with the exception of P. reichenowi. The 
ectodomain is subdivided into three domains (Dl, Dll, Dill) based on the disulphide bond pattern 
that has been identified. This type I integral membrane protein has a 21 amino acid 
transmembrane domain (TD), followed by a 55 amino acid C-terminal cytoplasmic tail (CT).
Sixteen cysteine residues are found in the ectodomain of Plasmodium AMA1, all of which are 
involved in disulphide bond formation. Three disulphide bonds are found in Dl, two in Dll and 
three in Dill. These are linked:
Dl:
1) C149-C302 (C1-C6)
2) C217-C247 (C2-C3)
3) C263-C275 (C4-C5)
Dll:
4) C320-C418 (C7-C10)
5) C337-C409 (C8-C9)
DIM:
6) C443-C502 (C11-C14)
7) C490-C507 (C12-C15)
8) C492-C509 (C13-C16)
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SP - signal peptide
PD - pro-domain
Dl - domain I
Dll - domain II
DIM - domain III
TM - transmembrane domain
CT - cytoplasmic tail
Figure 1.5: Schematic representation of PfAMAI proteolytic processing
PfAMAI localises to the micronemes of developing merozoites. Before release from the 
micronemes it is proteolytically processed to remove the N-terminal prodomain after Ser96 (1) 
and subsequently relocalises onto the parasite surface (2). One third of PfAMAI molecules 
undergo an additional processing event within DIM after Asn464 (3) to produce two fragments 
that are held together by a disulphide bond (Cys443-Cys502) in Dill. Finally, during the invasion 
process the molecule is proteolytically shed from the surface by a parasite protease (SUB2) 
which cleaves after Thr517.
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Chapter 2
Materials and methods
2.1: Molecular biology: DNA production and amplification
2.1.1: P. falciparum amal sequence used
A synthetic Pfamal gene (sgPfamal), designed to replace the A+T-rich codon usage of P. 
falciparum strain FVO with that of the methylotrophic yeast Pichia pastoris, was used for all 
expression work (Withers-Martinez et al., 1999). The sequence encoding six potential N- 
glycosylation sites were replaced with sequences encoding amino acid residues found in AMA1 
from other Plasmodium species. These residues are not glycosylated in P. falciparum (Kocken 
et al., 1998b).
2.1.2: Vectors 
2.1.2.1: Cloning vectors:
Vector pMOSBlue (Amersham Bioscience) was used as an intermediate vector to clone and 
amplify PCR products. PCR products were cloned and sequenced prior to transfer to other 
vectors for expression or parasite transfection.
2.1.2.2: Expression vectors:
(i) The mammalian expression vector pSecTag2a (Invitrogen) was used for expression of 
recombinant PfAMAI (rPfAMAI) in SV40 transformed African green monkey kidney fibroblast 
cells (COS-7) cells. In all constructs, the full-length sgPfamal sequence, or regions of it 
encoding portions of the PfAMAI ectodomain, was placed downstream of the vector-encoded 
Igx secretory signal sequence.
(ii) A construct comprising the pRE4 plasmid containing the herpes symplex virus type I 
glycoprotein D (HSVgDI) signal peptide and transmembrane domain fused to region II of the P. 
vivax Duffy binding protein (PvDBP) was a kind gift of C. E. Chitnis (Malaria Research Group, 
International Centre for Genetic Engineering and Biotechnology, New Delhi India). This 
construct was used to transfect COS-7 cells, acting as a positive control for erythrocyte binding 
assays (resetting).
(iii) The pPIC9k vector (Invitrogen) was used for expression of the following PfAMAI 
ectodomains: domain I (referred to as Dl hereafter), domains I and II (referred to hereafter as 
Dl-ll) and domains I, II and III (referred to as Dl-lll hereafter), in Pichia pastoris strain KM71H
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(Muts phenotype) (Fig 2.1) All were derived from sgPfamal, and were supplied by Chrislaine 
Wit hers-Martinez (Division of Parasitology, NIMR). The appropriate ectodomain sequence was 
inserted downstream of the vector-encoded a-factor secretory signal to allow secretion of the 
recombinant protein into the culture supernatant.
2.1.2.3: Parasite transfection plasmids:
(i) The pHAM-ACPGFP vector (kindly donated by Julie Healer, the Walter and Eliza Hall 
Institute, Melbourne, Australia) contains acyl carrier protein-green fluorescent protein (ACPGFP) 
under the control of the Pfamal promoter and P.bergei DT 3’ UTR. The ACPGFP coding 
sequence was replaced with that of sgPfamal, for construction of a sgPfamal expression 
cassette. This expression cassette was used for analysis of sgPfamal function in P. falciparum 
parasites.
(ii) The pHH1 transfection plasmid (Reed et al., 2000) was used for construction of a plasmid for 
episomal expression of sgPfamal and for single cross over integration plasmids designed to 
regenerate the endogenous Pfamal gene or to replace it with sgPfamal. This plasmid contains 
the human dihydrofolate reductase (hdhfi) selection cassette. This confers resistance on 
transfected parasites to the antifolate drug WR99210 (Jacobus Pharmaceuticals).
(iii) The pHH-TK plasmid was used to construct a transfection plasmid to replace the 
endogenous Pfamal gene with the sgPfamal expression cassette by double cross-over events. 
This plasmid contains the positive selection cassette hdhfr and the thymidine kinase (tk) 
negative selection cassette. Thymidine kinase (TK) confers parasites susceptible to the drug 
ganciclovir. In the presence of WR99210 and gancyclovir, only parasites that have undergone a 
double cross-over event and lost the tk gene while retaining the hdhfr gene will survive.
2.1.3: DNA modification and manipulation: 
2.1.3.1: Restriction enzymes and buffers:
Restriction enzymes and buffers (Roche or NEB) were used according to the manufacturer's 
instructions. All restriction digestion products were purified using either a QIAquick® PCR 
purification kit, if there was only a single recoverable fragment, or a QIAquick® gel purification 
kit, when there were multiple fragments of recoverable size (both kits were supplied by Qiagen).
2.1.3.2: Formation of blunt end linear DNA:
Blunt end formation from complementary DNA ends was achieved using either the Klenow 
fragment of DNA polymerase (Roche), that has 3’ to 5’ exonuclease activity, or mung bean 
exonuclease (Promega), for 5’ to 3’ exonuclease activity. Both enzymes were used according to 
the manufacturer's instructions. To remove 3’ overhangs and fill in 5’ overhangs for blunt end
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formation, T4 DNA polymerase (New England Biolabs, NEB) was also used according to the 
manufacturer's instructions.
2.1.3.3: Ligation:
Prior to ligation all vectors were alkaline phosphatase (Roche) treated to prevent religation, 
according to the manufacture's instructions and purified using a QIAquick® PCR purification kit 
(Qiagen). Ligations involving restriction enzyme modified DNA or Klenow blunt ended DNA, 
were carried out using a Rapid DNA ligation kit according to the manufacturer’s instructions 
(Roche).
2.1.3.4.: Polymerase Chain Reaction (PCR)
Oligonucleotide primers were obtained from Eurogentec Oswel. PCR for the amplification of 
sgPfamal was carried out using AmpliTaq® DNA polymerase (Roche), or cloned Pfu 
polymerase (Stratagene) according to the respective manufacturer’s instructions. PCR for the 
amplification of P. falciparum genomic DNA was performed using PLATINUM® Taq High Fidelity 
DNA polymerase (Invitrogen) or Pfu Turbo® DNA polymerase (Stratagene) according to the 
manufacturer’s instructions. These enzymes have higher stringency proof reading facilities and 
therefore amplify this A+T rich DNA more reliably. PCR reactions were carried out in a 
ThermoHybaid Omn-E PCR machine.
Cloning involving unmodified PCR products was carried out using the pMOSBlue blunt ended 
cloning kit, according to the manufacturer’s instructions (Amersham Bioscience).
All PCR products were purified using a QIAquick® PCR purification kit (Qiagen) according to the 
manufacturer’s instructions.
2.1.3.5: Automated sequencing:
Cloned DNA was sequenced using the BigDye™ Terminator v1.1 cycle sequencing kit 
according to the manufacturer’s instructions (Applied Biosystems). The amplification step was 
carried out in a ThermoHybaid Omn-E PCR machine using a program of 25 cycles of: 96°C for 
45 s, 50°C for 30 s and 60°C for 2 min. Samples (20 pi) were ethanol precipitated by incubating 
for 1 hour in 50 pi 95% ethanol and 2 pi 3 M sodium acetate followed by centrifugation at 13,000 
rpm in a micro-centrifuge (Biofuge pico Heraeus) for 20 min. The supernatant was discarded 
and the DNA washed in 500 pi 70% ethanol and centrifuged at 13,000 rpm for a further 5 min. 
The DNA pellet was dried by heating at 90°C for 3 min before resuspension in 10 pi 
MegaBACE™ loading solution (Amersham Bioscience). The sample was loaded onto a 
MegaBACE™ sequencing machine (Amersham Bioscience) using an injection voltage of 3 kV 
and injection run time of 40 s. The sample run was carried out at 9kV for 200 min.
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2.1.3.6: Site directed mutagenesis (SDM)
SDM was carried out using the QuikChange® Site-Directed Mutagenesis Kit (Stratagene). For 
cloning purposes this technique was used to introduce restriction sites into, or remove restriction 
sites from the Pfamal coding sequence. The coding sequence was modified in such a way that 
the primary amino acid sequence was either unaltered or resulted in conservative amino acid 
substitutions.
SDM was used to alter the primary amino acid sequence and secondary structure of PfAMAI to 
specifically disrupt recognition of the protein by the mAb 4G2dc1 (see section 2.4.1).
In order to systematically disrupt the disulphide bonds (DBs) in Dl-ll in the pSec/sg’Pfamal 
plasmid (2.4.1.1), the codon for the first cysteine of each bond was replaced with the codon for 
alanine (TGC -» GCC or TGT -> GCT) using SDM. This gave rise to the plasmids 
pSec/sg’Pfa1AsDB1 - pSec/sg’Pfa1 AsDB5. However, any expressed protein encoded by such a 
sequence would contain a free, reactive sulphydryl group (S-H), which may interfere with the 
folding of the protein. The second cysteine in each of the disulphide bonds in Dl-ll was 
subsequently replaced with alanine to stabilise the molecule, giving rise to the plasmids 
pSec/sg’Pfa1AdDB1 - pSec/sg’Pfal AdDB5.
Analysis of the PfAMAI Dl-ll primary sequence using JNet (Cuff and Barton, 2000) and Emini 
(Emini et al. 1985) algorithms, identified a large number of amino acid side chains predicted to 
be solvent accessible. Residues with the highest predicted solvent accessibility were analysed 
by SDM. Contiguous groups of residues were mutated primarily to alanine (e.g. XXX/AAA). 
Where an effect was observed on the subsequent reactivity with 4G2dc1, individual residues in 
the group were mutated either to alanine, or to a residue found in the analogous position of 
AMA1 sequence from another species of Plasmodium.
2.1.3.7: Bacterial strains (E. coli)
Sub-cloning efficiency DH5a™ competent cells (Invitrogen) were used for general cloning 
purposes with constructs intended for COS-7 cell expression. These cells were also used for 
amplification of parasite transfection plasmids. For increased cloning efficiency in the generation 
of random mutant libraries, "library efficiency" DH5a™ competent cells (Invitrogen) were used.
MOSBlue competent cells were used for cloning and amplification of PCR products, ligated into 
the pMOSB/ue vector (competent cells and vector from Amersham Bioscience).
A+T rich P. falciparum sequences are often found to be unstable in E. coli. This instability can 
usually be overcome by the use of PMC-103 competent cells (kindly provided by Rebecca 
O’Donnell) for the initial cloning steps. However, in this study DH5a™ competent cells were
45
found to give more reliable results, with higher DNA yields and therefore this was the preferred 
bacterial strain for cloning.
2.1.3.8: Transformation of E. coli
Transformation of plasmid DNA into DH5a™ and MOSBlue competent cells was carried out 
according to the manufacturer’s instructions. PMC-103 competent cells were transformed by 
adding DNA to 100 jul of competent cells and incubating them on ice for 1 hour. The cells were 
then heat-shock treated at 42°C for 45 sec before being returned to ice for 2 minutes. 50 pi 
Luria broth was added to the cells and the mixture was incubated in a shaking incubator (New 
Brunswick Scientific, Innova 4000) for 1 hour at 37°C. The cells were then plated on Luria agar 
plates containing 50 pg mr1Ampicillin (Sigma).
2.1.3.9: Plasmid DNA preparation
Bacteria were grown overnight in Terrific broth for maximal bacterial yields. Plasmid DNA was 
then harvested using S.N.A.P. miniprep kits (Invitrogen) according to the manufacturer’s 
instructions. DNA produced by this method was used for cloning, sequencing and for 
transfection of COS-7 cells. DNA for transfection into P. falciparum parasites was harvested 
using HiSpeed® plasmid Maxi kits, according to the manufacturers’ instructions (Qiagen). DNA 
yield and purity were determined using a spectrophotometer (UNICAM - UV1). DNA was then 
ethanol precipitated and resuspended in Tris-EDTA buffer (TE), pH 8.0, to a final concentration 
of 2.3 - 3.3 pg ml'1.
2.1.3.10: Genomic DNA extraction and plasmid recovery from P. falciparum parasites
DNA was extracted from 500 pi of parasitized erythrocytes containing 5% trophozoite/schizont 
stage parasites. To lyse the red blood cells (RBC), erythrocyte pellets (approximately 400 pi 
parasitised blood) were resuspended in 800 pi of 0.15% Saponin (BDH). Parasites were 
recovered by centrifugation at 13,000 rpm in a micro-centrifuge (MSE -  Micro Centaur). 
Parasite pellets were resuspended in 4 x volume of Buffer A (see Appendix) and 1 x volume of 
18% SDS was added to solubilise the parasites. This mixture was incubated at room 
temperature for 2 min. DNA was extracted by adding an equal volume of phenol chloroform 
(Sigma), vortexing to mix and centrifuging at 13,000 rpm in an micro-centrifuge (Heraeus -  
Biofuge pico) for 2 min. The aqueous phase was removed to a clean tube and the extraction 
repeated. DNA was then ethanol precipitated by adding 3 x volumes of absolute ethanol and 
1/10th volume of 3 M sodium acetate. The sample was vortexed to mix and incubated at -70°C 
for 20 min. The sample was centrifuged for 20 min, the supernatant removed and the pellet 
washed in 250 pi 70% ethanol. This was centrifuged for a further 5 min, the supernatant 
removed and the pellet air dried, before being resuspended in 200 pi TE, pH 8.0 (see 
Appendix).
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Plasmid DNA recovered from transfection line parasites by this method was cloned back into E. 
coli DH5a™ competent cells and tested by restriction digestion for rearrangements.
2.1.4: Plasmid construction
Oligonucleotide primers for all constructs are shown in Table 2.1.
2.1.4.1: Construction of pSec/sg’Pfamal for surface expression in COS-7 cells
The sgPfamal gene was previously cloned into the EcoRI site in the cloning vector pMOSBlue 
(called FIM252, kindly provided by Fiona Hackett, NIMR). This construct contains the full 
synthetic gene sequence of Pfamal encoding the N-terminal signal sequence and prodomain 
through to the C-terminal cytoplasmic tail. In P. falciparum, the signal sequence and prodomain 
are proteolytically removed from the rest of the protein before it is released onto the parasite 
surface. Thus, to simulate this situation with COS-7 cell surface expression, we only required 
the coding sequence downstream of the prodomain i.e. from the beginning of domain I (Dl, 
amino acid sequence 97IEIVE...) through to the cytoplasmic tail (amino acid sequence 
...MEKPYY622).
2.1.4.1.1: Removal of the Pfamal signal peptide and prodomain. The 5’ region of sgPfamal 
was removed from FIM252 by restriction digestion with Xba\ (this enzyme cleaves within the 
vector, upstream of the sgPfamal start site) and Afl\I (which cleaves within domain I). The 5’ 
region of Dl was amplified by PCR, using oligonucleotides AMAforl and synthetic gene 
oligonucleotide 78 (see table 2.1. below). AMAforl was designed to introduce a Xba\ site 
(shown in bold in table 2.1) for sub-cloning into XbaMAflW digested FIM252, followed by a Sma\ 
site (highlighted in bold and underlined respectively in table 2.1) at the 5’ end of Dl. 
Oligonucleotide 78 is downstream of the Afl\I site in Dl. The PCR product was digested with 
Xba\ and Afl\\ before cloning back into pre-digested FIM252 to give the intermediate plasmid 
pMOS/sg’Pfamal.
2.1.4.1.2: Cloning of sg1 Pfamal into pSecTag2A. The expression vector pSecTag2A was 
digested with SfH and blunt ended. This linearised vector was further digested with EcoRI. The 
sg’Pfamal coding sequence was excised from the plasmid pMOS/sg’Pfamal by restriction 
digestion with Sma\ (blunt ended digestion) and EcoRI. Gel purification of sg’Pfamal and 
ligation into pre-digested pSecTag2a gave the plasmid pSec/sg’Pfamal (Fig 2.1.).
2.1.4.2: Construction of pSec/sg’Di
This construct was designed for the expression of PfAMAI Dl in COS-7 cells. The 3’ half of Dl 
was amplified by PCR from the plasmid pSec/sg’Pfamal, using the synthetic gene 
oligonucleotide 17 and Domlrev. Oligonucleotide 17 is upstream of the unique Sacll site in the 
plasmid. The reverse primer was designed to introduce an EcoRI site (in bold) for cloning
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purposes, preceded by a stop codon (underlined) to be incorporated at the 3’ end of Dl. The 
plasmid pSec/sg’Pfamal was digested with restriction enzymes Sacll and EcoRI, thus excising 
the sgPfamal coding sequence from the downstream 3’ half of Dl. The PCR product was also 
digested with Sacll and EcoRI and ligated into pre-digested pSec/sg’Pfamal. This resulted in 
the formation of the construct pSec/sg’DI (Fig 2.2.).
2.1.4.3: Construction of pSec/sgPfaADI
This construct was designed for expression of sg’PfAMAI lacking Dl. The starting plasmid was 
pSecAPsfl/sg’Pfa (generated for making the random mutant library, Section 2.1.4.7.) because 
the process of excising the Pst I site from the vector also resulted in the loss of both EcoRI and 
EcoRV sites. SDM was used in two steps to introduce EcoRV sites (in bold) at the 5’ and 3’ 
ends of sequence encoding PfAMAI Dl in the plasmid pSecAPstl/sg’Pfa, using primers 
DI5’EcoRVf, DI5’EcoRVr, DI3’EcoRVf and DI3’EcoRVr. The resulting plasmid, sg’Pfa/EcoRV3’- 
5’DI, was digested with EcoRV to excise Dl and the vector backbone re-ligated to give the 
plasmid pSec/sgPfaADI (Fig 2.3. A).
2.1.4.4: Construction of pSec/sg’PfaADII
This construct was designed for the expression of PfAMAI lacking Dll. For this purpose Kpn\ 
sites were introduced by SDM at the 5’ and 3’ ends of the sg’Pfamal sequence encoding Dll in 
the plasmid pSecAPstl/sg’Pfa, using the primers DII5’Kpnlfor, Dl 15’Kp/ilrev, DII3’Kpnlfor and 
DII3’Kp/7lrev. Dl was then excised from the resulting plasmid, sg’Pfa/Kpnl5’-3’DII, using these 
Kpn\ sites and the vector re-ligated to give the plasmid pSec/sg’PfaADII (Fig 2.3. B).
2.1.4.5: Construction of pSec/sgPfaADHI
This construct was designed for expression of PfAMAI Dill with its transmembrane domain and 
cytoplasmic tail. A Kpn\ site (highlighted in bold) was introduced by SDM at the 5' end of the 
sequence encoding Dl using the primers DI5'Kpnlf and DI5'Kpnlr. The intermediate plasmid 
from section 2.1.4.4 with a Kpn\ site at the 3' end of the Dll coding sequence was used as the 
template, giving the plasmid sg’Pfa/Kpnl5'DI-3’DII, with Kpn\ sites flanking the coding sequence 
for Dl-ll. The plasmid was digested with Kpn\, thus removing the sequence encoding Dl-ll and 
the plasmid religated to give pSec/sgPfaADI-ll (Fig 2.3. C).
2.1.4.6: Construction of pSec/tr1-sgPfamal and pSec/tr2-sgPfama1
Two constructs were designed in which the 3’ region of sg’Pfamal was truncated up to the 
sequence prior to that encoding the first cysteine residue in Dl. The first truncation (T1) left the 
sequence encoding three native amino acid residues upstream of the first cysteine (SGKCt...), 
while the second truncation (T2) left the sequence encoding eleven such amino acid residues 
(AGTQYRLPSGKCi...). An EcoRV site (in bold) was introduced at the 5’ end of the sequence 
encoding Dl in the plasmid pSecAPstl/sg’Pfa, using the primers EcoRVDIfor and EcoRVDIrev. 
In both cases a further EcoRV site (in bold) was introduced into the appropriate position, using
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the primers Tr1 EcoRVf and Tr1 EcoRVr or Tr2EcoRVf and Tr2EcoRVr. The 5’ region of the gene 
was then excised via these EcoRV sites and the resulting plasmid backbones re-ligated back 
together, giving the plasmids pSec/tr1-sgPfamal and pSec/tr2-sgPfamal (Fig 2.4 a and b).
2.1.4.7: Construction of a pSecAPstl/sg’Pfa random mutant library
2.1.4.7.1: Removal of the PstI site from the pSecTag2a vector backbone. The plasmid 
pSec/sg’Pfamal was digested with EcoRI and EcoRV. Both restriction enzymes cleave within 
the vector just downstream of sg’Pfamal, flanking a Pst\ site, thus digestion with these enzymes 
excises this site from the vector backbone. The plasmid was blunt ended with the Klenow 
fragment of DNA polymerase and re-ligated. This resulted in the plasmid pSecAPstl/sg’Pfa. 
There is a unique PstI site at the 3’ end of sgPfamal sequence encoding domain II (Dll) of 
PfAMAI. Removal of the PstI site from the vector backbone allows the use of this site for 
subcloning purposes.
2.1.4.7.2: Cloning of sequence encoding Dl-ll random mutants. The plasmid pSecAPstl/sg’Pfa 
was digested with Xcm\ and Psfl, thus excising the sequence of sgPfamal encoding Dl-ll. The 
synthetic gene oligonucleotides 8 and 58 (see table 2.1), were used to amplify Dl-ll of sgPfamal 
under random mutagenic conditions. PCR conditions were selected to produce an average of 5 
point mutations every 1 kb. Reaction conditions were: 10 mM Tris.CI, 50 mM KCI, 7 or 9 mM 
MgCI2) 1 mM dCTP, 1 mM dTTP, 0.2 mM dATP, 0.2 mM dGTP, 2 pM 5' primer, 2 pM 3' primer, 
20 pg pi'1 template DNA, 0.5 mM MnCI2 and 0.05 U pi'1 Taq DNA polymerase. The PCR 
conditions were as follows: 94°C for 3 min followed by 58°C for 45 s, 72°C for 2 min and 94°C 
for 45 s repeated for 29 cycles with a 10 minute extension time at 72°C. PCR products were 
digested with Xcm\ and Psfl. The digestion products were gel-purified and ligated into XcmMPstS 
digested pSec/sg’Pfamal. In order to generate a library of random mutant forms of 
pSec/sg’Pfamal, E. coli transformed with the ligation mixture were grown directly in liquid 
culture. The library of sg’Pfamal random mutants obtained after plasmid recovery from E. coli 
was called sg’Pfal RML (Fig 2.5.).
2.1.4.8: Construction of pHH1-3’Pfama1
This construct was designed for integration into the 3’ region of Pfamal coding sequence of P. 
falciparum parasite strain 3D7, thus regenerating the Pfamal gene.
The 3’ coding region of Pfamal was amplified from P. falciparum strain T9/96 genomic DNA 
(kindly provided by Fiona Hackett) using primers 3D7-3’-900f and 3D7-3’-900r. These were 
designed to introduce 5’ Bgl\\ and 3’ Xho\ sites respectively (highlighted in bold). The Xho\ site 
in the reverse primer is immediately downstream of the TAA stop codon. The PCR product was 
cloned into pMOSE/ue (called pMOS/3’Pfamal) and subsequently digested with Bgl\\ and Xho\ 
and gel purified. The SERA4 gene was excised from the plasmid pHH1-pSERA4 (Miller et al., 
2000) using Bgl\\ and Xho\ and the vector backbone was gel purified. The Bgl\\/Xho\ digested 3’
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region of Pfamal was then ligated into the pHH1 vector backbone to produce plasmid pHH1- 
3’Pfama1 (Fig 2.6.).
2.1.4.9: Construction of pHH1-Pfa/HA
This construct was designed for integration into the Pfamal coding sequence in order to 
introduce a single haemagglutinin (HA) epitope tag (YPYDVPDYA) into the region of the gene 
just upstream of the transmembrane coding region. The gene sequence from 46bp downstream 
of the start codon was amplified to increase the likelihood of integration occurring upstream of 
the HA tag.
2.1.4.9.1: Amplifying the Pfamal coding sequence. The Pfamal gene was amplified by PCR 
from T9/96 P. falciparum genomic DNA using the primers 3D7-5’-for and 3D7-3’-900r (see 
above). The forward primer allows amplification from 46bp downstream of the Pfamal start 
codon and was designed to insert a Bgl\\ site (highlighted in bold) at the 5’ end of the amplified 
product for cloning purposes. The resulting PCR product was cloned into pMOSBIue (called 
pMOS/T9/96 Pfamal).
2.1.4.9.2: Introducing the HA epitope tag into the Pfamal gene. The HA epitope tag was 
introduced into the Pfamal coding sequence by SDM in a two-step process. The second half of 
the tag was introduced first using the primers 3D7HA2ndf and 3D7HA2ndr. Once this was 
successfully achieved, the first half of the HA tag was introduced using the primers 3D7HAflfor 
and 3D7HAflrev. This gave rise to the plasmid pMOS/Pfa/HA. The plasmid was digested with 
Bgl\\ and Xho\ and the insert purified by gel extraction. This was ligated into Bgl\\/Xho\ digested 
pHH1-pSERA4 vector backbone, previously digested for the construction of pHH1-3’Pfama1 
and resulted in the plasmid pHH1 -Pfa/HA (Fig 2.7.).
2.1.4.10: Construction of pHAM-sgPfa/HA
This construct was designed for episomal expression of HA-tagged sgPfamal, under the control 
of the Pfamal promoter and the 3’ termination sequence of the P. berghei DHFR-thymidylate 
synthase (DHFR-TS) gene (PbDT3’). Utilising the Pfamal promoter should ensure expression 
at the correct point in the parasite life cycle.
2.1.4.10.1: Removal of the Xho I site in sgPfamal. The Xho\ site in the region of sgPfamal 
encoding Dl of PfAMAI was removed by SDM of pSec/sg1 Pfamal, without altering the amino 
acid sequence encoded by the gene (the DNA sequences CTCGAG and CTGGAA both encode 
amino acid residues LE). SDM was carried out using the primers AXfrolfor and AXholrev giving 
the plasmid pSec/sg1 PfaAX.
2.1.4.10.2: Insertion of the HA epitope tag into the stub region of sgPfamal. The HA epitope tag 
was introduced into sgPfamal in the plasmid pSec/sg'PfaAX in two steps as for the
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endogenous gene. The second half of the tag was introduced first using the primers 
sgPfA2ndHAf and sgPfA2ndHAr. The primers sgPfAflHAf and sgPfAflHAr were then used to 
introduce the first half of the HA epitope tag giving the plasmid pSec/sg'PfaAX/HA. The region of 
sg'Pfamal from which the Xho\ site had been removed, and into which the HA epitope tag had 
been introduced, was subcloned into FIM252 via Kspl and Stu\ restriction sites giving rise to the 
plasmid pMOS/sgPfaAA/HA.
2.1.4.10.3: Cloning of sgPfamal into pHAM-ACPGFP. The modified sgPfamal was amplified 
from pMOS/sgPfaAX/HA by PCR using the primers 5’sgPfama1f and 3’sgPfama1r. These 
primers were designed to introduce Xho\ sites (highlighted in bold) at either end of the synthetic 
gene for cloning purposes. The PCR product was digested with Xho\ and purified. The vector 
pHAM-ACPGFP was digested with Xho\ to excise the ACPGFP fragment and the vector 
backbone (pHAMAACPGFP) alkaline phosphatase treated and PCR purified. The modified 
sgPfamal PCR product was ligated into pHAMAACPGFP, generating the plasmid pHAM- 
sgPfa/HA (Fig 2.8.).
2.1.4.11: Construction of pHH1-5’-sgPfa/HA
This construct was designed to integrate into the 5’ coding sequence of Pfamal, thus disrupting 
the endogenous amal gene and replacing it with the HA tagged synthetic gene sequence.
2.1.4.11.1: Amplification and cloning of the Pfamal 5’ coding sequence. The Pfamal 5’ coding 
sequence was amplified by PCR from T9/96 P. falciparum genomic DNA, using the primers 
3D7-5’-for (used for construction of pHH1-Pfamal/HA) and 3D7-5’-rev. The resulting PCR 
product was cloned into the pMOSBlue vector giving pMOS/5’Pfamal. This plasmid was 
digested with Bgl\\ and Xho\ to remove the 5’ Pfamal coding sequence and this fragment gel 
extracted and ligated into Bgl\\/Xho\ digested pHH1-pSera4 (prepared for construction of pHH1- 
3’Pfama1). This gives the plasmid pHH1-5’Pfama1. This plasmid was digested with Xho\ to 
linearise it and was subsequently blunt ended using T4 DNA Polymerase and alkaline 
phosphatase treated. The plasmid was PCR purified between steps and after the alkaline 
phosphatase treatment.
2.1.4.11.2: Cloning the sgPfamal expression cassette into pHH1-5Pfama. The sgPfamal 
expression cassette, consisting of the sgPfamal, flanked 5’ and 3’ by Pfamal 5’ UTR and 
PbDT3’ UTR respectively, was excised from the plasmid pHAM-sgPfa/HA by digestion with 
Hind\\\ and Not1. The expression cassette was blunt ended with T4 DNA Polymerase and ligated 
into pHH1-5’Pfama1 (previously blunt ended), downstream of the 5’ Pfamal coding sequence, 
thus producing the plasmid pHH1-5’-sgPfa/HA (Fig 2.9.).
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2.1.4.12: Construction of pHTK-sgPfa/HA
This construct was designed for double cross-over integration into the parasite genome on 
either side of the Pfamal coding sequence, thus excising the endogenous PfamaA gene and 
replacing it with the sgPfamal expression cassette.
2.1.4.12.1: Amplification and Cloning of the Pfamal 3’ UTR. The Pfama 1 3’ UTR was amplified 
from T9/96 genomic DNA by PCR using the primers Pfa1-3’UTRf and Pfa1-3’UTRr. The primers 
were designed to introduce Nco I and Bin I (Avr II) restriction sites at the 5’ and 3’ ends of the 
PCR product respectively. The amplified product was cloned into pMOSBlue (giving the plasmid 
pMOS-Pfa3') for amplification and then excised using Nco I and Bin I. The transfection plasmid 
pHHT-TK was also digested with Nco I and Bin I and the 3’ UTR fragment ligated into it to give 
the plasmid pHTK-Pfa3’.
2.1.4.12.2: Cloning the sgPfamal expression cassette into pHTK-Pfa3\ The pHTK-Pfa3’ 
plasmid was digested with the restriction enzymes Spe I and blunt ended using T4 DNA 
Polymerase. The sgPfamal expression cassette, prepared for cloning into pHH1-5’Pfama1, was 
ligated into pHTK-Pfa3’ to produce the plasmid pHTK-sgPfa/HA (Fig 2.10.).
2.1.5: Southern blot analysis 
2.1.5.1: DNA preparation and transfer
To produce suitable sized DNA fragments for analysis by Southern blot, DNA recovered from 
transgenic parasite lines was digested with restriction enzymes. Digested DNA was 
electrophoresed in 0.7% agarose gel (BioRad laboratories) containing 0.5 pg ml'1 ethidium 
bromide (BioRad laboratories) for 2 hours at 50 V. The gel was then exposed to UV on a 
transilluminator (UVP - BioDoc-lt™ System) for 5 min to nick the DNA, thus increasing the 
efficiency of the transfer. The gel was incubated in denaturing buffer (0.5 M NaOH, 0.75 M 
NaCI) for 1 hour, rinsed in double-distilled water (ddH20) and incubated for a further hour in 
neutralising solution (0.5 M Tris-HCl, pH 7.4, 0.75 M NaCI). The DNA was transferred to a 
Hybond N+ membrane (Amersham Biosciences), overnight by capillary transfer (Sambrook 
1989).
2.1.5.2: Labelling and hybridisation
The membrane was pre-hybridised for 20 min in hybridisation solution (6 x SSC [1X SSC is 
150mM NaCI, 15 mM Na citrate pH7] 5 x Denhardts [0.1% Bovine serum albumin, 0.1% Ficoll, 
0.1% polyvinylpyrrolidone], 0.5% SDS, 0.01 mg ml'1 salmon sperm DNA) at 62°C. Meanwhile, 
the probe was labelled with a-[32P] adenine triphosphate (dATP) (Amersham Biosciences) by 
random priming (Feinberg and Vogelstein, 1983), using a Prime-lt® II Random Prime Labelling 
kit (Stratagene) according to the manufacturer’s instructions. Unincorporated nucleotides were 
removed using ProbeQuant™ G-50 Micro Columns according to the manufacturer’s instructions
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(Amersham Biosciences). The labelled probe was then added to the hybridisation buffer in the 
hybridisation tube and incubated with the membrane overnight at 62°C. The probe was 
removed and the membrane washed three times in 2 x SSC for 20 min at 62°C. The bound 
probe was visualised by autoradiography, using Kodak® BioMax™ MR film, following incubation 
at -70°C.
2.2: Culture and manipulation of parasites 
2.2.1: In vitro culture of P. falciparum parasites
Plasmodium falciparum clone 3D7 parasites (supplied by M. Grainger, NIMR) were cultured and 
synchronised by modifying the methods described by Trager and Jensen (1976) and Lambros 
and Vanderberg (1979). Briefly, parasites were cultured in plastic tissue culture flasks (Nunc™) 
at approximately 10% parasitaemia and 1 - 4% haematocrit. The culture medium was replaced 
every 2 - 3 days at which time the cultures were also gassed (7% C 02, 5% 0 2, 88% N2). 
Parasite thin films were stained for light microscopic examination using 10% (v/v) Giemsa (Gurr) 
stain (BDH) in phosphate buffer pH 7.2 (43 mM KH2P04, 211 mM N2HP04).
2.2.2: In vitro synchronisation of P. falciparum parasites
Mature stage P. falciparum 3D7 parasites were isolated using a 70% Percoll density gradient as 
described by Rivadeneira et al., (1983). The immature trophozoites, rings and uninfected red 
blood cells (RBCs) in the pellet were discarded while the late trophozoites and schizonts floating 
on the top of the cushion were collected and incubated with fresh RBCs for 2 hours at 37°C in a 
G24 incubator shaker (New Brunswick Scientific) to allow reinvasion. The cultures were further 
synchronised using 5% D-sorbitol, as described by (Lambros and Vanderberg, 1979; Trager 
and Jensen, 1976). This procedure preferentially lyses erythrocytes containing late stage 
parasites (late trophozoites and schizonts), selecting for young ring stages. The parasites were 
returned to culture or used as required.
2.2.3: Parasite preparation for immunochemical analysis 
2.2.3.1: Purification of late trophozoites and schizonts
Mature stage parasites were isolated from mixed parasite culture on a 70% Percoll cushion, as 
described by (Trager and Jensen, 1976) washed in RPMI-1640 (Invitrogen) and frozen directly 
at -70°C. Alternatively the parasite pellet was treated with 1.5 volumes 0.15% (w/v) saponin, 
centrifuged in a micro-centrifuge and the pellets frozen until required. Merozoite preparations 
were made by culturing purified mature stage parasites with RPMI-Albumax (Invitrogen) 
supplemented with 2 mM L- glutamine and 5 mM EGTA, in the absence of fresh RBCs, for 3-5 
hours at 37°C to allow schizont rupture and merozoite release. The merozoites were harvested 
by centrifugation at 2000 rpm (Sorval TT7) and frozen at -70°C.
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2.2.3.2: Purification of ring stage parasites
Mature stage parasites were purified from a tightly synchronous culture of 3D7 parasites. The 
parasites were incubated for 2 hours with a 4-fold excess of RBCs, at 4% haematocrit, in a 
shaker incubator at 37°C to allow reinvasion. The resulting ring stage parasites were purified 
twice on a 70% Percoll cushion to remove all intact late stage parasites. The resulting purified 
ring stage parasites were washed in 50 ml RPMI-Albumax and subsequently used in RBC 
binding assays. This generated a tightly synchronous culture of parasites at about 85% 
parasitaemia.
2.2.4: Preparation of drugs used for selection of transfected parasites
WR99210 (Jacobus Pharmaceuticals) was made up as a 20 mM stock solution in dimethly 
sulphoxide (DMSO, Sigma) and stored in aliquots at -20°C. This stock solution was diluted to 
20 pM in RPMI-1640 and stored for use at +4°C. WR99210 was used as previously described 
(Duraisingh 2002). Ganciclovir (Sigma) was made up as a 2 mM stock solution in ddH20  and 
aliquots stored at -20°C for use in culture.
2.2.5: Parasite transfection
P. falciparum 3D7 ring stage parasites at approximately 1% parasitaemia were transfected as 
previously described (Wu et al., 1995) (Crabb and Cowman, 1996) (Crabb et al., 1997) 
(Duraisingh et al., 2002). Briefly, 80-100 pg ethanol precipitated DNA was dissolved in 200 pi of 
incomplete cytomix (120 mM KCI, 0.15 mM CaCI2, 2 mM EDTA, 5 mM MgCI2, 10 mM 
K2HP0 4 /KH2P0 4, 25 mM N-[2-hydroxyethyl]piperaxine-N’-[2-ethanesulfonic acid] (HEPES), pH 
7.6) and the DNA added to 200 pi parasitised RBCs. The mixture was transferred to a 0.2 cm 
electroporation cuvette (Bio Rad) and electroporated using a Bio-Rad Gene Pulser Xcell™ 
Electroporation System under conditions of 310 V and 960 pF (Fidock and Wellems, 1997). The 
electroporation mixture was transferred to an 80 cm2 culture flask (Nunc™) containing 25 ml 
RPMI-1640 medium supplemented with 25 mM HEPES, 200 pL hypoxanthine, 20 pg ml'1 
gentamicin, 0.25% (w/v) Albumax II, 0.2% NaHC03, pH 6.72, 2 mM L-glutamine and 5% AB+ 
human serum and fresh RBCs at 0.8% haematocrit.
The culture medium was changed daily for three days after transfection, to remove debris 
resulting from cell lysis and every other day thereafter. Parasites were cultured for 48 hours 
post-transfection before the addition of WR99210, at a final concentration of 10 nM. From this 
point onwards, drug pressure was maintained until parasites were detected. Fourteen days 
post-transfection (and every 14 days thereafter) parasite cultures were diluted 1 in 2 with 
medium containing fresh RBC at a 0.8% haematocrit. Following the detection of transfected 
parasites (generally about 4 weeks after transfection) parasites were cultured for 3 weeks in the 
absence of drug, followed by drug replacement. Drug pressure was maintained until parasites
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were again detected. Repeated cycles in the absence (and then presence) of drug were used to 
enrich the parasite population for parasites with integrated plasmid forms. Once WR99210 
resistant parasites were established, parasite lines requiring negative selection (for double cross 
over) were fed with media containing 10 nM WR99210 and 180 pM Ganciclovir. The integration 
of plasmid DNA into the parasite genome by homologous recombination was assessed by 
Southern blot analysis.
2.2.6: Invasion-inhibition assay:
Mature schizont stage parasites were isolated from a tightly synchronous culture of P. 
falciparum (3D7) as described above. The parasites were added to culture medium containing 
RBCs at 2% haematocrit to give a 10% parasitaemia.
Purified mAb 4G2dc1 or 4G2dc1 Fab (2.4.5.2.) was dialysed in Phospahate buffered saline 
(PBS) or desalted using a PD10 desalting column (Amersham Biosciences), eluted in PBS and 
filter sterilised. Varying concentrations of purified Ab or Fab were placed in 0.5 ml eppendorf 
tubes. Volumes were made up to 50 pi with sterile PBS to maintain a constant final volume.
The concentrations of Abs used in the invsion inhibition assays are shown in table 2.2. To each 
of the Ab preparations described, 100 pi of the prepared parasite culture was added. The 
cultures were incubated at 37°C on a rotating arm for 4 hours. Thin smears were made from the 
parasite cultures and stained with Giemsa’s stain. The number of invasion events per 104 RBCs 
was counted for each treatment condition.
2.2.7: Assay to determine whether 4G2dc1 Fab invasion-inhibition is blocked by 
rPf AMA1:
Recombinant PfAMAI Dl-lll expressed in P. pastoris (kindly provided by Mike Blackman) was 
purified and concentrated in a Vivaspin 500 pi concentrator with a 10 kDa molecular weight 
(MW) cut-off membrane (Vivascience). Prior to determining the effect of rPfAMAI Dl-ll on 
4G2dc1 Fab invasion-inhibition, the ability of mAb 4G2dc1 Fab to stabily bind rPfAMAI Dl-ll 
was assessed. Recombinant PfAMAI Dl-ll was incubated for 15 minutes on ice, at a 10 fold 
excess, with mAb 4G2dc1 Fab (50 pg and 2.4 pg, respectively). The mixture was run on a high 
performance liquid chromatography (HPLC) gel filtration column G300 SWXL (TSK) in 0.1 M 
phosphate buffer, pH 7.0. Equivalent amounts of rPfAMAI Dl-ll and 4G2dc1 Fab were run 
separately under identical conditions.
P. falciparum mature stage parasites were prepared at 10% parasitaemia, 2% haematocrit as 
described above. The 4G2dc1 Fab, with or without rPfAMAI Dl-lll (concentrations shown in 
table 2.3) was incubated for 20 min at 4°C in 0.5 ml eppendorf tubes in a total volume of 50 pi
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(made up with PBS).To each tube was added 100 pi of culture medium, containing RBCs at 2% 
haematocrit with 10% mature schizonts. Cultures were incubated and merozoite reinvasion 
assessed on thin smears as before (2.2.6).
2.3: Expression systems
2.3.1: COS-7 cell culture and transfection
COS-7 cells, adapted for growth in serum-free medium (Invitrogen) were cultured in Dulbecco's 
Modified Eagle's Medium (DMEM, Invitrogen), supplemented with 10% Ultra low IgG Foetal calf 
serum (FCS) (Invitrogen), 80 pg ml'1 L-glutamine and 50 U ml'1 penicillin/streptomycin (Sigma). 
Cells were cultured in 175 cm2 tissue culture flasks (Nunc™) and incubated at 37°C in 5% C02 
and grown until nearly confluent (about 1 x 107 cells per flask) before passage. Cells were 
harvested for passage using 5 ml 0.25% trypsin/EDTA (Sigma). Trypsin activity was neutralised 
using a two-fold excess of COS-7 cell culture medium.
Cells were transfected, according to the manufacturer’s instructions, using 6 pi Fugene 6 
(Roche) and 3 pg plasmid DNA in 6 well plates (Nunc™) (1.2 - 1.8 x 105 cells per well). For 
immunofluorescence assays (IFA), coverslips were placed in the bottom of the wells before 
adding COS-7 cells. Cells were harvested 48 hours post transfection. For Western blot analysis 
the cells were harvested by scraping whereas for antibody selection assays the cells were 
harvested using 200 pi 0.25% trypsin.
2.3.2: Pichia pastoris expression system 
2.3.2.1: Small-scale expression
A P. pastoris clone for expression of rPfAMAI Dl-ll (glycerol stock) was used to inoculate 25 ml 
BMGY (1% yeast extract, 2% peptone, 100 mM potassium phosphate, pFI6.0, 1.34% yeast 
nitrogen base, 4 x 10"5% biotin, 1% glycerol) in a 250 ml flasks and was incubated at 30°C in an 
incubator shaker (Innova 4000, New Brunswick Scientific) at 250 - 300 rpm, until the culture 
reached OD60o = 2-6 (16 - 18 hours). Cultures were centrifuged at 3000 rpm for 5 minutes 
(Centaur 2) the supernatant removed and the pellet resuspended to OD600 = 1 in BMMY (as for 
BMGY, with 0.5% methanol replacing the 1% glycerol). Methanol was added to a final 
concentration of 0.5% (v/v) every 24 hrs to maintain induction. Samples (1 ml) were taken at 24 
h intervals and the cells centrifuged at 3200 rpm for 1 minute (IEC MicroMax). The cell pellet 
and supernatant were frozen separately at -70°C.
2.3.2.2: Large-scale expression
Two 500 ml flasks, each containing 50 ml BMGY, were inoculated with a P. pastoris clone and 
incubated at 30°C for 24 hours as described for small-scale expression. Cultures were then
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expanded to 2 x 200 ml in 2 L flasks, incubated for a further 24 hours, pooled and their ODeoo 
measured. Cells were centrifuged at 4000 rpm (Beckman J6B) for 10 minutes and the cell pellet 
resuspended to OD600 = 3 in BMMY with chymostatin (2 pg ml'1) and methanol (1% v/v). The 
cells were divided between 2 L flasks (200 ml per flask) and grown as for small-scale 
expression, methanol being added every 8 hours to 1% (v/v).
2.3.3. Culturing of the 4G2 hybridoma cell line
Hybridoma cells were grown in 80 cm2 tissue culture flasks in 50 ml DMEM supplemented with 
10% Ultra low IgG FCS, 80 pg ml'1 L-glutamine and 50 U ml'1 penicillin/streptomycin. This was 
used to inoculate a 20 L culture (in the large-scale facility, NIMR) the culture supernatant of 
which was harvested, concentrated and filtered using a 22 pm filter unit. NaN3 was added to 
0.02% (w/v).
2.4: Immunochemical and biochemical methods 
2.4.1: Antibodies
The general properties of the primary Abs used in this study are outlined in Table 2.4.
The monoclonal antibody 4G2 recognises a reduction sensitive, conformational epitope in the 
ectodomain of PfAMAI. Culture supernatant of the 4G2 hybridoma (2.3.3.) was used in Western 
blots and indirect Immunofluorescence assays (IFA).
Mouse polyclonal antibodies against "native" (i.e. non-reduced) (N1) and reduced and alkylated 
(R1) recombinant PfAMAI (rPfAMAI) were raised by immunization of mice (a kind gift from Sue 
Fleck, MRCT) and used in Westerns and IFA. The polyclonal serum AdsN1 was generated by 
adsorbing the polyclonal serum N1 against reduced and alkylated rPfAMAI and has been 
shown in Western blot analysis (see Fig 4.19.) to recognise only reduction-sensitive epitopes 
within rPfAMAI.
Table 2.5 outlines the properties of the secondary Abs used in this study and table 2.6 
summaries the tertiary detection reagents used.
All antibodies were diluted in PBS or Tris buffered saline (TBS) with 1% (w/v) bovine serum 
albumin (BSA). Culture supernatants from hybridoma cells expressing 4G2dc1 and 12CA5 were 
used neat.
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2.4.2: Western blots
2.4.2.1: Basic Western blot analysis
COS-7 or P. pastoris cells were solubilised in 400 pi of 2X sodium dodecyl sulphate (SDS) 
sample buffer (1.51% Tris-base, 20% glycerol, 4.6% SDS, 1x10‘2% bromophenol blue) and cell 
supernatants were added at a ratio of 1:1 with 2X SDS sample buffer. Samples were 
electrophoresed on 10% or 12.5% SDS polyacrylamide gels (SDS-PAGE) (Laemmli 1970), 
under non-reducing or reducing conditions and then electrophoretically transferred to 
nitrocellulose membrane (Hybond-C extra, Amersham Biosciences) using a Trans-Blot™ Cell 
(Bio-Rad). Membranes were blocked in 5% milk in PBS containing 0.05% (v/v) Tween 20 for 30 
min. The antibodies used and the concentrations at which they were used are described in 
(Table 2.4 and 2.5). Samples from the immunoprecipitation of biotinylated (See section 2.4.4.1) 
parasite lysates were probed directly with Streptavidin-HRP polymer (Table 2.6). Bound 
antibody was detected using Enhanced Chemiluminescence solution (ECL) according to the 
manufacturer’s instructions (Perbio).
2.4.2.2: Western blots involving anti-phosphate antibodies
Western Blots to be probed with an anti-phosphate primary antibody were blocked in 5% BSA, 
rather than in 5% milk as many milk proteins are phosphorylated. Its use as a blocking agent 
would result in a high degree of non-specific binding by the anti-phosphate antibodies. Similarly, 
to reduce non-specific Ab binding, washes were performed in Tris buffered saline (TBS) 
containing 0.05% Tween 20 rather than PBS. All the antibodies used in these assays were 
diluted in TBS-Tween, 0.1% BSA and 0.02% sodium azide.
2.4.3: Indirect immunofluorescence assay (IFA)
IFAs were carried out on COS-7 cells grown on coverslips and either fixed with 100% acetone 
or left unfixed. Coverslips with unfixed COS-7 cells were handled with care to avoid dislodging 
the cells.
Sub-cellular localisation of transgenic proteins during the erythrocytic stages of the P. 
falciparum life cycle was analysed by IFA. P. falciparum thin smears were prepared from 
different life cycle stages and stored in the presence of silica gel dessicant (Sigma) at -70°C for 
future use. Prior to use, smears were fixed with ice cold 100% acetone or 80% acetone/20% 
methanol.
After antibody treatment the cells were stained with 4,6-diamidino-2-phenylindole (DAPI), for 
nuclear staining and Evans Blue, for cytoskeletal staining. Both COS-7 cell and parasite IFA 
preparations were mounted in Citifluor (Citifluor Ltd.) on slides and under coverslips respectively 
and the mounts sealed with nail varnish. Fluorescence labelling was detected using a Zeiss
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Axioplan 2 imaging system at 1000 x magnification. Images were captured using a Zeiss 
AxioCam HRc camera and AxioVision version 3.1 software.
2.4.4: Immunoprecipitation of PfAMAI from parasite lysate 
2.4.4.1: Biotin labelling
Merozoite samples were thawed directly into 1 ml PBS, 1mM EDTA and centrifuged at 13000 
rpm for 1 min, at 4°C. The merozoite pellet was carefully resuspended in 500 pi 0.2 mg ml'1 
Sepharose-NHS-Biotin in PBS, 1mM EDTA and incubated at 4°C for 15 min. The reaction was 
stopped by the addition of 500 pi PBS, 1mM EDTA, 100 mM glycine. The merozoites were 
centrifuged as above, the supernatant removed and the pellet washed three times in 500 pi 
glycine buffer. The parasites were aliquoted and solubilised in one of three different detergents 
for immunoprecipitation (section 2.4.4.4).
2A.4.2: l°5S] metabolic labelling
Mature stage parasites were purified as described above (section 2.2.3.1.) and washed in 2 x 
50 ml cysteine and methionine free medium (Invitrogen). Parasites were cultured for a further 30 
min in 30 ml cysteine and methione free medium supplemented with 10% AB+ filter sterilised 
human serum and 4 mM L-glutamine. Promix (Amersham Biosciences) containing L-[35S] -  
methionine and cysteine, was added to the culture at a specific activity of 100 pCi ml'1 and 
incubated for one hour at 37°C. The parasites were centrifuged at 2000 rpm for 3 minutes 
(Sorvall RT7, Du Pont), the cell pellet washed twice with 50 ml RPMI-Albumax and frozen 
directly for schizont samples. Merozoite samples were prepared as described above (section
2.2.3.1.).
2.4.4.3: Surface cross-linking of merozoites
Merozoite samples labelled with [35S]-methionine and cysteine (2.4.4.2.) were thawed into 200 
pi PBS. To thawed samples, 3,3’—dithiobis [sulfosuccinimidyl] propionate (DTSSP) (prepared as 
a 2 mM stock in PBS) was added to final concentrations of 100 pM, 200 pM and 300 pM and 
the samples incubated at room temperature for 15 min. The reaction was stopped by the 
addition of 1 M Tris-HCI, pH 7.4 in PBS, to a final concentration of 50 mM. The parasites were 
micro-centrifuged at 13000 rpm (Biofuge pico Heraeus) and washed twice in 1 ml of 50 mM 
Tris-HCI pH 7.4 in PBS. Merozoite pellets were frozen at -70°C until required.
2.4.4.4: Immunoprecipitation
Parasite pellets were thawed directly into 200 pi 50 mM Tris-HCI, pH 8.2 with 1 mM EDTA, 1 
mM phenylmethyl sulphonyl fluoride (PMSF), 1 pg ml'1 pepstatin A (Sigma) and 10 pM E64 
(Sigma), as well as one of the following detergents: 1% (v/v) Nonidet® P40 (NP40, Boehringer 
Mannheim), 1% (w/v) CHAPS (3-[(3cholamidopropyl)-dimethylammonio] propanesulfonate -
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Sigma), 1% (w/v) sodium deoxychoiate (Sigma). The parasite lysates were incubated on ice for 
30 min, before being clarified by centrifugation at 13000 rpm at 4°C for 20 min. The parasite 
lysate was then added to 100 pi prewashed, dried Sepharose® 4B (Pharmacia) or Protein-G 
Sepharose™ (Amersham Biosciences) and incubated at 4°C for 15 min. It was anticipated that 
this extra clarification step should eliminate or minimise non-specifiic interaction of protein with 
the beads. The Sepharose® 4B beads were removed using a Spin-X® filter (Corning) and 20 pi 
of the clarified lysate frozen for comparison. The remaining lysate was added to 100 pi 
prewashed, dried 4G2dc1-bound Sepharose beads (kindly provided by Mike Blackman) and 
incubated on a rotating wheel at 4°C for 2 hours. The beads were washed 4 times in 1 ml of the 
appropriate detergent solution (described above), dried and solubilised directly into 200 pi 2X 
SDS sample buffer (with or without 1 mM a-dithiothreitol, [DTT]) for Western Blot analysis. 
Samples from [35S] labelled parasites were electrophoresed on 10% SDS-PAGE and the gels 
dried (SCIE-PLAS gel dryer). Labelled bands were visualised using BioMax™ MR film (Kodak®).
2.4.5: Antibody selection assay
This assay was designed to identify mutant forms of rPfAMAI produced by random or SDM and 
that were altered only by virtue of the fact that they were no longer recognised by the mAb 
4G2dc1 (hereafter referred to as 4G2dc1' forms).
COS-7 cells were transfected with sg’PfamalRML as described (2.1.4.7.). The cells were 
harvested with 0.25% trypsin/EDTA as described. Trypsin activity was neutralised by washing 
the cells twice in 15 ml COS-7 cell culture medium and the cells resuspended in wash buffer 
(PBS, 0.1% BSA), containing the trypsin inhibitors 1 mg ml'1 soyabean trypsin inhibitor and 200 
pM tosyl-lysine chloromethyl ketone (TLCK). Transfected COS-7 cells were subjected to a 
double selection process, as follows (Fig 2.11.).
2.4.5.1: Negative selection
Firstly, the cells were selected for the absence of the mAb 4G2 epitope. For this, transfected 
cells were resuspended in 200 pi culture supernatant from mAb 4G2 hybridoma cells and 
incubated for 20 min at 4°C. The cells were washed 2 times in 1ml wash buffer (described 
above - 2.4.6) and incubated with Dynabeads coupled to anti-mouse IgG (Dynal Biotech.) for a 
further 20 min. Selection was carried out according to the manufacturer’s instructions using 20 
pi of resuspended Dynabeads per reaction. The Dynabead-bound and unbound fractions were 
separated using a Dynal magnet. The unbound 4G2' cells were recovered and washed in 3 x 1 
ml wash buffer.
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2A.5.2: Positive selection
For the selection of mutants with native conformation (native+), the 4G2' cells were resuspended 
in 200 pi wash buffer containing the polyclonal Ab N1 (1 in 100 dilution) and incubated at 4°C 
for 20 min. COS-7 cells bound to N1 were recovered by incubation with anti-mouse IgG-linked 
Dynabeads for 20 min at 4°C. The DNA from 4G2'/native+ cells was then recovered (using a 
SNAP kit [Invitrogen]), cloned and sequenced, to identify mutations that resulted in loss of the 
4G2 epitope
2.4.6: Protein purification 
2.4.6.1: Purification of recombinant PfAMAI Dl-ll
After 24 hours of induction of Dl-ll expression in P. pastoris, the cultures were pooled and the 
pH increased to 8.2 with NaOH. PMSF was added to a final concentration of 0.1 mM. The cells 
were centrifuged (as for 2.3.2.2.), and the supernatant passed through a 0.22 pm filter unit, to 
remove any remaining cell debris. PfAMAI Dl-ll was then purified using nickel nitrilotriacetic (Ni- 
NTA) resin agarose beads (QIAGEN) as follows. The culture supernatant (2 L) was incubated 
with Ni-NTA beads for 2 hours at 4°C. The beads were washed 5 times with 100 ml ice-cold 10 
mM imidazole in 1 x Ni-NTA buffer pH 8.2 (20 mM Tris-HCI, 300 mM NaCI, 30 mM imidazole) 
prior to elution of PfAMAI Dl-ll, by washing the beads three times in 33 ml ice-cold 200 mM 
imidazole in 20 mM Tris-HCI, 300 mM NaCI. PMSF (0.1 mM) and chymostatin (2 pg m l1) were 
added to the pooled eluates before further purification by gel filtration on a Superdex 200 HR 
gel filtration column, pre-equilibrated in Superdex running buffer (20 mM Tris-HCI, 150 mM 
NaCI, pH 8.2 - SRB). The column was run at 1 ml min'1 and 5 ml fractions were collected.
2.4.6.2:4G2 F(ab)2 and Fab (antigen binding) fragment production and purification
2A.5.2.1: Ab purification. Concentrated hybridoma supernatant was passed over a Protein G 
Sepharose™ column (Pharmacia Biotech) overnight and the column was washed in PBS. 
Bound antibody was eluted in 0.2 M glycine-HCI, 0.15 M NaCI, pH 2.7 with 0.02% NaN3, directly 
into 1 M Tris-HCI pH 8.2, to neutralise the eluate. The purified Ab was concentrated in a stirred 
concentrator fitted with a 50 kDa MW cut off ultrafiltration membrane (Amicon).
2.4.6.2.2: Pepsin digest to generate F(ab)2■ Purified mAb 4G2 (2.4.5.2.1.) was added to 1 M 
NaOH/citrate buffer, pH 3.5, to give a 0.1 M NaOH/Citrate solution and the mixture pre-warmed 
to 37°C. Pepsin (in 0.1 M NaOH/Citrate buffer, pH 3.5) was added to a final concentration of 0.1 
mg ml'1 and the mixture incubated at 37°C for 2 hours. The reaction was terminated by the 
addition of an equal volume of 1 M Tris-HCI, pH 8.2. The F(ab)2 was then purified by gel 
filtration as described in 2.4.5.1.
2.4.6.2.3: Reduction and alkylation to generate Fab. F(ab)2 was concentrated as described for 
the intact antibody, using a 10 kDa MW cut off ultrafiltration membrane (Amicon) and L-cysteine
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added to a final concentration of 10 mM from a 1 M stock in degassed gel filtration buffer (20 
mM Tris-HCI, 0.15 M NaCI, pH 8.2). The mixture was gassed with nitrogen and incubated at 
37°C for 2 hours, with stirring. The reaction was terminated by the addition of a freshly prepared 
solution of 1 M iodoacetamide, in 0.1 M Tris-HCI, pH 8.2, to a final concentration of 130 mM and 
the mixture incubated at room temperature for 2 hours. The resulting Fab fragment was purified 
by gel filtration, as described in 2.4.5.1.
The purified antibody and antibody fragments were electrophoresed on 15% SDS PAGE and 
visualised by staining with Coomassie blue.
2.4.6.3; 4G2 mAb F(ab)2 complexed to Dl-ll
Purified PfAMAI Dl-ll (2.3.2.3), was added to 4G2 F(ab)2 (2.4.3.2) and incubated at 4°C for 24 
hours. The resulting complex was purified by gel filtration as described in 2.4.5.1.
2.4.7: Proteolytic digestion of rPfAMAI
Digestion reactions were carried out using reagents prewarmed to 37°C. The reactions were 
incubated at 37°C and at time t = 0, 10, 30, and 60 minutes post initiation, 10 pi samples were 
taken and added directly to protease inhibitors (described below) to stop the reaction. Samples 
were boiled for 5 minutes, following the immediate addition of 20 pi 2 X SDS sample buffer.
2.4.7.1: Trypsin/Chymotrypsin
Trypsin and chymotrypsin (Sigma) at 50 pg ml'1 in SRB were added to rPfAMAI (in 10 mM 
CaCI2) at an enzyme:substrate ratio of 1:10 or 1:100. The reactions were stopped by the 
addition of an equal volume of 4 mM Pefabloc (Sigma). Digests were also carried out in the 
presence of 1 M urea, or 0.01% (w/v) SDS.
2.4.7.2: Subtilisin
Subtilisin (Sigma) at 50 pg ml'1 in SRB were used to digest rPfAMAI at enzyme:substrate ratios 
of 1:10 and 1:100. The reaction and reaction termination conditions used were the same as in
2.4.6.1.
2.4.7.3: Papain
Papain, (Boehringer Mannheim GmbH) at 1 mg ml'1 in SRB with 20 mM EDTA, was added to 
rPfAMAI with 10 mM cysteine, at an enzyme:substrate ration 1:10. The protease was 
neutralised by adding 0.1 M iodoacetamide (50 mM final concentration).
2.4.7.4: Pepsin
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Pepsin at 1 mg ml'1 in 0.1 M citrate/NaOH buffer, pH 3.5 was added to the rPfAMAI, in 0.1 M 
citrate/NaOH buffer (pH 3.5) to give an enzyme:substrate ratio of 1:10, or 1:100. The reaction 
was stopped by the addition of 1 M Tris-HCI, pH 8.0 (0.5 M final concentration).
Pepsin digestion of PfAMAI Dl-ll complexed with mAb 4G2 was carried out in 0.1 M 
citrate/NaOH buffer, pH 5.2. The pH of the buffer was chosen to ensure pepsin activity was 
maintained, without disrupting the Ab-protein interaction. Pepsin was used at an 
enzyme:substrate ratio of 1:10 or 1:100.
All digestion products were electrophoretically separated on 10% SDS-PAGE gels, which were 
stained with Coomassie blue or transferred to nitrocellulose for analysis by Western blot.
2.5: RBC binding assay
COS-7 cells were transfected on day 0 and the transfected cells used in erythrocyte binding 
assays on day 2 post-transfection. In all cases, the adherence of human erythrocytes to 
transfected COS-7 cells (rosette formation) was analysed using an inverted light microscope 
(Zeiss). Binding was assessed under a number of different conditions, as follows:
2.5.1: Normal conditions
The RBC binding assay was carried out essentially as described by Chitnis and Miller (1994). 
Briefly, COS-7 cells were transfected in 6 well plates as described above (section 2.3.1.). 
Medium was aspirated from the wells and 2 ml of a suspension of human RBCs (hRBCs) (0.1% 
haematocrit in RPMI-1640) were added. Plates were incubated at 37°C in a 5% C 02 incubator 
for 2 hours. COS-7 cells were then washed 3 times in complete medium and the COS-7 cell 
monolayer observed.
2.5.2: Static conditions
Transfected COS-7 cells were grown in 25 cm2 tissue culture flasks (Corning/Costar) and then 
the flask completely filled with a suspension of hRBCs in C02 gassed medium. After 2 hours 
incubation, as described above, flasks were gently inverted, allowing unbound erythrocytes to 
detach.
2.5.3: Sheer stress conditions
Cells were treated as described for normal conditions, but were incubated with a hRBC 
suspension in C 02 gassed medium, on a A600 rocker (Denley) at 37°C to simulate sheer stress 
conditions.
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2.5.4: Binding using ring stage parasites
Transfected COS-7 cells were incubated for 2 hours with purified ring stage parasites at about 
85% parasitaemia (2.2.2.2.), in suspension at 4% haematocrit with RPMI-1640, at 37°C under 
sheer stress conditions.
2.5.5: Recombinant PfAMAI bound to a solid support
Recombinant PfAMAI Dl-lll from 1 mg ml'1 stock was bound either to nitrocellulose (10 pg of 
protein loaded) or to polystyrene plates (Nunclon) using a two fold serial dilution (with a starting 
loading of 20 pg). The solid supports were then blocked in 5% BSA for 2 hours. These were 
incubated with hRBC suspensions (as described above) in C 02 gassed medium, under sheer 
stress conditions. Erythrocyte binding to nitrocellulose was assessed visually by placing the 
membrane on a light box. Erythrocyte binding to the polystyrene plates was assessed 
microscopically.
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Table 2.1: Oligonucleotide sequences used for plasmid construction.
Oligo. Name Sequence (5' ’to 3')
AMAforl GGGTTCTAGACCCGGGCAATCGAAATCGTGGAAAGATCC
sgOligo 78 TATTCGTTGTTCTTGTAGAAGTCACGCATACCGTTCAAAG
sgOligo 17 TGACTTTGTGTAGTAGACACGCTGGAAACATGAACCCTGA
Domlrev TTCACAGTTGAATTCGACCTACAGACCGAA
DI5'EcoRVf GACGCGGCCCGGATATCCGAAATCGTGGAA
DI5‘EcoRVr TTCCACGATTTCGGATATCCGGGCCGCGTC
DI3'EcoRVf AACCTCGAGAAGATATCGTTCGGTCTGTGG
DI3'EcoRVr CCACAGACCGAACGATATCTTCTCGAGGTT
DII5'Kpnlfor GT CGATGGTACCTGTGAAGAC
DII5'Kpnlrev GTCTTCACAGGTACCATCGAC
DII3’Kpnlfor GCGACTACTGGTACCTCTCATCCA
DII3’Kp/?lrev TGGATGAGAGGTACCAGTAGTCGC
DI5'Kpnlf GCGGCCCGGGCAATCGGTACCGTGGAAAGATCC
D\5'Kpn\r GGATCTTTCCACGGTACCGATTGCCCGGGCCGC
EcoRVDIfor GCGGCCCGGGATATCGAAATCGTG
EcoRVDIrev CACGATTTCGATATCCCGGGCCGC
Tr1 EcoRVf GCTGGTACTCAGTACAGAGATATCTCTGGTAAGTGCCCTGTT
Tr1 EcoRVr AACAGGGCACCTACCAGAGATATCTCTGTACTGAGTACCAGC
Tr2 EcoRVf CTGGGTGAAGATGCCGATATCGCTGGTACTCAGTAC
Tr2 EcoRVr GT ACT G AGTACC AG CG AT AT CG GC AT CTT C ACC CAG
EcoRVD If or GCGGCCCGGGATATCGAAATCGTG
EcoRVDIrev CACGATTTCGATATCCCGGGCCGC
sgOligo 8 TCTCTTCCATCGAAATCGTGGAAAGATCCAACTACATGGG
sgOligo 58 TCTTCTTGTTACCTTCGTCGTCGTTATCGTTCAACTTGAT
3D7-3’-900f GGGTCGATGGAAATTGTGAAGATCTACCACATG
3D7-3’-900r GTTCTCGAGTTAATAGTATGGTTTTTCC
3D7-5’-for CATATATGAAGATCTTTGGAAGAGGACAG
3D7HA2ndf CCT G AAC AT GT GCC AG ATT AT GCT AAAAT G AAA
3D7HA2ndr TTTCATTTTAGCATAATCTGGCACATGTTCAGG
3D7HAflfor AT ATGC AG ATTAT CCTTACG AT GT G CCAG ATT ATG CT AAAAT G A AA
3D7HAflrev TTT C ATTTTAG C AT AAT CT G GC AC AT CGTAAG GATA AT CT G CAT AT
AXholfor CCAAGAAAGAACCTGGAAAACGCAAAGTTCGGTCTGTGG
AXftolrev CCACAGACCGAACTTTGCGTTTTCCAGGTTCTTTCTTGG
sgPfA2HAf GAGCATAAGCCTGACTATGCTAACATGAAG
sgPfA2HAr CTTCATGTTAGCATAGTCAGGCTTATGCTC
sgPfAflHAf GCAGATTATCCATACGATGTGCCTGACTATGCTAACATGAAG
sgPfAflHAr CTTCATGTTAGCATAGTCAGGCACATCGTATGGATAATCAGCGTATTC
5’sgPfama1f ACCGAGCTCGAGTTCATGAGGAAG
3’sgPfama1 r GCCAGTCTCGAGTTAGTAGTAAGGC
3D7-5’-rev CT CG AG GTATATCTTCT C A ATTT CC AT CG ACCC
Pfa1 -3’UTRf CAACGTCTGCCATGGTCAGCTTCTCTTTTATGC
Pfa1-3’UTRr CCTTTTT AATT AT AT AT C CT AGGT CA CATACGTC
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Table 2.2: Antibody concentrations (mM) in invasion-inhibition assays
(a) 4G2dc1 and 4G2dc1 Fab
Sample 1 2 3 4 5
mg ml'1 0 0.4 0.7 1.6 2.7
(b) 4G2dc1 Fab
Sample 1 2 3 4 5 6
mg ml'1 0 0.07 0.05 0.11 0.27 0.43
6 6
Table 2.3: Concentrations of 4G2dc1 Fab and rPfAMAI used in invasion
-inhibition blocking assay
1 2 3 4
4G2dc1 Fab 0 0.98 mM 0.98 mM 0
rPfAMAI Dl-lll 0 0 1 mM 1 mM
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Table 2.4: Primary antibodies used in immunofluorescence assays (IFA) and 
Western blot analysis
Antibody Polyclonal/
Monoclonal
Species of 
Origin
Concentration 
IFA Western
Specificity
4G2* Monoclonal Rat Culture supernatant NR only
N1* Polyclonal Mouse 1/100 1/1000 NR/R
AdsN1* Polyclonal Mouse 1/100 1/1000 NR only
R1* Polyclonal Mouse 1/100 1/1000 R/NR
3F10** Monoclonal Rat 1/500 1/8000 HA tag
12CA5*** Polyclonal Mouse - Cult. Sup. HA tag
a-p-Thr**** Polyclonal Mouse - 1/100 p-Thr
a-p-Ser*** Polyclonal Mouse - 1/100 p-Ser
4G10 Monoclonal Mouse - 1/1000 p-Tyr
Notes:
* Antibodies recognising epitopes within the PfAMAI ectodomain.
** 3F10 (Roche) is a high affinity monoclonal antibody for detection of the HA epitope tag.
*** 12CA5 culture supernatant was the kind gift of Pippa Harris. This Ab gives a non-specific 
band in Western blot analysis of COS-7 cell lysate.
**** Anti-phospho-serine or threonine antibodies (Qiagen) recognise phosphorylated serine and 
threonine amino acid residues respectively.
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Table 2.5: Secondary antibodies used in IFA and Western blot analysis
Antibody
specificity
Species of 
Origin
Source Concentration 
IFA Western
Conjugate
a-mouse IgG Goat Pierce 1/10000 HRP
a-mouse IgG Goat Sigma 1/100 FITC
a-rat Goat Chemicon 1/500 1/8000 Biotin
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Table 2.6: Summary of tertiary reagents used in IFA and Western blot analysis
Streptavidin* Sigma 1/1000 HRP
Streptavidin* Vector 1/500 FITC
Note:
*A three step labelling procedure, which relies on the high affinity binding of streptavidin and 
biotin, was used with both rat monoclonal primary antibodies to enhance the observed signal.
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Figure 2.1: Construction of the plasmid pSec/sg'Pfamal for expression of the Pfamal
synthetic gene in COS-7 cells
(1) The 5’ region of Dl was PCR amplified from the full length synthetic gene in Fim252, 
introducing Xba\ and Sma\ sites just 5’ of the IEIVE processing site in Dl. The region amplified 
extended beyond the Afl\\ site in Dl. (2) The PCR product was digested with Xba\ and AflM. (3) 
Fim 252 was digested with Xba\ and Afl\I to remove the sequence coding for the signal peptide 
and prodomain. (4) The two digestion products were then ligated together to give the plasmid 
pMOS/sg'Pfamal, containing the PfAMAI synthetic gene minus the sequence encoding the 
signal peptide and prodomain (sg'Pfamal). (5) This gene was excised from the plasmid using 
the restriction enzymes Sma\ and EcoRI (at the 3’ end of the gene). (6) The expression plasmid 
pSecTag2A was digested with Sfil (3’ of the Igx secretory signal in the plasmid) and blunt 
ended. (7) This was followed by EcoRI digestion of the plasmid. (8) The gene sg'Pfamal was 
ligated into the plasmid pSecTag2A, to give the construct pSec/sg'Pfamal.
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Fig 2.2: Design of the plasmid pSec/sg'DI, for secreted expression of sg'DI in COS-7 cells
(1) Dl was PCR amplified from just 5’ of the Sacll site in Dl, to just downstream of the 3’ end of 
Dl. The reverse primer was designed to introduce an EcoRI site downstream of Dl. (2) The PCR 
product was digested with Sacll and EcoRI. (3) To remove Dll and Dill, the plasmid 
pSec/sg'Pfamal was digested with Sacll and EcoRI. (4) The plasmid backbone and digestion 
PCR product were then ligated together, giving the construct pSec/sg'DI.
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Figure 2.3: Construction of plasmids for the expression of different combinations of the 
PfAMAI subdomains in COS-7 cells.
A To generate a construct for expression of Dll and Dill in COS-7 cells (1) two rounds of SDM 
were carried out to introduce an EcoRV site at the 5’ and 3’ ends of Dl. (2) The plasmid was 
digested with EcoRV to excise Dl and then (3) re-ligated to give the plasmid sgPfaADI.
B A construct for expression of Dl and DIM together in COS-7 cells was created by (1) 
introducing Kpn\ sites at the 5’ and 3’ ends of Dll in two rounds of SDM. (2) The resulting 
plasmid was digested with Kpn\ to excise Dll and then (3) the plasmid backbone re-ligated to 
generate the plasmid sg'PfaADII.
C A plasmid was designed for expression of Dill on its own on the surface of COS-7 cells. (1) 
In two rounds of SDM, Kpn\ sites were introduced at the 5’ end of Dl and at the 3’ end of Dll. (2) 
The resulting plasmid was digested with Kpn\ to excise both Dl and Dll and then the plasmid 
backbone was re-ligated to give the construct sgPfaADI-ll.
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Figure 2.4: Plasmid design for the expression of a truncated form of sg'PfAMAI in COS-7 
ceils
(1) SDM was used to introduce an EcoRV site at the 5’ end of the sgPfamal coding sequence 
in the plasmid pSec/sg'Pfamal. SDM was used to introduce a further EcoRV site at the 5’ side 
of the first cysteine residue in Dl (C149), to leave the sequence encoding either (2) 146SGKC!... 
or (3) 138AGTQYRLPSGKC!... at the 5’ end of the gene. (4) The two plasmids were then 
digested to excise the 5’ end of the sequence encoding Dl and (5) the plasmid backbones re­
ligated to give constructs (a) pSec/tr1 -sgPfamal and (b) pSec/tr2-sgPfama1 respectively.
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Figure 2.5: Schematic representation of the approach used to generate a random mutant 
library of sg'Pfamal (sg'Pfamal RMLib)
(1) The Psfl site in the plasmid backbone was excised by digestion with EcoRI and EcoRV, so 
that the Psfl site at the 3’ end of the sequence encoding Dll of sg'Pfamal was unique. (2) The 
vector backbone was religated to give the construct pSecAPstl/sg’Pfa. (3) SDM was used to 
introduce a Cla\ site at the 5’ end of the sequence coding for Dl, giving the plasmid 
pSecAP/sg’Pfa/Clal. (4) This plasmid was digested with Cla\ and Psfl to excise the sequence 
encoding DM I. (5) Under random mutagenic PCR conditions, the sequence encoding Dl-ll, 
incorporating C/al and Psfl sites, was amplified from pSecAP/sg’Pfa/Clal and then (6) digested 
with C/al and Psfl. The ClaVPsfl digested PCR product was ligated into the linearised plasmid, 
giving the random mutant library sg'Pfamal RMLib.
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Figure 2.6: Construction of the plasmid pHH1-3’Pfa for 3’ replacement in P. falciparum
(1) The 900bp 3’ region of the Pfamal endogenous gene sequence was amplified by PCR from 
P. falciparum strain T9/96 genomic DNA. The PCR primers were designed to incorporate a BglW 
site at the 5’ end of the coding sequence and an Xho\ site at the 3’ end for cloning purposes. (2) 
The PCR product was cloned into pMOSblue, giving rise to the plasmid pMOS/3’Pfam al. (3) 
The 3’ coding region was excised from this plasmid by restriction digestion with Bglll and Xhol.
(4) The plasmid pHH1-pSERA4 was digested with BglW and Xho\ to remove the sera4 gene and
(5) the Bgl\\/Xho\ digested 3’ coding region of Pfamal was ligated into the plasmid backbone, 
giving rise to the plasmid pHH1-3’Pfa.
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Figure 2.7: Construction of the plasmid pHH1-Pfa/HA designed to introduce an HA
epitope tag into the 3’ region of the Pfamal endogenous gene sequence
(1) The Pfamal gene sequence (minus the first 46 bp) was amplified by PCR from the T9/96 
genomic sequence. The PCR primers were designed to introduce a BglW site and a Xho\ site at 
the 5’ end and 3’ end of the gene sequence respectively. (2) The PCR product was cloned into 
pMOSblue and (3) the HA epitope tag introduced into the sequence encoding the stub region of 
PfAMAI by two rounds of SDM. (4) The modified am al gene was excised by restriction 
digestion using the enzymes BglW and Xho\. (5) This digestion product was cloned into 
Bglll/Xhol digested pHH1, from construction of pHH1-3’Pfa (see figure 2.6, step 4), giving rise to 
the plasmid pHH1-Pfa/HA.
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Figure 2.8: Construction of the plasmid pHAM-sgPfa/HA for episomal expression of an
HA epitope tagged version of sg'PfAMAI in P. falciparum
(1) The Xho\ site found in the sequence encoding Dl in sg'Pfamal was removed by SDM of the 
plasmid pSec/sg'Pfamal. In addition, two rounds of SDM-PCR were performed to introduce a 
copy of the HA epitope tag into the sequence encoding the stub region of sg'PfAMAI. (2) The 
region encoding the incorporated HA tag and the mutated Xhol site (AXhol + HA) was excised 
by restriction digestion using the enzymes Ksp\ and Stu\. (3) The construct Fim252, comprising 
sgPfamal in pMOSblue was digested using the restriction enzymes Ksp\ and Stu\ to remove 
the corresponding region of the sgPfamal gene. (4) The excised fragment, AXhol + HA, was 
ligated into the linearised Fim252 backbone. (5) The entire sgPfamal gene, including AXhol + 
HA, was PCR amplified to introduce Xhol sites at both 5’ and 3’ ends and then (6) the PCR 
product was digested with Xhol. (7) The plasmid pHAM-ACPGFP was digested with Xhol to 
remove the sequence encoding ACPGPF. (8) The sgPfamal gene sequence containing the 
sequence encoding the HA tagged was cloned into the linearised pHAM vector backbone, 
giving rise to the plasmid pHAM-sgPfa/HA.
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Figure 2.9: Construction of the plasmid pHH1-5’-sgPfa/HA designed to replace the 
endogenous Pfamal gene sequence with that of sgPfamal, by single cross-over 
homologous recombination
(1) The 5’ region of the PfAMAI coding sequence was amplified by PCR, to introduce a 5’ BglW 
site and a 3’ Xhol site. (2) The PCR product was cloned into pMOSblue, giving rise to the 
plasmid pMOS/5’Pfamal and (3) then excised by restriction digestion using the enzymes Bglll 
and Xhol and (4) ligated into the Bglll/Xhol digested pHH1 plasmid prepared for generation of 
the plasmid pHH1-3’Pfa earlier (see figure 2.6 step 4), giving rise to the plasmid pHH1- 
5’Pfama1. (5) This plasmid was digested with Xhol and blunt ended. (6) The sgPfamal 
expression cassette was excised from the plasmid pHAM-sgPfa/HA (see figure 2.8 step 8) by 
restriction digestion using the enzymes HindlW and A/o/l and blunt ended. (7) The synthetic gene 
expression cassette was then ligated into the linearised pHH 1-5’Pfamal downstream of the 
5’Pfama1 sequence, giving rise to the plasmid pHH1-5’-sgPfa/HA.
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Figure 2.10: Construction of the plasmid pHTK-sgPfa/HA designed to replace the 
endogenous Pfamal gene sequence in P. falciparum by double integration homologous 
recombination
(1) A 900 bp stretch of the Pfamal 3’ UTR was amplified by PCR from the T9/96 genomic 
sequence. The primers used were designed to introduce a 5’ Nco\ site and a 3’ Bin\ site. (2) The 
PCR product was cloned into pMOSblue to generate the plasmid pMOS-Pfa3’. (3) The plasmid 
was restriction digested with Nco\ and Bin\, to excise the Pfamal 3’ UTR sequence. (4) the 
plasmid pHHT-TK was digested with Nco\ and Bin\ and (5) the Pfamal 3’ UTR ligated into it to 
generate the plasmid pHTK- Pfa3’. (6) This plasmid was digested with SpeI and blunt ended 
and (7) the sgPfAMAI expression cassette, generated during the cloning of pHH1-5’-sgPfa/HA 
(see Fig 2.9. step 5), ligated into it.
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Figure 2.11: Schematic representation of the selection procedure for isolating random 
mutants that are correctly folded (native+) but lack the 4G2dc1 epitope (4G2dc1)
(1) COS-7 cells transfected with the random mutant library (sg'Pfamal RMLib) were harvested 
by trypsinisation to generate a single cell suspension. After trypsin neutralisation, these cells 
were incubated with 4G2dc1 (2), followed by incubation with anti-mouse IgG coupled to 
Dynabeads (3). Cells expressing a form of sg'PfAMAI on their surface in which the 4G2dc1 
epitope was intact (4G2dc1+) bound indirectly to the Dynabeads and were extracted from the 
sample by application of a Dynal magnet (4). The unbound cell culture (containing 4G2dcT 
cells) was isolated (5) and incubated with the polyclonal serum N1 (6), followed by incubation 
with fresh anti-mouse IgG coupled to Dynabeads (7). The bound cells (4G2dc17native+) were 
again isolated by application of a Dynal magnet (8) and the unbound cells discarded (9). 
Plasmid was rescued from the IgG-Dynabead bound cells (10), amplified in E. coli and 
transfected back into COS-7 cells (11) to repeat the selection process.
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Chapter 3
Analysis of the RBC binding properties of PfAMAI 
3.1: Introduction
While recognition of erythrocyte receptors by Plasmodium merozoite ligands is an essential 
prerequisite to erythrocyte invasion, there appears to be a degree of "built-in" redundancy 
associated with the process. Thus, if a particular RBC receptor is enzymatically removed from 
the erythrocyte surface, or the gene for a particular parasite invasion-associated ligand is 
knocked out, merozoites may still invade, albeit possibly with reduced efficiency (Reed et al., 
2000; Miller et al., 1977; Haynes et al., 1988). This redundancy possibly contributes to an 
increased likelihood of invasion of RBCs of different phenotypes and to survival of the parasite 
in diverse hosts.
Erythrocyte binding peptides have been identified from the sequence of PfAMAI from a library 
of non-overlapping peptides covering the entire length of the protein (Urquiza et al., 2000). 
These peptides were found to inhibit erythrocyte invasion and development by P. falciparum. 
Interestingly, one of these peptides (MIKSAFLPTGAFKADRYKSH) overlaps with the second 
half of the domain II loop indicating a potential erythrocyte binding function for this region of the 
loop. However, caution should be exercised in drawing too many conclusions about the function 
of an entire protein, based on the properties of small peptides within the molecule. This point is 
highlighted by the fact that one of the peptides demonstrating high binding activity lies within the 
cytoplasmic tail of PfAMAI. It is difficult to envisage the functional significance of an erythrocyte 
binding motif in this region of this type I integral membrane protein.
The identification of phage-display peptides from a random phage display library that bind to 
PfAMAI, inhibiting merozoite invasion of RBCs has been used as evidence of the erythrocyte 
binding activity of AMA1 (Li et al., 2002; Keizer et al., 2003). However, it is equally possible that 
peptide binding inhibits the interaction of AMA1 with some other parasite protein. Interestingly, 
binding of one of these phage display peptides to PfAMAI was inhibited by the mAb 4G2dc1, 
suggesting that they have similar binding sites and possibly similar mechanisms of invasion- 
inhibition.
P. falciparum AMA1 Dl-ll share 12% similarity with the PfMAEBL erythrocyte binding domains 
M1 and M2 (Ghai et al., 2002). Thus, the suggestion has been made that AMA1 is a member of 
the MAEBL family of erythrocyte binding proteins (Kappe et al., 1998a). Furthermore, COS-7 
cells expressing recombinant AMA1 Dl-ll, from the rodent malaria P. yoelii (PyAMAI), on their 
surface were found to bind rodent RBCs (Fraser et al., 2001). In the current study, to determine
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whether the P. falciparum protein shares this capacity, PfAMAI was expressed on the surface 
of COS-7 cells and a number of experiments performed to assess RBC binding.
3.2: Surface expression of PfAMAI in COS-7 cells
The COS-7 cell expression system has been used successfully in numerous studies assessing 
the erythrocyte binding capabilities of putative Plasmodium erythrocyte binding antigens (Sim et 
al., 1994a; Ranjan and Chitnis, 1999; Fraser et al., 2001; Prasad et al., 2003). This adherent 
cell line forms monolayers on the bottom of plastic tissue culture dishes and flasks in which they 
are cultured. The erythrocyte binding activity of Plasmodium antigens expressed in this system 
can easily be determined by incubating the transfected cells with dilute solutions containing the 
appropriate erythrocytes. Unbound erythrocytes are then washed off, leaving the COS-7 cells 
and any bound erythrocytes intact on the bottom of the culture dish. Rosettes formed by 
erythrocytes bound specifically to transfected COS-7 cells are readily detected by light 
microscopy at 200 X magnification. Most of these studies have relied on conjugation of the 
malaria antigen, or subdomains thereof, to the transmembrane domain and cytoplasmic tail of 
the type I integral membrane protein HSVgDI to ensure membrane association. The HSVgDI 
signal peptide was used in these studies to target the chimera to the secretory pathway and 
from there to the cell surface. In the current study, the COS-7 cell system was used to assess 
the erythrocyte binding capabilities of PfAMAI. However, and for the first time reported here, 
PfAMAI was expressed in a heterologous system with its cognate transmembrane domain and 
cytoplasmic tail. It was hoped that this would increase the likelihood of the molecule being 
presented on the surface in a form comparable to that seen on the merozoite surface.
In P. falciparum merozoites, the signal peptide is cleaved from translated PfAMAI on entry to 
the endoplasmic reticulum. The PfAMAI83 kDa form is targeted to the micronemes and in these 
organelles is proteolytically processed, by removal of the prodomain, to the PfAMA48 kDa form 
that is redistributed to the merozoite surface. The exact function of the prodomain is unclear as 
it is only found in AMA1 from P. falciparum and P. reichenowi. However, Healer et al. (2005) 
demonstrated that the inability of the parasite to proteolytically remove the prodomain from a 
chimeric version of AMA1, comprising the PfAMAI prodomain, Dl and Dll and PcAMAI Dill, 
resulted in the inhibition of surface relocalisation of the molecule. The proteases required for this 
processing event may not be present in the COS-7 cell system and therefore the unprocessed 
molecule may be presented on the COS-7 cell surface. Furthermore, the ability of AMA1 from 
most other parasite species to function without the presence of a prodomain, together with the 
fact that in P. falciparum the prodomain is cleaved prior to relocalisation onto the surface, 
suggests that this domain is not essential for the erythrocyte binding activity of the molecule. For 
this reason the sequence encoding the prodomain and signal peptide of PfAMAI were not 
included in the construct for expression in COS-7 cells, in this study.
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In the current study, COS-7 cells were transfected with pSec/sg'Pfamal. This construct was 
designed for expression of the entire sgPfamal gene minus the authentic signal peptide and 
prodomain (sg'Pfamal) and directed for secretion using the murine Igx signal sequence 
(2.1.4.1). Correct expression of the gene product was assessed by mAb 4G2dc1 studies. 
Expression of PfAMAI on the surface of the transfected COS-7 cells was confirmed by IFA of 
live, unfixed cells (Fig. 3.1 A). By comparison, no surface fluorescence is exhibited by 
untransfected COS cells when examined under the same conditions (Fig. 3.1 B). The synthetic 
gene product expressed in these cells ran at just below 67 kDa when the cell lysate was 
electrophoresed under non-reducing conditions in SDS-PAGE, as shown by Western blot 
analysis (data not shown).
3.3: Analysis of the human RBC binding activity of sg'PfAMAI
3.3.1: Does sg'PfAMAI expressed on the surface of COS-7 cells facilitate RBC binding
The binding activity of sg'PfAMAI expressed on the surface of COS-7 cells for human 
erythrocytes was assessed using the conditions described by Chitnis and Miller (1994). Briefly, 
COS-7 cells expressing sg'PfAMAI (referred to hereafter as COS-7-sg'PfAMAI cells) on their 
surface were incubated with human erythrocytes in RPMI-1640 for two hours at 37°C. The cells 
were then washed in prewarmed RPMI-1640 to remove unbound RBCs and visualised using an 
inverted light microscopy at 200 X magnification. No difference in RBC binding activity was 
observed between the transfected and untransfected cells. However, this does not rule out the 
possibility that this protein binds human erythrocytes under different reaction conditions.
3.3.2: The use of static conditions to prevent disruption of PfAMAI-erythrocyte 
interactions
It is possible that the affinity of PfAMAI for its receptor on the human erythrocyte is very low and 
that this affinity is enhance by increasing the number of AMA1-receptor interactions. If the 
concentration of sgPfAMAI on the COS-7 cell surface in the previous assay was too low to 
facilitate the stable attachment of RBCs to the transfected COS-7 cells, any lightly interacting 
RBCs would have been lost during the vigorous washing steps. To test this hypothesis, flasks 
containing transfected COS-7 cells were filled completely with RBCs in pre-gassed RPMI-1640 
and incubated for 2 hours at 37°C as before. The flasks were then very gently inverted to allow 
detachment of unbound RBCs. Binding was then assessed by microscopic examination of the 
COS-7 cell monolayer. Once again, there was no detectable difference between the RBC 
binding to the transfected and untransfected cells.
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3.3.3: sg'PfAMAI binding activity under shear stress conditions
Shear stress is used to define the hydrodynamic forces acting upon objects in conditions of fluid 
flow, typically in the blood stream. In certain cell binding systems, shear stress above a critical 
threshold is required for the initiation and maintenance of the intermolecular interactions 
mediating binding (Finger et al., 1996; Alon et al., 1997; Lawrence et al., 1997). Under normal 
physiological conditions in the blood stream, the parasite surface antigens interacting with 
receptors on the erythrocyte surface must be subjected to a considerable amount of flow 
induced shear stress. It is possible that this stress is required to generate and maintain a stable 
interaction between PfAMAI and its erythrocyte receptor. To assess the requirement for shear 
stress to facilitate PfAMAI-erythrocyte binding, RBCs in RPMI-1640 were incubated with 
sg'PfAMAI transfected and untransfected COS-7 cells for 2 hours at 37°C on a rocker. The 
movement of the rocker washed the RBCs back and forth across the surface of the COS-7 cells, 
simulating a low level of shear stress. The RBCs were then washed off as before and the cells 
examined for rosette formation. As with the static conditions used above, no difference in RBC 
binding was observed between the transfected and untransfected COS-7 cells. Under 
physiological conditions, the shear flow experienced by parasites would be considerably greater 
than that induced in these experiments. This may account for the lack of binding observed in 
this study.
3.3.4: Does Dill of sgPfAMAI bind human erythrocytes?
Kato et al. (2005) have suggested that Dill of PfAMAI when expressed on the surface of CHO 
cells facilitates erythrocyte binding to the transfected cells. In the current study, a construct 
(pSec/sg1 Pfamal Dl-ll) was designed for expression of sgPfAMAI Dill, in conjunction with its 
transmembrane domain and cytoplasmic tail, on the surface of COS-7 cells. To investigate the 
possibility that Dill of PfAMAI possesses RBC binding properties, the transfected COS-7 cells 
were analysed for their ability to mediate the binding of human erythrocytes. The erythrocyte 
binding activity of this truncated form of AMA1 was assessed under normal conditions as well as 
shear stress conditions, as described above (sections 3.3.1. and 3.3.3. respectively). No 
difference was observed between the RBC binding activity of the transfected and untransfected 
COS-7 cells, under either of the conditions used. This suggests that PfAMAI DIM may not 
mediate RBC binding as has been asserted.
3.3.5: Binding of sg'PfAMAI to the modified erythrocyte surface of ring stage parasites
It has been suggested that the malaria parasite modifies the RBC surface during invasion 
(Dluzewski et al., 1986). These modifications may be required for the interactions necessary for 
successful binding, reorientation and tight junction formation. If AMA1 is required at any of these 
stages in the invasion pathway, it is possible that the interaction between recombinant AMA1
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and its host cell receptor would not be observed in the absence of such modifications. To 
investigate this hypothesis, ring stage parasites (at about 85% parasitaemia) were prepared by 
double synchronisation on a 70% percoll cushion within two hours of reinvasion. These 
parasites were mixed at 0.1% haematocrit with RPMI-1640 and incubated for 2 hours with COS- 
7-sg'PfAMA1 cells, at 37°C, under shear stress conditions. The cells were washed in RPMI- 
1640 and then once again inspected microscopically as described above for the presence of 
bound erythrocytes. No RBC binding was observed under these conditions.
3.3.6: Analysis of the binding of sg'PfAMAIto enzyme treated erythrocytes
To further assess the requirement for erythrocyte modifications for PfAMAI interaction, human 
RBCs were enzymatically treated with trypsin, chymotrypsin or neuraminidase. The 
enzymatically modified RBCs were resuspended at 0.1% haematocrit in RPMI-1640 and 
incubated at 37°C for 2 hours with COS-7-sg'PfAMA1 cells under the shear stress conditions 
described above. The cells were analysed microscopically, as described above, to determine 
the binding activity of sg'PfAMAI. No detectable erythrocyte binding activity was observed 
under these conditions.
3.4: Analysis of erythrocyte binding activity of rPfAMA1
Surface fluorescence of COS-7-sg'PfAMA1 cells (Fig 3.1 Ai) in IFA analysis using the mAb 
4G2dc1 appeared to be greater in intensity than that of free P. falciparum merozoites. This 
suggests that at any point on the COS-7-sg'PfAMA1 cell surface, the local concentration of 
AMA1 is greater than that at any point on the merozoite surface. COS-7 cells are 
morphologically diverse, so it is difficult to specify their exact size. Flowever, in comparison with 
merozoites (1.2 - 1.8 pm long and 0.7 pm wide) COS-7 cells are very large. A crude, 
conservative estimate of 10 pm for the COS-7 cell diameter (assuming the cell surface to be 
circular) would put the 2D surface area of the COS-7 cell at 2 orders of magnitude greater than 
that of the merozoite (assumed to be elliptical). It is possible that the apparent fluorescence 
intensity with COS-7-sg'PfAMAI is more a result of visual interpretation because of the large 
cell size than a reflection of the true local surface fluorescence intensity. Thus, the apparent 
surface fluorescence may not reflect the true cell surface density in COS-7-sg'PfAMAI cells. A 
more quantitative method of comparison would be required to confirm this.
It follows therefore that one possible explanation for the lack of rosette formation in the RBC 
binding assays using transfected COS-7 cells, was that the sg'PfAMAI concentration on the cell 
surface was insufficient to mediate RBC binding. The use of recombinant protein immobilised on 
a solid support would allow tighter regulation of the protein concentration present. For this 
reason, solid phase RBC binding assays were carried out, in which purified rPfAMAI Dl-ll I was 
bound either to nitrocellulose or polystyrene plates. In the first assay, 10 pg rPfAMAI Dl-lll was
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electrophoresed on 10% SDS-PAGE and then electrophoretically transferred to nitrocellulose 
membrane. The membranes were blocked in 5% BSA and then incubated with RBCs at 0.1% 
haematocrit in RPMI-1640. The membrane was washed and observed by light microscopy. 
Alternatively, drops of rPfAMAI were placed onto polystyrene tissue culture plates using 2-fold 
serial dilution, from a starting sample of 20 pg. The plates were incubated overnight at 4°C and 
then incubated for 2 hours at 37°C with a human RBC suspension as described earlier, under 
shear stress conditions. The plates were visualised by light microscopy to assess RBC binding 
to the immobilised rPfAMAI. However, no RBC binding was observed to either the nitrocellulose 
or the polystyrene plates.
3.5: Analysis of PfAMAI-protein interactions
A possible explanation for the lack of RBC binding observed in this study is that PfAMAI forms 
a complex with another parasite surface protein and complex formation is a prerequisite to RBC 
interaction. To assess this possibility, AMA1 was immunoprecipitated from late schizont stage 
parasites and free merozoites under different detergent conditions and analysed for the 
presence of associated molecules. The technique has been used extensively in many systems 
to identify protein-protein interactions. One such example is the identification of the MSP142- 
MSP9 (or acidic basic repeat antigen, ABRA) complex (Li et al., 2004a) in P. falciparum 
merozoites by immunoprecipitation with polyclonal Abs raised against a region of MSP9 that 
has previously been shown to bind band 3 on the erythrocyte surface. Immunoprecipitation was 
carried out in the presence of a detergent to ensure the extraction of PfAMAI from the lipid 
bilayer. If the interactions holding AMA1 and its putative partner protein together are weak, the 
use of detergent may result in the disruption of the complex. For this reason, three different 
detergents were used in an attempt to identify one that supported this potential interaction.
3.5.1: Detection of a putative PfAMAI partner protein of 55 - 60 kDa
Naturally-released free merozoites were surface-labelled with biotin then solubilised into buffers 
containing NP40, CHAPS or sodium deoxycholate (DOC) and supplemented with protease 
inhibitors PMSF, Pepstatin A and E64. Immunoprecipitation was carried out on the detergent 
soluble fraction using mAb 4G2dc1 immobilised on Sepharose beads (4G2 Sepharose) and 
immunoprecipitated proteins analysed by Western blot with HRP-conjugated streptavidin or with 
the polyclonal serum R1.
Immunoprecipitation from the NP40 and CHAPS soluble fractions resulted in the isolation of a 
large number of faint bands when blots were probed with HRP-streptavidin, probably due to 
non-specific binding of biotin-labelled proteins to the 4G2 Sepharose (Fig 3.2 A, lanes N and C 
respectively). However, clear, strong bands indicated the presence of the 83 kDa and 66 kDa 
forms of PfAMAI. An additional strong band could be seen at about 55 kDa and a doublet at
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about 34 kDa. When analysed further, all these bands were reactive with the polyclonal Ab R1 
(Fig 3.2 B, lanes N and C respectively), identifying them as break down products of PfAMAI. By 
contrast, little immunoprecipitation was observed from the DOC solubilised fraction (Fig 3.2 A, 
lane S). In this sample, the 83 kDa and 66 kDa 4G2dc1 bands were very weak but the 34 kDa 
doublet still gave a strong signal (Fig 3.2 A and B, lane S). This doublet may represent 
fragments that were membrane associated and therefore preferentially partitioned into the DOC 
fraction over the membrane bound forms. A 55 - 60 kDa band was recognised by the secondary 
Ab in all samples (Fig 3.2 C). A band of this size was present in all the samples probed with 
streptavidin, though only very weakly in the DOC sample compared with very strongly in the 
NP40 and CHAPS samples. However, when probed in Western with either the polyclonal serum 
R1 or the secondary Ab on its own, this band was of equal intensity in all samples. This 
suggests that in the NP40 and CHAPS extracted samples two proteins co-migrated at 55 - 60 
kDa. One of these proteins was of low intensity and was detected by the secondary Ab, possibly 
representing the mAb 4G2dc1 light chain from the immunoprecipitation. The other protein, 
highly abundant in the NP40 and CHAPS extracted samples when probed with streptavidin, was 
distinct from PfAMAI as it was not recognised by the polyclonal serum R1 and may have been 
a parasite protein that co-precipitated with PfAMAI. This raises the possibility that the strong 
intensity band detected with streptavidin in the NP40 and CHAPS fractions was a potential 
PfAMAI partner protein.
3.5.2: Immunoprecipitation of PfAMAI from metabolically radiolabelled P. falciparum
Biotin labelling of schizont stage parasites will also result in the labelling of RBC structures. It is 
therefore possible that immunoprecipitation of PfAMAI from this mixture would result in the non­
specific co-precipitation of a RBC protein. Such proteins would be indistinguishable from 
parasite proteins in this assay and might complicate interpretation of the result. In addition, the 
interactions between PfAMAI and other parasite proteins may only occur once PfAMAI is 
transported onto the merozoite surface. In schizonts, most of the protein is present in the 
micronemes, therefore such interactions might not be readily observed at this stage of the life 
cycle. To investigate this possibility, immunoprecipitation profiles of schizont and free 
merozoites were compared. A highly synchronous culture of P. falciparum schizonts was 
metabolically labelled with L- [35S] -methionine and cysteine to specifically label only parasite 
proteins. Schizonts were either returned to culture in the absence of labelled amino acids to 
allow merozoite development and release or harvested directly. PfAMAI was 
immunoprecipitated with mAb 4G2dc1 or with the polyclonal serum N1 from CHAPS solubilised 
fractions as NP40 and CHAPS gave similar results previously (3.5.1.).
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3.5.2.1: Identification of a 46 kDa putative PfAMAI merozoite partner protein by 
immunoprecipitation with mAb 4G2dc1
Fluorometric analysis of mAb 4G2dc1 immunoprecipitated samples (Fig 3.3 A) revealed major 
bands corresponding to the PfAMAI 83 and 66 kDa processed forms, as well as many other 
bands. However, the 83 kDa form was less obvious in the merozoite fraction (Fig 3.3 A, lane m) 
indicating that processing of PfAMAI to the 66 kDa form had almost gone to completion in free 
merozoites. There was a doublet in the merozoite fraction at about 46 kDa (Fig 3.3 A, lane m) 
only the upper band of which was present in the schizont fraction (Fig 3.3 A, lane s). The lower 
band in the merozoite fraction was detectable by Western blot analysis with the polyclonal 
serum R1 (Fig 3.3 B, lane m) indicating that it was of PfAMAI origin. This band was also 
present in the CHAPS immunoprecipitated fraction of biotinylated merozoites (3.5.1) after longer 
exposure (data not shown). This raises the possibility that the upper band of the 46 kDa doublet 
was a putative PfAMAI partner protein. A 55 - 60 kDa band detected by the HRP-conjugated 
secondary antibody was present in Western blot analysis (Fig 3.3 C, lanes s and m) but not the 
[35S] autoradiograph indicating that it represented a mAb 4G2dc1 fragment. This probably 
corresponds to the low intensity 55 - 60 kDa band observed in the previous assay. The high 
intensity band detected previously in NP40 and CHAPS extracted samples were not present in 
the [S35] labelled samples. It is possible that this molecule was of RBC origin, labelled with 
biotin, and co-precipitated non-specifically in the previous assay.
3.5.2.2: Attempts to identify the putative PfAMAI partner protein by immunoprecipitation 
from f sS] metabolically labelled parasites using the polyclonal serum N1
The mAb 4G2dc1 is invasion inhibitory and may function by blocking the interaction between 
PfAMAI and its partner protein on the merozoite surface. If so, it might be impossible to 
immunoprecipitate the putative AMA1-partner protein complex using this mAb. For this reason, 
immunoprecipitations using metabolically labelled parasites from both developmental stages 
were repeated using the polyclonal serum N1. When this was done, the upper band of the 
doublet previously observed at 46 kDa was no longer present (Fig 3.4 A, lanes s and m). 
However, the lower band was again present in the merozoite fraction only (Fig 3.4 A, lane m). 
This band was also detected in the merozoite fraction by Western blot analysis using the 
polyclonal serum R1 (Fig 3.4 B, lane m) and this time a faint band was detected at this position 
in the schizont fraction (Fig 3.4 B, lane s). This suggests that in the mAb 4G2dc1 
immunoprecipitation the larger of the 46 kDa double bands immunoprecipitated non-specifically. 
Alternatively, immunoprecipitation with the polyclonal serum N1 may have resulted in disruption 
of the interaction between PfAMAI and this protein. When probed with the secondary Ab alone 
(Fig 3.4 C), the 55 kDa band previously detected was again visible for both samples.
No additional proteins co-precipitated with PfAMAI from the merozoite fraction than the schizont 
fraction. This suggests that during these developmental stages PfAMAI does not interact with 
any other parasite proteins.
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3.5.3. Attempts to cross-link PfAMAI and its putative partner protein prior to 
immunoprecipitation
It was hypothesised that one reason for the lack of co-precipitation observed so far with PfAMAI 
may be that the interaction between PfAMAI and its partner protein is transient and weak. If this 
was the case, the detergent conditions used might disrupt this interaction. To overcome this 
potential problem, merozoite and schizont samples metabolically labelled with [35S], were 
covalently cross-linked using DTSSP prior to immunoprecipitation with mAb 4G2dc1.
Under these conditions nothing appeared to co-precipitate with PfAMAI and the PfAMAI 83 
and 66 kDa bands themselves were very weak (Data not shown).
3.6: Discussion
Invasion of erythrocytes by the malaria parasite is a complex process, involving multiple 
parasite-host interactions at each stage. The initial interaction occurs between any point on the 
merozoite surface and the RBC membrane. Reorientation of the parasite to bring its apical 
prominence into direct contact with the host cell is rapidly followed by tight junction formation 
between the parasite and host cell membranes (Dvorak et al., 1975). The merozoite enters the 
RBC and the membrane pinches off behind it, enclosing it in the PV. The whole process takes 
about 30 seconds.
3.6.1: Does AM A1 mediate the initial attachment of the merozoite to the RBC?
Molecules involved in the initial interaction must either already be on the surface of the parasite 
at the time of schizont rupture or be released onto the surface immediately following it. As this 
interaction may occur at any point on the parasite surface, this receptor/ligand is likely to be 
present across the entire surface. The parasite determinants responsible for reorientation, if this 
is a controlled rather than random process, must show some directionality so that the movement 
is exclusively towards the apical end. This may be achieved by protein release from an 
organelle within the apical complex and redistribution across the parasite resulting in the 
formation of a concentration gradient. Proteins involved in tight junction formation need only be 
released from the apical organelles as the apical prominence comes into contact with the RBC 
membrane. Furthermore, it may be deleterious to the parasite if these proteins are released 
before the parasite has reorientated. These proteins can therefore be retained until some signal 
to the parasite indicates the need for their release. This signal could occur as a result of 
initiation of either of the preceding steps.
Other than the major merozoite surface proteins, such as MSP1, two other potential candidates 
for a role in initial attachment are the DBL-EBP MAEBL and AMA1. Both these proteins have an
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apical localisation in developing merozoites but are released onto the surface around the time of 
schizont rupture and can be shown to have a circumferential localisation in free merozoites 
(Kappe et al., 1998a). Thus, unlike other DBL-EBPs, MAEBL (and AMA1) are in the correct 
location at the appropriate time to facilitate initial binding of invasive merozoites to host 
erythrocytes.
3.6.2: Does AMA1 interact directly with the host erythrocyte?
That AMA1 plays a role in erythrocyte invasion has been demonstrated. Triglia et al. (2000) 
demonstrated that P. chabaudi AMA1 (PcAMAI) was unable to completely complement the 
function of PfAMAI. However, transgenic expression of PcAMAI under the control of the 
Pfamal promotor, in addition to endogenous PfAMAI, enabled P. falciparum parasites to 
invade human erythrocytes in the presence of anti-PfAMA1 antibodies at 35% the efficiency of 
wild type D10 parasites in the absence of antibodies (Triglia et al., 2000; Healer et al., 2005). In 
the presence of anti-PfAMA1 Abs invasion by wild type D10 parasites was almost completely 
inhibited. This indicates that PcAMAI can partially complement the function of PfAMAI. In 
addition, invasion of murine erythrocytes by this transgenic line was enhanced (Triglia et al., 
2000). Thus, AMA1 plays a critical role in host cell invasion and in addition contributes to host 
species specificity, suggesting that it interacts directly with the host erythrocyte.
3.6.3: Could AMA1 play a role in erythrocyte invasion down-stream of the initial 
attachment event?
Due to the initial localisation in the micronemes and the subsequent redistribution to the surface 
via the apical prominence, AMA1 could participate in parasite reorientation once the initial 
attachment has been achieved. In support of this, in the presence of an invasion inhibitory rat 
mAb against PkAMAI, the initial interaction between P. knowlesi merozoites and erythrocytes 
occurs, however reorientation and tight junction formation do not (Mitchell et al., 2004). This 
suggests that the initial interaction occurs independently of AMA1, which must perform a role in 
erythrocyte invasion downstream of this initial attachment event. The membranous vesicles 
previously observed during normal invasion (Dvorak et al., 1975) were found to be present in 
some RBCs, suggesting that some merozoites did contact the erythrocyte via their apical 
prominence, releasing some of the contents of their apical organelles, but were unable to 
complete the invasion process (Mitchell et al., 2004). It is possible that merozoite reorientation 
following initial binding is a random process facilitated by the deformations of the RBC following 
the initial binding step (Dvorak et al., 1975). During this process the RBC membrane is 
observed to wrap itself around the parasite (Mitchell et al., 2004). This parasite-induced activity 
brings the RBC membrane into contact with different regions of the merozoite membrane and 
thus may randomly promote interaction with the apical end of the parasite.
102
3.6.4: AMA1, a component of the tight junction?
In P. knowlesi and P. vivax, the DBPs have been implicated in tight junction formation(Miller et 
al., 1979a). This role may be filled in other parasite species, not dependent on the Duffy antigen 
for invasion, by other EBPs. As antibodies against AMA1 block invasion in several species of 
Plasmodium (Deans et al., 1982; Thomas et al., 1984; Kocken et al., 2000) and it is highly 
conserved across the genus at the amino acid level (Waters et al. 1990), it is likely that AMA1 
function is also conserved. The requirement for the DBPs in P. vivax and P. knowlesi for tight 
junction formation and the essential, conserved nature of AMA1 across Plasmodium spp 
suggests that if AMA1 participates in tight junction formation it is unlikely to do so in isolation. 
One possible scenario is that AMA1 is involved in tight junction formation in the context of a 
multi-component complex comprising other parasite proteins, such as the DBPs. However, the 
time of relocalisation of AMA1 across the parasite surface argues against a role in tight junction 
formation. If AMA1 is a member of the complex that forms a tight junction between the apical 
end of the merozoite and the RBC it must then be translocated across the parasite surface as 
the merozoite invades. If this occurs, what is its function on the surface of the merozoite so early 
after and in some cases before (Waters et al., 1990) schizont rupture? One possible explanation 
is that the surface distributed AMA1 is drawn into the tight junction as it necessarily expands to 
move around the parasite surface. The observation in IFA that the MESH SUB2 is translocated 
around the surface of free merozoites from anterior to posterior in a manner mirroring tight 
junction movement (Harris et al. submitted) suggests that during invasion it is a component of 
the tight junction. This suggests a sheddase role for SUB2 at the orifice of entry, allowing 
internalisation of the parasite and invagination of the RBC membrane. The identification of 
SUB2 as the protease that cleaves AMA1 from the merozoite surface (Harris et al. submitted) 
and its putative presence in the tight junction would support the hypothesis that AMA1 is a tight 
junction component. The surface localisation of AMA1 would allow the replenishment of parasite 
molecules within the junction that are shed during this internalisation process. Miller et al. (1979) 
demonstrated that cytochalasin B treated P. knowlesi merozoites attach to and reorientate 
normally with Duffy-positive and negative erythrocytes. However, in the absence of the Duffy 
antigen on the RBC surface tight junction formation does not occur. By comparison, Mitchell et 
al. (2004) demonstrated that anti-AMA1 antibodies allow the initial interaction between the 
merozoite and RBC membranes, but inhibit reorientation and subsequent tight junction 
formation. In contrast with the arguments for AMA1 involvement in tight junction formation, 
these findings suggest a role for AMA1 in the interim between initial attachment of the parasite 
to the host cell and junction formation. Whether this is the role of SUB2 in the tight junction, or if 
this is indeed where it is located during erythrocyte invasion, is unclear.
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3.6.5: sgPfAMAI may not mediate erythrocyte binding
To investigate the role of PfAMAI in invasion of human erythrocytes in the current study, the 
full-length synthetic gene product (sgPfAMAI) was expressed in COS-7 cells with its cognate 
transmembrane and cytoplasmic domains. Recognition of the expressed protein by mAb 
4G2dc1, on unfixed, unpermeabilised cells confirmed that the protein was expressed in the 
correct topological orientation on the cells (Fig 3.1). Despite numerous attempts in a variety of 
assays, it was not possible to demonstrate binding of human RBC to these transfected cells. 
Further assays using recombinant protein immobilised at high density on polystyrene or 
nitrocellulose similarly failed to demonstrate any capacity for the protein to bind RBCs even 
though solid phase binding assays have been used previously to demonstrate binding of 
parasite antigens to host cells (Buffet et al., 1999). This group demonstrated that parasitised 
erythrocytes (trophozoite stage) bound to the erythrocyte receptors CD36 and chondriotin 
sulphate A that had been bound to plastic Petri dishes. In a "cell blot" assay involving the T. 
gondn antigen MIC3, Garcia-Reguet et al. (2000) demonstrated binding of Vero cells to purified 
TgMIC3 and mouse intestinal epithelial cells (MODE-K cells) to MIC3 from parasite lysates, 
electrophoresed in SDS-PAGE and electrophoretically transferred to nitrocellulose membrane 
as in the current study. In the current study there was no positive control for erythrocyte binding 
to immobilised antigen with either of the methods used. It is possible that a cell lysate from the 
COS-7 cells transfected with PvDBL region II could have been electrophoresed in SDS-PAGE 
and transferred to nitrocellulose as a positive control in this assay. However, the identity of the 
protein supporting erythrocytes binding could not have been confirmed, as no anti-PvDBL 
region II Abs were available. The method of detection used to determine RBC binding to 
nitrocellulose-bound rPfAMAI in the current study would not have allowed the detection of low- 
level erythrocyte binding. More reliable detection might have been achieved by fixing bound 
erythrocytes to the nitrocellulose and then carrying out a Western blot using an anti-RBC Ab, 
such as an anti-Band 3 Ab. An alternative approach would have been to generate RBC ghosts 
and solubilise these in SDS-sample buffer before electrophoresis in SDS-PAGE. An overlay 
assay could then have been carried out using a solution of rPfAMAI and binding of this 
recombinant protein to its erythrocyte receptor molecule determined by Western blot analysis 
using an anti-PfAMA1 Ab. This approach was used by Maier et al. (2003) to demonstrate 
binding of the DBL-EBP BAEBL to erythrocyte ghosts. One problem with the use of this 
approach in the current study is that it relies on the one-to-one binding affinities of PfAMAI and 
its receptor being strong enough to maintain the interaction. It has already been noted that 
Howell et al. (2001) were unable to demonstrate that the ectodomain of PfAMAI shed from 
merozoites possessed RBC binding activity. This suggests that the binding affinity of monomeric 
PfAMAI is not great enough to maintain such interactions and allow detection. It is possible that 
after release from the merozoite surface PfAMAI undergoes conformational changes that might 
disable its RBC binding activity, however, evidence from the current study suggests that even 
when membrane bound, PfAMAI does not exhibit such activities.
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3.6.6: Shear stress is unlikely to be required for AM A1-erythrocyte interactions
It has been demonstrated that leukocyte adhesion to endothelial venules mediated by the 
selectins (L-, P- and S-selectin) is enhanced by fluid shear stress (Finger et al., 1996; Lawrence 
et al., 1997; Alon et al., 1997). The physiological conditions under which merozoites adhere to 
and invade RBCs in the blood stream are the same as those encountered by leukocytes near a 
site of infection or tissue damage, except that both merozoites and erythrocytes are moving. To 
investigate the possibility that shear stress forces, operating on interacting merozoites and 
RBCs in vivo, might enable RBC binding to COS-7 cells expressing sgPfAMAI in vitro, 
transfected cells expressing sgPfAMAI were incubated with human erythrocytes under 
conditions designed to simulate such forces. A possible explanation for the inability to observe 
erythrocyte binding in these assays is that the conditions did not accurately resemble those 
experienced by the merozoite in the blood stream. In leukocyte binding studies, parallel wall- 
flow chambers are used in which the flow rate can be determined and varied (Alon et al., 1997; 
Chen and Springer, 2001). This allows direct and quantifiable analysis of the effects of shear 
flow/stress on ligand interaction and the determination of the critical flow rate to maintain such 
interactions. Clearly the use of a flow chamber in the current study would have provided clearer 
evidence of whether such flow is required for PfAMAI-erythrocyte interactions in this system.
Chitnis and Miller (1994) have shown by transfection in COS-7 cells that region II of the P. vivax 
DBP is responsible for RBC binding. By using region II of P. vivax DBP (PvDBP) in the current 
binding assays it was shown that the conditions used in the current study were conducive to 
binding at least for this molecule. It might be imagined that the effects of shear stress acting 
against two free moving cells is greatest before they bind to each other. The involvement of 
DBPs in tight junction formation, when the stress acting on the cells to pull them apart is 
possible reduced as they are already interacting, is unlikely to be dependent on shear stress. 
This may explain why erythrocyte binding by region II of PvDBP occurs in this study irrespective 
of the flow conditions used. If the initial interaction between merozoite and erythrocyte is 
mediated by a resident surface parasite molecule, as has already been suggested, and PfAMAI 
functions down stream of this event (Mitchell et al., 2004) it is probable that shear stress is not 
critical for PfAMAI based RBC binding. This would suggest that if PfAMAI is an erythrocyte 
binding molecule some other factor, lacking in the current study, is required for this interaction to 
be observed.
3.6.7: Is the PfAMAI synthetic gene product functional?
The failure of this study to attribute erythrocyte-binding activity to PfAMAI may in part be due to 
differences between the synthetic gene product and the endogenous gene sequence. The FVO 
AMA1 sequence contains 6 potential N-glycosylation sites. Despite early reports that P. 
falciparum lacked the machinery for N-glycosylation (Dieckmann-Schuppert et al., 1992) recent
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studies have shown this parasite to have a low N-glycosylation capability (Gowda et al., 1997; 
Gowda and Davidson, 1999). However, identification of five of the six potential N-glycosylation 
sites by MALDI-TOF analysis of proteolytically digested PfAMAI 83 and PfAMA148/44 failed to 
show any glycosylation (Howell et al., 2001). For this reason all six sites were replaced in the 
Pfamal synthetic gene sequence with amino acids found at the corresponding position in AMA1 
from other species of Plasmodium. These alterations in the primary sequence of PfAMAI may 
have had a deleterious effect on function. It is possible that the sixth N-glycosylation site that 
was not identified in the study of Howell et al. (2001), is in fact glycosylated and that 
glycosylation at this position is essential for the adhesive properties of the protein. Alternatively 
the alteration in amino acid sequence itself could deleteriously alter the charge interactions 
between receptor and ligand. The functionality of the Pfamal synthetic gene sequence is 
considered in chapter 6.
3.6.8: Potential erythrocyte binding domains in the PfAMAI ectodomain
The similarity identified between AMA1 Dl-ll with domains M1 and M2 of the EBP MAEBL (Ghai 
et al., 2002) add weight to the suggestion that AMA1 is an erythroycte binding protein. Thus, the 
implication is that Dl-ll of AMA1 facilitate invasion of erythrocytes by Plasmodium species by 
binding to a ligand on the RBC surface. The work of Fraser et al. (2001) added support to this 
idea. This group expressed the ectodomains of PyAMAI on the surface of COS-7 cells as a 
chimera with the transmembrane region and cytoplasmic domain of HSVgDI. Significantly less 
erythrocyte binding activity was then observed with a chimera of Dl-lll (full length ectodomain) 
than with Dl-ll, even though the molecule was properly folded and expressed on the cell surface 
(shown by IFA using mAb 45B1, which recognises a conformation dependent epitope in the 
PyAMAI ectodomain). Indeed, Dl-lll demonstrated less erythrocyte binding than Dl and Dll 
together or alone, or Dll and III together. The possibility that PfAMAI Dl-ll mediates erythrocyte 
binding was not investigated in the current study. However, if RBC binding was a genuine 
property of AMA1, it could be argued that the full-length protein would also be expected to 
demonstrate this property. Therefore, it is possible that erythrocyte binding is not a function of 
AMA1. The RBC binding property of Dl-ll may be a non-specific property of these two domains 
expressed on their own, exposing a normally buried region of the molecule.
In a recent study (Kato et al., 2005) varying regions of the PfAMAI ectodomain (FVO clone) 
were expressed in GPI anchored form on the surface of CHO-K1 cell. When expressed alone, 
Dill was found to bind trypsin treated erythrocytes but not intact erythrocytes. Neither Dl-lll nor 
Dl-ll was able to facilitate binding of normal or trypsinised RBC. The authors suggest that 
proteolytic processing of AMA1 may explain the binding of DIM in preference to Dl and Dll. It is 
unclear how this can occur when none of the processing of AMA1 thus far described (Howell et 
al., 2001; Howell et al., 2003b; Howell et al., 2005) identifies DIM on the erythrocyte surface in 
the absence of the rest of the ectodomain. Furthermore, this finding was not corroborated by the
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current study. Expression of Dill on the surface of COS-7 cells did not induce RBC binding to 
the transfected cells.
The possibility cannot be ruled out that a parasite induced conformational change occurs in the 
PfAMAI ectodomain at the time of invasion, which results in the exposure of otherwise hidden 
domains, that are artificially exposed in these studies in heterologous systems. However, this 
does not explain the inconsistency between the results of Kato et al. (2005) and the current 
study.
3.6.9: AMA1 Dl-ll comprises characterised adhesion modules
The crystal structure of PvAMAI has identified two PAN modules, one in each of Dl and Dll 
(Pizarro et al. 2005). In other systems PAN modules are functionally diverse (Baglia and Walsh, 
1996; Ho et al., 1998; Tordai et al., 1999). However, they share the common feature of 
mediating protein-protein or protein-carbohydrate interaction (Ho et al. 1998). Owing to the 
functional diversity of these proteins it is impossible to suggest a precise role for AMA1, other 
than that it probably has some adhesion function (Tordai et al. 1999). This lends support to the 
idea outlined above that Dl-ll possess erythrocyte binding properties.
Pizarro et al. (2005) compared the PAN module of PvAMAI Dll with the heparin-docking site of 
the hepatocyte growth factor, NK1. The putative receptor-binding site of Dll could be composed 
of strand p14 and helix a7, equivalent to p2 and the PAN domain helix of NK1 respectively. The 
loop connecting the helix and sheet p15 is not in a position to interact with the substrate as the 
equivalent loop is in NK1. However, it is feasible that upon substrate docking the flexible Dll 
loop closes over it to lock it in place (Fig 3.5). Clearly heparin need not be the ligand for AMA1 
and the charge distribution at this site on AMA1 is unlikely to support interactions with such a 
ligand. However, this identifies at least one potential, sterically favourable binding site on AMA1. 
It is possible that AMA1 may directly, or in conjunction with a parasite encoded partner protein, 
interact with an erythrocyte ligand via this site. PAN modules have been identified in micronemal 
proteins from the apicomplexan parasites T. gondii and Eimeria tenella (Brown et al., 2001) 
(Brecht et al., 2001). As micronemal proteins have been implicated in host cell recognition and 
attachment, it is possible that these parasites use conserved structures to overcome this 
problem despite the fact that they invade very different cell types.
Determination of the crystal structure of PfAMAI has enabled (Bai et al., 2005) to identify a 
hydrophobic trough in Dl of the PfAMAI ectodomain, two residues of which are contributed by 
the Dll loop. The work from this group suggests that the trough acts as a binding pocket for the 
PfAMAI ligand. The group have obtained several crystal structures for PfAMAI Dl-ll. In two of 
these structures the Dll loop occupied different orientations and in the third this loop lacked 
electron density and its structure could not be solved (Adrian Batchelor, personal
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communication). This suggests that, as was indicated from the PvAMAI structure Pizarro et al. 
2005) the loop is flexible and can adopt multiple conformations. One possibility is that two 
binding sites exist in the PfAMAI ectodomain, one in Dl and the other in Dll. Ligand interaction 
with the heparin-like binding site in Dll requires the Dll loop to close over it, thus holding it in 
place. In contrast, ligand interaction with the hydrophobic trough of Dl requires that the Dll loop 
be in a suitable orientation to provide two residues that lie at the base of the trough. In the event 
that both sites could be occupied simultaneously, the Dll site could bind the AMA1 partner 
molecule on the parasite surface, while the Dl site binds the ligand on the erythrocyte surface. 
Alternatively occupation of one site may preclude binding to the other. For instance, homo- 
multimerisation of AMA1 may occur when AMA1 is at a high local concentration. When AMA1 is 
released onto the parasite surface and the local concentration decreases, this could result in 
dissociation of the homo-multimer, thus allowing the Dll loop to complete formation of the 
hydrophobic trough in Dl, allowing binding of the erythrocyte ligand. A mechanism of this type 
may prevent the premature interaction of AMA1 with its erythrocyte ligand, for instance on the 
cell from which the merozoite is egressing. However, this is not consistent with the inability to 
detect AMA1 complex formation in schizonts or free merozoites in the current study.
3.6.10: AMA1 as a component of a parasite protein complex involved in erythrocyte 
attachment
PfAMAI may interact indirectly with a RBC surface receptor(s) via a complex, containing 
proteins expressed at or released onto the merozoite surface during invasion. Alternatively, a 
homo-multimer mediated by the PfAMAI transmembrane domain, may form at the merozoite 
surface. Whilst COS-7 cell expression of full-length sgPfAMAI could also support such 
multimerisation, the possibility cannot be ruled out that multimerisation requires some form of 
protein modification to occur. PfAMAI is shed from the merozoite membrane in two forms, two 
thirds as PfAMA148, being cleaved downstream of Dill and one third as PfAMAI44, cleaved 
within as well as downstream of Dill (see Fig 1.5) (Howell et al., 2003a). The same proportion of 
secondary processing is also seen in AMA1 derived from other Plasmodium species (Blackman, 
unpublished data). This might suggest some functional significance for the internal Dill 
cleavage. While Howell et al. (2003) have shown conclusively that PfAMAI is shed as a 
monomer, multimerisation may be dependent upon membrane association. Thus, the cleavage 
ratio of 48 to 44 kDa forms (2:1) may be explained by the presence of PfAMAI as a homo- 
trimer, consisting of two intact molecules interacting via their transmembrane domains and a 
third molecule cleaved within and possibly also downstream of DIM.
To investigate the possibility that PfAMAI forms a complex at the parasite surface with other 
parasite proteins, co-precipitation studies were carried out from purified schizont and merozoite 
samples. Multiple bands immunoprecipitated with mAb 4G2dc1 and the polyclonal serum N1 in 
the absence of cross-linking agents, however, most of these were of PfAMAI origin. Co­
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precipitated of proteins that were not of AMA1 origin were not reproducible, suggesting that co­
precipitation of these proteins was non-specific.
In the event that interactions between AMA1 and its putative partner protein(s) were too weak to 
be detected under the detergent conditions used, merozoite and schizont samples were cross- 
linked in order to stabilise the interaction(s) prior to immunoprecipitation. The results from this 
attempt were inconclusive as nothing co-precipitated although the actual AMA1 bands were 
very faint suggesting the immunoprecipitation itself was relatively inefficient. To be able to draw 
any conclusions from this, it will be necessary to repeat these experiments.
Camus and Hadley (1985) demonstrated that EBA-175 bound to P. falciparum merozoites as 
well as human erythrocytes. Schizonts from which these merozoites were purified had been pre­
treated with trypsin, which abrogates EBA-175 recognition, suggesting that EBA-175 bound 
specifically to the merozoites and not to erythrocyte membrane contamination resulting from the 
parasite preparation. If this result is valid, EBA-175 may form a bridge between a membrane 
bound receptor at the merozoite surface (e.g. AMA1) and a ligand on the erythrocyte surface. 
The formation of a bridge between a parasite and host cell is not without president. The T. 
gondii microneme protein MIC3 (TgMIC3) is secreted from the micronemes during invasion and 
detected on the surface of invading tachyzoites (Garcia-Reguet et al., 2000). This protein has 
no transmembrane domain and the finding that TgMIC3 binds both host cells and tachyzoites 
has led this group to deduce that TgMIC3 forms a bridge between the parasite and host cell 
membranes during invasion. In Plasmodium, a complex involving soluble and membrane bound 
parasite antigens may assemble in the micronemes of developing merozoites or at the parasite 
surface upon schizont rupture. EBA-175 is believed to form homo-dimers on contact with its 
erythrocyte receptor, glycophorin A, on the RBC surface (Tolia et al., 2005). From the crystal 
structure of EBA-175, with and without glycophorin A, this group have identified six glycan 
binding sites within the dimer, all six of which are important for glycophorin A binding. In 
addition, as these binding sites all contact both monomers, this suggests that dimerisation is 
important for receptor binding. Dimerisation of TgMIC3 is also required for host cell receptor 
binding although this is believed to be mediated by its C-terminal region while receptor binding 
is mediated via its N-terminal lectin-like domain (Cerede et al., 2002). Camus and Hadley (1985) 
demonstrated that human erythrocytes coated with EBA-175 were successfully invaded by the 
homologous strain of parasite, but were refractory to invasion by heterologous strains. This 
suggests that EBA-175 from the homologous parasites can act as a bridge between the 
merozoite and the RBC, thus mediating binding. It further indicates that the cytoplasmic tail of 
EBA-175 may not be essential at the time of invasion. In contradiction to the possibility of EBA- 
175 being released from the micronemes in soluble form is the observation by Gilberger et al. 
(2003) that its cytoplasmic tail is essential for invasion, though not for microneme targeting. 
Putting these two findings together, it is possible that EBA-175 requires membrane tethering to 
prevent premature release from the micronemes, but not for signal transduction during invasion
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as was suggested by Gilberger etal. (2003). EBA-175 could be proteolytically released from the 
micronemes by a resident microneme rhomboid, such as ROM1 (O’Donnell unpublished data). 
In T. gondii, soluble microneme proteins such as MIC3 are present in complex with integral 
membrane proteins. Among other functions, this membrane association may prevent premature 
release of soluble proteins from the micronemes. In Plasmodium, microneme proteins appear 
largely to be integral membrane proteins and it is possible that these parasites utilise different 
mechanism for the regulation of microneme secretion. In the case of AMA1 interacting with a 
soluble partner protein involved in tight junction formation, it would be anticipated that the 
complex would form at the apical tip of the parasite immediately prior to junction formation. This 
may explain why the current study failed to identify any specific PfAMAI -partner protein 
interaction in schizonts and free merozoites. If invasion could be halted, for instance using 
cytochalasin D, this possibility could be analysed further.
In conclusion, the results from erythrocyte binding studies involving AMA1 as discussed above, 
are varied and not easy to interpret. While on the one hand there is evidence to suggest that 
AMA1 is an erythrocyte binding protein (Mitchell et al. 2004; Triglia et al., 2000), the studies 
purporting to provide direct evidence of such activity are not conclusive (Fraser et al. 2001; Kato 
et al. 2005). This latter conclusion is supported in the current study. If the function of AMA1 in 
erythrocyte invasion is one of erythrocyte binding, more work is required to understand the 
conditions under which such interactions are able to occur.
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Figure 3.1: IFA revealing surface localisation of sg'PfAMAI in transfected COS-7 cells
COS-7 cells were analysed unfixed and unpermeabilised to detect surface localised protein 
only. COS-7 cells transfected with the plasmid pSec/sg1 Pfamal (A) or untransfected (B) as a 
negative control, were incubated with (i) culture supernatant from 4G2dc1 expressing 
hybridoma cells (undiluted) or (ii) the polyclonal serum N1 (at 1 in 100 dilution). The image is a 
composite of DAPI (blue), Evans blue (red) and FITC conjugate (green) images from 
fluorescence microscopy as described in materials and methods (section 2.4.3).
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Figure 3.2: Immunoprecipitation of PfAMAI from biotin surface labelled P. falciparum
schizonts using mAb 4G2dc1
Biotin labelled schizont samples were solubilised in buffers containing either NP40 (N), CHAPS 
(C) or sodium deoxycholate (S) and processed for immunoprecipitation using Sepharose bound 
4G2dc1. The immunoprecipitated protein samples were separated by SDS-PAGE on 12.5% 
gels. The samples were transferred to nitrocellulose and probed with; (A) HRP-conjugated 
streptavidin, (B) polyclonal serum R1 followed by HRP-conjugated anti-mouse IgG or (C) HRP- 
conjugated anti-mouse IgG) alone. Major bands detected are highlighted (black arrows) and 
their calculated masses indicated in kDa.
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Figure 3.3: Immunoprecipitation of PfAMAI from [35S] cysteine/methionine metabolically
labelled P. falciparum (3D7) schizonts and merozoites, using mAb 4G2dc1
PfAMAI was immunoprecipitated from CHAPS extracts of metabolically radiolabelled merozoite 
(m) and schizont (s) fractions. Immunoprecipitates were electrophoresed on 12.5% SDS-PAGE 
gels and transferred to nitrocellulose for either; (A) direct detection of radiolabelled proteins by 
fluorography or Western blot analysis, using; (B) polyclonal serum R1 followed by HRP- 
conjugated anti-mouse IgG or (C) secondary Ab only. The major bands detected are indicated 
(black arrows) and their calculated masses indicated in kDa.
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Figure 3.4: Immunoprecipitation of PfAMAI from [35S] cysteine/methionine metabolically
labelled P. falciparum (3D7) schizonts and merozoites, using polyclonal serum N1
PfAMAI was immunoprecipitated from CHAPS extracts of metabolically radiolabelled merozoite 
(m) and schizont (s) fractions. Immunoprecipitates were electrophoresed on 12.5% SDS-PAGE 
gels and transferred to nitrocellulose for either; (A) direct detection of radiolabelled proteins by 
fluorography or Western blot analysis using; (B) polyclonal serum R1 followed by HRP- 
conjugated anti-mouse IgG or (C) secondary Ab only. The major bands detected are indicated 
(black arrows) and their calculated masses indicated in kDa.
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Figure 3.5: Surface view of PfAMAI Dl (orange) and Dll (blue) demonstrating the potential 
binding surfaces in this region of the ectodomain.
(A) Surface view of the hydrophobic trough of PfAMAI (the residues involved in this trough are 
highlighted in red) as determined by Bai et al. (2005). The two residues (Phe367 and Leu357) 
contributed by the Dll loop are indicated (black arrows) as is the remainder of the Dll loop (blue 
arrow). In this conformation, the Dll loop can be seen to reach up over the top of the molecule.
(B) Surface view of the putative Dll binding site as determined by Pizarro et al. (2005). The 
surfaces contributed by a-helix 7 and p-sheet 14 (indicated by black arrows) are denoted in 
green.The top of the hydrophobic trough and part of the 4G2dc1 binding site are visible (red and 
black respectively). From the proximity of the loop to both sites, it is possible that under different 
conditions it can adopt alternative conformations to interact with one or other of the sites.
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Chapter 4
Mapping the PfAMAI epitope recognised by the invasion-
inhibitory mAb 4G2dc1
4.1: Introduction
Many different Abs reactive against AMA1 have been described that block asexual replication 
by different species of Plasmodium in vitro (Dutta et al., 2005; Casey et al., 2004; Mueller et al., 
2003; Hodder et al., 2001; Kocken et al., 2000; Crewther et al., 1996b) as well as in vivo 
(Rodrigues et al., 2005; Polley et al., 2004; Stowers et al., 2002; Anders et al., 1998). The 
finding that Abs against AMA1 inhibit erythrocyte invasion by Plasmodium merozoites indicates 
a fundamental role for the protein in this process. However, the mechanism of action of such 
Abs is unclear and may be diverse. The relatively large molecular mass (approximately 160 
kDa) of invasion inhibitory anti-AMA1 Abs (IgG) suggests that they may block the function of 
AMA1 indirectly by steric hindrance. They may bind close to a region of AMA1 that is of 
functional significance, thus blocking access to some receptor or ligand in the parasite or on the 
RBC surface. Alternatively they may bind directly to a functional site, thus inhibiting its activity.
Several different mechanisms of Ab-mediated invasion-inhibition have been postulated. AMA1 
is synthesised in late schizogony and localises to the micronemes of developing merozoites. 
Around the time of schizont rupture, the protein undergoes proteolytic maturation and 
redistributes across the surface of the merozoite. Some invasion-inhibitory antibodies have 
been shown to cross-link AMA1 at the apical end of the parasite, thus blocking redistribution of 
the molecule across the merozoite surface (Dutta et al., 2005; Dutta et al., 2003). These authors 
postulated that, either redistribution of AMA1 is essential for invasion or that cross-linked AMA1, 
retained at the apical end of the parasite, acts as a plug preventing efficient microneme 
secretion of other molecules essential for merozoite invasion.
Following translocation onto the merozoite surface, the ectodomain of PfAMAI is shed from the 
merozoite surface by a calcium-dependent serine protease or "sheddase" (Howell et al., 2003b) 
(Howell et al., 2001) with cleavage occuring 29 residues N-terminal to the predicted membrane 
spanning sequence. An alternative mechanism proposed for the invasion-inhibitory activity of 
certain anti-AMA1 antibodies is that of blocking this processing event, presumably by preventing 
access of the protease to the cleavage site (Dutta et al. 2005). Whether this consequence of 
antibody binding is directly responsible for invasion-inhibition is unclear. The identification of 
Abs to PfMSPI that directly preventing its processing and shedding and thus inhibit merozoite 
invasion of erythrocytes (Blackman, 1994; Nwuba et al., 2002) may lend support to a similar 
mechanism of operation against AMA1.
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Studies in all apicomplexan parasites investigated so far indicate a high conservation of function 
of AMA1 during host cell invasion. The (lgG2a) mAb 4G2dc1 inhibits P. falciparum merozoite 
invasion of human erythrocytes by 60 - 70% compared with isotype control antibodies (Kocken 
et al., 1998b). In addition, this mAb has also been shown to inhibit invasion of chimpanzee 
erythrocytes by the phylogenetically closely related chimpanzee parasite P. reichenowi (Kocken 
et al., 2000). The presence of the epitope recognised by this mAb in both parasite species 
indicates a similarity of structure in AMA1. In the current study, an attempt was made to map the 
epitope recognised by the mAb 4G2dc1 in PfAMAI to identify a functionally significant region of 
its ectodomain. Subsequent strategic modification of this region of the molecule by site directed 
mutagenesis might then aid elucidation of the function of AMA1 in these parasites.
4.2: The mAb 4G2dc1 Fab fragment exhibits greater invasion-inhibition 
than the intact Ab
Characterisation of the anti-parasitic activity of the mAb 4G2dc1 was based on its inhibitory 
effect on erythrocyte invasion by P. falciparum merozoites. The possibility that this inhibitory 
activity resulted from a steric hindrance effect when 4G2dc1 bound to AMA1 was investigated in 
the current study by assessing the inhibitory potential of Fab fragments of 4G2dc1 (4G2dc1- 
Fab) on merozoite invasion.
At varying concentrations of intact 4G2dc1 and 4G2dc1-Fab, invasion-inhibition was calculated 
as a percentage of that observed in control assays, in the absence of Ab (Table 4.1). The mAb 
4G2dc1 is of the IgG isotype, which is bivalent. A comparison between the concentrations of 
intact 4G2dc1 versus 4G2dc1-Fab is not direct, as it does not reflect the concentration of 
4G2dc1 binding domains. Only about two thirds of an intact mAb fragment is composed of Fab 
fragments, the remainder comprising the Fc (crystalIisable) fragment. In order that a direct 
comparison can be made, the concentration of mAb 4G2dc1 has been adjusted to reflect the 
concentration of these antigen binding sites (shown in brackets in Table 4.1). All future 
discussion will refer to the concentration of 4G2dc1 binding sites. As shown in Fig 4.1 (A), the 
4G2dc1-Fab was a more potent inhibitor of invasion than the intact Ab. The mAb 4G2dc1 
mediated about 74% invasion-inhibition at a concentration of 0.18 mg ml'1, compared with about 
99% inhibition produced by the approximately equivalent concentration (0.16 mg ml'1) of 
4G2dc1 -Fab.
The assay was repeated with lower concentrations of the 4G2dc1-Fab, to investigate the degree 
to which the Fab preparation could be diluted while retaining its inhibitory properties. In 
accordance with the previous results, on titration the 4G2dc1-Fab was found to mediate 
significant invasion-inhibition down to relatively low concentrations, showing 24% inhibition at 
0.05 mg ml'1 (Fig 4.1 B). This represents a concentration of 4G2dc1-Fab fragment one fifth that 
found in the intact antibody assay, giving a percentage inhibition of 30%.
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4.2.1: Recombinant PfAMAI Dl-lll exhibits anti-invasion inhibitory properties
After purification of 4G2dc1-Fab (see section 2.4.5.2.), the Ab fragment was dialysed against 
PBS to remove the salts present in the gel filtration running buffer (SRB). However, it was 
possible that the enhanced inhibitory activity of 4G2dc1 -Fab over that of the intact mAb resulted 
from the presence of residual salts in the Fab preparation, rather than a direct effect of the Fab. 
In an attempt to rule out this possibility, the invasion-inhibition assay was repeated in the 
presence of rPfAMAI Dl-lll.
4.2.1.1: Binding assay confirming the interaction between 4G2dc1-Fab and rPfAMAI Dl-lll
To ensure that the 4G2dc1-Fab and the antigen PfAMAI Dl-lll were able to interact, binding 
assays were performed prior to repeating the invasion-inhibition assay. Binding of the Fab and 
antigen were monitored by HPLC (Fig 4.2.). This resulted in a shift in the position of the peaks, 
due to complex formation. The peak representing the soluble unbound antigen diminished 
slightly, while the Fab alone peak was no longer visible. The antigen concentration was far in 
excess of the Fab, and therefore it was anticipated that only a fraction of the antigen would bind. 
The Fab and antigen on their own are eluted from the column very close together. When 
complexed and separated by HPLC, there was a slight broadening of the antigen alone peak. 
This was probably due to overlap between the two peaks due to their close migration and 
indicates that some Fab remains unbound, perhaps due to an inablility to bind to the antigen. 
However, the size of the peak that is generated by complex formation indicates that a 
considerable amount of Fab has bound. This suggested that the presence of the recombinant 
ectodomain of PfAMAI in invasion-inhibition assays with Fab-4G2dc1 could be effective at 
countering the activity of the Fab-4G2dc1.
4.2.1.2: Merozoite invasion-inhibition in the presence of rPfAMAI Dl-lll
The invasion-inhibition assays were repeated in the presence of 1 mg ml'1 rPfAMAI Dl-lll, with 
4G2dc1-Fab at the lower concentrations described earlier. Thus, at the highest Fab 
concentration, there was over a two fold excess of antigen to 4G2dc1-Fab (Table 4.2.). It was 
anticipated that during pre-incubation of the 4G2dc1-Fab with the antigen, they would bind to 
each other, thus reducing or eliminating free 4G2dc1-Fab from the reaction mixture and 
consequently disrupting the invasion inhibitory effect of the Fab. However, if the invasion 
inhibitory effect was not a direct consequence of 4G2dc1-Fab in the assay, there would have 
been no difference in invasion-inhibition in the presence or absence of antigen. Once again, 
invasion-inhibition was calculated as a percentage of the invasion rate in the absence of 
4G2dc1-Fab and antigen. Figure 4.3 shows the invasion-inhibition observed in this assay. There 
was an overall increase in invasion-inhibition as the concentration of 4G2dc1-Fab increased, in 
the presence and absence of rPfAMAI Dl-lll. Overall, there was slightly greater inhibition of 
invasion in the absence of rPfAMAI, as was expected. However this anti-invasion inhibitory
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effect was not significant. There was an inexplicable drop in invasion-inhibition at a 4G2dc1-Fab 
concentration of 0.16 mg ml'1. In addition, invasion-inhibition in the presence of antigen at a 
4G2dc1 -Fab concentration of 0.43 mg ml'1 was greater than that observed in its absence. The 
assay was repeated, this time with a 10 fold excess of rPfAMAI Dl-lll over 4G2dc1-Fab (Data 
not shown). On this occasion, no invasion-inhibition was observed in the presence of 4G2dc1- 
Fab and in contrast PfAMAI Dl-lll had an invasion enhancing effect, both in the presence and 
absence of 4G2dc1-Fab. These findings were unexpected and need further investigation. In this 
assay rPfAMAI Dl-lll was able to bind nearly all the 4G2dc1-Fab present resulting in a shift in 
the position of the peak in FIPLC. This indicated that in the invasion-inhibition assay these two 
molecules should interact, thus diminishing the invasion inhibitory effect of the Fab. One 
explanation for the inability to detect a significant difference in invasion-inhibition in the 
presence and absence of PfAMAI Dl-lll is that the affinity of the interaction between soluble 
antigen and the monovalent Fab fragment is low. As a result, competition for 4G2dc1-Fab 
binding is high between the released merozoites and the soluble antigen, thus reducing the anti- 
invasion-inhibition effect of the antigen.
The 4G2dc1-Fab fragment is approximately one third the size of the intact antibody. The ability 
of the 4G2dc1-Fab to inhibit erythrocyte invasion by P. falciparum merozoites to a greater 
degree than the intact antibody increases the likelihood that the inhibition mediated by this mAb 
results from binding to a functionally important region of the PfAMAI ectodomain. For this 
reason, the focus of this study was to identify the amino acid residues that contribute to the 
epitope recognised by this mAb and in this way identify a region of the molecule that contributes 
significantly to its function.
4.3: Identification of the PfAMAI subdomains that contribute residues to 
the epitope recognised by the mAb 4G2dc1
Several different combinations of the subdomains of the rPfAMAI ectodomain were expressed 
in heterologous systems (P. pastoris or COS-7 cells). The aim behind this approach was to 
identify the subdomains that contributed amino acid residues to the epitope recognised by the 
mAb 4G2dc1. This method might narrow the region of the ectodomain known to accommodate 
this epitope thereby reducing the number of amino acids under consideration.
4.3.1: The epitope recognised by mAb 4G2dc1 is located within Dl-ll of the rPfAMAI 
ectodomain
Cell pellets and culture supernatants from recombinant P. pastoris clones expressing regions 
(Dl, Dl-ll and Dl-lll) of the rPfAMAI ectodomain were harvested by centrifugation. The samples 
were analysed by Western blot with the polyclonal sera N1 and R1 (data not shown) and with
124
mAb 4G2dc1 (Fig 4.4) to check for expression and the presence of the 4G2dc1 epitope, 
respectively.
The full-length rPfAMAI ectodomain (Dl-lll) was successfully expressed as confirmed by 
4G2dc1 binding (Fig 4.4, lane 9). When expressed alone, Dl was not detectable in either the P. 
pastoris cell pellet (result not shown) or in the culture supernatant in Western blots probed with 
either mAb 4G2dc1 (Fig 4.4, lanes 6-8) or the polyclonal sera N1 or R1 (data not shown). 
However, Dl-ll was readily detected in culture supernatants by Western blots analysis when 
probed with mAb 4G2dc1 (Fig 4.4, lanes 2 - 5) showing that this epitope lies within Dl-ll of the 
rPfAMAI ectodomain.
4.3.2: Use of the COS-7 cell expression system to identify the subdomain(s) within which 
the epitope recognised by mAb 4G2dc1 lies
The PfAMAI synthetic gene product was expressed successfully in COS-7 cells (section 3.2.). 
For this reason it was decided to express Dl of PfAMAI ectodomain in this system, as 
expression of this subdomain was not possible in P. pastoris. In addition to Dl, several 
combinations of the subdomains within the PfAMAI ectodomain were expressed in this system 
with a view to pinpointing the epitope recognised by mAb 4G2dc1. It was anticipated that this 
system might be more conducive to expression and adoption of the correct conformation of non­
native forms of PfAMAI, as this expression system has frequently been used for expression of 
regions of Plasmodium antigens (Sim et al., 1994b; Ranjan and Chitnis, 1999; Fraser et al., 
2001; Prasad et al., 2003). COS-7 cells transfected with constructs designed for the expression 
of various regions of PfAMAI were analysed by Western blot using mAb 4G2dc1 and the 
polyclonal sera AdsN1 and R1. A schematic representation of the different domain combinations 
used is shown in Figure 4.5 (A).
4.3.2.1: Expression of Dl alone
Construct pSec/sg’DI was designed for expression of PfAMAI Dl. In order to target the Dl 
protein to the secretory pathway of the host cell, the sequence was cloned downstream of the 
Igx secretory signal. However, Western blot analysis with the polyclonal serum R1 
demonstrated expression of Dl in the cell pellet but not in the culture supernatant suggesting 
that the protein was being synthesised but not secreted (Data not shown). Multiple bands were 
detectable on the Western blot indicating the Dl product may have been partially aggregated 
and/or degraded (Fig 4.5 B). A shift in the migration of the protein product was detected under 
reducing condition, suggesting that it was reduction sensitive and indicating that a measure of 
secondary structure (disulphide bond formation) had been achieved (Fig 4.5 B). The finding that 
the protein was expressed but not secreted in this expression system, together with the 
absence of recognition by AdsN1 on Western blots, supports the idea that it may only have 
been partially folded.
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4.3.2.2: Expression of ADII
An artificial construct was designed for expression of Dl linked directly to Dill, the 
transmembrane region and cytoplasmic tail (ADII) using the plasmid pSec/ sg’PfamalADII. 
Expression was confirmed by R1 in Western blot (Fig 4.5 C, i). However, recognition by AdsN1 
was reduced (Fig 4.5 C, ii), and recognition by 4G2dc1 was abolished (Fig 4.5 C, iii) suggesting 
that this chimeric protein did not fold correctly.
4.3.2.3: Expression of rPfAMA1 tacking Dl
A further construct (pSec/sg’Pfama1ADI) was designed for expression of rPfAMAI lacking Dl 
(ADI). Expression was confirmed by R1 in Western blot (Fig 4.5 D, i). However recognition by 
Ads N1 was significantly reduced (Fig 4.5 D, ii) and mAb 4G2dc1 (Fig 4.5 D, iii) showed no 
recognition of this recombinant protein. The reduced recognition by Ads N1 indicates that the 
protein was only partially folded.
4.3.2.4: Expression of two truncated forms of PfAMA1, T1 and T2
In P. falciparum, the prodomain of AMA1 is cleaved from the molecule when located in the 
micronemes. The processed form is then relocalised to the merozoite surface. This processing 
event occurs immediately prior to Ile97, which denotes the beginning of Dl.
To determine whether the N-terminal region of Dl, preceding to the first cysteine residue 
(Cys149), contributes to mAb 4G2dc1 recognition of the molecule, two constructs were 
designed for the expression of truncated forms of PfAMAI in COS-7 cells (T1 and T2 from the 
plasmids pSec/tr1-sgPfama1 and pSec/tr2-sgPfama1 respectively). The constructs were 
designed to leave two varying length sequences upstream Cys149 in Dl. The presence of a 
cysteine at the extreme N-terminus of a molecule may inhibit its ability to participate in 
disulphide bonding. As all the cysteine residues in the AMA1 ectodomain are involved in 
disulphide bonding and 4G2dc1 recognition of the molecule is reduction sensitive, it was 
considered expedient to design two truncated forms. Thus, if T1 (having only three amino acid 
residues preceding Cys149) failed to be expressed or fold correctly, T2 (with eleven amino acid 
residues immediately preceding the Cys149) may successfully do so. Expression of both these 
recombinant forms of PfAMAI was detected by means of the polyclonal Ab R1 (Fig 4.6 A and 
B). However, they displayed incorrect folding as indicated by nearly complete loss of recognition 
by AdsN1 (Fig 4.6 C and D) and loss of recognition by mAb 4G2dc1. It is therefore apparent 
that the extreme N-terminus of Dl is critical for the correct folding of the molecule. Despite this 
there is some indication of disulphide bond formation with T1, indicated by a slight shift when 
electrophoresed under reducing conditions compared to non-reducing conditions (Fig 4.6 E).
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4.4: Proteolytic digestion of the PfAMAI ectodomain to generate small 
fragments containing the intact 4G2dc1 epitope
From the above results it can be concluded that the epitope recognised by mAb 4G2dc1 lies 
within Dl-ll. Attempts to express these two domains in isolation from each other have failed 
suggesting that their tertiary structure is interconnected and therefore folding of these two 
domains are interdependent. These findings indicate that the epitope recognised by 4G2dc1 
may overlap the two domains; alternatively it may be contained solely within either one of them. 
The inability to express either of these domains in isolation in a correctly folded form has made 
it impossible to distinguish between these possibilities.
In an attempt to further delineate the 4G2dc1 epitope, a proteolytic digestion approach was 
adopted to identify a small fragment within Dl-ll containing this epitope (Fig 4.7). The regions of 
a molecule likely to be accessible to protease digestion are exposed loops and regions of the 
polypeptide chain that form inter-domain links. Due to the lack of structural information 
pertaining to the ectodomain of PfAMAI, regions of the polypeptide chain that might be 
accessible to proteolytic digestion were unknown. For this reason, a range of proteolytic 
enzymes was used and the digestion products were analysed by Western blot under non­
reducing conditions for recognition by 4G2dc1.
4.4.1: Digestion of rPfAMA1 Dl-lll 
4.4.1.1: Trypsin/Chymotrypsin
Within 40 minutes of digestion with trypsin, (Fig.4.8 A), only a 40kDa product was observed, 
suggesting that this part of the protein is fairly resistant to further digestion. However, after 4 
hours of digestion some small fragments appeared. In the case of chymotrypsin, Dl-lll of 
rPfAMAI was first digested to products of 40 -  43 kDa and then to fragments of 18 - 30kDa 
(Fig.4.8 B). In Western blot analysis none of the trypsin/chymotrypsin digestion products were 
recognized by 4G2dc1 (data not shown).
4.4.1.2: Subtilisin
At an enzyme:substrate ratio of 1:100, subtilisin degraded rPfAMAI Dl-lll to a 40kDa product, 
similar to that seen with trypsin and chymotrypsin (data not shown). Increasing this ratio to 1:10 
led to rapid (within 30 minutes) degradation of the protein to small fragments (Fig. 4.9 A). 
However, after 30 minutes of digestion, no fragments were detectable on Coomassie stained 
gels. When probed with 4G2dc1 on a Western blot, a 30 kDa fragment was the smallest 
detected (Fig. 4.9 B).
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4.4.1.3: Pepsin and Papain
Pepsin degraded the full-length ectodomain almost immediately (Fig. 4.10 A), resulting in small 
fragments (<14kDa) showing no reactivity with 4G2dc1 in a Western blot (data not shown).
Papain digestion gave two products, the smallest of which (35kDa) appeared to be relatively 
stable overtime (Fig. 4.10 B) and also reacted with 4G2dc1 in a Western blot (Fig 4.10 C).
4.4.2: Digests of rPfAMAI Di /II alone
None of the enzymes described so far were able to generate sufficiently small fragments within 
Dl-lll that may have contained the 4G2dc1 epitope. The same approach was used with 
rPfAMAI Dl-ll to try to achieve this.
4.4.2.1: Trypsin/Chymotrypsin
Recombinant PfAMAI Dl-ll appeared initially to be resistant to trypsin and chymotrypsin 
digestion (Fig. 4.11 A and B respectively). However, in the presence of chymotrypsin, it 
eventually degraded (4 hours) and no small fragments appeared.
In order to enhance enzyme access to rPfAMAI Dl-ll, trypsin and chymotrypsin digestion was 
repeated in the presence of 0.1% (w/v) SDS (Fig. 4.11 C and D respectively) and 1M urea 
(results not shown). Under both sets of conditions Dl-ll was completely degraded by trypsin and 
chymotrypsin, as shown by SDS PAGE analysis and confirmed in Western blots (data not 
shown). Again, no small fragments were recognized by 4G2dc1. This suggests that in the 
previous experiments, under non-denaturing conditions, the folding of Dl-ll may have delayed 
enzymatic digestion.
4.4.2.2: Pepsin
When digested with pepsin at enzyme:substrate ratios of 1:100 and 1:10, Dl-ll remained fairly 
stable (data not shown). In the latter case, when pepsin began to digest the molecule, no small 
fragments were detectable with Coomassie blue or in Western blot analysis with 4G2dc1.
As previously observed for rPfAMAI Dl-lll, digestion of Dl-ll did not lead to the identification of 
small fragments retaining the 4G2dc1 epitope (data not shown).
4.4.3: Proteolytic digestion of the 4G2dc1 F(ab)2/PfAMA1 Dl/ II complex
The F(ab) 2 fragment of mAb 4G2dc1 was prepared by pepsin digestion of the intact antibody 
(section 2 .4 .5 .2 .2 ). This protease is relatively non-specific but will preferentially cleave the 
peptide chain after aromatic or other hydrophobic residues (at the position). Pepsin cleaves 
the IgG heavy chain immediately down-stream of the hinge region between F(ab) 2 and Fc
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regions of the Ab. The F(ab) 2  region of 4G2dc1 purified from the resulting mixture is relatively 
resistant to pepsin digestion. From the results obtained in the current study, rPfAMAI Dl-ll is 
initially resistant to pepsin digestion; however, when pepsin does begin to digest the molecule it 
does so to completion, generating no stable intermediate products. Thus, a protection assay 
was carried out on rPfAMAI Dl-ll complexed to 4G2dc1 F(ab) 2 fragment, in the presence of 
pepsin, to see if the enzyme would digest exposed regions of the molecule, while leaving the 
4G2dc1 epitope intact. However, the digestion pattern for Dl-ll in the complex (Fig 4.12 A) was 
similar to that seen for Dl-ll on its own (Fig 4.12 B) and no small fragments were produced. This 
was confirmed in Western blot analysis probed with 4G2dc1 (Fig 4.12 C) and in the Western 
probed with the secondary Ab alone (Fig 4.12 D) in order to distinguish Ab fragments from 
rPfAMAI Dl-ll digestion products.
In conclusion, proteolytic digestion of the rPfAMAI ectodomain did not result in the isolation of a 
region significantly smaller than Dl-ll that could be shown to contain the 4G2dc1 epitope.
4.5: Site-directed mutagenesis of PfAMAI Dl and Dll to disrupt 4G2dc1 
recognition
Using proteolytic digestion to generate intact fragments of a molecule that may retain a certain 
structure or function is a fairly crude approach to analysing the properties of a protein. This 
approach did not produce any additional information regarding identification of the 4G2 epitope. 
For this reason, it was decided to use SDM, as this technique allows specific regions of the 
molecule to be targeted. Strategic modifications within Dl-ll may allow the identification of amino 
acid residues of which the epitope recognised by mAb 4G2dc1 is comprised.
4.5.1: Identification of the disulphide bonds (DBs) responsible for the reduction 
sensitivity of the 4G2dc1 epitope
The epitope recognise by mAb 4G2dc1 is reduction sensitive. For this reason, it was decided to 
sequentially disrupt the DBs in Dl-ll (outlined in Table 4.3) to differentially affect or reduce 
4G2dc1 binding and thereby identify a region within the molecule that contains this epitope. Two 
approaches were used to target the disulphide bonds.
4.5.1.1: Mutagenesis of the first cysteine residue in each disulphide bond
Using construct pSec/sg’Pfamal as a template, SDM was carried out to replace the first 
cysteine residue (in the PfAMAI amino acid sequence) of each disulphide bond in Dl-ll with 
alanine. The resulting constructs (pSec/sg’PfaAsDB1 - AsDB5) were expressed in COS-7 cells, 
giving rise to the mutants’ AsDB1 - AsDB5. Western blot analysis and I FA were carried out on
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the transgenic cells. Table 4.3 summarises the specific residues and mutations carried out to 
achieve this.
Western blot analysis of reduced samples using polyclonal serum R1 showed that each 
cysteine mutant was expressed (Fig 4.13 A). However, non-reduced samples probed with 
4G2dc1 showed that only one mutant retained 4G2 recognition (Fig 4.13 B). In this mutant the 
third disulphide bond in domain I was disrupted (AsDB3). Moreover, when unfixed, transfected 
COS-7 cells were analysed by IFA using polyclonal serum N1, all cysteine mutants were 
expressed on the surface (Fig 4.14), though only AsDB3 (mutation in cysteine 4) showed 
expression at a level comparable to the wild type. When analysed in IFA using 4G2dc1 
however, AsDB1 (mutation in cysteine 1) and AsDB4 (mutation in cysteine 7) exhibited no 
surface fluorescence, indicating loss of the 4G2dc1 epitope (Fig 4.15).
4.5.1.2: Mutagenesis of both cysteines in each disulphide bond
Disruption of a disulphide bond by mutagenising only one of the bonded cysteines leaves a free 
reactive sulphydryl group in the structure. It was possible that 4G2 recognition of the cysteine 
mutants in IFA might be due to loss of integrity of the overall fold resulting from the presence of 
these free reactive sulphydryl groups. To investigate this possibility, the remaining free cysteine 
from each DB was also mutated to alanine (in the constructs pSec/sg’PfaAdDB1 - AdDB5), 
giving rise to the mutants AdDB1 - AdDB5. Table 4.3 summarises the details of the mutations 
carried out to achieve this. As predicted, by Western blot analysis with the polyclonal serum N1, 
the double cysteine mutants were all clearly expressed (Fig 4.16 A). Furthermore, all still 
retained 4G2dc1 recognition except AdDB1 (mutations in cysteines 1 and 6 ) and AdDB4 
(mutations in cysteines 7 and 10) in Western blot (Fig 4.16 B). These findings are confirmed by 
IFA of unfixed and unpermeabilised COS-7 cells, with the polyclonal serum N1, in which all 
mutants were expressed on the cell surface (Fig 4.17). The mutant AdDB1 only shows a low 
level of surface fluorescence with this polyclonal serum. In addition, analysis by IFA using the 
mAb 4G2dc1 shows that all the mutants, with the exception of AdDB1 and AdDB4, retain the 
epitope recognised by this mAb (Fig 4.18). This suggests that the epitope recognised by this 
mAb is constrained by both of these disulphide bonds but not by any of the others. Disulphide 
bond 1 links the extreme termini of Dl, thus disruption of this DB is likely to have a global effect 
on protein fold. This is reflected in the low level of surface localisation of AdDB1 detected with 
the polyclonal serum N1. In comparison, DB4 links the termini of Dll (via cysteines 7 and 10), 
however, this DB is adjacent to DB5 (linking cysteines 8  and 9). Therefore, disruption of DB4 
will have less effect on the global fold of the molecule due to the stabilising effect of DB5. This 
may explain the higher level of surface expression of DB4 than DB5 detected in IFA by the 
polyclonal serum N1.
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4.5.2: SDM to target surface exposed residues in Dl-ll
Sequential disruption of the disulphide bonds in Dl-ll indicated that both domains are likely to be 
important for 4G2dc1 recognition. These results have not added any information as to the actual 
residues involved in this recognition event, nor have they reduced the target area within which 
these residues are located. The epitope recognised by an Ab to Pf AMA1 must be exposed on 
the surface of the molecule. For this reason, the sequence of PfAMAI Dl-ll was analysed using 
the JNet (Cuff and Barton, 2000) and Emini (Emini et al., 1985) computer algorithms. These 
algorithms analyse the local (hexapeptide) environment of a particular amino acid in a protein 
sequence and determine its surface probability using the accessible surface probabilities 
defined by Janin et al. (1978). A value greater than 1 for a given hexapeptide indicates an 
increased probability of it being located on the surface of the protein. Thus, applied to the amino 
acid sequence of pfAMAI Dl-ll, these algorithms could be used to predict potential amino acid 
residues that contribute to recognition by mAb 4G2dc1. These algorithms give the surface 
accessibility probabilities for peptides in the protein sequence, not for individual amino acids. A 
SDM approach was used to specifically replace groups of amino acids (triplets) within Dl-ll of 
PfAMAI that were predicted using these algorithms to be located on the proteins surface. It was 
considered that mutating more than three consecutive amino acids simultaneously might affect 
the local conformation of the protein. Thus, any disruption of mAb 4G2dc1 recognition of this 
protein might be an indirect effect of loss of the local fold, rather than a direct effect of the loss 
of Ab-antigen interaction. Amino acid residues were mutated to either alanine, or where the 
residue was already alanine, to a residue present in the AMA1 sequence from another species 
of Plasmodium (Table 4.4.). Alanine was selected as it is a small, non-polar residue and is 
therefore unlikely to disrupt the protein fold. Mutations were introduced into the plasmid 
pSec/sg'Pfamal, used previously for expression of sgPfAMAI in COS-7 cells and the resulting 
mutants were expressed in this cell line. Cell lysates were analysed by Western Blot analysis 
using the mAb 4G2dc1 and the polyclonal Ab sera R1 and AdsN1. The polyclonal serum R1 
was raised against the reduced and alkylated rPfAMAI ectodomain. This polyclonal serum 
recognised mutants expressed in this system, showing no preference for protein conformation 
as it recognised reduced and non-reduced proteins equally. As a result, this serum gave a 
measure of the total level of sgPfAMAI expression. The polyclonal serum N1 was raised 
against the non-reduced (native conformation) rPfAMAI ectodomain. This serum showed some 
recognition of linear epitopes in the rPfAMAI ectodomain, as it recognised the reduced and 
alkylated rPfAMAI ectodomain. For this reason, the polyclonal serum was adsorbed out against 
reduced and alkylated rPfAMAI ectodomain, giving the serum AdsN1 that recognised only 
"native", conformational epitopes in the rPfAMAI ectodomain, as confirmed in Western blot 
analysis of rPfAMAI Dl-ll and Dl-lll under reducing or non-reducing conditions (Fig 4.19). 
Finally, the mAb 4G2 was used in Western blot analysis of SDMs, to determine whether the 
mutations introduced had any effect on 4G2dc1 recognition of the molecule. Using mAb 4G2dc1 
in conjunction with AdsN1, allowed the distinction to be made between mutations affecting
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protein conformation as well 4G2dc1 recognition and those that specifically disrupted 4G2dc1 
recognition without altering the remainder of the molecule. In the case of a triplet mutation that 
specifically disrupted 4G2dc1 recognition, the individual mutations were subsequently made, 
replacing the amino acids one at a time and screening each of them against the same panel of 
Abs.
All the mutants were expressed at a high level, as indicated by strong recognition with the 
polyclonal serum R1 (Fig 4.20 A). In the first round of mutagenesis, mutants 110WTE/AAA, 
115AKYD/EAAA, 233NYK/AAA, and 278PAK/AAA all affect the overall fold of the protein, as 
indicated by reduced recognition by polyclonal serum AdsN1 (Fig 4.20 B). Only three mutants 
(348DQP/AAA, 351KQY/AAA and 388DRY/AAA) were shown to have a specific effect on 
4G2dc1 recognition (data not shown). To investigate these mutations further, the residues in 
each triplet were mutated individually to alanine and again analysed in Western blot with the 
three antibodies. Interestingly, none of the individual point mutations in isolation completely 
abrogated 4G2dc1 recognition, however, substitution of five residues (highlighted in bold in 
table 4.4) were found to significantly reduce the 4G2dc1 signal (Fig 4.20 C, lanes 9, 10, 11, 15 
and 16). On the basis of these results it seems likely that these five residues are components of 
the epitope recognised by mAb 4G2dc1. None of the remaining point mutations generated from 
these three triplet mutants appeared to affect 4G2dc1 recognition. From these results it would 
appear that the epitope recognised by mAb 4G2dc1 may be localised exclusively within Dll. 
Several mutations introduced into Dl disrupted the overall conformation of the molecule. Thus, 
the effect on 4G2 recognition was not considered to be a specific effect on the epitope. The 
identification of components of the 4G2dc1 epitope within Dll, suggests that these domains are 
interconnected and disruption of the "native" conformation in one region of the molecule can 
alter the conformation in distal regions. It is possible that residues within Dl have a structural 
role within PfAMAI and that altering these residues disrupts the stability of the molecule, 
detected in this study as a decrease in recognition by the polyclonal serum AdsN1 and loss of 
4G2dc1 recognition.
As has been indicated, none of the point mutations identified as specifically disrupting 4G2dc1 
recognition completely disrupted this recognition. The possibility therefore existed that this 
decrease in 4G2dc1 recognition was the result of a conformational change in the molecule, too 
subtle to be detected by the serum AdsN1. For this reason, two of these mutations (K351 and 
R389) were combined to determine whether these had an additive effect on 4G2dc1 
recognition. In addition, it was anticipated that if the disruption of 4G2dc1 recognition was a 
result of an undetectable conformational change, combining the mutations might increase this to 
within detectable levels. Furthermore, these two residues were mutated to corresponding 
residues from the PvAMAI sequence (K3517T and R389/N). Residues that are present at the 
equivalent position in the AMA1 sequence from P. vivax are unlikely to adversely affect the 
function or structure of the molecule, thus minimising the conformational disruption induced by
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the double mutation. If the effect of the individual mutations was specific for 4G2dc1 recognition, 
this double mutation should generate a 4G2dc1 negative form of PfAMAI. As anticipated, the 
double mutant (K351/T and R389/N) was not recognised by 4G2dc1 in Western blot analysis 
(Fig 4.20 C, lane 18). However, recognition by both polyclonal sera R1 and AdsN1 was 
unaltered (Fig 4.20 A and B respectively, lane 18).
At the beginning of this analysis, no tertiary structure data was available for Dl-ll of AMA1 from 
any species of malaria parasite. However, the crystal structure of PvAMAI has subsequently 
become available (Pizarro et al. 2005). Superimposing the residues apparently involved in 
4G2dc1 recognition of PfAMAI onto a model of PfAMAI constructed by homology with the 
recently published structure of PvAMAI, indicates that the 4G2dc1 epitope lies within the base 
of a flexible or unstructured loop within Dll. To investigate the possibility that other residues 
within this region of the molecule may contribute to 4G2dc1 recognition, a series of further 
SDMs (listed in Table 4.5) were analysed using the COS-7 expression system (Fig 4.21). As 
observed previously, no single point mutation resulted in complete abrogation of 4G2dc1 
binding. However, the mutation F385/A (Fig 4.21 C, lane 9) significantly reduced 4G2dc1 
recognition of sgPfAMAI.
No electron density was present for the forty amino acid stretch in Dll corresponding to the Dll 
loop. This region was therefore mobile or disordered. For this reason, structural algorithms were 
used to predict the secondary structural components within the loop, based on the primary 
sequence. These algorithms indicated the presence of two a-helices, helix 1: 353- 
YEQHLTDYEKIKEGFK-368 and helix 2: 373-DMIKS-377. To investigate the function of these 
putative helices in 4G2dc1 recognition of PfAMAI, two mutants were generated in which one or 
other of the helices was deleted from the sequence. Both of the mutant forms of sgPfAMAI 
(Ahelixl and Ahelix2) were expressed at levels equivalent to that of "wild type" sgPfAMAI, as 
shown in Western blot analysis with the polyclonal sera R1 and AdsN1 (Fig 4.21 A and B 
respectively, lanes 5 and 6 ). In addition, deletion of helix 2 had no effect on 4G2dc1 recognition 
(Fig 4.21 C, lane 6 ). By comparison, Ahelixl showed complete abrogation of 4G2dc1 
recognition (Fig 4.21 C, lane 5). A possible explanation for this effect was that the loss of helix 1 
destabilised the Dll loop, thus disrupting 4G2 recognition. For this reason, a mutant was 
constructed that lacked the entire stretch from 353Y-S377, thus removing both helices 
(Ahelix1/2). Despite being strongly expressed, as indicated in Western blot analysis with the 
polyclonal sera R1 and AdsN1 (Fig 4.21 A and B respectively, lane 7), this mutant was not 
recognised by mAb 4G2dc1 (Fig4.21 C, lane 7).
Based on the results from the helix deletions in the Dll loop, it was considered likely that (a) 
residue(s) within helix 1 contributed directly to 4G2dc1 recognition. To assess this possibility, 
two mutants were produced in which proline substitutions were introduced into the loop 
sequence, at H356 or K364 (both in helix 1). As a result of conformational constraints placed
133
upon it by its pyrrolidine side chain, proline introduces a kink in the amino acid chain, so these 
substitutions might be expected to disrupt any downstream a-helical structure. If an amino acid 
residue downstream of the newly introduced proline participated in 4G2dc1 binding, it might be 
predicted that the substitution would result in loss of Ab recognition. Western blot analysis 
indicated that only the first substitution H356/P abrogated 4G2dc1 recognition (Fig 4.21 C, lane 
3). This suggests that a residue between H356 and K364 contributed to the epitope recognised 
by 4G2dc1. Of this stretch of residues (356HLTDYEKI363) the only ones not previously 
investigated by substitution were L357, T358 and H356 itself. Substitution 357LT/AA had no 
effect on 4G2dc1 recognition (Fig 4.21 C, lane 4). By comparison, the substitution 354EQH/AAA 
resulted in complete abrogation of 4G2dc1 recognition (Fig 4.21 C, lane 2). This suggested that 
one of the latter residues (354E, 355Q or 356H) contributed to the epitope. However, when 
each of these residues was individually mutated to alanine they were highly expressed and 
recognised by both R1 and AdsN1 (data not shown) but none produced any observable 
disruption of 4G2dc1 recognition in Western blot analysis (Fig 4.21 D).
The above results indicated that residues 354EQH collectively affect 4G2dc1 binding, as does 
the mutation of 356H/P, whereas K364/P has no effect. Thus, it was considered possible that 
only the first part of helix 1 contributed to 4G2 binding. To investigate this possibility, two 
mutants were constructed in which sections of the second half of helix 1 were deleted 
(357LTDYEKIKEGFK368, or 361EKIKEGFK368). The only residue in this region still untested 
was E365, but as mutation K364/P had no effect on 4G2dc1 binding, it seemed unlikely that this 
residue contributed to Ab recognition. Both helix truncation mutants showed loss of 4G2dc1 
binding (data not shown). Thus, although the individual residues within helix 1 did not appear to 
have an effect on the ability of the antibody to bind, complete disruption of the helix prevented 
binding. This finding was supported by the fact that the mutations Ahelixl and Ahelix1/2 resulted 
in loss of 4G2 recognition (Fig 4.21 C, lane 5 and 7 respectively). In contrast, deletion of helix 2 
had no effect on 4G2dc1 recognition of the molecule (Fig 4.21 C, lane 6 ). It is therefore possible 
that helix 1, but not helix 2, has a local stabilising role in the molecule, that influences 4G2 
recognition and binding.
Figure 4.22 (A) shows the surface location of residues identified as contributing to the 4G2dc1 
epitope in the ectodomain of PfAMAI. In addition, residues that lie in close proximity to this 
epitope are indicated for future analysis (Figure 4.22 B). The SDM approach used above relied 
on surface predictive algorithms. Residues were selected for mutagenesis according to their 
likelihood of being surface exposed as predicted by these algorithms. Such algorithms rely on 
calculations of the probability of an amino acid residue within a sequence being localised on the 
surface, based on the empirical calculations derived from other proteins with known structure. It 
is therefore possible that certain amino acid residues localised on the surface of PfAMAI were 
not identified as such and as a result that potential components of the epitope recognised by 
mAb 4G2dc1 might have been overlooked. It was decided therefore to take a broader approach
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to determine which amino acid residues are important for 4G2dc1 recognition of PfAMAI. 
Rather than targeting specific residues by SDM, a random mutagenic approach was devised to 
screen the entire Dl-ll sequence.
4.6: Random mutagenic screen to isolate 4G2dc1 negative (4G2dcT) 
forms of PfAMAI
A library of sg'PfAMAI random mutants (sg’PfalRML, with mutations in Dl-ll) was generated 
using the pfasmid pSec/sg'Pfamal previously used for expression of sg'PfAMAI in COS-7 cells. 
It was anticipated that transfection of COS-7 cells resulted in a single cell receiving on average 
a single plasmid. Thus, transfection of COS-7 cells with sg’PfalRML would result in different 
cells in the population expressing single mutant forms of sg'PfAMAI. As with previous use of 
this construct, expression of these mutants in COS-7 cells should have resulted in surface 
localisation of the protein. The resulting mixed cultures were screened for expression of mutant 
forms of PfAMAI that retained the 4G2dc1 epitope and were therefore recognised by this mAb. 
In a negative selection step, these cells were extracted from the culture and discarded. Any 
cells remaining in the culture would be expressing 4G2dcT mutant forms of sg'PfAMAI but the 
culture would contain a mixture of cells. Some of these cells should express 4G2dc1 mutant 
forms of sg'PfAMAI, in which the overall protein conformation was correct (native+) and others 
express 4G2dcT mutant forms of sg'PfAMAI, in which the mutations had resulted in partial or 
full loss of protein conformation. In addition, some cells might not be expressing sg'PfAMAI, as 
transformants were not positively selected for (see below).
A positive selection step was used to isolate cells expressing 4G2dcT, native+ mutant forms of 
sg'PfAMAI. Plasmid DNA was rescued from this cell sample, amplified in E. coli and the 
selection procedure repeated two further times. In this way, the number of mutant forms of 
sg'PfAMAI that retained the 4G2dc1 epitope but escaped the negative selection step would be 
further diminished by repeated cycles of negative selection.
The selection steps relied on the use of anti-mouse IgG coupled to Dynabeads. The transfected 
COS- 7  cells were pre-incubated with either the mAb 4G2dc1 (negative selection step) or the 
polyclonal serum N1 (positive selection step), followed by incubation with the Dynabeads. Thus, 
cells to which the primary antibody was bound would subsequently be bound by the anti-mouse 
IgG coupled to the Dynabeads. Cells that were bound to the Dynabeads were then isolated 
from the cell suspension using a Dynal magnet.
Random mutagenic PCR conditions were used to introduce mutations within the sequence 
encoding Dl-ll of the PfAMAI ectodomain. These were incorporated back into the plasmid 
pSecAPsfl/sg’Pfa for expression in COS-7 cells. To enable screening for random mutants in 
which the 4G2dc1 epitope was disrupted, adherent transfected COS-7 cells were released into
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single cell suspension using trypsin:EDTA. However, this treatment also removed much of the 
surface expressed sg'PfAMAI, rendering selection impossible. To overcome this, the trypsin 
inhibitors soyabean trypsin inhibitor and TLCK were used to inactivate the enzyme after 
suspension of the cells and also during the incubation steps.
Preliminary experiments were performed to test the efficiency of the above-described approach, 
using COS-7 cells transfected with constructs expressing either "wild type" sg'PfAMAI 
(pSec/sg’Pfamal) or a mutant already shown to lack the 4G2 epitope, AdDB4 (construct 
pSec/sg’PfaAdDB4 in which the disulphide bond in Dll between Cys320 [C7] and Cys418 [C10] 
had been disrupted by replacement of both cysteines in the bond with alanine, see section 
4.5.2). As previously described, IFA analysis using the polyclonal serum N1 had shown this 
mutant to be expressed on the surface of transfected cells. Cells transfected with each of these 
constructs were subjected to a single selection step either with or without one of the primary 
antibodies 4G2dc1 or N1. If selection was working efficiently it was expected that neither set of 
transfected COS-7 cells would bind Dynabeads in the absence of primary antibody. By contrast, 
both were predicted to bind in the presence of N1 and only the cells expressing wild type 
PfAMAI were expected to bind in the presence of 4G2dc1. For each transfected culture, a 
sample was harvested immediately after treatment a trypsin. This gave a measure of the total 
amount of mutant and wild type sg'PfAMAI present prior to the selection steps. The samples 
were analysed by Western blot, using the polyclonal sera R1 and N1 (Fig 4.23 i and ii) and the 
mAb 4G2dc1 (Fig 4.23 iii). In the following description of this result, B, UB and T, refer to bound 
unbound and trypsin treated respectively. As expected, neither set of transfected cells bound 
the Dynabeads in the absence of primary antibody (Fig 4.23 I and II, a, B). The AdDB4 mutant 
(Fig 4.23 II) appeared to bind to 4G2dc1 at a low level as indicated by a faint signal in Western 
blot analysis of the 4G2dc1 bound fraction (Fig 4.23 II, b, B). This mutant was 4G2dc1', so this 
result suggested that a small proportion of cells were able to bind non-specifically in the 
negative selection step of the screen. In addition, with N1 nearly all the AdDB4 mutant was 
found in the unbound fraction, as determined by Western blot analysis (Fig 4.23 II, c, UB). 
Some cells expressing the wild type sg'PfAMAI were present in the unbound fraction from both 
antibodies (Fig 4.23 I, b and c, UB), though most was found in the bound fraction (Fig 4.23 I, b 
and c, B). The wild type sg'PfAMAI appeared to be expressed at a higher level than the AdDB4 
mutant (Fig 4.23 I and II respectively, T) therefore it was possible that insufficient 4G2dc1 was 
used in the negative selection step to bind efficiently to, and allow extraction of, all the wild type 
sg'PfAMAI expressing cells. These results indicate that the selection process was efficient for 
wild type sg'PfAMAI transfected COS-7 cells, but it appeared to be less specific for the DB 4 
mutant.
Several experiments were carried out to assess the efficiency of the (double negative followed 
by positive) selection procedure (data not shown). In all of these, the second (positive) selection 
step appeared to be very inefficient, with most cells not binding to N1 even though they were
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detected by N1 in Western blot analysis. By contrast nearly all cells expressing wild type 
PfAMAI were found in the 4G2dc1 bound fraction, suggesting that although there was a small 
degree of non-specific binding in this step, the positive selection was almost absolute. This 
suggested that most cells expressing mutant forms of rPfAMAI, in which the 4G2dc1 epitope 
was still intact, were able to bind during this step and anything that did not bind here was likely 
to lack the epitope. For this reason it was decided to subject the random mutant library 
(sg’PfalRML) to three round of negative selection to enhance the population for 4G2dc1' 
mutants before using the positive selection step. At each round of negative selection two 
4G2dc1 binding steps were performed. Between each round of selection the plasmid from the 
unbound fraction was recovered and amplified in E. coli, before being re-transfected back into 
COS-7 cells. After three round of negative selection the mutant library was transfected back into 
COS-7 cells and subjected to a further negative selection step, this time followed by a positive 
selection step with N1. Plasmid recovered from the N1 bound fraction was cloned in E. coh for 
sequencing and subsequent expression in COS-7 cells. The clones were transfected into COS- 
7 cells and expression analysed by Western blot with the polyclonal antibodies AdsN1 and R1 
and the mAb 4G2dc1, for expression and the presence of the 4G2dc1 epitope respectively (as 
for the SDM screening above).
Despite screening over 100 mutant clones, only 10 mutants were identified that were 4G2dcT, 
but correctly folded (native+) by the criteria described above (Fig 2.11). Many of the mutants 
screened retained the 4G2dc1 epitope (Fig 4.24, lanes 10, 14, 17, 19, 22, 28 ) and a number of 
others did not appear to express sg'PfAMAI in any form (Fig 4.24, lanes 1, 2, 7, 9, 11, 15, 16, 
17, 19, 21, 22, 25, 26, 29*). A small proportion of the clones screened expressed a truncated 
form of sg'PfAMAI (Fig 4.23, lane 12). In one such case, the 4G2dc1 epitope remained intact. 
All twelve 4G2dc17native+ mutants were sequenced to determine the amino acids responsible 
for loss of 4G2dc1 recognition (Fig 4.25). In all cases between 5 and 10 amino acid 
substitutions were observed within Dl-ll (representing 342 amino acids), indicating a much 
higher level of mutation at the nucleotide level than that initially determined (5 per kb). The 
amino acid substitutions were found to be evenly distributed over Dl-ll and one of the mutations 
(Clone 5; Phe385/Cys) coincided with a residue identified by SDM as being a component of the 
4G2dc1 epitope (Fig 4.25). An additional mutation present in one of these clones (clone 26 
Phe379/Tyr) was found in one of the residues considered as a potential component of the 
4G2dc1 epitope based on its proximity to the residues already identified.
4.7: Discussion
4.7.1. The invasion inhibitory activity of 4G2dc1-Fab
Erythrocyte invasion by P. falciparum merozoites can be inhibited by mAb 4G2dc1, which 
recognises a reduction sensitive, conformation dependent epitope in the PfAMAI ectodomain
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(Kocken et al. 1998). This suggests that the PfAMAI ectodomain is important for invasion, thus 
identification of the 4G2dc1 epitope may reveal a functionally important or crucial region of the 
AMA1 ectodomain. In this study it has been shown that 4G2dc1-Fab fragments also block 
erythrocyte invasion, with a higher percentage inhibition, at much lower (nearly 1 0  fold) 
concentrations than the intact Ab. This finding was confirmed in a recently published work by 
Dutta et al. (2005). However, the level of inhibition (20% inhibition at 360 pg ml"1) demonstrated 
by Dutta et al for intact IgG was lower than that observed in the current study. These finding are 
not without precedent, Thomas et al. (1984) demonstrated that F(ab) 2 and Fab fragments of the 
P. knowlesi AMA1 specific rat mAb R3/1C2 produced the same level of invasion-inhibition as 
intact IgG at a 10 fold lower concentration. As discussed earlier, only two thirds of the 
concentration of an intact IgG is contributed by Fab fragment. For this reason, in the current 
work, the concentration of the intact antibody was adjusted to represent the concentration of 
Fab present in the sample. Intact 4G2dc1 exhibited 44% invasion-inhibition at 0.47 mg ml"1 
compared with 97% inhibition by 4G2dc1-Fab at 0.4 mg ml"1. At higher concentrations, the level 
of inhibition was much closer with the intact Ab exhibiting 74% invasion-inhibition at 1. 8  mg ml"1, 
compared with 99% invasion-inhibition for 4G2dc1-Fab at 1.6 mg ml"1. Interestingly, 4G2dc1- 
Fab mediated significant invasion-inhibition down to relatively low concentrations, showing 24% 
inhibition at 0.05 mg ml"1 (Fig 4.1 B). This represents a concentration of 4G2dc1-Fab fragment 
one fifth that found in the intact antibody assay, giving a percentage inhibition of 30%. Overall 
these results indicate that the 4G2dc1-Fab has a higher level of inhibition than the intact 
antibody at equivalent molar concentrations of the Fab fragment. This suggests that the 
inhibition mediated by this Ab is not one of steric hindrance. One possible explanation for this 
increased inhibition is a result of the Fab fragment being one third the size of the intact antibody
4.7.2: Interactions between the subdomains of PfAMAI
By Western blot analysis of different regions of the PfAMAI ectodomain (Dl, Dl-ll and Dl-lll) 
expressed in P. pastoris, the current study demonstrated that the mAb 4G2dc1 epitope lies 
within Dl-ll, confirming previous suggestions to this effect (Lalitha et al., 2004; Howell et al., 
2001). Expression of rPfAMAI Dl on its own has previously been demonstrated using phage 
display (Coley et al., 2001; Lalitha et al., 2004), however, in the current study expression of this 
domain on its own in a correctly folded form was not possible in P. pastoris or in COS-7 cells.
The PvAMAI X-ray crystal structure (Pizarro et al. 2005) highlights an interactive interface 
between Dl and Dll. Residue Lys280 (corresponding to Lys225 in PvAMAI), which is invariant 
in AMA1 throughout Plasmodium, is buried in the PvAMAI structure and interacts via its amino 
group with an equally invariant Asn (Asn338 and 283 in PfAMAI and PvAMAI respectively). 
This study showed that substitution of this residue with alanine resulted in loss of mAb 4G2dc1 
recognition (Fig 4.20 a, lane 7) but also reduced recognition by the conformation dependent 
polyclonal sera AdsN1 (Fig 4.20 b, lane ). This suggests that the two domains are
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interdependent and may not fold correctly in isolation. In the current study, digestion of rPfAMAI 
Dl-lll with subtilisin, trypsin and chymotrypsin produced stable fragments about the same size 
as Dl-ll and still recognised by 4G2dc1. Confirmation that these fragments were likely to be Dl-ll 
came from the observation that Dl-ll was resistant to digestion with both trypsin and 
chymotrypsin. Furthermore, the presence of low levels of the denaturants SDS and urea were 
required for digestion of rPfAMAI Dl-ll to occur. These results confirm the findings of Pizarr o et 
al. (2005) and suggest that Dl and Dll may be closely apposed in the intact molecule, rendering 
the inter-domain sequences inaccessible to these proteases. 4G2dc1 recognition of the 
molecule therefore probably requires the stable complex of both domains even though the 
epitope appears to be formed by residues that lie exclusively within Dll. By comparison, the 
production of a Dl-ll sized fragment on digestion of Dl-lll and the stability of Dl-ll in the absence 
of denaturing agents, demonstrated in the current study, suggests that Dill is not so closely 
packed in the structure as Dl-ll. It is possible that DIM, which lies adjacent to the merozoite 
plasma membrane, provides the molecule with a degree of flexibility while the functionally 
important regions of the molecule (Dl-ll) retain a more rigid structure.
The findings and interpretations of this study are supported by the observations of Gupta et al. 
(2005), that the PfAMAI ectodomain is fairly resistant to proteolytic digestion. This group 
identified four susceptible sites in a construct comprising the PfAMAI ectodomain and 
prodomain when digested with elastase. The N-terminal prodomain and C-terminus of the 
ectodomain were digested by this enzyme at almost exactly the same positions as those 
observed during the normal processing events (Howell et al. 2001). A single cleavage at 
position Ile460 (Gupta et al. 2005) corresponds closely to the Dill nick, giving rise to the 
PfAMAI44 form (Howell et al. 2003). Finally and perhaps of most interesting in relation to the 
current study, residues H356 to A384 were degraded (Gupta et al. 2005). The sequence 
delineated by these residues corresponds to the unstructured or flexible region identified during 
determination of the PvAMAI structure i.e. the Dll loop (Pizarro et al. 2005). Thus, unlike the 
rest of Dl-ll, the Dll loop is less tightly packed within the tertiary structure, perhaps more mobile 
and therefore likely to be accessible to extramolecular interacitons.
In the current study it proved impossible to express any of the individual domains of the PfAMAI 
ectodomain in isolation, with the exception of Dl-ll. Reports exist of expression of PfAMAI 
ectodomains in isolation and in varying combination (Lalitha et al. 2004), but these have usually 
required refolding to obtain the disulphide bonded conformations necessary to induce growth 
inhibitory antibodies (Dutta et al., 2002). In addition, the solution structures of Dll (Feng et al., 
2005) and DIM (Nair et al., 2002), expressed in E. coli and refolded, showed the presence of 
some secondary structural element(s), however, in both cases the majority of the molecule was 
unstructured. These findings suggest that in the intact molecule these domains are stabilised by 
multiple interdomain interactions and that in isolation they are unable to adopt their native 
conformation.
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In an attempt to protect the mAb 4G2dc1 epitope, rPfAMAI Dl-ll was complexed to 4G2dc1 
F(ab) 2 before digestion with pepsin. The complex was initially resistant to degradation by 
pepsin, although when digestion did commence it went to completion, a finding similar to that 
seen with Dl-ll alone. One interpretation of this finding is that even if the 4G2dc1 epitope is 
protected by 4G2dc1 F(ab)2, when the digested complex is electrophoresed on SDS-PAGE in 
the absence of the remainder of the molecule the loops making up the epitope dissociate. While 
this approach has not helped in the elucidation of the 4G2dc1 epitope, it has given some 
structural information about the ectodomain of PfAMAI. This includes the observation that 
interactions exist between Dl and Dll, keeping them closely packed together in the intact 
PfAMAI ectodomain. In addition, the apparent susceptibility of DIM to proteolytic digestion 
suggests that it is less tightly associated with Dl-ll. However, this latter finding is not 
substantiated by the findings of Gupta et al. (2005), who showed the whole ectodomain to be 
resistant to elastase digestion. In addition, the PvAMAI X-ray crystal structure shows that the N- 
terminus of Dl lies across the surface of Dll and DIM, interacting extensively with them (Pizarro 
et al. 2005). In the present study, mutations of amino acid residues in the N-terminus of Dl 
(110WTE/AAA, 115AKYD/EAAA and NYK/AAA) or truncations of Dl (T1 and T2), affected 
protein fold as well as 4G2dc1 recognition, suggesting that interactions between these 
segments and DM stabilise the molecule and are required for correct folding. In combination, 
these finding suggest that there is a considerable amount of interconnection between all three 
subdomains of the AMA1 ectodomain.
4.7.3: Identification of amino acid residues involved in 4G2dc1 recognition of PfAMAI
Random mutagenesis of Dl-ll of the PfAMAI ectodomain could be a powerful tool to identify the 
epitope recognised by the mAb 4G2dc1, as it allows screening of large numbers of mutants very 
rapidly. However, in this study the mutation rate that was originally calculated was much lower 
than that finally achieved. This resulted in large numbers of mutations per clone, many of which 
probably resulted in loss of protein fold rather than specific disruption of the 4G2dc1 epitope. 
Furthermore, there was a considerable degree of non-specificity in the selection steps in the 
Dynabead binding assay. Although the first selection step was very efficient in depleting the 
sample of 4G2dc1+ cells, depletion was incomplete and during subsequent recovery, 
amplification and selection steps the proportion of 4G2dc1+ cells did not appear to decrease. 
This may be a result of the delicate balance between treating the cells with trypsin for a time 
sufficient to obtain a single cell suspension without removing all the surface protein. Incomplete 
trypsin treatment may have resulted in clumping of the cells and consequently non-specific 
selection.
Site directed mutagenesis conclusively identified six amino acid residues that participate in 
4G2dc1 recognition and binding (Asp348, Iys351, Gln352, Phe385, Asp388 and Arg389). These
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have all been shown to lie at the base of a flexible loop in Dll. Figure 4.22 shows the position of 
these residues in the Dll loop (A) and highlights several other residues that might be worth 
considering as potential candidates which contribute to 4G2dc1 recognition (B). In this structure 
Asp348 is not exposed on the surface, which might suggest that its disruption has an indirect 
effect on 4G2dc1 recognition. However, the observation that the Dll loop is flexible and may 
take up several alternative conformations suggests that 4G2dc1 may bind when the loop is in a 
different conformation and Asp348 is exposed. The observation that disruption of DB4 
(substitution of Cys320 and Cys418) disrupts 4G2dc1 recognition but DB5 (substitution of 
Cys337 and Cys409) does not is unexpected. From the primary amino acid sequence, the 
epitope lies in close proximity to DB5. For this reason, it would seem likely that disrupting this 
bond would destabilise the local structure of the molecule. DB4 on the other hand draws 
domains I, II and III together, therefore, loss of this interaction may have a more wide reaching 
influence on protein structure.
Proteins targeted for secretion enter the secretory pathway via the endoplasmic reticulum (ER). 
Quality control mechanisms prevent the exit of incorrectly folded proteins from the ER. Thus, 
only properly folded proteins reach the plasma membrane or are secreted. For this reason, 
secretion and surface localisation are usually good measures of protein folding. In the case of 
the AdDB4, a strong surface signal was obtained with the polyclonal Ab N1 in IFA, suggesting 
that the protein is secreted and therefore folded. By contrast, mutant AdDB1 (substitution of 
Cys149 and Cys302) gives weak surface fluorescence with the polyclonal Ab N1, indicating that 
most of the molecule does not fold sufficiently to be secreted. This is understandable, as the DB 
between these two cysteine residues draws together the extreme ends of the Dl primary 
sequence, therefore this DB must have a significant stabilising influence on the whole molecule. 
By comparison, DB3 links a very small loop in the primary structure of PfAMAI. It is not 
surprising therefore that disruption of this disulphide bond had no effect on expression and 
folding of the molecule in transfected COS-7 cells, with 4G2dc1 recognition in Western and IFA 
at the level of wild type. PAN domains are typically stabilised by three disulphide bonds, 
however, in AMA1 only DB2 (Cys217-Cys247) in Dl and DB5 (Cys337-Cys409) in Dll conform 
to the PAN motif (Pizzaro et al. 2005). Clearly the DBs in AMA1 must have a stabilising effect 
on the tertiary structure of the molecule, but the analogies drawn between the role of the DBs in 
classical PAN motifs and those in AMA1 are limited.
4.7.4: Possible mechanisms of invasion inhibitory activity of 4G2dc1
Dutta et al (2005) suggested that 4G2dc1 and 4G2dc1-Fab, as well as other anti-AMA1 
antibodies, inhibit erythrocyte invasion by blocking processing/shedding of PfAMAI, as has 
been observed with PfMSPI (Blackman et al., 1994). In addition, rabbit anti-AMA1 immune 
serum has been shown to cross-link AMA1, preventing its relocalisation across the merozoite 
surface (Dutta et al. 2005). In invasion-inhibition assays, intact Abs from this rabbit antiserum
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exhibited greater inhibitory activity than their Fab fragment or than that of 4G2dc1, except at 
high concentrations. The Fab fragments, being monovalent, are unable to cross-link protein 
molecules. Thus, the ability of some antibodies to block relocalisation of PfAMAI across the 
merozoite surface may increase their potency. Relocalisation of PfAMAI across the parasite 
surface may be essential for invasion. In addition, cross-linkage of PfAMAI at the apical 
prominence may interfere with normal secretion of the apical organelles. Such a mechanism of 
inhibition would be extremely efficient as many proteins involved in the invasion process are 
released onto the merozoite surface from the micronemes and rhoptries via the apical 
prominence (Preiser et al., 2000; Dubremetz et al., 1998). The mAb 4G2dc1 does not exhibit 
this cross-linking activity.
The location of the 4G2dc1 epitope at the base of the flexible domain II loop suggests that this 
region of the molecule is functionally important. The PvAMAI crystal structure has shown that 
Dl and Dll belong to the PAN module family, implicated in adhesion of protein or carbohydrate 
receptors. The domain II loop of PvAMAI lies within the region connecting helix a7 (the PAN 
domain helix) and strand p15. This region is equivalent to the loop connecting the PAN domain 
helix and strand p3 of the Hepatocyte Growth Factor NK1. This loop in NK1 makes direct 
contact with its ligand heparin (Lietha et al., 2001). Comparison of the PAN domains of PvAMAI 
with the PAN domain of NK1 complexed to its ligand suggests that the domain II loop of AMA1 
replaces the NK1 loop, and may function by closing over its putative receptor once it is in place. 
Thus mobility of the domain II loop would be essential for AMA1 function. The mAb 4G2dc1 may 
directly interfere with PfAMAI function by anchoring the domain II loop, thus preventing it from 
stabilising the ligand-receptor interaction or locking it over the receptor binding site.
In conclusion, residues identified in this study as contributing specifically to the recognition of 
PfAMAI by the mAb 4G2dc1, lie at the base of the Dll loop. This loop appears to be flexible and 
may adopt different conformations during the invasion process. Binding of 4G2dc1 to PfAMAI 
may reduce the flexibility of the loop, which may be an essential property of the molecule for 
RBC binding during invasion by P. falciparum merozoites. It is possible that residues not yet 
identified are also involved in 4G2dc1 binding. These residues may also be in the Dll loop, 
some of which (at the C-terminus of the loop) have not yet been mutated. Alternatively, they 
may be on the surface of AMA1 against which the loop rests. In this way, 4G2dc1 binding may 
anchor the loop against Dl, thus reducing its flexibility. Future work will focus on identifying 
these residues.
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Table 4.1: Percentage invasion-inhibition of the mAb 4G2dc1
(a) Comparison of 4G2dc1 IgG with its purified 4G2dc1-Fab fragment
Concentration % Invasion-inhibition
mg ml'1 (Fab binding sites) Intact 4G2 4G2dc1-Fab
0.4 (0.27) 30 97
0.7 (0.47) 43 99
1 . 6 (1 .1 ) 2 1 99
2.7 (1 .8 ) 74 99
(b) Activity of the purified 4G2dc1 Fab fragment at low concentrations
Concentration (mg ml'1) 4G2dc1-Fab
0 0
0.03 18
0.05 24
0 . 1 1 50
0.27 62
0.43 6 8
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Table 4.2: Recombinant PfAMAI Dl-lll complexed to 4G2dc1-Fab reduces the merozoite 
invasion inhibitory activity of the Fab fragment
Concentration of 4G2dc1- 
Fab (mg ml'1)
% Invasion-inhibition
4G2dc1 -Fab 4G2dc1-Fab + rPfAMAI Dl-lll
0 0 32
0.03 18 1 1
0.05 24 17
0 . 1 1 50 43
0.16 14 4
0.27 62 38
0.43 6 8 75
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Table 4.3: The disulphide bond (DB) linkage in Dl-ll and nomenclature of the disulphide 
bond mutants
DB Cysteine in 
sequence
Cysteine
numbering
Single mutants (AsDB) Double mutants 
(AdDB)
DB1 C149-C302 C1-C6 C149(C1) - AsDB1 C1+C6 - AdDB1
DB2 C217-C247 C2-C3 C217 (C2) - AsDB2 C2+C3 - AdDB2
DB3 C263-C275 C4-C5 C263 (C4) - AsDB3 C4+C5 - AdDB3
DB4 C320-C418 C7-C10 C320 (C7) - AsDB4 C7+C10 -AdDB4
DB5 C337-C409 C8-C9 C337 (C8 ) - AsDB5 C8+C9 - AdDB5
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Table 4.4: Summary of SDMs generated on the basis of surface prediction and their 
recognition by Abs 4G2dc1, N1 and R1.
Mutations 4G2dc1 AdsN1 R1
102RSN/AAA + + +
110WTE/AAA - +/- +
115 AK YD/E AAA - +/- +
140TQYR/AQAA + + +
160NSKT/AAKA + + +
174QDL/AAA + + +
224MN P/AAA + + +
227DND/AAA + + +
230KNS/AAA + + +
233NYK/AAA - +/- +
257NNG/AAA + + +
266DQS/AQA + + +
269KRN/AAA + + +
278PAK/AAA - +/- +
305KNL/AAA + + +
348DQP/AAA - + +
351KQY/AAA - + +
359DYE/AAA + + +
362K IK/AAA + + +
366GFK/AAA + + +
369NKN/AAA + + +
388DRY/AAA - + +
403N RE/AAA + + +
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Table 4.5: The effect on Ab recognition of mutations introduced within or adjacent to the 
Dll loop of PfAMAI
Mutation 4G2dc1 AdsN1 R1
E120/A + + +
E121/A + + +
G 124/A + + +
R277/A + + +
R319/T + + +
354EQH/AAA - + +
EQH356/EQP - + +
357LT/AA + + +
Y353 - K368 deletion - + +
D373 - S377 deletion + + +
Y353 - S377 deletion - + +
L357-K368 deletion - + +
E361-K368 deletion - + +
K368/P + + +
L380/A + + +
T382/A or T382/R + + +
F385/A +/- + +
K391/A + + +
H393/A + + +
K395/A + + +
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Figure 4.1: P. falciparum merozoite invasion-inhibition by mAb 4G2dc1: 4G2dc1-Fab is 
more potent than the intact Ab
(A) Assays were perfomed at 2% haematocrit and 10% parasitaemia in the presence of purified 
4G2dc1-Fab (blue) or intact 4G2dc1 (pink). For each sample, counts were made of the number 
of rings per 104 RBCs. The 4G2dc1-Fab and 4G2dc1 concentrations (mg ml'1) were calculated 
to represent the amount of Fab binding sites present. Results were expressed as a percentage 
of the mean parasitaemia observed in the absence of IgG (PBS only). The Fab shows a greater 
degree of invasion-inhibition than the intact Ab at equivalent concentrations of the Fab binding 
domain. (B) Assay repeated at lower concentrations of 4G2dc1-Fab where, even at relatively 
low concentrations, 4G2dc1-Fab fragment exhibit potent invasion-inhibition.
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Figure 4.2: 4G2dc1-Fab forms a stable complex with rPfAMAI Dl-lll
Purified 4G2dc1-Fab was incubated with an approximate 40 fold excess of rPfAMAI Dl-lll to 
allow binding of Fab and antigen species. The mixture was then separated by HPLC gel 
filtration (yellow) to determine the proportion of 4G2dc1-Fab to rPfAMAI Dl-lll in the complex. 
Identical amounts of 4G2dc1 (blue) and rPfAMAI del (pink) were run separately to determine 
the elution points and absorbance peaks of the individual species. The slight reduction in height 
of the Dl-lll peak in the combined sample indicates some complex formation. This is confirmed 
by the presence of a new peak, eluting earlier from the column (and therefore of greater mass) 
than either of the individual species. The 4G2dc2-Fab peak is no longer visible however, slight 
broadening of one edge of the Dl-lll peak indicates that the monomeric species eluted close 
together due to their similar masses.
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Figure 4.3: P. falciparum merozoite invasion-inhibition by 4G2dc1 is not significantly 
reduced by pre-complexing with rPfAMAI
Purified rPfAMAI Dl-ll I (at a constant concentration) was incubated with varying concentrations 
of 4G2dc1-Fab prior to performing invasion-inhibition assay (red). At the highest Fab 
concentration there was a two fold excess of rPfAMAI to 4G2dc1-Fab compared to a forty fold 
excess at the lowest 4G2dc1-Fab concentration, the latter ratio corresponding to that used in 
the Fab-antigen binding assay (section 4.2.1.1). As a control for invasion-inhibition, the assay 
was performed in parallel with Fab alone (blue).
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Figure 4.4: Expression of PfAMAI subdomains in P. pastoris: confirmation that the 
epitope recognised by 4G2dc1 lies in Dl-ll
P. pastoris clones transfected with constructs for the expression of PfAMAI subdomains Dl, Dl- 
ll and Dl-lll were cultured as described. Culture supernatants were electrophoresed on 10% 
SDS-PAGE under non-reducing conditions, transferred to nitrocellulose and Western blot 
membranes probed with mAb 4G2dc1. Recombinant PfAMAI Dl was not detected by mAb 
4G2dc1 (lanes 5 - 8) or with the polyclonal sera R1 or AdsN1 (data not shown). Detection of 
recombinant PfAMAI Dl-ll (lanes 2-4) and Dl-lll (lane 9) indicates the presence of the epitope 
within these two molecular forms of the ectodomain. Their positions are highlighted (black 
arrows) and their calculated masses indicated in kDa. It can therefore be concluded that the 
4G2dc1 epitope lies within Dl-ll.
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Figure 4.5: The subdomains of PfAMAI are interconnected and in isolation from each 
other are unable to fold completely
Constructs were designed for expression of different regions of the sg‘PfAMAI ectodomain in 
COS-7 cells. A construct was designed for expression of Dl on its own in soluble form (Dl). 
Other expression constructs were designed in which either Dll or Dl was deleted (ADII and ADI, 
respectively). (A) Schematic representations of these constructs are compared with that of the 
construct for expression of full length sg'PfAMAI (sg1). (B) Culture supernatant from Dl 
transfected cells was run on 10% SDS-PAGE under non-reducing (n) and reducing (r) 
conditions, transferred to nitrocellulose and probed in Western blot with the polyclonal serum 
R1, to assess disulphide bond formation. A difference in migration of the two samples on SDS- 
PAGE was detected (black arrows) confirming some disulphide bond formation. This 
recombinant form of sg'PfAMAI was only faintly detected with polyclonal serum AdsN1 and not 
at all with mAb 4G2dc1, suggesting an absence of native fold (data not shown).
COS-7 cells transfected with the constructs for expression of ADII (C) and ADI (D) were 
solubilised directly into SDS sample buffer (non-reducing) and electrophoresed on 10% SDS- 
PAGE. In Western blot analysis, the samples were probed with polyclonal sera; (i) R1 or (ii) N1, 
or (iii) mAb 4G2dc1. Expression of these modified recombinant forms was compared with that 
of sg'PfAMAI as a positive control. In addition, COS-7 cells transfected with the construct for 
expression of Dll were additionally compared in Western blot with untransfected COS-7 cells as 
a negative control. Expression of ADII, ADI (red and blue arrow heads) and sg'PfAMAI (short 
black arrows) is indicated. The strong bands observed after Western blot membranes were 
probed with polyclonal serum R1 indicate that high levels of expression of both modified forms 
had occurred. However, reduced recognition with polyclonal serum AdsN1 indicated a loss of 
native fold. Neither form was recognised by mAb 4G2dc1.
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Figure 4.6: PfAMAI only adopts its native conformation when the N-terminus of PfAMAI 
Dl is present
Two constructs (T1 and T2) were designed for the expression of N-terminally truncated forms of 
PfAMAI. The constructs differed only in terms of the number of amino acid residues encoded 
prior to the first cysteine in Dl (three in the case of T1 and eleven in T2). Both were expressed in 
COS-7 cells in membrane bound form and cell lysates analysed by Western blot under non­
reducing conditions. Blots were probed with polyclonal sera R1 (A and B) and AdsN1 (C and D). 
T1 and T2 were both recognised strongly by R1 indicating that they were expressed at a high 
level (red and blue arrow heads). However, neither form was detected by AdsN1 indicating that 
the N-terminal truncations deleteriously affect the folding of the protein. Western blot analysis of 
COS-7 cells expressing sg'PfAMAI gave a strong band with both Abs (black arrows). T1 was 
analysed by Western blot under reducing and non-reducing conditions to investigate disulphide 
bond formation in this truncated form (E). A single reduced sample was run on SDS-PAGE, with 
non-reduced samples on either side. The presence of disulphide bonds in T1 would result in 
differential migration of the protein from the centre of the blot outwards due to diffusion of the 
reducing agent in the gel. Evidence of some disulphide bond formation was detected in Western 
blot analysis.
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Figure 4.7: Can protease digestion of rPfAMAI Dl-lll be used as a tool to map the epitope 
recognised by mAb 4G2dc1?
(1) Digestion of the rPfAMAI ectodomain with different proteolytic enzymes generates different 
sized protein fragments. (2) The digested samples can then be separated by SDS-PAGE on 
10% gels, transferred to nitrocellulose and Western blot membranes probed with mAb 4G2dc1. 
(3) Small fragments that retain recognition by the mAb can then be analysed by Mass 
spectroscopy. Comparing results from different proteolytic digestions may identify the fragment 
of the PfAMAI ectodomain containing the epitope responsible for mAb 4G2dc1 binding.
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Figure 4.8: Trypsin and chymotrypsin digestion of rPfAMAI Dl-lll generates stable Dl-ll
sized (35 - 40 kDa) protein fragments
Purified rPfAMAI Dl-lll was digested with trypsin or chymotrypsin at enzyme:substrate ratios of 
1:10. Samples were removed at 0, 40, 60, 120 and 240 minutes after enzyme addition and 
added directly to Pefabloc (to a final concentration of 2 mM) to neutralise the enzyme. Digestion 
products were separated by SDS-PAGE on 12.5% gels and stained with Coomassie blue. The 
smallest major product following trypsin (A) or chymotrypsin (B) digestion are highlighted (blue 
and red arrows respectively) and their calculated masses indicated in kDa.
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Figure 4.9: Subtilisin digestion of rPfAMAI Dl-lll generates a small fragment of (~8 kDa)
fragment
Purified rPfAMAI was digested with subtilisin at an enzyme substrate ratio of 1:10. Samples 
were removed at 0, 30, 70, 120, and 240 minutes and added directly to the protease inhibitor 
Pefabloc (at a final concentration of 2 mM). Digestion fragments were separated by SDS-PAGE 
on 12.5% gels and (A) stained with Coomassie blue or (B) transferred to nitrocellulose and 
probed with mAb 4G2dc1. Immediately after the addition of papain (at time 0), PfAMAI Dl-lll 
was digested to produce several fragments, the smallest of which was approximately 8 kDa, all 
the fragments generated were rapidly degraded. The smallest fragment identified as retaining 
4G2dc1 recognition by Western blot was of approximately 30 kDa. The major small digestion 
products identified by these methods are highlighted (red and blue arrows) and their calculated 
masses indicated in kDa.
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Figure 4.10: Pepsin and papain digestion of rPfAMAI Dl-lll generates small unstable 
fragments that are not recognised in Western blot analysis by mAb 4G2dc1
Purified PfAMAI was digested with pepsin and papain at an enzyme:substrate ratio of 1:10. 
Samples were removed at 10, 40, 60, 120 and 240 minutes after the addition of the enzyme and 
added directly to Tris-HCI, pH 8.0 (final concentration 0.5 M) and iodoacetamide (final 
concentration 10 mM) respectively, to inhibit enzyme activity. Digestion products were 
separated by SDS-PAGE and either stained with Coomassie blue or probed with mAb 4G2dc1 
in Western blot. Digestion with pepsin (A) generated fragments of approximately 8 and 10 kDa, 
while papain (B) generated fragments of approximately 8 and 12 kDa detectable by Coomassie 
blue staining. However, probing papain digestion products with mAb 4G2dc1 in Western blot 
only resulted in the detection of fragments of approximately 35 and 40 kDa (C). Major fragments 
are highlighted (black arrows) and their calculated masses indicated in kDa.
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Figure 4.11: Recombinant PfAMAI Dl-ll is resistant to digestion with trypsin and 
chymotrypsin
Purified PfAMAI Dl-ll was digested with trypsin or chymotrypsin at enzyme:substrate ratios of 
1:10. Samples were taken at 30, 60, 120 and 240 minute time points after enzyme addition and 
added directly to pefabloc (2 mM final concentration) to inhibit enzyme activity. Digestion 
products were separated by SDS-PAGE on 10% gels and stained with Coomassie blue. The 
molecule was initially resistant to digestion by both enzymes. In the case of trypsin (A), 
continued digestion resulted in no stable digestion products. With chymotrypsin (B) there was 
an initial intermediate product (red arrow head), migrating fractionally lower on SDS-PAGE than 
the intact molecule (black arrow), followed by complete degradation. In an attempt to increase 
accessibility of the molecule to digestion by these proteases, the digestions were repeated in 
the presence of 0.1% SDS. All other reaction conditions remained constant. Samples were 
taken at 0, 20, 40, 90, 120 and 240 minute time points after enzyme addition. Under these 
modified conditions neither trypsin (C) nor chymotrypsin (D) produced any stable digestion 
intermediates.
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Figure 4.12: PfAMAI Dl-ll complexed with 4G2dc1-F(ab)2 is partially protected against 
degradation by pepsin
Recombinant PfAMAI Dl-ll was incubated with 4G2dc1-F(ab)2 to allow immune complex 
formation which was then purified by gel filtration. The complex was digested with pepsin 
(enzyme:substrate ratio 1:10), to determine whether this Ab fragment would specifically prevent 
degradation of the epitope to which it was bound, thus allowing identification of the PfAMAI 
ectodomain fragment containing this epitope. Digestion products were separated by SDS-PAGE 
on 10% gels and either stained with Coomassie blue or transferred to nitrocellulose for analysis 
by Western blot. Coomassie stained gels of pepsin digestion of the complex (A) were compared 
with that of the antigen (B) under identical conditions. In the presence of F(ab)2, PfAMAI Dl-ll 
remained resistant to pepsin digestion, whereas in its absence it was gradually degraded 
although no stable intermediates were detected. Western blot membranes of pepsin digestion of 
the complex were probed with either (C) 4G2dc1 or (D) the secondary Ab only. Recombinant 
PfAMAI Dl-ll was detected by 4G2dc1, but not by the secondary Ab. Western blot analysis 
confirms the potent protective activity of mAb 4G2dc1-F(ab)2 against PfAMAI Dl-ll degradation. 
The band representing PfAMAI Dl-ll is highlighted (black arrows) and its calculated molecular 
weight indicated in kDa.
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Figure 4.13: The disulphide bond between Cys263 and Cys275 (DB3) is not critical for the 
overall conformation of PfAMAI
Disulphide bond mutants of sg'PfAMAI were generated by sequentially replacing a single 
cysteine residue from each of the five disulphide bonds in Dl-ll with alanine. The resulting 
disulphide bond mutants were denoted AsDB1 - AsDB5. COS-7 cells transfected with constructs 
for the expression of these mutants were solubilised directly in SDS sample buffer under non­
reducing conditions, the extract run on 10% SDS-PAGE and transferred to nitrocellulose. 
Western blot membranes were probed with polyclonal serum R1 and mAb 4G2dc1. All DB 
mutant forms (labelled 1 - 5 )  produced strong bands in Western blot analysis when probed with 
R1 (A) indicating high level expression. By comparison, only DB3 (linking Cys263 and Cys275) 
was recognised by 4G2dc1 (B). The band representing the PfAMAI 66 form of the DB mutants is 
highlighted (black arrows) and the calculated mass indicated in kDa.
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Figure 4.14: IFA with antisera to PfAMAI confirms that single cysteine mutants of 
sgPfAMAI are correctly localised on the surface of COS-7 cells
COS-7 cells were analysed unfixed and unpermeabilised to detect surface localised protein 
only. Antibody (polyclonal serum N1) binding was examined in cells transfected with constructs 
for expression of single cysteine mutants (AsDB1 - AsDB5, labelled 1 - 5 )  and compared with 
those expressing wild type sg'PfAMAI (6) as a positive control and untransfected cells (7) as a 
negative control. Polyclonal serum N1 was used at 1 in 100 dilution. The image is a composite 
of DAPI (blue), Evans blue (red) and FITC conjugate (green) images from fluorescence 
microscopy as described in the materials and methods (section 2.4.3).
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Figure 4.15: IFA reveals that two single cysteine sg'PfAMAI mutants (AsDB1, between 
Cys149 and Cys302 and AsDB4, between Cys320 and Cys418) are no longer recognised 
by 4G2dc1
Monoclonal Ab 4G2dc1 binding was examined in COS-7 cells transfected with constructs for 
expression of single cysteine mutants (AsDB1 - AsDB5, labelled 1 - 5 )  and compared with those 
expressing wild type sg'PfAMAI (6) as a positive control and untransfected cells (7) as a 
negative control. Cells were incubated with mAb 4G2dc1 without prior fixation to determine 
surface localisation. The image is a composite of DAPI (blue), Evans blue (red) and FITC 
conjugate (green) images from fluorescence microscopy as described in materials and methods 
(section 2.4.3). Only AsDB3 retains 4G2dc1 recognition at an equivalent level to the wild type 
sg'PfAMAI.
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Figure 4.16: Western blot analysis confirms that disruption of DB1 (Cys149 and Cys302) 
and DB4 (Cys320 and Cys418) abrogates recognition by mAb 4G2dc1
Disulphide bond mutants of sg'PfAMAI were generated by sequentially replacing both cysteine 
residues from each of the five disulphide bonds in Dl-ll with alanine. The resulting disulphide 
bond mutants were denoted AdDB1 - AdDB5. COS-7 cells transfected with constructs for the 
expression of these mutants were solubilised directly in SDS sample buffer (non-reducing) and 
the extract run on 10% SDS-PAGE and transferred to nitrocellulose. Western blot membranes 
were probed with polyclonal serum R1 and mAb 4G2dc1. All DB mutant forms of PfAMAI 
produced strong bands in Western blot analysis when probed with R1 (A) indicating high level 
expression. 4G2dc1 recognition was completely disrupted in mutants AdDB1 and AdDB4, while 
all the remaining mutants retained some level of recognition by this mAb (B). The band 
representing the DB mutant forms of PfAMAI 66 is highlighted (black arrows) and the calculated 
mass indicated in kDa.
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Figure 4.17: IFA with antisera to PfAMAI confirms that all double cysteine mutants of 
sg'PfAMAI are correctly localised on the surface of COS-7 cells
COS-7 cells were analysed unfixed and unpermeabilised to detect surface localised protein 
only. Antibody binding using polyclonal serum N1, was examined in cells transfected with 
constructs for expression of the double cysteine mutants (AdDB1 - AdDB5, labelled 1 - 5 )  and 
compared with those expressing wild type sg'PfAMAI (6) as a positive control and 
untransfected cells (7) as a negative control. N1 was used at 1 in 100 dilution. The image is a 
composite of DAPI (blue), Evans blue (red) and FITC conjugate (green) images from 
fluorescence microscopy as described in materials and methods (section 2.4.3).
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Figure 4.18: 4G2dc1 recognition of PfAMAI is lost after disruption of DB1 and DB4
COS-7 cells were analysed unfixed and unpermeabilised to detect surface localised protein 
only. Monoclonal Ab 4G2dc1 binding was examined in cells transfected with constructs for 
expression of double cysteine mutants (AdDB1 - AdDB5, labelled 1 - 5 )  were compared with 
those expressing wild type sg'PfAMAI (6) as a positive control and untransfected cells (7) as a 
negative control. The image is a composite of DAPI (blue), Evans blue (red) and FITC 
conjugate (green) images from fluorescence microscopy as described in materials and methods 
(section 2.4.3).
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Figure 4.19: Western blot analysis confirms the specificity of the polyclonal sera Ads N1 
and R1 and mAb 4G2 for non-reduced and reduced rPfAMAI ectodomain
Purified samples of rPfAMAI Dl-lll and Dl-ll were electrophoresed on 10% SDS-PAGE gels 
under (A) non-reducing or (B) reducing conditions and transferred to nitrocellulose for Western 
blot analysis using the polyclonal serum N1 (i) or R1 (ii), or mAb 4G2dc1 (iii) The position of 
Dl-lll and Dl-ll bands is indicated (red and blue arrow heads).
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Figure 4.20: The PfAMAI epitope recognised by mAb 4G2dc1 lies predominantly in Dll
To map the 4G2dc1 epitope, amino acid residues within Dl-ll of PfAMAI ectodomain with a high 
probability of being exposed at the surface of the molecule were mutated by SDM. Mutations 
were primarily to alanine, but in those cases where the residue was already alanine, the amino 
acid was mutated to one found at the corresponding position in the AMA1 sequence from 
another species of Plasmodium. Mutants were transfected into COS-7 cells and cell lysates 
analysed by Western blot to confirm expression and determine the effect on 4G2dc1 
recognition. Western blot membranes were probed with polyclonal sera R1 (A) and N1 (B) and 
mAb 4G2dc1 (C). Results for a selection of these mutants (numbered 1 to 18) are shown and 
the sg'PfAMAI band indicated (black arrow). Mutations that abrogate 4G2dc1 recognition and 
those that affect overall protein conformation are highlighted (red and blue asterisks).
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Figure 4.21: The domain II loop plays a key role in 4G2dc1 recognition
Residues in the 4G2dc1 epitope lie at the base of the flexible Dll loop. Amino acid residues in 
this loop were specifically targeted for mutagenesis to determine the role played by this 
structure in 4G2dc1 recognition. In addition, secondary structure predictions indicate the 
presence of two helices in the loop (353Y-K368 and 373D-S377), both were deleted 
(individually and together) to determine whether their presence was essential for 4G2dc1 
binding. Constructs for the expression of mutant forms of sg1 PfAMAI were transfected into 
COS-7 cells and cell lysates analysed by Western blot to confirm expression and determine the 
effect on 4G2dc1 recognition. Western blot membranes were probed with polyclonal sera R1 
(A) and N1 (B) and mAb 4G2dc1 (C). Results for a selection of these mutants are shown and 
the presence of sg'PfAMAI indicated (black arrow). Mutations that specifically abrogate 4G2dc1 
recognition and those that indirectly affect binding are highlighted (red and blue asterisks).
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Figure 4.22: Surface structure of PfAMAI Dl-ll, showing the position of 4G2dc1 epitope in 
the Dil loop.
(A) The residues of which the 4G2dc1 epitope is comprised (black) are shown to cluster 
together in one region of the Dll loop (shown in blue, as is the rest of Dll) which itself extends 
across the surface of Dl (orange). One residue (Phe 385, shown in black) lies in a four amino 
acid stretch that was not detected in the crystal structure. This stretch is depicted in this figure 
as a loop extending from the side of the Dll loop where it is located in the primary sequence. (B) 
Several residues in the Dll loop, some of which appear to lie in close proximity to the 4G2dc1 
epitope, have not been mutated. These residues and additional residues from Dl (all shown in 
pink) are potential components of this epitope.
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Figure 4.23: The selection process to isolate 4G2dc1'/native* random mutants: the 
negative selection step is very efficient, but the positive selection step is inefficient
To assess the efficiency of each step in the selection process for 4G2dc1'/native* random 
mutants, COS-7 cells expressing either (I) non-mutated (4G2dc1+/native+) sg'PfAMAI or (II) 
AdDB4 (4G2dc17native*) were subjected to a single round of selection using either (a) 
Dynabeads (coupled to anti-mouse IgG) alone, (b) mAb 4G2dc1 or (c) polyclonal serum N1. In 
the latter two cases, after incubation with the primary Ab, the cells were incubated with 
Dynabeads and then (for all three treatment conditions) the cells were separated using a Dynal 
magnet into Dynabead bound (B) and unbound (UB) fractions. For both transfected COS-7 cell 
lines, a sample was harvested by trypsin treatment (T) and not subjected to further selection to 
give an indication of the starting protein concentration. Cell fractions were solubilised directly 
into SDS sample buffer (non-reducing) the extract run on 10% SDS-PAGE gels and transferred 
to nitrocellulose. Western blot membranes were probed with either polyclonal sera (i) R1 or (ii) 
N1, or (iii) mAb 4G2dc1.
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Figure 4.24: 4G2dc1 "/native* mutant forms of PfAMAI are identified by screening the 
sg'PfAMAI random mutant library
COS-7 cells were transfected with sg’PfalRML. The selection procedure involved three rounds 
of negative selection followed by a single round of positive selection as detailed in the materials 
and methods (section 4.6). At the final round of selection (positive) plasmid DNA was recovered 
from the isolated cells and transformed into E. coli for cloning, following which DNA was 
transfected into COS-7 cells for expression. Cells were harvested, solubilised into SDS-sample 
buffer (non-reducing), the extract run on 10% SDS-PAGE gels and transferred to nitrocellulose 
for analysis in Western blot. Western blot membranes were probed with polyclonal sera (A) R1 
or (B) N1 or mAb (C) 4G2dc1. Mutants forms that were 4G2dc1'/native+or 4G2dc1+/native+ are 
indicated (red and blue asterisks). COS-7 cells expressing non-mutated sg'PfAMAI (sg1) and 
untransfected COS-7 cells (neg) were used as positive and negative controls respectively.
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Figure 4.25: Clustal alignment of DHI of sg'PfAMAI and 4G2dc1-/natives random mutant 
clones: residues identified by SDM and random mutagenesis as specifically disrupting 
4G2dc1 recognition show minimal overlap
Amino acid residues identified by SDM as being components of the 4G2dc1 epitope and those 
considered as potential candidates on the basis of their proximity to the Dll loop and the defined 
epitope are highlighted (red and blue, respectively) in sg'PfAMAI. Residues found to be altered 
in the random mutant clones are also indicated (yellow).
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Chapter 5
Function of PfAMAI in signal transduction 
5.1: Introduction
Living cells of both unicellular and multicellular organisms are faced with the requirement for 
sensing changes in their environment and the need for rapid adaptive responses to that 
environment. Eukaryotic cells have evolved several complex and highly conserved mechanisms 
for overcoming this problem.
Signals from the extracellular milieu are detected via a receptor embedded in the plasma 
membrane. Binding of the signalling molecule to the receptor initiates a downstream cascade of 
events, often involving phosphorylation of the receptor cytoplasmic domain and/or downstream 
effector molecules, the end result of which can be regulation of specific cytoplasmic machineries 
or of the activation of certain genes in the nucleus. Signalling pathways are tightly regulated to 
ensure the correct timing, duration and magnitude of the signal. To this end, the protein kinases 
(PK) and phosphatases (PP) that often regulate signalling are themselves tightly regulated. The 
addition of phosphate groups to protein substrates significantly affects their activity, stability, 
binding properties and subcellular localisation (Kappes et al., 1999).
5.1.1: Receptor molecules involved in signal transduction
Several major classes of cell surface receptor exist that are involved in signal transduction. 
These include the receptor tyrosine kinase family, cytokine receptors (type I and II), 
haematopoietic antigen receptors, protein serine/threonine kinase receptors, the tumour 
necrosis factor (TNF) receptor family and G-protein coupled receptors. These receptors have 
extracellular receptor domains. Ligand binding often induces receptor dimerisation. The 
cytoplasmic domains of signalling receptor molecules often allow transduction of the signal by 
mediating interactions between the receptor and downstream effector molecules. These 
domains include Src homology (SH) and pleckstrin homology (PH) domains and have been 
implicated in facilitating protein-protein and protein-lipid interactions, thus mediating the 
assembly of signalling complexes at the cytoplasmic face of the plasma membrane. In addition, 
some classes of receptors possess catalytic domains in their cytoplasmic tail that are capable of 
autophosphorylation. Residues in the SH domains of such receptors, that are required for 
protein-protein interaction, may be phosphorylated in this way.
Class I cytokine receptors and haematopoietic antigen receptors (e.g. T-cell antigen receptors, 
TCRs) appear to lack these homology domains and instead possess conserved amino acid
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motifs that facilitate protein-protein interactions. For instance, the TCR is composed of two 
largely extracellular variable polypeptide chains (ap or y8) capable of binding diverse ligands. 
These interact non-covalently via their short cytoplasmic tail with invariant polypeptide chains 
comprising the CD3 complex (y, 5 and two e chains) and ^-homodimer. The invariant chains 
contain a total of ten immunoreceptor tyrosine activation motifs (ITAMs; YX2(Lyi)X^8YX2(L7l)) 
(Reth, 1991; Irving and Weiss, 1991; Irving et al., 1993). ITAM sequences are essential for the 
signalling capacity of the antigen receptor complex (Weiss et al., 1993; Burkhardt et al., 1994). 
Phosphorylation of tyrosine residues within the ITAM sequence, by Src-family kinases (Lck and 
Fyn) is thought to generate docking sites for downstream signalling molecules such as the 
cytosolic tyrosine kinase Zap-70. Binding of Zap-70 occurs via tandem SH2 domains (Chan et 
al., 1992). Thus receptor molecules interact directly or indirectly with downstream signalling 
molecules via conserved domains or motifs.
5.1.2: Signal transduction in apicomplexan parasites
Plasmodium is evolutionarily divergent from both yeast and higher eukaryotes. Identity between 
the catalytic domains of protozoan PKs and those of their putative homologues in other 
eukaryotes is typically only 40 - 60%, exceeding 60% only rarely (Doerig et al., 2002). This 
allows for considerable functional and structural divergence. Thus, functional predictions 
resulting from comparison-based analysis can be difficult and may prove misleading. Open 
reading frames (ORFs) have been identified from the genome of P. falciparum that encode 
polypeptides with clearly recognisable PK catalytic domains but, on the basis of identity alone, 
these cannot be consigned to a specific family. Furthermore, several enzymes have been 
identified in the P. falciparum kinome (the group of genes in the P. falciparum genome believed 
to encode for parasite protein kinases) having regions of homology to two distinct PK families 
(Bracchi-Ricard et al., 2000; Dorin et al., 2005; Ward et al., 2004).
While Plasmodium and other protozoan parasites share many of the classical components of 
signalling pathways, there are also apparent gaps in the signalling machinery. Members of the 
conventional protein tyrosine kinase family of PKs have not been identified in the Plasmodium 
genome (Doerig, 2004). Flowever, tyrosine phosphorylation has been observed in P. falciparum 
(Sharma, 2000) and it has been postulated that this may be carried out by members of a dual­
specificity PK family that phosphorylate serine or threonine as well as tyrosine residues (Doerig 
et al. 2002). Such dual-specificity PKs have been identified in budding yeast where typical 
tyrosine kinases also appear to be missing (Flunter and Plowman, 1997). The absence of the 
tyrosine kinase family has been observed in most single celled eukaryotes, so it is perhaps not 
surprising that it is also absent in the Plasmodium kinome (Shiu et al. 2004).
A further example of Plasmodium divergence from higher eukaryotes in terms of signal 
transduction pathways is the absence of a classical tripartite mitogen-activation protein kinase
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(MAPK, also known as extracellular regulated kinases, ERKs) pathway. In mammalian systems 
MAPK pathways regulate responses to a wide variety of stimuli. These are activated by dual 
phosphorylation of Thr and Tyr in a conserved MAPK activation motif, TXY by a specific MAPK 
kinase (MAPKK). These are activated by phosphorylation of two Ser or Thr residues in the 
conserved motif SMANS by a MAPK kinase kinase (MAPKKK). Activation of MAPKKK occurs in 
response to a number of extracellular or intracellular stimuli. Two P. falciparum homologues of 
MAPKs have been identified to date; Pfmap-1 encodes a protein with a classical TXY activation 
motif (Doerig et al., 1996) whereas Pfmap-2 encodes a protein having an atypical TSH motif, in 
which both T and H are essential for kinase activity of recombinant Pfmap-2 (Dorin et al., 1999). 
However, no classical MAPKK or MAPKKK genes have been identified in the genome (Ward et 
al., 2004). The P. falciparum PK Pfnek-1 has an activation site with more similarity to that of 
MAPKKs than the never-in-mitosis/Aspergillus (NIMA) or NIMA-like (Nek) kinase family to which 
it displays more overall homology (Dorin et al., 2001). The putative activation site of Pfnek-1 
possesses a SMAHS motif, rather than the activation sequence normally found in the active site 
of mammalian MAPKK enzymes. Pfnek-1 specifically phosphorylates recombinant Pfmap-2 but 
not Pfmap-1 or mammalian ERK2 in vitro and acts synergistically with Pfmap-2 in 
phosphorylation of the exogenous substrate myelin basic protein (MBP), consistent with a role 
in an atypical MAPK pathway. It remains to be seen whether Pfnek-1 functions as a MAPKK in 
vivo. Searches of the P. falciparum genome database led to the identification of a novel PK, 
PFPK7, having homology to MAPKK in its C-terminal lobe (subdomains VI and XI) (Dorin et al., 
2005). However, it contains certain residues that are more similar to those found in protein 
kinase A (PKA). Recombinant PfPK7-GST fusion protein was capable of autophosphorylation, 
but was unable to phosphorylate recombinant Pfmap-1 or Pfmap-2 in vitro, suggesting the 
absence of MAPKK activity. Furthermore, inhibitors of PKA had no effect on phosphorylation of 
MBP by PfPK7 while only two MAPKK inhibitors had any effect and then only at high 
concentrations. However, it cannot be ruled out that in vivo this protein functions as a MAPKK 
via some atypical pathway. Despite the discovery of a G-protein oc-subunit that may be involved 
in triggering the switch from asexual to sexual development, G-protein-coupled receptors are 
also apparently absent from the Plasmodium genome (Aravind et al. 2003). MAPK pathways 
are often activated in response to G-protein-coupled receptor activation (Doerig, 1997; Cobb et 
al. 1995).
A further area of disparity between the kinome of Plasmodium and that of vertebrates is the 
presence of members of the calcium dependent protein kinase (CDPK) family (Li and Cox, 
2000; Zhao et al., 1993; Kappes et al., 1999; Ward et al., 2004). This family of PKs have only 
previously been identified in plants and some protozoan species, including the apicomplexan 
parasites Eimeria tenella and E. maxima (Dunn et al., 1996) where they are usually members of 
multigene families.
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In contrast to the PKs that are apparently absent in the P. falciparum kinome, many have been 
identified that belong to "orphan" groups as they do not cluster with any of the established 
eukaryotic PK groups. In particular is the FIKK (motif) family (20 members in P. falciparum), 
members of which have only been identified to date in Apicomplexan parasites (Ward et al., 
2004). These contain the vast majority of residues in the catalytic site thought to be important 
for kinase activity. In addition they possess several fully conserved amino acid "signature" 
motifs that are characteristic of the family, for instance, protein sequences of all FIKK family 
members have a conserved tryptophan in the motif [ILV][YF]W[NTS]XX[GC] about 100 amino 
acid residues upstream of the FIKK motif. The glycine triad (GXGXXG) normally present in 
subdomain I of PKs is incomplete in FIKK protein sequences, no family member having the full 
complement of glycines. Apart from the glycine triad, all residues required for phospho-transfer 
in PKs are present in the FIKK sequences, suggesting that these proteins are PKs. However, no 
experimental evidence exists to substantiate this claim. Some FIKK family members in P. 
falciparum contain putative signal peptides and/or transmembrane spanning domains N-terminal 
to the predicted catalytic domain. With these exceptions and the similarities in the predicted 
catalytic domain, this protein family possess no other previously characterised protein domains.
5.1.3: Signalling during host cell invasion by apicomplexan parasites
Invasion of host cells by apicomplexan parasites is a complex and tightly regulated process (see 
section 1.1.1.). The necessity for signal transduction for successful invasion by these parasites 
has been known for some time. Ward et al. (1994) showed that staurosporin, a serine/threonine 
PK inhibitor, arrests invasion at the point of tight junction formation and concluded that 
phosphorylation was essential for merozoite invasion of host erythrocytes. Dobrowolski et al. 
(1997) demonstrated that the protein kinase inhibitor KT5926 blocks T. gondii tachyzoite motility 
and attachment to host cells. Loss of these activities is likely to result directly from the observed 
loss of microneme, and therefore MIC2, secretion. Kieschnick et al. (2001) identified TgCDPKI 
as the specific target of this inhibitor, implicating this PK in playing a role in microneme secretion 
and host cells attachment of T. gondii tachyzoites. Thus, it would appear that the activation of 
TgCDPKI leads to phosphorylation of the parasite proteins involved in secretion of MIC2 and 
possibly other microneme proteins.
In T. gondii, ionophore induced elevation of intracellular calcium concentrations ([Ca2+],) triggers 
microneme secretion (Carruthers et al., 1999a; Carruthers et al., 1999b; Carruthers and Sibley, 
1999). Secretion of rhoptry and dense granule components did not occur under these 
conditions, suggesting that there is differential regulation of apical organelle secretion 
(Carruthers and Sibley, 1999). Additionally, Carruthers et al. (1999c) demonstrated that 
microneme discharge was regulated by a staurosporin sensitive kinase, essential for parasite 
invasion of host cells. The addition of the Ca2+ ionophore A23187, in the presence of high levels 
of extracellular Ca2+ was unable to reverse the effects of staurosporin. Carruthers et al. (1999)
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concluded that the calcium-dependent step in the signalling pathway triggering microneme 
secretion preceded the staurosporin-sensitive kinase step. Bumstead and Tomley (2000) 
demonstrated that microneme secretion in E. tenella sporozoites occurred in the presence of 
albumin in vitro. In the blood, albumin is believed to be crucial for regulating free calcium 
(Aguanno et al. 1982). For this reason, the group suggest that the presence of albumin in in 
vitro culture facilitates the uptake of calcium by Eimeria sporozoites, possibly triggering 
microneme secretion (Bumstead and Tomley, 2000). In P. falciparum, the requirement for Ca2+ 
in invasion of human erythrocytes was noted as early as 1982. Wasserman et al. (1982) 
showed that in the presence of the Ca2+ chelator EGTA, merozoites were unable to progress 
beyond cell attachment. Whether this effect was due to loss of microneme secretion, as 
indicated for T. gondii, was not determined but is none-the-less possible. Thus, signal 
transduction is necessary for microneme secretion and this signal can be induced in the 
absence of host cells. Furthermore, the signals required for microneme and rhoptry secretion 
appear to be distinct.
Thus, for successful invasion of host cells by apicomplexan parasites signals must be 
successfully transduced across the parasite plasma membrane. The receptor molecules 
responsible for induction of this signal remain to be identified.
5.1.4: Merozoite surface receptors involved in signal transduction
Despite many potential cytosolic signalling molecules having been identified in apicomplexan 
parasites, the signalling pathways within which they play a role have yet largely to be 
elucidated. Furthermore, no parasite signalling receptor molecules have been identified. For 
instance, while it appears likely that Ca2+ signalling plays a key role in microneme secretion 
during host cell invasion, the precise event that initiates this signal is unknown.
In the cell membrane, sphingolipids and cholesterol cluster together into moving platforms or 
rafts (Simons and Ikonen, 1997). These lipid rafts are plasma membrane microdomains rich in 
glycosphingolipids, sphingomyelin and cholesterol (Brown and London, 1998). Membrane 
associated proteins such as glycosylphosphatidylinositol (GPI) anchored proteins and dually 
acylated proteins as well as transmembrane proteins are all able to interact with the rafts. 
Simons et al. (1997) observed that cross-linking of GPI-anchored proteins led to raft formation 
and activation of lymphoid cells. In addition, it has been observed that several signalling 
molecules partition into detergent-insoluble glycolipid-enriched complexes (Anderson et al. 
1993; Lisanti et al. 1994). Harder and Simons (1999) showed that cross-linking the ganglioside 
GMi using cholera toxin B subunit led to an increase in cytosolic phosphotyrosine. They 
demonstrated that the phosphotyrosine signal was significantly reduced by incubation with PP1, 
a specific inhibitor of the tyrosine kinases Lck and Fyn that are implicated in TCR signalling. 
Both Lck and Fyn have been shown to localise to lipid rafts, association with the rafts being
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mediated by the acyl modifications of these PKs (Kabouridis et al. 1997) . Upon activation of the 
TCR, the receptor itself is recruited to lipid rafts (Montixi et al., 1998; Xavier et al. 1999). GPI- 
anchored proteins and gangliosides do not span the plasma membrane. It is therefore difficult to 
anticipate how they could, on their own, transduce a signal across the membrane. Harder and 
Simons (1999) concluded that under physiological conditions the activated TCR might act 
synergistically with the raft-associated components in T-cell activation. GPI anchored proteins 
have also been implicate in signal transduction in haematopoietic cells (Peles et al., 1997), 
leading to stimulation of Src-family PKs, and in neurons (Robinson, 1991). At the time of 
Plasmodium schizont rupture the majority of proteins making up the merozoite surface coat are 
GPI-anchored (Dubremetz et al., 1998). As in the mammalian system, it is unlikely that in 
merozoites GPI-anchored proteins alone are responsible for signal transduction. It therefore 
seems likely that some transmembrane protein(s) participate in the signalling events that occur 
during the invasion process.
AMA1 is a type I integral membrane protein expressed in late schizogony when it is trafficked to 
the micronemes. Around the time of schizont rupture AMA1 is secreted from the micronemes 
and can be detected on the merozoite surface. With the exception of MAEBL, none of the DBLs 
have been detected on the surface of merozoites (Kappe et al., 1998a) suggesting that AMA1 
and MAEBL may be the first transmembrane proteins to localise to the merozoite surface after 
schizont rupture. The cytoplasmic tail of EBA-175 does not play a role in protein trafficking to 
the micronemes (Gilberger et al., 2003a). For this reason, it seems unlikely that the cytoplasmic 
domain of AMA1 could be involved in microneme targeting if that of EBA-175 is not. Rather, it 
seems probable that the parasite uses a conserved mechanism for protein targeting to these 
organelles.
The high degree of conservation observed in the cytoplasmic tail of AMA1 (Fig 5.1.) across the 
phylum is suggestive of a conserved, essential function of this region of the molecule. 
Furthermore, there are several tyrosine, serine and threonine residues that are absolutely 
conserved in all Plasmodium AMA1 sequences identified to date. One of each of these residues 
is also conserved in the sequence of the T. gondii AMA1 homologue. Although the cytoplasmic 
tail of AMA1 does not contain any typical signalling motifs, the unusual nature of many of the 
signalling molecules already identified in Plasmodium, raises the possibility that these residues 
in AMA1 could be targets for kinase activity during signal transduction. This, together with its 
presence on the merozoite surface so early after schizont rupture, makes AMA1 an ideal 
candidate for a novel Plasmodium receptor for transducing a signal to the parasite cytosol at the 
time of "appropriate" host cell contact.
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5.2: Analysis of the role of PfAMAI as a signalling molecule
AMA1 is considered to be a valuable potential component of a subunit anti-malarial vaccine. As 
a signalling molecule it would also become a potential target for chemotherapeutic intervention. 
Because of the atypical nature of many Plasmodium signalling molecules, they are ideal 
candidates for drug design. In addition, some Plasmodium PKs share features found in PKs 
from other protozoans, such as Trypanosoma brucei and Leishmania that are not shared by 
other eukaryotes. Others share homology to PKs unique to plants and a few other protozoans 
(Li and Cox, 2000; Zhao et al., 1993; Kappes et al., 1999; Ward et al., 2004). These unique 
characteristics are valuable qualities in drug targets, as drugs that effectively inhibit their activity 
should be specific for the target species. As an essential gene product (Triglia et al., 2000; Hehl 
et al., 2000) chemotherapeutic agents that effectively prevent AMA1 participation in a signalling 
pathway would also prevent erythrocyte invasion by merozoites and thus disrupt parasite growth 
and development. To explore the possibility of a role for PfAMAI in signal transduction, the 
phosphorylation status of this protein in purified merozoites extracts was analysed.
P. falciparum schizonts were synchronised on a 70% percoll cushion, returned to culture in the 
absence of fresh RBCs and allowed to rupture for 4 hours. Merozoites were collected and 
analysed under reducing conditions by Western blot using the polyclonal serum R1 and mAbs 
specifically recognising phosphoserine (p-Ser), phosphothreonine (p-Thr) and phosphotyrosine 
(p-Tyr).
In this study, the presence of PfAMAI 6e in merozoite lysates was confirmed using polyclonal 
serum R1, giving a clear band running just above the 67 kDa marker band (Fig 5.2, D). The anti- 
p-Thr mAb detected several bands, one of which migrated at a similar size to that detected by 
R1 (Fig 5.2, A). To determine whether this was also PfAMAI, each of the two blots was re­
probed this time with the alternative antibody, i.e. the blot that had been probed with R1 was 
now probed with anti-p-Thr, and vice versa. In both cases a doublet was detected (Fig 5.2, E 
and F respectively) indicating the presence of the first band that had not been removed by 
stripping the blots, and a novel band detected by the second primary antibody. This confirmed 
that the two antibodies were detecting different proteins migrating at slightly different sizes. This 
result was confirmed by repeating the Western blot using larger gels to obtain better resolution. 
Once again probing a blot with the two different antibodies (polyclonal serum R1, Fig 5.3 A, and 
anti-phosphothreonine consecutively) produced a doublet (Fig 5.3, B).
The blot probed with anti-p-Ser mAb showed high background, with multiple bands (Fig 5.2, B). 
However there appeared to be a band at about 67 kDa, close to the size of PfAMAI. This result 
was not however reproducible. Probing with anti-p-Tyr mAb (4G10) produced several faint 
bands, none of which were at the correct size for PfAMAI (Fig 5.2, C).
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Results obtained from similar analysis of different preparations of merozoites gave variable 
results. However, none led to the detection of phosphorylation of any type in PfAMAI.
5.3: Discussion
5.3.1: Phosphorylation status of PfAMAI
Receptors that lack intrinsic kinase activity are often phosphorylated upon activation by 
associated kinases (Ihle, 1995; Taniguchi, 1995). For Plasmodium merozoites this receptor 
activation would occur when the parasite makes the initial attachment with the appropriate host 
cell and/or at some stage downstream of this event. In this study phosphorylation of PfAMAI 
was not detected with any of the antibodies used. For this study, schizonts were isolated from 
cultures using a 70% percoll cushion. The schizonts floating on top of the cushion were washed 
and then returned to culture in the absence of fresh RBCs to complete their development and 
rupture. Schizonts purified in this way were about 95% pure, there being about 5% 
contamination with trophozoite stage parasites and some uninfected cells. Because of the low 
level of contamination it is unlikely that the released merozoites, harvested from these samples 
by centrifugation, would have encountered any uninfected RBCs. As a result, the conditions 
necessary for transducing the signal to initiate the chain of events leading to erythrocyte 
invasion would not have been met by these merozoites. However, some merozoites may have 
come into contact with RBC debris from ruptured schizonts although whether such membranes, 
which have been extensively modified (Berendt et al., 1994) by the parasite, are capable of 
triggering the necessary signals for parasite invasion is unknown. It is possible however, that 
some low level stimulation would occur under these conditions. Nevertheless, the degree of 
phosphorylation of PfAMAI might have been insufficient for detection by these antibodies. To 
increase the likelihood of detecting low-level phosphorylation, PfAMAI could first be purified by 
immunoprecipitation using a PfAMAI specific antibody. Alternatively purification of all 
phosphorylated parasite proteins would have enhanced the small fraction of phosphorylated 
PfAMAI protein present. Increasing the concentration of phosph-PfAMAI by either of these 
methods would make detection by Western blot analysis easier. This approach will be 
considered in more detail in the future.
5.3.2: Regulation of receptor activation
Signal transduction can result in diverse, or diametrically apposed downstream effects, such as 
apoptosis and cell proliferation (Shiu et al., 2004; Ward et al., 2004; Caraglia et al., 2005; Dailey 
et al., 2005). In order that these processes are kept in check, the receptors and PKs involved 
are tightly regulated. Regulation of PK activity can be achieved by phosphorylation and/or 
dephosphorylation of inhibitory sites outside the catalytic domain. For instance, members of the 
Src tyrosine kinase family have an inhibitory tyrosine phosphorylation site in the C-terminal tail
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(Cooper and King, 1986) and stimulatory tyrosine phosphorylation sites in the catalytic domain. 
Regulation of Src activity involves interplay between these sites, activation requiring 
phosphorylation in the kinase domain and inhibition resulting from C-terminal phosphorylation 
(Kmiecik et al., 1988). Only a small energy barrier lies between the two states enabling the 
molecule to flip rapidly between them (Cooper et al. 1993). Thus, regulation of Src kinase 
activity requires the interplay of phosphatases and kinases in the cell (Okada and Nakagawa et 
al. 1989). Indeed, there appears to be a rapid turnover of phosphate at both sites.
The catalytic domains of most eukaryotic kinases are about 250 - 300 residues in length (Hanks 
and Quinn 1993). The cytoplasmic tail of PfAMAI is only 54 amino acid residues long and is 
therefore unlikely to be a functional kinase domain unless it does so as an atypical protein 
kinase. If this were the case, the potential phosphorylation sites in the AMA1 cytoplasmic tail 
could function in receptor regulation as either inhibitory or stimulatory sites. If both types were 
present one might expect to see receptor phosphorylation regardless of whether the receptor 
was activated or not. The only difference might be in the nature and position of the residue 
phosphorylated. The absence of any detectable phosphorylation in PfAMAI under the 
conditions used in this study, argues against the presence of inhibitory phosphorylation sites.
One further possibility for the lack of PfAMAI phosphorylation found in this study is the absence 
of phosphatase inhibitors. Phosphorylation is usually a reversible and dynamic process, the 
phosphorylated residues being rapidly de-phosphorylated by phosphoprotein phosphatases to 
prevent over stimulation (Roskoski 2005). Phosphorylation of PfAMAI might not have been 
observed due to rapid removal of the phosphate group by active protein phosphatase 
contamination present in the merozoite lysates.
5.3.3: PfAMAI as a signalling receptor molecule
From the data discussed here, it would appear that PfAMAI does not undergo phosphorylation. 
However, these results are only preliminary and a much more detailed analysis of signalling 
during invasion is required before PfAMAI can be demonstrated conclusively to play a role in 
signalling or not. For a more thorough examination of AMATs role as a signalling molecule it will 
be necessary to be able to dissect out and/or “freeze in time” different stages in the invasion 
process, i.e. the points of initial interaction, reorientation and tight junction formation and assess 
the phosphorylation status of AMA1 at each of these time points. This is particularly difficult in 
Plasmodium as the invasion process is extremely rapid (about 20 seconds) and the invasive 
half-life of merozoites is very short, in the order of 10-30 minutes at 23°C and 4-7 minutes at 
37°C in P. knowlesi (Johnson et al., 1980). Cytochalasin B "freezes" parasites at the point of 
tight junction formation (Miller et al., 1979a) and merozoite attachment is stable at 0°C (Johnson 
et al., 1980). However this latter result was obtained using purified P. knowlesi merozoites. 
Viable P. falciparum merozoites have never been purified and it is debatable whether schizont
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rupture could occur normally at 0°C. Isolation of P. falciparum merozoites attached to human 
erythrocytes may therefore not be possible. Isolation of merozoites at the point of reorientation, 
prior to tight junction formation may also be difficult. However, if these difficulties could be 
overcome, the progress of PfAMAI could be followed through the invasion process and its 
phosphorylation status fully characterised.
The transport of PfAMAI to the merozoite surface around the time of schizont rupture suggests 
that it plays a role in the early stages of invasion (Peterson et al., 1989). MAEBL is the only 
other integral membrane protein purported to be an erythrocyte binding protein that has been 
localised to the merozoite surface (Kappe et al., 1998a). This suggests that the role these two 
proteins play in invasion is distinct from that of the other erythrocyte binding antigens. 
Furthermore, if release of this second group of binding proteins from the micronemes is 
delayed, a signal is presumably necessary for their subsequent release. Whether a separate 
signal is required for AMA1 and MAEBL relocalisation is unclear. Their presence on the surface 
is detected so rapidly after schizont rupture, that if a signal is required it may be temporally 
linked to schizont rupture itself rather than to initial erythrocyte interaction. From previous 
studies in T. gondii, it is clear that microneme and rhoptry release are triggered by different 
stimuli (Carruthers et al., 1999a; Carruthers et al., 1999b; Carruthers and Sibley, 1999). 
Keischnick et al. (1998) suggest a role for T. gondii CDPK1 in microneme secretion. Dense 
granule secretion is also distinct from microneme release (Carruthers et al., 1999a).
5.3.4: Signal transduction and host cell invasion
Signal transduction plays a crucial role in host cell invasion by apicomplexan parasites. Several 
steps in the invasion process appear to require signals to allow the parasite to traverse to the 
next stage. A possible scenario for the interaction of signal transduction and host cell invasion 
by the malaria merozoite is as follows: Upon schizont rupture, daughter merozoites are released 
into the blood stream of the host. This triggers the first wave of microneme release, which sees 
the redistribution of AMA1 and MAEBL (possibly from the rhoptries) onto the merozoite surface. 
The parasite collides with host cells as it passes through the blood vessels and must rapidly be 
able to detect whether a cell is permissive to invasion or not. The parasite reorientates so its 
apical tip is in contact with the host cell membrane. At this stage, if an appropriate cell has been 
identified, a Ca2+ dependent signal triggers the second wave of microneme secretion and these 
proteins interact with host cell proteins to form the tight junction. This triggers release of the 
rhoptry proteins that participate in PV formation. The parasite enters the host cell and the PV 
membrane seals behind it, enclosing it in the PV. Release of the dense granules into the PV is 
triggered and parasite differentiation to the next developmental stage, the ring stage, must be 
stimulated. The signalling molecules and stimuli involved at each of these stages are unknown.
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The unique nature of many of the Plasmodium signalling molecules identified so far makes them 
important potential drug targets. Furthermore, those involved in invasion are of particularly 
interest as inhibition of merozoite invasion would abolish infection and blood-stage replication. 
This area should clearly be a major focus for future study.
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Figure 5.1: Clustal alignment shows a considerable degree of amino acid conservation in 
the sequences of the predicted cytoplasmic tail of AMA1 from different species of 
apicomplexan parasites
Dashes indicate gaps in the alignment. The residues in the cytoplasmic tail of AMA1 that are 
potentially involved in signal transduction are highlighted in red. Other highly conserved (or 
conservatively substituted) residues present in all the sequences are highlighted in blue, while 
those conserved only in other species of Plasmodium are highlighted in yellow. The complete 
sequence of P. reichenowi was not available. If this sequence corresponds to the rest of those 
from Plasmodium, the N-terminal 9 amino acids are missing. There is a large degree of 
conservation among sequences from Plasmodium. In addition, even those of T. gondii and B. 
bovis show a considerable degree of overall conservation. However, with respect to the amino 
acid residues potentially involved in signalling, these do not overlap strongly between phyla 
though the threonine at the position equivalent to 613 in P. falciparum is absolutely conserved. 
In addition, the 601SFW motif in P. falciparum is absolutely conserved in Plasmodium and T. 
gondii. This corresponds to YFW in B. bovis.
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Figure 5.2: Determination of the phosphorylation status of PfAMAI in P. falciparum 
merozoites by Western blot analysis
Merozoite samples were solubilised directly into SDS sample buffer and the extract 
electrophoresed on 10% SDS-PAGE. The samples were analysed by Western blot to detect 
phosphorylated parasite proteins using; (A) anti-phosphothreonine (a-pThr), (B) anti- 
phosphoserine (a-pSer) or (C) anti-phosphotyrosine (4G10) Abs. To confirm the presence and 
location of PfAMAI in the samples, the polyclonal serum R1 (D) was also used. The 66 kDa 
bands are indicated in A and D (black arrows). To determine the identity of the approximately 66 
kDa band detected with the a-pThr Ab, Western blot membranes probed with the polyclonal 
serum R1 and a-pThr were reprobed with (E) a-pThr and (F) R1 respectively. The presence of 
PfAMAI 66 (black arrow) in the samples is indicated.
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Figure 5.3: Merozoite-derived PfAMAI is not recognised by an anti-phosphothreonine 
antibody.
P. falciparum merozoites were solubilised directly into SDS sample buffer (with reducing agent) 
and the extract electrophoresed on SDS-PAGE. Large gels were used for increased resolution. 
In Western blot analysis, the samples were probed first with polyclonal serum R1 (A) followed 
by the anti-phosphothreonine (a-pThr) Ab (B). The location of PfAMAI ee (black arrow) and the 
additional anti-phosphothreonine-specific band (red arrow) are indicated. Therefore, the proteins 
detected by these two antibodies appear to be distinct.
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Chapter 6
Functionality of sgPfAMAI in P. falciparum 
6.1: Introduction
The nucleotide composition of the P. falciparum genome is extremely A+T-rich. For this reason, 
early attempts to express PfAMAI in eukaryotic systems resulted in truncated products due to 
premature transcription termination (Kocken et al., 2002). To overcome this problem, Kocken et 
al. (2002) designed a synthetic Pfamal gene (sgPfamal), replacing the A+T-rich codon usage 
of P. falciparum strain FVO with that of the methylotrophic yeast Pichia pastoris. This gene 
sequence was used for the expression of rPfAMAI protein in all the functional studies carried 
out in the current project.
P. falciparum exhibits low N-glycosylation capability. Furthermore, mass spectrometric peptide 
fingerprinting of schizont derived PfAMAI (PfAMAI83 and PfAMAI^) showed that five of the 
potential N-glycosylation sites were not glycosylated (Howell et al., 2001). Howell et al. were 
unable to detect any peptide containing the sixth potential N-glycosylation site, N371, leaving 
open the possibility that this site is modified in the parasite. However, this site is not highly 
conserved in Plasmodium (Fig 6.1) perhaps suggesting that it has no functional/structural 
significance as an N-glycosylation site. Collectively, therefore, the evidence indicates that N- 
glycosylation is not a requirement for AMA1 function. On the other hand, the presence of 
inappropriate N-glycosylation may alter the structure and/or function of the molecule. Removal 
of the potential N-glycosylation sites eliminates this potential problem as well as the requirement 
for tunicamycin during heterologous expression. Tunicamycin prevents the addition of N- 
acetylglucosamine to dolichol phosphate, thus preventing the formation of the lipid-linked 
oligosaccharide precursor. This blanket inhibition of N-linked glycosylation can be detrimental to 
surrogate expression systems, as many eukaryotic proteins require N-glycosylation to function. 
In addition, N-glycosylation does not produce predetermined structures and non-homogeneous 
populations of glycoproteins can result. These potential problems were avoided by replacing all 
six sites. Thus, in addition to the codon usage adjustments described, the coding sequence of 
sgPfama 1 was altered to replace the six potential N-glycosylation sites (N-X-S/T) present in the 
AMA1 gene sequence of the P. falciparum FVO strain with the corresponding sequence from 
other species of Plasmodium (replacements made were: N162/K, T288/V, S373/D, N422/S, 
S423/K and N499/E).
Alterations to the amino acid sequence of a protein potentially alter its structure and/or function. 
That the rPfAMAI expressed in the heterologous systems utilised in this study retains its native 
conformation has been confirmed by means of the mAb 4G2dc1 and the polyclonal serum
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N1Ads. The mAb 4G2dc1 recognises a reduction sensitive, conformational epitope in Dll of the 
PfAMAI ectodomain (see Chapter 4), while N1Ads recognises only the "native" conformation of 
the PfAMAI ectodomain. However, subtle alterations that might affect the proteins function in 
the parasite might pass undetected. It was therefore decided to attempt to assess the 
functionality of sgPfAMAI in P. falciparum. To this end, sgPfamal was transfected into P. 
falciparum using constructs designed either to replace the endogenous gene with the synthetic 
gene (by homologous recombination) or for episomal expression of the synthetic gene product 
alongside that of the endogenous gene. In order to distinguish the sgPfAMAI from the 
endogenous gene product (wtPfAMAI), a single HA epitope tag (YPYDVPDYA) was embedded 
in frame in the stub region of sgPfAMAI (sgPfAMAI /HA). This was achieved by minimal 
modification of the amino acid sequence (Fig 6.2 A). The HA epitope tag can be detected using 
the mAb 3F10. All transfections were carried out using the P. falciparum clone 3D7. To ensure 
the correct timing of expression of sgPfAMAI, the synthetic gene was transfected under the 
control of the Pfamal promoter.
Stable transfection in P. falciparum is a relatively inefficient and technically demanding 
technology, sensitive to minor alterations in conditions (Cowman and Crabb, 2002). During 
transfection as few as 1 in 106 P. falciparum parasites take up plasmid (O'Donnell et al., 2002). 
Although transfection in other Plasmodium parasite species is carried out using purified mature 
schizonts (van Dijk et al., 1995; Waters et al., 1997), with P. falciparum the use of schizonts 
results in reduced transfection efficiency, possibly due to increased susceptibility of this stage to 
rupture during electroporation (Waterkeyn et al., 1999). As a result transfection of P. falciparum 
relies on the use of immature ring stage parasites. The inefficiency observed with P. falciparum 
transfection may in part be due to host cell damage during the transfection procedure. In 
addition, stable transfection of intracellular parasites necessitates the movement of transfected 
DNA across four membranes (the RBC plasma membrane, PVM as well as the parasite's 
plasma and nuclear membranes) further reducing the efficiency of transfection (Wu et al. 1995).
Attempts to induce stable transfection of P. falciparum can have several different outcomes. 
Furthermore, even successful integration results in a mixed parasite population in which some 
parasites retain episomally maintained plasmid while others have undergone integration. As the 
asexual stages of Plasmodium parasites are haploid, gene deletions or replacements that are 
lethal to the parasite result in the death of parasites in which integration has occurred 
(O'Donnell et al., 2000). The failure of a plasmid to integrate could result from the inability of the 
target sequence to undergo homologous recombination. In both these cases, parasites 
recovered after drug selection pressure will contain episomal plasmid only. Interpreting the 
cause of a failure to recover stable transfectants is therefore complex. In addition to lethal gene 
deletions or replacements are those that have a deleterious effect on parasite growth, 
replication or invasion. In mixed parasite cultures, these parasites may be outgrown by those in 
which integration has not occurred. Cycling of transfected parasites on and off drug selection
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pressure should favour the isolation of integrants (Wu et al., 1996), as episomal plasmids are 
rapidly lost in the absence of drug pressure (O'Donnell et al., 2001; O'Donnell et al., 2 0 0 2 ). 
However, parasite lines must eventually be cloned in order to fully analyse the phenotypic 
effects of integration. Not all gene deletions or modifications result in an identifiable phenotypic 
effect. One possible explanation for this is that the parasites may utilise an alternative pathway, 
thus side-stepping the loss or modification of function of a particular gene. For example, the loss 
of functional EBA-175 results in parasite utilisation of an EBA-175/sialic acid independent 
invasion pathway (Reed et al., 2000; Duraisingh et al., 2003a).
All plasmids used for transfection in this study contained the gene encoding the positive 
selectable marker human dihydrofolate reductase (hDHFR). This gene encodes the mutation 
L22/Y in the active site of the enzyme that confers resistance to the antifolate drug WR99210 
(Fidock and Wellems 1997), so parasites lacking this gene are susceptible to WR99210. For 
plasmid integration by single cross-over, the plasmid pHH1 was used (Reed et al., 2000). 
Transfected parasites were subjected to repeated cycles of three weeks off drug pressure, 
followed by the addition of WR99210 to cultures until the parasites had re-established. For 
double integration transfection, the plasmid pHHT-TK, additionally containing the Herpes 
simplex virus gene encoding the negative selectable marker thymidine kinase (TK), was used 
(Duraisingh et al. 2002). Thymidine kinase converts nucleoside analogues into toxic 
metabolites. The nucleoside analogue ganciclovir was therefore used in conjunction with 
WR99210 at the point of parasite re-establishment after the reintroduction of WR99210. Thus, 
parasites that had undergone the second integration event, losing the tk gene whilst retaining 
the hdhfr gene, were selected for.
6.2: Analysis of sgPfAMA1/HA expression in COS-7 cells
The HA epitope tag was introduced into the stub region of PfAMAI placing it between the bulk 
of the PfAMAI ectodomain and the merozoite plasma membrane. Thus, it may be largely 
hidden from the extracellular milieu on surface-expressed protein. At the time of designing this 
tagged form of sgPfAMAI, the structure of AMA1 was unknown. For this reason, it was not 
possible to select a region of the PfAMAI ectodomain that was know to be located on the 
surface of the molecule. Furthermore, as the mechanism of AMA1 function is unknown, the 
insertion of an epitope tag in an exposed region of the ectodomain, supposing such a region 
could be identified, would be risky as it might deleteriously affect the function of the protein. 
Because transfection in P. falciparum is a slow process, the plasmid pSec/sg'Pfama1/HA was 
transfected into COS-7 cells to more rapidly assess expression of sg'PfAMA1/HA and the 
accessibility of the HA tag for analysis. This plasmid contains the sg'Pfamal gene sequence 
that was used for COS-7 cell expression (Section 3.2.) with the addition of the sequence 
encoding the HA tag. In P. falciparum, processing of AMA1 to remove the prodomain appears to 
be necessary for its release from the micronemes (Narum and Thomas, 1994b). Thus, PfAMAI
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found on the surface of merozoites lacks the prodomain. Processing of PfAMAI 83 to PfAMA166 
may not occur successfully in COS-7 cells where, in addition, the presence of the prodomain 
may inhibit secretion of sgPfAMAI. For these reasons, the construct used in this study for COS- 
7 cell expression comprised a modified version of the synthetic gene, lacking the prodomain 
{sg'Pfamal).
In IFA of unfixed COS-7 cells (ulFA), sg'PfAMA1/HA was shown to be surface localised using 
the mAb 4G2dc1 (Fig 6.3 A) and the polyclonal serum N1 (Fig 6.3 B) both of which recognise 
epitopes in the PfAMAI ectodomain (2.4.1). This suggested that in this system the HA epitope 
tag does not deleteriously affect the targeting of the protein to the secretory pathway. However, 
for detection of the HA tag using the mAb 3F10, acetone fixation (fIFA) was required (Fig 6.3 C). 
The gentle fixative paraformaldehyde was insufficient to allow detection of the tag in IFA. One 
interpretation of this result is that, on the surface of the cell, the epitope tag is buried beneath 
the bulky ectodomain of PfAMAI and is therefore inaccessible to antibodies unless the cells are 
fixed and extensively permeabilised. The presence of AMA1 in transfected cells was confirmed 
in Western blot analysis with the polyclonal serum R1 (Fig 6.3 D) and mAb 4G2dc1 (Fig 6.3 E). 
Reducing condition were required in Western blot analysis for the detection of the HA tag in 
sg'PfAMA1/HA transfected cells with the Abs 12CA5 and 3F10 (Fig 6.3 F and G respectively). 
Similar conditions were therefore applied for analysis of parasite-derived material after 
transfection. The Ab 12CA5 binds non-specifically to an additional band in COS-7 cell lysates. 
This is confirmed by the presence of this band in samples from COS-7 cells transfected with 
"wild-type" sg'PfAMAI and untransfected cells (Fig 6.4 F).
6.3. Episomal expression of sgPfAMAI in P. falciparum
Selection of transiently transfected parasite lines is generally a relatively rapid process 
compared with selection of integrants. The parasite genome is unaltered by the presence of an 
episomally maintained plasmid. Transiently transfected parasites lines express the same 
repertoire of genes as wild type parasites with the additional expression of episomally encoded 
genes. For this reason, so long as the episomal gene product has no deleterious effects on 
parasite replication, the expression, localisation and processing of modified genes can be 
observed without threatening parasite survival.
In this study, to ensure that expression of sgPfAMAI was possible in P. falciparum, the 
construct pHAM-sgPfa/HA was designed for episomal expression of the HA tagged synthetic 
gene product (Fig 2.8). In this construct, expression of the sgPfamal gene was under the 
control of the Pfamal promoter and the 3’ termination sequence of the P. berghei DHFR- 
thymidylate synthase (DHFR-TS) gene (PbDT3’). This 3 UTR has previously been 
demonstrated to be functional in P. falciparum (Crabb et al., 1997; O Donnell et al., 2000). The 
expression cassette described here was used in all subsequent transfection studies.
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Demonstration of its functionality in the parasite was therefore important. It was considered a 
possibility, for example, that the presence of sgPfAMA1/HA might have a dominant negative 
effect, thus inhibiting the activity of wtPfAMAI. As PfAMAI appears to be essential for parasite 
survival (Triglia et al., 2000) this would be lethal to the parasite and therefore transfected 
parasites would not be recovered. Provided that sgPfAMAI/HA did not behave in a dominant 
negative manner, it was predicted that episomal expression would allow localisation and 
processing of sgPfAMAI to be ascertained without affecting parasite survival.
P. falciparum parasites transfected with pHAM-sgPfa/HA (referred to as 3D7-sgPfa/HA) were 
detected on day 28 post-transfection. The overall level of PfAMAI expression in late schizont 
samples was determined by Western blot analysis using the polyclonal serum R1, PfAMAI 
being expressed maximally late in this parasite stage. A lower level of PfAMAI expression was 
detected in the transfected compared with the wild type parasite lines (Fig 6.4 A). This was 
probably a result of a lower parasite loading in this sample. Low levels of sgPfAMAI/HA were 
detected in schizonts by Western blot analysis with mAb 3F10 (Fig 6.4 B). Only the PfAMAI66 
form was detected, suggesting that the synthetic gene product was correctly processed. The 
absence of the PfAMAI 83 form, suggests that in these late stage parasites most of the 
processing had gone to completion. However, sgPfAMAI/HA expression was not observed in 
fIFA using the mAb 3F10. As was demonstrated for the COS-7 cell expression of 
sg'PfAMA1/HA, the mAb 3F10 was not as sensitive as the polyclonal serum N1 used here or as 
the mAb 4G2. This is probably partly due to the location of the single HA tag in the relatively 
inaccessible stub region of the PfAMAI ectodomain. The only method of distinguishing between 
endogenous and synthetic gene products was the presence of the HA tag. It is also possible 
that the inability to detect sgPfAMAI in IFA resulted from it being present at levels too low to be 
detected by mAb 3F10.
To investigate the possibility that expression of sgPfAMAI from the episome was affected by 
plasmid rearrangement, plasmid recovery was performed on 3D7-sgPfa/HA and the resulting 
DNA analysed by restriction digestion. Genomic DNA was treated with Dpn\ prior to 
transformation into E. coli. This restriction enzyme preferentially digests the sequence GATC in 
which the adenine residue is dam methylated. As dam methylation does not occur in 
Plasmodium, residual E. coli derived plasmid from the transfection step should be degraded by 
this treatment, leaving only plasmid, which has undergone replication within the parasite. This 
allowed the direct comparison between the original parent plasmid and that replicated in the 
parasite. To test the recovered plasmid for rearrangement, three different digestions were 
performed (Fig 6.5 A). Restriction digestion with Afl\I (Bfr\) should linearise the plasmid (Fig 6.5 
D), giving a single digestion product (9.0 kb). Digestion with Xho\ should excise sgPfamal (Fig 
6 . 5  C), cutting the plasmid into two fragments (1.9 kb and 7.2 kb). In contrast, there are two 
sites each for BamHI and Hind\\\ in the plasmid and therefore digestion with these enzymes in 
combination (Fig 6.5 D) should produce four digestion products (3.3 kb, 1.0 kb, 0 . 6  kb and 4.2
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kb). When the recovered plasmid and the parent plasmid were subjected to these digestions, 
the same band patterns were observed on ethidium bromide stained agarose gels. The 
expected fragment sizes were observed with all digests (Fig 6.5 B, C and D). However, 
digestion with BamYW and Hind\\\ produced additional fragments. The reason for this is unclear, 
as neither enzyme is prone to star activity. As the parent plasmid gave the same pattern of 
digestion and this had previously been analysed by sequencing and digestion, the problem was 
not investigated further and the parasite-derived plasmid was assumed to be unaltered.
6.4: Pfamal 3’ replacement
The introduction of the nine amino acid HA epitope tag into the stub region of sgPfAMAI may 
have a deleterious effect on the function of this protein. To investigate this possibility, plasmid 
pHH1-Pfa/HA was designed to introduce the same HA epitope tag into the equivalent region of 
the endogenous Pfamal coding sequence (Fig 6.2 B) by single cross-over homologous 
recombination. In the event that this integration might be unsuccessful or deleterious, a similar 
plasmid (pHH1 -3’Pfamal) was designed for direct 3’ replacement. In this case the stub region 
consisted of endogenous gene sequence lacking the HA tag. Thus, upon integration the 
plasmid should reconstruct the endogenous Pfamal gene confirming that targeting to this 
region of the gene was possible. In both cases expression of the resulting gene product would 
be under the control of the endogenous gene promoter, and transcription termination controlled 
by the PbDT3’ provided within the plasmid.
Parasites transfected with pHH1-3'Pfama1 and pHH1-Pfa/HA (3D7-3’Pfama1 and 3D7-Pfa/HA 
respectively) were detected on days 32 and 39 post-transfection respectively. Parasites were 
subjected to drug selection cycles using the antifolate WR99210 as described earlier. The 
predicted digestion pattern observed for DNA recovered from 3D7-3’Pfamal and 3D7-Pfa/HA 
parasites is depicted in figure 6 . 6  A and B respectively. DNA loadings for Southern blot analysis 
were determined using ultraviolet illumination of ethidium bromide stained gels prior to transfer 
of DNA to Hybond N+ membrane (Fig 6.7 A and B). After two cycles, integration was suggested 
from Southern blot analysis (Fig 6.7 C and D, respectively) by a decrease in the intensity of the 
plasmid and endogenous gene band (5.9 kb and 3.7 kb respectively for 3D7-3'Pfama1; Fig 6 . 6  
A and 6 . 8  kb and 2.5 kb respectively for 3D7-Pfa/HA; Fig 6 . 6  B). In both cases the DNA loading 
for cycle 2 was greater than that for cycle 1 (Fig 6.7 A and B). This suggested that the decrease 
in intensity observed for the episome and endogenous gene bands was not the result of 
insufficient DNA in the samples. Integration of pHH1-3'Pfama1 was further confirmed by the 
presence of the smaller integration band (2.8 kb) after a longer exposure (Fig 6.7 C). The larger 
band (6.7 kb) was probably obscured by the persistent plasmid band (5.9 kb). Identification of 
the integration doublet in 3 D7 -Pfa/HA (3.8 and 4.8 kb) was more difficult. The endogenous gene 
band was clearly visible at 2.5 kb at cycle 0 (Fig 6.7 E) and clearly decreased in intensity from 
drug cycles 1 to 3 (Fig 6.7 E). However, for the 3D7 digestion there were two additional bands
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present at 3.7 kb and 6  kb (Fig 6.7 E) probably resulting from incomplete digestion. The smaller 
of these bands was equivalent in size to the endogenous gene band observed in the A/del 
digest of 3D7-3'Pfama1 (Fig 6.7 C and D). Digestion of DNA for the 3D7-Pfa/HA Southern blot 
analysis was carried out using Nde\ and SnaBI. Therefore, the band at 3 . 7  kb probably resulted 
from digestion of the endogenous gene locus with Nde\ only. In the event of successful 
integration, this band would be lost, as was indicated in cycle 2 (Fig 6 . 7  E) by loss of band 
intensity. By cycle 3 (Fig 6.7 E) the band appeared to run marginally higher and possibly 
represents the smaller (3.8 kb) integration band.
PfAMAI was detected in 3D7-Pfa/HA by Western blot analysis using the polyclonal serum N1 
(Fig 6 . 8  A). Furthermore, the HA tagged version of the endogenous gene product (PfAMAI/HA) 
was detected in 3D7-Pfa/HA by Western blot analysis in schizont stage parasites using the mAb 
3F10 (Fig 6 . 8  B) confirming the presence of HA-tagged protein in this parasite line. However, 
the signal could not be detected by fIFA using the same Ab, perhaps due to the lower sensitivity 
of this detection method. This is consistent with the earlier finding for 3D7-sgPfa/HA parasites. 
However, these analyses were not carried out on a cloned parasite population. Hence, the 
proportion of parasites in which plasmid integration occurred upstream of the sequence 
encoding the HA tag may have been low, making their detection by IFA unlikely.
6.5: Functional complementation of PfAMAI
In order to formally test the functionality of the synthetic gene product, it was finally necessary to 
completely replace the Pfamal endogenous gene with the synthetic gene. Two approaches 
were taken to attempt this.
6.5.1: Single cross-over approach targeting the endogenous gene sequence
The construct pHH1 -5 ’/sgPfa/HA was designed to target the PfAMAI coding sequence (Fig
2.9). The synthetic gene expression cassette used for episomal expression of sgPfAMA1/HA 
(Section 2.1.4.10) was inserted into the plasmid downstream of the target sequence, a 5’ region 
of the Pfamal coding sequence. Single cross-over integration would result in the insertion of the 
entire plasmid within the 5’ region of the Pfamal coding sequence. A stop codon inserted in 
frame at the 3 ’ end of the target sequence would result in synthesis of a truncated gene product 
of about 300 amino acid residues, comprising the prodomain and most of domain I. If this region 
of the molecule is expressed it is unlikely to be functional as it lacks the bulk of the PfAMAI 
ectodomain and has no membrane association. Thus, disruption of the endogenous gene 
coding sequence as a result of integration at the targeted locus should be accompanied by 
expression of the synthetic gene product.
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Viable parasites containing episomal plasmid were detected by day 2 1  after transfection with 
this construct. Figure 6.9 (A) shows the expected digestion pattern after SnaBI and Pad 
digestion of DNA recovered from these transfected parasites (referred to as 3D7-5’/sgPfa/HA). 
Ultraviolet illumination of the ethidium bromide stained gel prior to DNA transfer for Southern 
blot analysis, indicated a slightly lower loading of DNA in cycle 4 than cycle 0 (Fig 6.9 B). 
Southern blot analysis (Fig 6.9 C) after 4 cycles of positive drug (WR99210) pressure indicated 
loss of intensity of the endogenous band (1.7 kb; Fig 6.9 A) suggesting integration of the 
plasmid into the endogenous gene locus. However, the predicted integration bands (2.4 and 
10.2 kb; Fig 6.9 A) were not observed. The decrease in DNA loading observed in the ethidium 
bromide stained gel from cycles 0 to 4 (Fig 6.9 B) was probably not sufficient to account for the 
observed loss of the endogenous band. Expression of sgPfAMAI/HA was detected by Western 
blot analysis using the mAb 3F10 (Fig 6.10 A). The synthetic gene appeared to be successfully 
processed from the 83 kDa form (sgPfAMAI 83) to the 6 6  kDa form (sgPfAMAI ee). The 
processed form appeared to migrate slightly faster on the gel than the 3D7 endogenous gene 
product when probed with the polyclonal serum R1 (Fig 6.10 B), suggesting that the synthetic 
gene product has a slightly smaller mass. This may be due to the amino acid modifications 
introduced to remove the potential N-glycosylation sites. The PfAMAI 83 form was not detectable 
in the Western blot, but presumably this also has a slightly greater mass than sgPfAMAI 35. In 
fIFA with mAb 3F10, sgPfAMAI/HA exhibited an apical localisation, consistent with microneme 
association, in the merozoites of mature schizonts (data not shown). Thus, it would appear that 
the targeting of this gene product in developing merozoites is comparable to that of the wild type 
protein. The apical staining observed prior to schizont rupture was still present in free 
merozoites, but there was no detectable redistribution of sgPfAMAI/HA onto the merozoite 
surface. So far it has not been possible to determine whether shedding of the sgPfAMAI 
ectodomain occurs normally. If this occurred and invasion proceeded normally, the HA tagged 
cytoplasmic tail would be present in ring stage parasites. This study has been unable to 
demonstrate this by either Western blot analysis or IFA due to time restrictions. This clearly 
requires further investigation.
It should be noted that expression of the synthetic gene product in 3D7-5’/sgPfa/HA parasites 
does not confirm integration of the plasmid. The presence of the entire synthetic gene 
expression cassette would allow expression from episomally maintained plasmid. To confirm 
integration further Southern blots must be carried out using different restriction enzymes. 
Nevertheless, results from the current study have conclusively shown that the synthetic gene 
product is expressed, localises to the apical tip of developing merozoites, presumable to the 
micronemes, and is correctly processed from sgPfAMAI 83 kDa to sgPfAMAI 66 -
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6.5.2: Double cross-over approach to excise the endogenous gene
The second approach taken was designed to replace the endogenous Pfamal gene entirely 
with the synthetic gene by double cross-over homologous recombination (Duraisingh et al., 
2002)(Duraisingh et al. 2002). Plasmid pHTK-sgPfa/HA was designed to integrate into the 
genomic DNA sequence within both the 5’ and 3’ UTRs of the Pfama 1 endogenous gene, thus 
excising the endogenous gene and replacing it with the synthetic gene expression cassette (Fig
2.10). This transfection approach can result in four possible outcomes; namely that parasites 
maintain the plasmid episomally, that integration occurs by single cross-over at either the 5 ’ or 
3’ UTR or finally that integration occurs by double cross-over. As with single cross-over 
homologous recombination, transfected parasites were subjected to cycles of positive drug 
selection using WR99210. The thymidine kinase (TK) gene present in the pHHT-TK plasmid 
confers ganciclovir susceptibility to the parasites providing an additional negative selection step 
to select for the double integration event. This is accompanied by loss of the TK cassette and 
excision of the intervening genomic DNA sequence (the Pfamal gene sequence in this case - 
see Fig 6.11).
There are several advantages to the double cross-over approach. Single cross-over 
recombination into the coding sequence of a gene can be used to disrupt the function of the 
gene (as described above). Flowever, in the event that gene disruption or replacement is 
deleterious but non-lethal, parasites having undergone single cross-over recombination in this 
way could be outgrown by parasites retaining episomal plasmid copies even after growth in the 
absence of drug. The negative selection step inherent in the double cross-over recombination 
approach actively selects against parasites carrying the intact plasmid and the single cross­
overs as these retain the tk gene and are therefore susceptible to ganciclovir. This means that 
parasites having undergone the double integration event should be recovered even if they 
exhibit growth defects, as they have a selection advantage in the presence of ganciclovir. In 
addition, plasmids integrated by single cross-over recombination can be lost from the genome 
by the same method resulting in regeneration of the endogenous gene. As integration by double 
cross-over homologous recombination results in excision of the endogenous gene, no 
subsequent recombination event can reverse this as the rest of the plasmid has been discarded 
in the recombination event. The resulting transgenic line is therefore stable even in the absence 
of drug pressure.
In the current analysis, parasites transfected with the plasmid pFITK-sgPfa/FIA were detected 25 
days post transfection. In recent studies (O'Donnell unpublished data) the concentration (4|iM) 
of ganciclovir normally used for negative selection (Duraisingh et al., 2002) was insufficient to 
force/select for the second recombination event. In the current study negative selection was 
only applied after the third cycle of positive selection using elevated levels of ganciclovir (180 
jj,M). This level was selected based on dose response assays using wild type 3D7 parasites and
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transfected parasite lines and has been demonstrated to result in successful double 
recombination (O'Donnell unpublished data). In these cultures the parasitaemia increased to 5% 
within 6  days of the addition of ganciclovir, even though some cell death was initially observed 
after drug treatment. The expected digestion pattern after digestion with the restriction enzymes 
EcoRI and Age I for Southern blot analysis is depicted in figure 6 .1 1 . Illumination (UV) of 
ethidium bromide stained gels prior to DNA transfer (Southern blot) indicated considerably lower 
DNA loadings for cycles 2, 3 and 3G (Fig 6.12 A). Persistence of the (2.5 kb) endogenous gene 
band at was observed in Southern blot analysis after ganciclovir selection at cycle 3 (Fig 6 . 1 2  
B). Bands presumed to represent digested plasmid were observed at about 7 kb and 8.2 kb. 
These were smaller than the 8.9 kb band expected for digested plasmid (Fig 6.11) and possibly 
represent incompletely linearised plasmid. These enzymes are not prone to star activity and so, 
these products should not be the result of aberrant digestion. An additional band of about 9 kb 
was present after one cycle of drug treatment (Fig 6.12 B) and this band, together with the 
larger plasmid band, was present in subsequent cycles. Integration by 3’ cross-over was 
predicted to produce fragments of 2.5 kb (comparable to the endogenous gene band) and 10.3 
kb. It is possible that in the agarose gel the DNA ran smaller than predicted and that the larger 
(9 kb) band, observed at cycle 1 and thereafter, represented the 10.3 kb band resulting from the 
3’ cross-over event. The persistence of the endogenous gene band would support this 
suggestion. The 5’ cross-over was predicted to generate bands of 3.2 kb and 8.3 kb. The 8.3 kb 
band observed from cycle 2  onwards may represent the larger band of this cross-over event. 
However, the absence of a corresponding band at 3.2 kb suggests that the 5’ integration event 
did not occur, in which case, the identity of the 8.3 kb band is unclear. Furthermore, the 
absence of the 3.2 kb band confirms that the double integration event did not occur 
successfully, unless at undetectable levels. From these results it would appear that, at most, a 
3’ integration event may have occurred. Time restraints prevented further analysis of this line, 
but the use of alternative restriction enzymes in Southern blot analysis may go some way to 
clarifying these results in future work.
6.6: Discussion
6.6.1. Functionality of the sgPfAMAI expression cassette
Plasmid pHAM-sgPfa/HA contains the synthetic gene expression cassette, comprising 
sgPfama 1 under the control of the Pfamal 5’ promoter and the PbDT3’ UTR. The simplest 
method to assess the functionality of the expression cassette was by stable episomal 
expression of this plasmid in P. falciparum parasites. Healer et al. (2004) demonstrated that 
episomal expression of PfAMAI resulted in an overall level of protein roughly equivalent to that 
observed in wild type parasites although the episomally encoded gene product dominated. 
Healer et al used equal numbers of segmented transfected or wild type schizonts in Western 
blot analysis and the resulting band intensities were comparable. This suggests the existence of
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inhibitory regulation of endogenous gene expression to prevent over-expression of PfAMAI. 
Extrapolating this result to the current study, it might expect that a predominance of synthetic 
gene product over wtPfAMAI would be seen. However, the low level of PfAMAI expression 
detected in 3D7-sgPfa/HA parasite samples, made it impossible to draw any conclusions about 
the relative levels of endogenous versus episomal gene expression. In both studies, episomal 
expression was under the control of the Pfamal 5’ promoter (with the PbDT3’). If this region 
contributes to regulation of expression then the two studies would be expected to give similar 
results, namely a higher level of expression of episomally encoded than endogenous gene 
product. The low level of PfAMAI detected in this transfected parasite line compared to wild 
type 3D7 parasites, may result from differential loadings of parasite extract and/or low levels of 
mature schizonts present in the samples. The synthetic gene product detected here may reflect 
the lack of sensitivity of detection methods based on the mAb 3F10 rather than the level of 
protein expression from this expression cassette. Thus, Western blot analysis using this 
antibody may not be a reliable method to determine the relative expression levels of these gene 
products.
Kocken et al. (1998) previously demonstrated in transgenic P. berghei parasites that the timing 
of expression of PfAMAI83 was critical for its correct localisation. In the current study, the use of 
the Pfamal promoter should have ensured that expression of sgPfAMA1/HA occurred at the 
correct time in late schizogony. Localisation of sgPfAMA1/HA by IFA (using the mAb 3F10) to 
the apical complex of developing merozoites transfected with pHH1-5’/sgPfa/HA confirmed that 
this timing was correct. This work demonstrates that the synthetic gene expression cassette is 
functional in P. falciparum, a finding that validates the use of this cassette in all of the current 
work described.
6.6.2: Analysis of the HA epitope tag integrated into PfAMAI
Green et al. (1982) demonstrated that antibodies raised against peptides from the influenza 
virus antigen haemagglutinin, were able to recognise the whole protein. Subsequently, a nine 
amino acid fragment of one of the peptides (HA1 residues 75-110) used by Green et al. (1982) 
was demonstrated to comprise the complete antigenic determinant of that peptide (Wilson et al. 
1984). This nine amino acid sequence has since been successfully used as a fusion peptide for 
affinity purification purposes (Field et al., 1988). The amino acid sequence of the endogenous 
and synthetic gene products is not sufficiently different ordinarily to allow them to be easily 
distinguished, so in order to be able to distinguish between them it was necessary to introduce a 
tag into the synthetic gene coding sequence. Normal tagging procedure suggests that a tag be 
incorporated at either the N- or the C-terminus of the protein. However, AMA1 is N-terminally 
processed so a tag could not be fused at this end. In addition, it has been suggested that the 
cytoplasmic tail of AMA1 is involved in signal transduction, so addition of a tag at the carboxy- 
terminus was considered likely to interfere with its function (although this has not been formally
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tested). For this reason the decision was made to introduce the HA epitope tag into the coding 
sequence of the mature protein, by minimal substitution, in a position that might not be expected 
to affect the function of the protein. The stub-region of the PfAMAI ectodomain contains the site 
at which the proteolytic processing occurs and which results in shedding of the molecule from 
the parasite surface. Insertion of the tag in this region may therefore interfere with this 
processing step. As the normal shedding site is 17 residues N-terminal to the first residue in the 
inserted HA-tag, it was anticipated that inhibition of shedding would not occur. The function of 
AMA1 is unknown and at the time of designing these constructs no structure was available for 
the PfAMAI ectodomain, thus it was impossible to accurately determine which regions of the 
ectodomain could be altered without deleteriously affecting the structure and/or function of the 
molecule. The safest strategy was therefore to alter the amino acid sequence within the stub 
region to incorporate this tag. However, it was necessary to determine that the tag itself had no 
deleterious effect on AMA1 function. For this reason, as a control, the sequence encoding this 
HA-epitope tag was also introduced into the endogenous PfAMAI coding sequence.
The integration-targeting sequence in the pHH1-Pfa/HA plasmid consisted of the P. falciparum 
T9/96 PfAMAI coding sequence from 46 bp downstream of the start site to the end of the 
cytoplasmic tail. The sequence encoding the HA epitope tag was embedded in the coding 
sequence for the stub region. Nearly 1.5 kb of coding sequence lay upstream of the HA tag 
sequence, compared to about 230 bp downstream of it. Therefore, integration upstream of the 
HA epitope tag was over six times more likely than downstream. From Southern blot analysis, it 
appeared that integration had occurred (Fig 6.7). Detection of the HA epitope tagged protein in 
Western blot analysis using the mAb 3F10 (Fig 6 . 8  B) confirmed that, in at least some parasites, 
integration had occurred upstream of the tag encoding sequence. Furthermore, the intensity of 
the signal in Western blot analysis using this mAb suggests that in this parasite population, a 
large proportion of integration events had occurred upstream of the tag encoding sequence.
Analysis of the parasite line 3D7-5’/sgPfa/HA demonstrated expression of sgPfAMAI/HA, as 
previously mentioned. Furthermore, in I FA the HA-tagged synthetic gene product appeared to 
localise correctly, at least as far as the apical tip of the parasites. This suggests that the 
presence of the HA epitope tag in the stub-region of the PfAMAI ectodomain did not affect 
targeting of the molecule to the secretory pathway and from there to an apical compartment 
consistent with a microneme localisation. However, and despite several attempts, the tagged 
protein could not be detected on the surface of free merozoites and in ring stage parasites. One 
possible explanation for this is that the presence of the tag in these parasites has some effect 
on relocalisation of the protein onto the merozoite surface and on the final processing step 
during RBC invasion by merozoites. As this is likely to affect erythrocyte invasion, it is more 
likely that the inability to detect the HA tag in free merozoites and ring stage parasites results 
from the more diffuse distribution of the protein. This, coupled with the low sensitivity of the mAb 
3F10 has made detection increasingly difficult. Several studies have been carried out in which
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multiple consecutive copies of the HA-epitope tag have been used to tag proteins and increase 
the sensitivity of the detection method (Tyers et al., 1992; Krawchuk and Wahls, 1999; Harris et 
al. submitted, O'Donnell et al. unpublished). These studies have relied on terminally fused tags 
but this approach, as mentioned earlier, was not possible with this protein, Furthermore, 
embedding multiple tags into the ectodomain would have increased the likelihood of disrupting 
the proteins function. It is worth noting that the existence now of high resolution structural 
determinations of both PfAMAI and PvAMAI should aid the placement of epitope tags in future 
work.
The HA epitope tag was embedded in endogenous and synthetic genes to ensure minimal 
modification of the amino acid sequence in the stub region of these proteins. It is nevertheless 
possible that key residues in the PfAMAI ectodomain have been altered. Modification of the 
amino acid sequence in this region of the protein is clearly not lethal to the parasite, as 3D7- 
Pfa/HA parasites having integrated the plasmid pHH1-Pfa/HA upstream of the HA tag encoding 
sequence survive. While these modifications do not abrogate the function of the protein, it is 
possible that they diminish its functionality. To assess the effect of the HA epitope tag in this 
position of the PfAMAI ectodomain on the function of the protein 3D7-Pfa/HA parasites should 
be cloned. Growth rate assays (and invasion rate assays) should then be carried out to 
determine whether the tag confers any growth defect on the parasite. This should be a focus of 
future work in this area.
Plasmid pHH1-5’/sgPfa/HA was designed for integration into the PfAMAI endogenous gene 
coding sequence. Integration in this position is predicted to result in disruption of the 
endogenous gene, replacing it with the synthetic gene sequence that has been further modified 
to include the coding sequence for the HA-epitope tag. Southern blot analysis suggests that this 
construct may have integrated into the endogenous gene locus, thus disrupting expression of 
wtPfAMAI. This further supports the finding that the amino acid mutations generated during 
introduction of the HA epitope tag into the stub region of the sg PfAMAI ectodomain did not 
abrogate the function of this protein in the parasite. Integration of this construct needs to be 
confirmed by Southern blot analysis after digestion with alternative restriction enzymes.
In addition, integration of the HA epitope tag into the stub region of the PfAMAI ectodomain 
does not appear to affect the correct processing of the wtPfAMAI from PfAMAI S3 to PfAMAI 66 - 
Western blot analysis of 3 D7 -5 ’/sgPfa/HA (Fig 6.10 B lane 2) shows that the synthetic gene 
product also undergoes this processing event. Narum and Thomas (1994) demonstrated that 
the full-length 83 kDa and 6 6  kDa forms of AMA1 differentially localise to the micronemes and 
merozoite surface respectively. This suggests that processing between these two forms is a 
prerequisite for microneme secretion of this protein. The observation that processing occurs in 
the presence of the HA-epitope tag suggests that, barring some other tag-induced functional 
defect, the processed ( 6 6  kDa) form of PfAMAI/HA should be relocalised onto the parasite
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surface. This further supports the notion that the inability to detect tagged forms of PfAMAI on 
the surface of free merozoites, or in ring stage parasites, by I FA reflects a lack of sensitivity in 
the detection method rather than the absence of the protein in these parasite stages.
6.6.3: Analysis of sgPfAMA1 functionality in P. falciparum
Gene replacement by homologous recombination has been used extensively to assess 
functional complementation of Plasmodium proteins. (Triglia et al., 2000) demonstrated using 
this technique that not only could PcAMAI partially complement the function of PfAMAI in P. 
falciparum parasites but that these transfected parasites demonstrated increased invasiveness 
of murine erythrocytes. Healer et al. (2005) took this finding one step further, by assessing the 
degree of complementation conveyed by the different sub-domains within the AMA1 
ectodomain. Constructs were designed for the expression of chimeras of AMA1, comprising 
mixtures of the PfAMAI and PcAMAI domains, for transfection into P. falciparum. The group 
determined that Dl-ll of PcAMAI in conjunction with the prodomain and Dill of PfAMAI, was 
processed normally and partially complemented the function of PfAMAI, though to a lesser 
extent than intact PcAMAI. However, processing of the 83 kDa form of the chimeric protein 
containing the PfAMAI prodomain and Dl-ll and PcAMAI DIM to the 66 kDa form did not occur 
and the protein was unable to redistribute onto the surface of the parasite. As a result, this 
chimeric protein was unable to complement PfAMAI function. In an analogous study with a 
different merozoite protein, O'Donnell et al. (2000) demonstrated that the C-terminal 19 kDa 
fragment of P. falciparum MSP1 could be complemented in function with the corresponding 
sequence from P. chabaudi MSP1. This region of PcMSPI diverges significantly in sequence 
from that of PfMSPI, indicating that the role of this fragment in erythrocyte invasion is 
conserved across the genus.
As was observed in chapter 4, single point mutations (for example K280/A) can disrupt the 
overall architecture of a protein. Confirmation that the mutations introduced into the PfAMAI 
synthetic gene to replace the potential N-glycosylation sites did not affect protein folding and 
function was therefore necessary. For this reason, complementation studies were carried out 
using sgPfamal.
In plasmid pHH1-5’/sgPfa/HA the synthetic gene expression cassette lies downstream of the 
PfAMAI 5’ coding sequence. The presence of this coding sequence should target the construct 
for integration into the Pfamal gene sequence and result in the disruption of the endogenous 
gene. In the event that integration does not occur, expression of the synthetic gene product 
should still take place from the episomally maintained plasmid. Southern blot analysis suggests 
that this plasmid may have integrated (Fig 6.9 C). However, the absence of the predicted 
integration bands suggests that caution is required in drawing conclusions from this. If the 
decrease in the endogenous gene band intensity is a genuine indication of integration, this
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suggests that most of the parasites present have integrated the plasmid. In addition, it would 
indicate that the synthetic gene product can indeed complement the function of the endogenous 
gene. To ascertain whether this gene replacement has produced any phenotypic effect, growth 
and invasion rate assays should be carried out using cloned parasite lines.
Integration by double cross-over using the TK selection cassette is a slow and unreliable 
process. The inability to isolate any double integrants in the current study does not necessarily 
suggest that this gene locus cannot be targeted for double cross-over. It may suggest that the 
conditions required for this integration have not yet been identified. Integration into non-coding 
sequence in P. falciparum is less favourable than integration into coding sequence (Wu et al. 
1996), possibly due to the increased A+T content in intragenic regions (Aravind et al., 2003). It 
follows therefore that double integration into non-coding sequence is an extremely rare event. If 
replacement of the endogenous gene with the synthetic gene product by targeting the 
endogenous gene coding sequence has occurred, this would suggest that the lack of gene 
replacement by the double cross-over method results from methodological problems rather than 
the inability of the synthetic gene product to complement the function of the wtPfAMAI.
If the integration of pHH1-5’/sgPfa/HA into the endogenous Pfamal gene can be validated it 
would suggest functional complementation of the endogenous gene product. To confirm 
conclusively the level of complementation, transfected parasite lines in which the endogenous 
gene has been replaced with the synthetic gene must be cloned and compared in growth and 
invasion rate assays with wild type 3D7 parasites. To distinguish between growth defects 
conferred by the HA epitope tag and the synthetic gene product itself, these parasites should 
also be compared with parasites in which the endogenous gene has been tagged (3D7-Pfa/HA 
parasites).
In conclusion, the ability to target the 3’ region of Pfamal by single cross-over homologous 
recombination has been confirmed using the plasmids pHH1-3’Pfama1 and pHH1-Pfa/HA. In 
addition, Western blot analysis and I FA have confirmed that embedding the HA-epitope tag into 
the stub-region of the PfAMAI ectodomain is not lethal to the parasite. It has yet to be 
confirmed that the HA-tagged protein can be redistributed onto the parasite surface at the time 
of schizont rupture and that the tag does not interfere with the final shedding of the protein from 
the merozoite surface. Use of a triple-HA tag may overcome the sensitivity problems 
encountered with 3F10, but this raises additional problems of where to locate such a tag. 
Expression of the synthetic gene product and correct targeting to the apical organelles has been 
confirmed in Western blot analysis and I FA of 3D7-5’/sgPfa/HA parasites, respectively. It 
remains to be conclusively demonstrated that the HA-tagged synthetic gene product can 
complement the function of the native protein. This will clearly be the focus of future work in this 
area. Not only will this justify the use of the synthetic gene in further reverse genetics studies
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designed to investigate the function of AMA1, it will also validate the use of the synthetic gene 
product in functional studies of PfAMAI.
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Fig 6.1: Clustal alignment of Plasmodium AMA1 amino acid sequences shows a lack of 
sequence homology at the putative N-glycosylation site at position 371 in the PfAMAI 
ectodomain
The position of N371 is highlighted in red. Residues corresponding to the third position of the 
glycosylation motif (N-X-S/T) are indicated in blue. This sequence alignment shows that the 
asparagine is highly conserved at the equivalent position in other species of Plasmodium, 
deviating only (to aspartic acid) in P. fragile. By comparison, the third amino acid in the motif (S) 
is only conserved in P. reichenowi and P. cynomolgi.
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Figure 6.2: Integrating the HA Tag into the PfAMAI ectodomain.
The nucleotide and amino acid modifications required in order to embed the HA epitope tag into 
the stub region of the PfAMAI ectodomain of (A) the synthetic and (B) the endogenous 3D7 
gene sequences. Nucleotide modifications are shown in red. Amino acid modifications are 
highlighted in blue.
233
AI H K
Synthetic gene ATJ CCA GAG CAT c c t  a c g  t a c  g a t
sequence
HA tag 
sequence TAT CCA TAC GAT GTG CCT GAC TAT GOT 
Y P Y D V P D Y A
B
H K
Endogenous 
gene sequence ATT CCT GAA CAT AAG CCA ACT TAT GAT
HA tag 
sequence TAT CCT TAC GAT GTG CCA GAT TAT GCT 
Y P Y D V P D Y A
234
Figure 6.3: IFA and Western blot analysis confirm expression of sg'PfAMA1/HA in COS-7
cells
IFA was carried out on acetone fixed COS-7 cells expressing sg'PfAMA1/HA, using the 
polyclonal serum N1 (A) and the mAbs 4G2dc1 (B) and 3F10 (C). The cells were additionally 
stained with DAPI (blue) and Evans blue (red). Western blot analysis was carried out on COS-7 
cell lysates from lines expressing sg'PfAMAI/HA (1) or sg'PfAMAI (3) or on untransfected COS- 
7 cells as a negative control (3). The polyclonal serum R1 (D) and the anti-HA Abs 12CA5 (F) 
and 3F10 (G) were used to probe samples prepared under reducing conditions, whereas the 
mAb 4G2dc1 (E) was used to analyse samples under non-reducing conditions. The non-specific 
band recognised in COS-7 cell lysate by 12CA5 is indicated (arrow).
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Figure 6.4: Western blot analysis indicates low level expression of sgPfAMA1/HA from 
the sgPfAMAI expression cassette in 3D7 parasites
Lysates from wild type 3D7 and 3D7-sgPfa/HA schizont stage parasites were electrophoresed 
under reducing conditions and analysed by Western blot with the polyclonal serum R1 (A) and 
the mAb 3F10 (B). The 83 and 66 kDa fragments of PfAMAI are indicated (arrows). The HA- 
tagged form of sgPfAMAI is also indicated (B, arrow).
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Figure 6.5: Confirmation of the fidelity of the plasmid pHAM-sgPfa/HA by plasmid rescue
Plasmid DNA was recovered from the transfected parasite line 3D7-sgPfa/HA, after treatment 
with Dpn\ to destroy any remaining parent plasmid, and cloned in E. coli. Five bacterial clones 
were selected, the plasmid purified and analysed by restriction digestion with BamH\ and HindlW 
(B), Xho\ (C) and Afl\I (D). The positions of the restriction sites in the plasmid are indicated (A). 
Expected plasmid sizes are also indicated. Digestion products of the five clones (lanes 2 - 6 )  
were run along side those of the parent plasmid (lane 1).
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Figure 6.6: Plasmids used and potential integration events following transfection of P. 
falciparum parasites
The 3’ replacement plasmids pHH1-3’Pfama1 and pHH1-Pfa/HA were constructed by ligating 
the target DNA fragment into unique Bglll and Xhol sites in the vector pHH1. The target DNA 
consisted of a 0.9 kb 3’ region (A, yellow) and the entire Pfam al sequence (B, pink) minus that 
encoding the N-terminal 46 amino acids and modified by the addition of the sequence encoding 
the HA-epitope tag, respectively. Both sequences extended to include the 3’ stop codon. The 
predicted structures of the am al gene loci after plasmid integration are shown below. The 
location of the restriction enzyme sites {Nde\ and SnaBI) used to map these loci is indicated. 
The predicted sizes are not drawn to scale.
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Figure 6.7: Southern blot analysis of genomic DNA from transfected P.falciparum 
parasites indicating integration of pHH1-3’Pfama1 and pHH1-Pfa/HA
UV gels to confirm the DNA loading used in the Southern blots shows greater loading for cycles 
0 and 2 for pHH1-3'Pfama1 (A) and cycle 2 for pHH1 Pfa/HA (B) than for other cycles. In order 
to compare the restriction profile of these transfected parasite lines with that of 3D7 wild type 
parasites, DNA from 3D7-3'Pfama1 parasites was restriction digested with the enzyme Ndel, 
while 3D7-Pfa/HA DNA was digested with Ndel and SnaBI. A 0.5 kb fragment from within the 3’ 
target region of the plasmid was used to probe these blots. The restriction profile for these 
transfected parasite lines was compared with that of 3D7 wild type parasites as a control. 
Integration was indicated for both 3D7-3'Pfama1 (C) and 3D7-Pfa/HA (D) parasites, by a 
decrease in intensity of the endogenous gene band (3.7 and 2.5 kb respectively) by cycle 2. 
This was accompanied in both cases by a decrease in the plasmid band (5.9 and 6.8 kb 
respectively). Concomitant with this for 3D7-3'Pfama1 parasites was the appearance of the 
integration band (2.9 kb). The larger integration band (6.8 kb) is probably obscured by the 
plasmid band. Integration bands were not apparent for parasite line 3D7-Pfa/HA but this may 
have been due to incomplete digestion by SnaBI. The digestion band at about 3.7 kb, present at 
all cycles, corresponded to the endogenous gene band digested with Ndel alone (D).
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Figure 6.8: Western blot analysis confirms expression of HA tagged PfAMAI in 3D7- 
Pfa/HA parasites
Schizont stage parasites were analysed under reducing conditions in Western blot, using the 
polyclonal serum R1 (A) and mAb 3F10 (B). In each case wild type 3D7 parasites were used as 
a positive control. The PfAMAI 83 and 66 kDa forms are indicated (arrows).
245
BkDa
r/ •
4>
94-
67-
83 kDa 
66 kDa
94-
67-
66 kDa
246
Figure 6.9: Plasmids used and potential integration events following transfection of P. 
falciparum parasites with pHH1-sgPfa/HA
(A) The gene replacement vector was constructed by ligating the PfAMAI synthetic gene 
expression cassette (green) downstream of the target sequence, 0.9 kb of the PfAMAI 5’ 
coding sequence (purple). The selectable marker (hDHFR) cassette is shown. The predicted 
structure of the AMA1 locus following integration is depicted below. The position of SnaBI and 
Pad restriction sites for mapping these loci is indicated. Map sizes were not drawn to scale. (B) 
UV gel image, taken prior to the transfer of DNA to nitrocellulose for the Southern, indicated that 
the loadings were approximately equivalent. (C) Southern blot analysis of 3D7-5’/sgPfa/HA 
parasite genomic DNA followed drug selection cycles 0 and 4. A 0.5 kb 5’ fragment of 
endogenous Pfamal was used to probe the membrane. Wild type 3D7 parasites were used as 
a positive control. Endogenous gene and plasmid bands are indicated (1.7 and 10.9 kb, 
respectively). No integration bands are evident, however at cycle 4 the endogenous gene band 
is reduced.
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Figure 6.10: IFA and Western blot analysis indicate correct expression of sgPfAMAI/HA
in P. falciparum parasites.
Protein extracts from schizont enriched 3D7-5’/sgPfa/HA wild type 3D7 parasites were 
analysed under reducing conditions in Western blot, using the mAb 3F10 (A) and polyclonal 
serum R1 (B). Both PfAMAI 83 and PfAMAI 66 forms were detected by mAb 3F10 indicating the 
correct processing of this product.
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Figure 6.11: Schematic representation of the plasmid and potential integration events
following transfection of P. falciparum with pHTK-sgPfa/HA
(A) The vector designed for gene replacement by double cross-over was constructed by ligating 
the synthetic gene expression cassette (green) as well as a 0.9 kb sequences from the 3’ UTR 
(brown) of Pfamal into the pHHT-TK plasmid. The two selectable marker cassettes (hDHFR 
and TK) are shown. The integration target sequence were the 0.9 kb 3’ UTR and the 1.4 kb 5’ 
promoter region of Pfama 1 (dark green) present in the synthetic gene expression cassette. The 
predicted structures of the am al locus after integration are shown below (B, C, and D). The 
location of EcoRI and Age I restriction sites used to map these loci are indicated and their 
calculated masses indicated in kb. The sizes of the predicted maps are not drawn to scale.
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Figure 6.12: Southern blot analysis of pHTK-sgPfa/HA transfected parasite and parent 
3D7 genomic DNA
(A) The UV image of restriction enzyme digested samples for Southern blot analysis indicated 
that drug cycles 0 and 1 have the highest DNA loading. Southern blot analysis was carried out 
on genomic DNA extracted after cycles 0, 1, 2 and 3 and on drug cycle 3 after growth of 
parasites in the presence of ganciclovir (3G). After electrophoretic transfer of the DNA to 
nitrocellulose, the membranes were probed with a 0.4 kb fragment from the 5’ promoter region 
(5’ target sequence) in the synthetic gene expression cassette (B) Parental 3D7 genomic DNA 
was used as a control. The presence of endogenous gene (2.6 kb) and plasmid (8.9 kb) bands 
is indicated as is the predicted large 3’ integration band (10.2 kb) that is possibly present from 
cycle 2 onwards. There is no indication of the presence of the band corresponding to the 3’ or 
double integration fragments (3.2 kb), although the larger fragment (8.3 kb) corresponding to the 
3’ integration could be masked by the plasmid band, the absence of the smaller fragment 
refutes this.
253
0 1 2 3 3G
B
0 1 2 3 3G W
8.9 kb f ®
2.6 kb  ►
10.2 kb
■i
254
Chapter 7
Discussion 
7.1: AMA1 as an erythrocyte binding molecule
AMA1 plays an essential role in host cell invasion by apicomplexan parasites. For this reason, a 
considerable amount of effort has gone into understanding the immunogenicity, structure and 
function of the molecule. The structure of both PvAMAI Dl-lll and PfAMAI Dl-ll have provided 
significant insight into understanding the immune selection pressure that this conserved 
molecule is under and the structural and possibly functional constraints placed upon it (Pizarro 
et al. 2005; Bai et al. 2005). In addition an increasing body of evidence implicates this antigen 
as having a role in RBC binding during invasion. The functional and immunogenic importance of 
AMAI have resulted in its being one of the leading candidates for inclusion in an asexual stage 
vaccine against P. falciparum malaria.
The existence of mAbs against AMA1 that block merozoite invasion of erythrocytes by 
preventing the formation of a close interaction between the two cells, suggests that AMA1 
participates in host cell invasion by interacting with an erythrocyte receptor molecule (Deans et 
al., 1982; Mitchell et al., 2004). This is further supported by the observation that expression of 
PcAMAI in P. falciparum allows this parasite species to invade murine erythrocytes, albeit 
inefficiently (Triglia et al., 2000). The absolute requirement by the parasite for AMA1 together 
with its integral involvement in the invasion process and apparent host-cell specificity, support 
the idea that AMA1 plays a role in merozoite adhesion to the RBC surface. The identification of 
two PAN modules (one in each of Dl and Dll) in PvAMAI and PfAMAI, together with the 
evidence from other systems that PAN modules facilitate protein-protein and/or protein- 
carbohydrate interactions (Tordai et al., 1999) suggests an adhesive role for these domains in 
the AMA1 ectodomain (Pizarro et al., 2005). Furthermore, the identification of PAN or Apple 
domains in many microneme proteins from different apicomplexan parasites and the perceived 
role for microneme proteins in host cell attachment during invasion, raises the possibility that 
apicomplexan parasites exploit the PAN domain fold to overcome the problem of host cell 
recognition and receptor binding (Klein et al., 1996; Brown et al., 2000; Brown et al., 2001; 
Brecht et al., 2001). Fraser et al. (2001), demonstrated that Dl-ll of PyAMAI, but not the full- 
length ectodomain, bound murine erythrocytes, whereas Kato et al. (2005), demonstrated 
binding of PfAMAI DIM to human erythrocytes. This raises the possibility that in different species 
of Plasmodium AMA1 utilises different domains to facilitate erythrocyte binding. The degree of 
structural similarity observed in the crystal structures obtained from PvAMAI and PfAMAI, 
argues against this possibility. Several attempts to demonstrate erythrocyte binding using the 
PfAMAI ectodomain shed from the parasite surface have proven unsuccessful (Howell et al.
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2001; E. knuepfer, personal communication). However, the loss of binding capabilities as a 
result of proteolytic shedding from the parasite surface is not without precedent, as the full- 
length cellular form of T. gondii MIC2 binds host cells, while the proteolytically shed form does 
not (Carruthers et al. 1999c).
The present study has failed to demonstrate any erythrocyte binding activity for the full-length 
ectodomain of PfAMAI or for DIM on its own when expressed on the surface of COS-7 cells. 
Erythrocyte binding was, however, easily observed with region II of the PvDBP, used in this 
study as a positive control. The ability of PvDBP to support erythrocyte binding under the same 
conditions, suggests that the inability to demonstrate erythrocyte binding with PfAMAI was 
because of the choice of antigen, not because of the system. The question therefore remains; 
why was sgPfAMAI unable to support erythrocyte binding activity if this is a genuine property of 
the molecule? The study further failed to demonstrate erythrocyte binding with Dl-lll of 
sgPfAMAI expressed in P. pastoris, in a solid phase assay system, suggesting that the local 
concentration of sgPfAMAI on the COS-7 cell surface was not a limiting factor in the former 
assay. The ability noted by the other workers, referred to above, of PyAMAI Dl-ll, and to a 
lesser extent Dl-lll, to bind murine erythrocytes in the same expression system could result from 
parasite species differences in AMA1-, Alternatively, chimeric expression of PyAMAI Dl-ll in 
association with the HSVgDI transmembrane domain may have resulted in the presentation of 
PyAMAI on the COS-7 surface in a conformation not normally observed in AMA1 on the 
parasite surface (or when shed from the surface). The ability of Dl-ll to bind with higher 
efficiency than Dl-lll, suggests that even in P. yoelii the full-length ectodomain is not 
immediately accessible in a conformation likely to favour erythrocyte-binding. The current study 
has argued for the existence of a partner protein, which may act in conjunction with AMA1 at the 
parasite surface. One possible explanation for the apparent inconsistency between these two 
sets of results is that AMA1 undergoes some conformational change when it encounters such a 
putative partner protein on the parasite surface. This conformational change may expose a 
region of the AMA1 that is otherwise concealed, but that was exposed when PyAMAI Dl-ll was 
expressed on its own in COS-7 cells in the study of Fraser et al. (2001). The revealed domain 
may then be able to interact with its receptor on the erythrocyte surface. If this were the case, 
using 4G2dc1 recognition in this assay as a measure of native fold may be inappropriate. This 
mAb recognises the shed fragments of PfAMAI, which do not support erythrocyte binding. 
Furthermore, 4G2dc1 results in the immunoprecipitation of PfAMAI in isolation from any 
putative partner protein which, as it has just been argued may be required for induction of the 
conformational change necessary for erythrocyte binding. Thus, while this mAb is a useful tool 
in confirming disulphide bond formation and the correct overall architecture of the PfAMAI 
ectodomain, it may not be sensitive enough to distinguish between functionally active and 
inactive conformations. The method of action by this mAb in invasion-inhibition may be to 
actively block the binding of PfAMAI to its partner on the merozoite surface. Alternatively, it may 
prevent the conformational change required for PfAMAI to interact with its erythrocyte receptor.
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7.2: Characterisation of the AMA1 epitope recognised by the invasion 
inhibitory mAb 4G2dc1
The mAb 4G2dc1 inhibits invasion of erythrocytes by P. falciparum and P. reichenowi 
merozoites (Kocken et al., 1998b; Kocken et al., 2000). Thus, the epitope recognised by this 
mAb is of considerable interest for understanding the function of this molecule during this 
parasite stage and for vaccine development. Results described in the current study and 
reported elsewhere (Pizarro et al. 2005) have for the first time identified amino acid residues in 
the PfAMAI ectodomain that are specifically responsible for recognition of the molecule by this 
important mAb. These residues lie within a region of the molecule now termed the domain II 
loop (Pizarro et al. 2005). This loop displayed no electron density in the crystal structure of 
PvAMAI, suggesting that this region of the molecule adopts a flexible conformation that extends 
from the molecule (Pizarro et al. 2005). The accessibility of the loop to tryptic digestion is in 
agreement with this hypothesis (Gupta et al. 2005). The flexible nature of this loop is also 
supported by work on the PfAMAI Dl-ll crystal structure; although in the published structure the 
majority of the loop was structured, with the exception of four residues located in the C-terminus 
of the loop (Bai et al. 2005), two further structures of these domains solved by the same group 
gave different results for the Dll loop region. In one, the loop took up an alternative 
conformation while in the other it was unstructured as for the P. vivax structure (A. Batchelor, 
personal communication). Locating the 4G2dc1 epitope at the base of the Dll loop, as described 
in the current study, raises the possibility that this mAb interferes with the essential flexibility of 
this region and identifies an important functional region of the PfAMAI ectodomain.
In support of these findings, Urquiza et at. (2001) identified four peptides from AMA1 that bound 
human erythrocytes in vitro and which blocked merozoite invasion. The peptide exhibiting the 
highest percentage invasion-inhibition (peptide 4325-MIKSAFLPTGAFKADRYKSH) derives 
from the Dll loop (Urquiza et al. 2001; Cubillos et al. 2003). Peptide 4337, deriving from the 
cytoplasmic tail of PfAMAI, also exhibited a high degree of invasion-inhibition in this assay 
(Urquiza et al. 2001; Salazar et al. 2002). The location of this latter peptide in the cytoplasmic 
tail of PfAMAI calls into question its ability to bind to RBCs and inhibit merozoite invasion. If this 
is the case, this also calls into question the validity of the result observed for the peptide derived 
from the Dll loop, as it suggests there is non-specific interaction occurring in the assay. 
However, if the erythrocyte binding/invasion-inhibition activity of the peptide derived from the Dll 
loop is indeed physiologically significant, this could suggest that the Dll loop and the 
hydrophobic trough with which it interacts are specifically involved in erythrocyte binding. This 
suggestion seems increasingly likely when considering the invasion inhibitory properties of 
4G2dc1 and the conserved nature of the residues in the hydrophobic trough. The enhanced 
inhibition observed in the current study and elsewhere (Dutta et al. 2005) by the 4G2dc1 Fab 
fragment, compared to that mediated by the intact antibody, suggests that inhibition by this mAb 
is specific to the function of the protein rather than some non-specific steric effect. The Dll loop-
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hydrophobic trough interaction could either result in the formation of an erythrocyte binding 
pocket in the PfAMAI ectodomain, or in the concealment of that pocket. Without the structure of 
the 4G2dc1-PfAMAI complex and with the information available at present, it is impossible to 
state which of these possibilities is the more likely. These questions clearly require further 
consideration.
7.3: Validation of the use of the PfAMAI synthetic gene product
The possibility that the synthetic gene product used in the binding assays in this study was not 
functionally active was assessed by reverse genetics approaches in P. falciparum parasites. 
Thus, it was possible to demonstrate expression of sgPfAMAI in these parasites and locate this 
gene product to the apical complex (probably micronemes) of developing merozoites. The ability 
of this synthetic gene product to complement the function of that of the endogenous gene 
remains to be confirmed.
7.4: Interaction of AMA1 with a putative partner protein at the RBC surface
Despite the inability of this study to demonstrate erythrocyte binding activity for PfAMAI, the 
weight of evidence supporting such a function is extremely persuasive. As has already been 
suggested, one mechanism by which PfAMAI interacts with the erythrocyte receptor is by 
means of a conformational change induced by interaction with a putative partner protein on the 
parasite surface. In this study, PfAMAI was not shown to interact with any parasite partner 
proteins during schizont and merozoite stages of parasite development. However, in T. gondii, 
TgAMAI interaction with a rhoptry protein at the time of tight junction formation has been 
reported. To re-assess this possibility in PfAMAI, it would be necessary to halt invasion after 
the formation of the tight junction and immunoprecipitate AMA1 from the parasite lysate. It is 
possible that this could be achieved using cytochalasin B, which blocks the invasion process 
after tight junction formation. Furthermore, certain signalling molecules are brought together 
with their partner molecule only after the interaction of one of them with their ligand. For 
instance, the transforming growth factor p (TGF-p) receptor is composed of two subunits, TpR-l 
and TpR-ll, both of which are required for signal transduction (Anders et al. 1998) TpR-ll can 
bind in the absence of TpR-l, but signal transduction only occurs if TpR-l then binds. TpR-l 
cannot bind in the absence of TpR-ll. It is possible that the AMA1 partner protein must bind its 
erythrocyte receptor first, thus allowing AMA1 to complex with both partner protein on the 
parasite surface and receptor molecule on the erythrocyte surface. Thus, the erythrocyte 
binding capability of AMA1 may only be observed in the context of its parasite partner protein 
already interacting with the host erythrocyte. Such an interaction would not have been observed 
in the current study, where PfAMAI was expressed in COS-7 cells in isolation from any other 
parasite molecule. This may also explain the inability of other studies to demonstrate 
erythrocyte binding of the parasite derived soluble forms, PfAMAI 48 and PfAMAI44.
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The position in PvAMAI corresponding to the proteolytic processing or shedding site identified 
in PfAMAI (Thr517-Ser518) (Howell et al., 2003b) appears to be inaccessible to proteases in 
the crystal structure (Chesne-Seck et al. submitted). Domain III of PvAMAI and PfAMAI show 
least sequence homology (33%) of the three sub-domains (Chesne-Seck et al. submitted). It is 
therefore possible that these domains also exhibit the least structural homology, perhaps 
reflecting host-cell specificity. It has been suggested that proteolytic shedding of PfAMAI is 
required for host cell invasion by P. falciparum merozoites (Dutta et al. 2003; Dutta et al. 2005). 
Thus, if the processing site were inaccessible in PfAMAI, a conformational change would be 
required to allow access to the site for the sheddase and protein release from the parasite 
surface. AMA1 binding to its receptor on the erythrocyte surface or to its putative partner protein 
on the merozoite surface may be responsible for inducing such an alteration of conformation. As 
the process of invasion is very rapid, these two steps (erythrocyte binding and AMA1 shedding) 
are likely to be tightly coupled. The binding of PfAMAI by its putative partner protein may be the 
single event required to couple these two essential processes.
7.5: Could AMA1 play a role in signal transduction?
The inability of this study to demonstrate phosphorylation of schizont or merozoite derived 
PfAMAI does not rule out its participation in a signalling cascade during the invasion process. 
Phosphorylation is a dynamic process. Many signalling molecules are only transiently 
phosphorylated, the phosphate group being rapidly removed by protein phosphatases. Protein 
phosphatase inhibitors were not used in this study. For this reason, contaminating protein 
phosphatases present in the assay could have reversed any phosphorylation of the PfAMAI 
cytoplasmic tail in these parasite stages. In addition, cytoplasmic phosphorylation of PfAMAI 
may require interaction with its erythrocyte receptor, which in turn may require the interaction of 
a putative parasite partner protein. Thus, phosphorylation might only be observed at the time of 
erythrocyte binding. This possibility was not tested here and therefore requires further 
investigation. The involvement of AMA1 in signalling during host cell invasion is suggested by 
the observation that in T. gondii, rhoptry secretion is inhibited by the loss of AMA1 (Mital et al., 
2005). This indicates that AMA1 directly or indirectly activates a signalling pathway that results 
in secretion from these apical organelles. The development of a conditional system for gene 
expression in P. falciparum (Meissner et al., 2005) will allow a thorough investigation of AMA1 
function in this parasite.
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7.6: A proposed mechanism for AMA1 function in merozoite invasion of 
erythrocytes
A mechanism for AMA1 function in erythrocyte invasion is thus proposed (Fig 7.1.). AMA1 is 
released from the micronemes around the time of schizont rupture. Thus, when the merozoite 
contacts a host cell there is a concentration gradient of AMA1 across the surface of the 
merozoite, decreasing from anterior to posterior. The initial interaction between the merozoite 
and erythrocyte membranes is mediated by a parasite resident surface protein, such as MSP1, 
allowing attachment in any orientation. Following this long-range interaction, AMA1 interacts 
with its ligand on the erythrocyte surface. This interaction may be initiated by the AMA1 partner 
protein binding to the receptor on the erythrocyte surface, thus enhancing the affinity of AMA1 
for both its partner protein and the receptor. Alternatively, erythrocyte binding mediated by 
AMA1 may require multiple AMA1 molecules, possibly interacting with each other in the form of 
a homo-multimer. Individually the molecules of this complex might have a low affinity for the 
erythrocyte receptor, but collectively they may have an additive effect on the AMA1-receptor 
binding affinity. In addition, the concentration of AMA1 on the surface may correlate with this 
binding affinity. Thus, weaker interactions in regions of low AMA1 concentration will be 
abandoned in favour of higher affinity binding in regions of higher AMA1 concentration. This will 
induce the reorientation of the merozoite until the apical tip is in contact with the erythrocyte 
surface. At this point tight junction formation ensues, mediated by other components of the 
invasion pathway. Furthermore, AMA1-receptor binding may result in a conformational change 
in the molecule that allows it to interact with parasite kinases in the parasite cytosol thus 
inducing phosphorylation of amino acid residues within its cytoplasmic tail. The signal 
transduced initiates a cascade of events resulting in the secretion of the rhoptry contents. These 
proteins induce deformation of the erythrocyte membrane and PV formation. AMA1 -partner 
protein or -receptor binding also induces a conformational change in the C-terminal region of the 
AMA1 ectodomain, allowing access of MESH (SUB2) to the cleavage site within DIM. SUB2 is 
translocated by the actomyosin motor from anterior to posterior (Harris et al. submitted) forming 
a zone or ring of shedding around the parasite as it cleaves MSP1 and AMA1 in its path.
7.7: Conclusion
This study has helped identify a region of the PfAMAI ectodomain that may play a critical role in 
erythrocyte binding and invasion by the malaria parasite P. falciparum. In addition, results from 
this study suggest that PfAMAI is unable to bind its erythrocyte receptor, if such a receptor 
exists, in isolation, requiring interaction with a partner protein on the parasite surface and 
perhaps a conformational change, exposing regions of the molecule otherwise concealed. It 
would also appear likely that any possible role PfAMAI plays in signal transduction is only 
detectable at the time of parasite-host cell binding.
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Figure 7.1: A hypothetical role for AMA1 in erythrocyte invasion by Plasmodium
merozoites
A merozoite released from a mature schizont (1) has a coating of surface proteins that it utilises 
to make the initial weak interaction with the (target) erythrocyte surface (2). Around this time, 
AMA1 (red) is released from the (anterior) apical complex onto the surface of the merozoite and 
forms a decreasing concentration gradient towards the posterior end of the merozoite. The 
hypothetical AMA1 parasite partner protein, binds to an erythrocyte receptor which may be the 
same as that of AMA1 (3) thus enabling AMA1 to interact with partner and receptor (4). This key 
event results in a signal being transduced across the merozoite plasmalemma, possibly as a 
result of phosphorylation of the AMA1 cytoplasmic tail. The signal triggers rhoptry secretion (5), 
which results in the perturbation of the erythrocyte membrane, leading to PV formation (6) and 
parasite internalisation (7 and 8).
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